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ABSTRACT 
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LEPTIN AND PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA: 
UNDERSTANDING THEIR CONTRIBUTION TOWARDS NORMALISING THE 
PROGRAMMED PHENOTYPE IN THE PERIPHERAL TISSUES OF IUGR OFFSPRING 
 
By Emma Sian Garratt 
 
In a rat model of intrauterine growth restriction (IUGR) induced by maternal global undernutrition, 
adult offspring are obese with associated metabolic disturbances.  These metabolic abnormalities 
are all augmented by feeding a high calorie postnatal diet and reversed by neonatal leptin treatment.  
Evidence is now accumulating which indicates that altered epigenetic regulation and gene 
expression may underpin the relationship between the early life environment and metabolic 
disturbances in adult life.  Therefore, to determine the mechanism responsible for the alterations in 
energy balance in the IUGR rat, this study investigated the effect of maternal diet, neonatal leptin 
treatment and a postnatal high fat diet on the expression and DNA methylation of genes involved in 
energy balance in the liver and adipose tissue of adult offspring.  These genes included the 
peroxisome proliferator activated receptors (PPARs) and their target genes; acyl-coA oxidase 
(AOX), carnitine palmitoyl transferase-1 (CPT-1) and lipoprotein lipase (LPL). 
 
Real time PCR indicated that the expression of several key genes involved in energy balance, 
including PPARα, PPARγ and their target genes, was not altered by maternal diet or postnatal diet 
in the liver or adipose tissue of these offspring.  However, in adipose tissue, neonatal leptin 
treatment resulted in an increase in the expression of most genes tested, including PPARα, PPARγ 
and their target genes.  The increased PPARγ and LPL would facilitate the uptake of fatty acids 
into the adipocyte, whilst the upregulation of PPARα and its target genes AOX and CPT-1, not 
normally expressed in adipocytes, would direct fatty acids taken up towards the β-oxidation 
pathway instead of storage.  This would imply that the fat cell had transformed from a fat storing 
cell to a fat metabolising cell.  Gene expression data therefore indicated that the phenotypic 
changes induced by neonatal leptin treatment, i.e. the reduced weight gain, could be due to 
increased expression of PPARα, PPARγ and their target genes in adipose tissue: Furthermore, the 
effects of this are persistent, due to the specific period of leptin administration during neonatal 
development.  There was, however, no evidence of altered DNA methylation in the promoter 
regions measured which could account for these persistent effects.   
 
To investigate mechanisms underlying the regulation of the PPARα promoter by leptin, the rat 
PPARα promoter was mapped, cloned and characterised.  As part of this process, six alternatively 
spliced variants were identified; one from adipose tissue (P1), two from the liver (P2, P3), one from 
the heart (P4) and two from the kidney (P5, P6).  These transcripts were found to differ in their 
5’untranslated region due to tissue specific promoter usage and alternative transcription start sites.  
The liver and adipose specific promoters were cloned and characterised using a reporter gene 
strategy.  They were shown to differ in their basal activity, response to known activators of 
transcription and to neonatal leptin treatment.  The regulation of the PPARα promoter by leptin was 
investigated and shown to function via a non-canonical mechanism requiring both signal transducer 
and activators of transcription (Stat3) and specificity protein-1 (Sp1), which act at a unique region 
of the liver specific P2 promoter.  The adipose specific P1 promoter was shown to be unresponsive 
to leptin treatment.  Furthermore, real time PCR with primers specific to the P1 and P2 PPARα 
transcripts indicated that the increased PPARα expression seen in leptin treated offspring was due 
to an increase in the P2 specific transcript, not the P1 transcript.  This indicated that the neonatal 
leptin treatment facilitated a selective switch in promoter usage to increase the expression of 
PPARα and its target genes in a tissue in which they are not normally expressed, thus inducing an 
altered metabolism within the adipocytes of these offspring.   ii
 TABLE OF CONTENTS 
 
 
ABSTRACT 
TABLE OF CONTENTS 
FIGURES AND TABLES 
DECLARATION OF AUTHORSHIP 
ACKNOWLEDGEMENTS 
ABBREVIATIONS 
i 
ii 
ix 
xvii 
xviii 
xix 
 
 
Chapter 1 
INTRODUCTION 
Page 1-49 
 
1.0 
 
1.1 
 
1.2 
 
1.2.1 
1.2.2 
1.2.3 
1.2.4 
1.2.5 
1.2.5.1 
1.2.5.2 
1.2.5.3 
1.2.6 
 
1.3 
 
 
1.4 
1.4.1 
1.4.2 
1.4.3 
1.4.4 
INTRODUCTION 
 
ORIGINS OF OBESITY 
 
THE DEVELOPMENTAL ORIGINS OF HEALTH AND DISEASE 
HYPOTHESIS 
Programming of the adult phenotype by maternal undernutrition 
Programming of the adult phenotype by maternal overnutrition 
Developmental plasticity and predictive adaptive responses 
Animal models of programming 
Nutritional models of programming 
Maternal global undernutrition 
Maternal low protein diet 
Maternal and postnatal high fat diet 
Programming by excess glucocorticoid exposure  
 
PPARα, LEPTIN AND THEIR ROLE IN DEVELOPMENTAL 
PROGRAMMING 
 
PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA 
Nutritional programming and peroxisome proliferator activated receptors 
PPAR functions 
PPAR expression in programmed offspring 
PPAR expression during development and in the adult 
2 
 
2 
 
2 
 
3 
4 
6 
7 
9 
9 
10 
12 
13 
 
14 
 
 
14 
14 
14 
15 
16   iii
1.4.5 
1.4.6 
 
1.5 
1.5.1 
1.5.2 
1.5.3 
1.5.3.1 
1.5.3.2 
1.5.4 
1.5.5 
1.5.6 
 
1.5.7 
 
1.6 
1.6.1 
1.6.2 
1.6.3 
1.6.4 
1.6.5 
1.6.6 
1.6.7 
1.6.8 
1.6.9 
1.6.9.1 
1.6.9.2 
1.6.10 
1.7 
1.7.1 
1.7.1.1 
1.7.1.2 
1.7.1.3 
1.7.1.4 
 
1.7.1.5 
1.7.2 
1.7.2.1 
1.7.2.2 
Regulation of PPAR expression 
The structure and activation of PPARs 
 
LEPTIN 
Leptin function in bodyweight regulation 
Leptin, insulin and the adipoinsular axis 
Leptin in early development 
Leptin concentrations in early development in humans 
Leptin concentrations in early development in rodents 
The neonatal leptin surge 
The role of leptin in the formation of hypothalamic feeding circuits 
Alterations to the leptin surge and hypothalamic circuitry in programmed 
offspring 
Neonatal leptin treatment and the reversal of developmental programming 
 
EPIGENETICS AND DEVELOPMENTAL PROGRAMMING 
Methylation of DNA 
DNA methyltransferases 
Maintenance methylation 
Epigenetic reprogramming and de novo methylation 
Demethylation of the parental genomes in the embryo 
De novo methylation 
What directs de novo methylation 
Histone modifications 
DNA methylation and repression of gene expression 
DNA methylation and transcription factor binding 
DNA Methylation and methyl DNA binding proteins 
Micro RNA and epigenetics 
Evidence implicating epigenetic alterations in developmental programming 
Evidence of altered epigenetic regulation in rodents 
Epigenetic alterations arising from maternal behaviour and stress 
Epigenetic alterations arising from maternal nutrition 
Epigenetic alterations to GR and PPARs arising from maternal nutrition 
Epigenetic alterations to other genes implicated in acquisition of the 
programmed phenotype 
Epigenetic alterations arising from postnatal nutrition 
Evidence of altered epigenetic regulation in humans 
Epigenetic alterations arising from childhood abuse 
Epigenetic alterations arising from maternal nutrition 
16 
19 
 
22 
22 
24 
24 
25 
25 
27 
28 
28 
 
30 
 
31 
31 
33 
33 
34 
34 
35 
36 
36 
38 
38 
38 
40 
40 
41 
41 
41 
42 
44 
 
45 
46 
46 
46   iv
1.7.2.3 
1.8 
 
1.9 
Epigenetic alterations arising from assisted reproductive technologies 
Methods for measuring DNA methylation 
 
THESIS AIMS 
47 
48 
 
49 
 
 
Chapter 2 
MATERIALS AND METHODS 
Page 50-85 
  
2.0 
 
2.1 
2.1.1 
2.1.2 
2.1.3 
2.1.4 
2.1.5 
 
2.2 
2.2.1 
2.2.2 
2.2.3 
2.2.4 
2.2.5 
2.2.6 
2.2.7 
2.2.8 
2.2.9 
2.2.10 
2.2.11 
MATERIALS AND METHODS 
 
MATERIALS 
Sterilization 
Bacterial cell culture 
DNA purification 
Agarose gel electrophoresis 
Cell culture 
 
METHODS 
Animal methods 
Isolation and digestion of genomic DNA 
Agarose gel electrophoresis of DNA/RNA 
Isolation of RNA from liver, adipose, muscle and kidney tissue 
cDNA synthesis 
Real time PCR 
Gene cloning 
5’ RNA ligase mediated rapid amplification of cDNA ends (5’ RLM RACE) 
pGL3 Basic constructs 
Cell culture 
Methylation analysis by pyrosequencing 
51 
 
51 
53 
53 
54 
54 
55 
 
56 
56 
57 
58 
58 
58 
58 
61 
63 
68 
79 
82 
 
 
Chapter 3 
GENE EXPRESSION AND METHYLATION IN THE LIVER OF FEMALE AND MALE 
IUGR RATS 
Page 86-106 
                
3.1 INTRODUCTION  87   v
3.1.1 
3.1.2 
 
3.2 
3.2.1 
 
 
3.2.2 
 
 
3.2.3 
 
 
 
 
3.3 
Liver function in energy homeostasis 
Aims 
 
RESULTS 
The expression of genes involved in energy balance in the liver of adult female 
offspring differ in their response to maternal diet, postnatal diet and neonatal 
leptin treatment 
The methylation of GR and PPARα in the liver of adult female offspring is not 
altered by maternal diet or postnatal diet.  The methylation status of GR but 
not PPARα is affected by neonatal leptin treatment 
The expression of genes involved in energy balance in the liver of adult male 
offspring is not altered by maternal diet or postnatal diet.  The effect of 
neonatal leptin treatment is gene specific and dependent on maternal and 
postnatal diet 
 
DISCUSSION 
87 
88 
 
90 
90 
 
 
96 
 
 
99 
 
 
 
 
104 
 
 
Chapter 4 
GENE EXPRESSION AND METHYLATION IN ADIPOSE TISSUE OF FEMALE IUGR 
RATS 
Page 107-150 
                      
4.1 
4.1.1 
4.1.2 
4.1.3 
4.1.4 
4.1.5 
4.1.6 
 
4.2 
4.2.1 
 
 
4.2.2 
 
 
4.2.3 
INTRODUCTION 
Adipose tissue, obesity and developmental programming 
Storage and mobilisation of energy stores 
Adipokines and obesity 
Adipogenesis 
De-differentiation of adipocytes 
Aims 
 
RESULTS 
The expression of genes involved in energy balance in the adipose tissue of 
adult female offspring is not altered by maternal diet or postnatal diet, but is 
altered by neonatal leptin treatment 
The expression of DNA methyl transferases in the adipose tissue of adult 
female offspring in programmed rats is not significantly altered by maternal 
diet, postnatal diet or neonatal leptin treatment 
The methylation of genes involved in energy balance in the adipose tissue of 
108 
108 
108 
109 
110 
113 
114 
 
116 
116 
 
 
123 
 
 
126   vi
 
 
4.2.4 
 
4.2.5 
 
 
4.3 
adult female offspring in programmed rats is not altered by maternal diet, 
postnatal diet or neonatal leptin treatment 
Leptin undergoes a surge in expression during differentiation of 3T3-L1 pre-
adipocytes 
Endogenous leptin treatment alters the expression of specific genes involved in 
energy  balance before and during the differentiation of 3T3-L1 adipocytes 
 
DISCUSSION 
 
 
131 
 
133 
 
 
143 
 
 
Chapter 5 
IDENTIFICATION OF ALTERNATIVE PPARα TRANSCRIPTS AND 
CHARACTERISATION OF PROMOTER REGIONS 
Page 151-210 
 
5.1 
5.1.1 
5.1.2 
5.1.3 
5.1.4 
5.1.5 
5.1.6 
 
5.2 
5.2.1 
 
5.2.2 
 
5.2.3 
 
5.2.4 
 
 
5.2.5 
 
5.2.6 
 
 
5.2.7 
INTRODUCTION 
Nuclear hormone receptors and their regulation 
Genomic organisation of nuclear receptors 
Genomic organisation of PPARγ gene in humans and mice 
Genomic organisation of PPARδ in different species 
Genomic organisation of PPARα gene in different species 
Aims 
 
RESULTS 
5’ RLM RACE indicates that rat PPARα has multiple tissue specific transcript 
variants 
Sequencing of the PPARα 5’ RLM RACE products identifies multiple novel 
5’UTR exons and six tissue specific 5’UTR variant transcripts 
All the novel PPARα transcripts intron exon boundaries conform to the GT-
AG splice site rule 
A comparison of the rat PPARα 5’UTR exons after 5’RACE with 
corresponding exons in mouse and human 5’UTR reveals more homology than 
previously known 
The alternative PPARα transcripts have structurally diverse 5’UTR and P3 has 
the potential to produce an variant N-terminal extended protein 
Analysis of three distinct upstream regulatory regions from the multiple 
PPARα transcriptional start sites indicates that they differ in the presence of 
CpG islands, core promoter elements and transcription factor binding sites 
The PPARα P2 and P1 promoters are active in HepG2 Cells, but the P3 
152 
152 
152 
153 
155 
157 
161 
 
163 
163 
 
165 
 
170 
 
171 
 
 
174 
 
186 
 
 
192   vii
 
5.2.8 
 
5.2.9 
 
 
5.3 
promoter region is inactive 
The alternative PPARα promoter constructs respond differently to factors 
known  to activate PPARα transcription in HepG2 cells 
PPARα P2 promoter deletion constructs indicate locations of main basal 
activity 
 
DISCUSSION 
 
195 
 
198 
 
 
200 
 
 
Chapter 6 
I) LEPTIN ACTIVATION OF THE PPARα PROMOTER 
II) METHYLATION STATUS OF THE PPARα PROMOTER IN ADULT RATS  
IN RESPONSE TO NEONATAL LEPTIN TREATMENT 
Page 211-240 
                       
6.1 
6.1.1 
6.1.2 
 
6.2 
6.2.1 
 
6.2.2 
 
 
6.2.3 
 
 
6.2.4 
 
6.2.5 
 
6.2.6 
 
6.2.7 
 
 
 
 
INTRODUCTION 
Leptin receptor signalling mechanisms 
Aims 
 
RESULTS 
The P1 and P2 PPARα promoters respond differently to leptin treatment in 
HepG2 cells 
The expression of the PPARα P2 specific transcript but not the P1 specific 
transcript is significantly altered by neonatal leptin treatment in the adipose 
tissue of adult female offspring from the IUGR rat study 
MatInspector analysis of the unique region of the liver specific P2 PPARα 
promoter indicates an absence of Stat3 binding elements but the presence of a 
potential Sp1 binding site 
A highly potent Stat3 inhibitor prevents activation of the liver specific P2 
PPARα promoter by leptin 
Mutation of the Sp1 response element present within the unique region of the 
liver specific P2 PPARα promoter prevents its activation by leptin 
Methylation of the P1 and P2 PPARα luciferase promoter constructs abolishes 
all promoter activity 
Pyrosequencing analysis of 30 CpG’s within the proximal CpG island of the 
PPARα P2 promoter in adipose tissue of adult female offspring fed a high fat 
diet indicates that all CpG’s are unmethylated and unaltered by neonatal leptin 
treatment 
 
212 
212 
216 
 
218 
218 
 
220 
 
 
223 
 
 
225 
 
227 
 
229 
 
231 
 
 
 
   viii
6.3  DISCUSSION  235 
 
 
Chapter 7 
DISCUSSION 
Page 241-247 
 
7.0 
7.1 
7.2 
7.3 
7.4 
DISCUSSION 
Summary of main findings 
Discussion of main findings 
Future work 
Implications 
242 
242 
243 
245 
247 
 
 
Appendix 1 
CLUSTAL 2.0.12 MULTIPLE SEQUENCE ALIGNMENT 
Page 248-251 
 
 
Appendix 2 
PPARα ALTERNATIVE 5’UTR PREDICTED SECONDARY STRUCTURES 
Page 252-257 
 
  
REFERENCES 
Page 258-274   ix
FIGURES AND TABLES 
 
 
Chapter 1 
INTRODUCTION 
Page 1-49 
 
Figure 1.1 
 
Figure 1.2 
Figure 1.3 
Figure 1.4 
Table 1.1 
Figure 1.5 
Figure 1.6 
Figure 1.7 
The relationship between predictive adaptive responses and the risk of 
disease in later life 
The relationship of an altered fetal environment with adult disease 
Mechanisms of PPARα expression and activation 
Central and peripheral actions of leptin on energy balance 
Main functions of DNA methylation 
Formation of 5-methylcytosine 
Common modifications of histone 3 
Mechanism of repressive action by MeCP2 
7 
 
8 
21 
23 
32 
33 
37 
39 
 
 
Chapter 2 
MATERIALS AND METHODS 
Page 50-85 
 
Table 2.1 
Figure 2.1 
Table 2.2 
 
Figure 2.2 
 
Table 2.3 
Figure 2.3 
Figure 2.4 
Figure 2.5 
 
Figure 2.6 
 
Table 2.4 
Figure 2.7 
 
Figure 2.8 
Reagents and chemicals used in experiments 
Design of rat study 
Sequence and anneal temperatures of methylation sensitive PCR and real 
time PCR primers 
A schematic diagram showing the location of MSP amplicons relative to 
CpG islands for all MSP amplicons 
Gene specific primer sequences for PPARα  5’ RLM RACE 
Locations of primers for PPARα 5’ RLM RACE 
Circular map and multiple cloning region of the pGem T-Easy plasmid 
Digests of PPARα liver and adipose 5’ RACE PCR - pGEM T-Easy clones 
with EcoRI 
Pictorial representation of the PPARα promoter constructs showing the 5’ 
and 3’ restriction sites for cloning 
Sequences of the PPARα promoter cloning primers 
Circular map and multiple cloning region of the pGL3 Basic reporter 
vector 
Digested and gel extracted pGL3 Basic vector and PPARα promoter 
51 
57 
60 
 
61 
 
65 
66 
67 
68 
 
70 
 
70 
71 
 
72   x
 
Figure 2.9 
 
Figure 2.10 
 
Figure 2.11 
Figure 2.12 
Figure 2.13 
 
Table 2.5 
Table 2.6 
Figure 2.14 
Figure 2.15 
Figure 2.16 
Table 2.7 
Figure 2.17 
Figure 2.18 
 
Figure 2.19 
 
fragments 
Digests of PPARα promoter-pGL3 Basic clones to drop out promoter 
insert 
Schematic representation of the PPARα promoter 5’ deletion mutant pGL3 
Basic constructs 
Location of primers used for PPARα promoter 5’ deletion mutants 
Gel extracted PPARα promoter 5’ deletion mutant PCR products 
Digests of PPARα promoter 5’ deletion mutant-pGL3 basic clones to drop 
out the promoter insert 
Sequences of the PPARα promoter deletion mutant primers 
Sequences of PPARα P2 SP1 mutagenesis primers 
PPARα P2 SP1M PCR products 
Digests of PPARα P2 SP1M-pGL3 basic clones 
Digests of methylated PPARα-pGL3 constructs 
Sequences of the PPARα pyrosequencing PCR and sequencing primers 
Diagram showing the location of the PPARα pyrosequencing amplicons 
PPARα promoter sequence showing the location of the 290-380 
pyrosequencing amplicon 
PPARα promoter sequence showing the location of the 395-475 
pyrosequencing amplicon 
 
72 
 
73 
 
74 
75 
75 
 
76 
77 
77 
78 
79 
83 
83 
84 
 
85 
 
 
 
Chapter 3 
GENE EXPRESSION AND METHYLATION IN THE LIVER OF FEMALE AND MALE 
IUGR RATS 
Page 86-106 
 
Figure 3.1 
Figure 3.2 
 
 
Figure 3.3 
 
Figure 3.4 
 
 
Table 3.1 
 
Figure 3.5 
The effect of a reduced insulin:glucagon ratio on energy metabolism 
The expression of PPARα and its target genes CPT-1 and AOX in the liver 
of adult female offspring differ in their response to maternal diet, postnatal 
diet and neonatal leptin treatment 
The expression of LPL in the liver of adult female offspring is not altered 
by maternal diet, postnatal diet or neonatal leptin treatment 
The expression of GR and its target gene PEPCK, and 11βHSD-2 in the 
liver of adult female offspring differ in their response to maternal diet and 
postnatal diet, but are not altered by neonatal leptin treatment 
Table showing tests of between subject effects on the mRNA expression of 
genes measured in the liver of female offspring 
The methylation status of the PPARα and GR promoters in the liver of 
88 
92 
 
 
93 
 
94 
 
 
95 
 
97   xi
 
 
Table 3.2 
 
Figure 3.6 
 
 
 
Figure 3.7 
 
 
 
Figure 3.8 
 
Table 3.3 
adult female offspring is not altered by maternal diet or postnatal diet, but 
GR methylation is altered by neonatal leptin treatment 
Table showing tests of between subject effects on DNA methylation for 
genes measured in liver of female offspring 
The expression of GR110, PEPCK and 11βHSD-2 in the liver of adult male 
offspring is not altered by maternal diet or postnatal diet.  Expression of 
PEPCK is altered by neonatal leptin treatment, and the effect is dependent 
on both maternal and postnatal diet 
The expression of PPARα and its target gene AOX in the liver of adult 
male offspring is not altered by maternal diet, postnatal diet or neonatal 
leptin treatment.   Expression of CPT-1 is altered by neonatal leptin 
treatment, and the effect is dependent on both maternal and postnatal diet 
The expression of LPL in the liver of adult male offspring is not altered by 
maternal diet, postnatal diet or neonatal leptin treatment 
Table showing tests of between subject effects on the mRNA expression of 
genes measured in the liver of male offspring 
 
 
98 
 
100 
 
 
 
101 
 
 
 
102 
 
103 
 
 
Chapter 4 
GENE EXPRESSION AND METHYLATION IN ADIPOSE TISSUE OF FEMALE IUGR 
RATS 
Page 107-150 
 
Figure 4.0 
 
Figure 4.1 
 
 
Figure 4.2 
 
 
Figure 4.3 
 
 
Figure 4.4 
 
 
 
Figure 4.5 
The involvement of adipogenic transcription factors in adipocyte 
differentiation 
The expression of PPARα and its target genes CPT-1 and AOX in adipose 
tissue of adult female offspring is altered by neonatal leptin treatment but 
not maternal diet or postnatal diet 
The expression of PPARγ2 and its target gene LPL in adipose tissue of 
adult female offspring is altered by neonatal leptin treatment but not 
maternal diet or postnatal diet 
The expression of GR, GR 110 and 11βHSD2 in adipose tissue of adult 
female offspring is altered by neonatal leptin treatment but not maternal 
diet or postnatal diet 
The expression of HSL in adipose tissue of adult female offspring is not 
affected by maternal diet, postnatal diet or neonatal leptin treatment.  The 
expression of Insulin Receptor is effected by leptin treatment, and this 
effect is dependent on maternal diet and postnatal diet 
The expression of leptin and its receptor in adipose tissue of adult female 
112 
 
118 
 
 
119 
 
 
120 
 
 
121 
 
 
 
122   xii
 
 
Figure 4.6 
 
 
Table 4.1 
 
Figure 4.7 
 
 
Figure 4.8 
 
 
 
Figure 4.9 
 
 
Table 4.2 
 
Figure 4.10 
 
Figure 4.11 
 
Figure 4.12 
 
Figure 4.13 
 
Figure 4.14 
 
Figure 4.15 
 
Figure 4.16 
 
Figure 4.17 
 
Figure 4.18 
offspring is altered by neonatal leptin treatment but not maternal diet or 
postnatal diet.  effect of leptin treatment is dependent on maternal diet 
The expression of DNA methyltransferases in adipose tissue of adult 
female offspring is not significantly altered by neonatal leptin treatment, 
maternal diet or postnatal diet 
Table showing tests of between subject effects on the mRNA expression of 
genes measured in the adipose tissue of female offspring 
The methylation of the GR, PPARγ1 and 11βHSD2 promoters in adipose 
tissue of adult female offspring are not altered by maternal diet, postnatal 
diet or neonatal leptin treatment 
Methylation of the PPARα promoter in adipose tissue of adult female 
offspring is affected by neonatal leptin treatment but not maternal diet or 
postnatal diet.  the methylation of the AOX promoter is not altered by 
maternal diet, postnatal diet or neonatal leptin treatment 
Methylation of the leptin and leptin receptor promoters in adipose tissue of 
adult female offspring are not altered by maternal diet, postnatal diet or 
neonatal leptin treatment 
Table showing tests of between subject effects on DNA methylation for 
genes measured in adipose tissue of female offspring 
Appearance of 3T3-L1 adipocytes and expression profile of leptin mRNA 
during differentiation 
Expression profile of leptin in 3T3-L1 pre-adipocytes undergoing 
differentiation at day 2 treated with exogenous leptin 
Expression profile of PPARα in 3T3-L1 pre-adipocytes undergoing 
differentiation at day 2 treated with exogenous leptin 
Expression profile of GR in 3T3-L1 pre-adipocytes undergoing 
differentiation at day 2 treated with exogenous leptin 
Expression profile of 11βHSD2 in 3T3-L1 pre-adipocytes undergoing 
differentiation at day 2 treated with exogenous leptin 
Expression profile of leptin in 3T3-L1 pre-adipocytes undergoing 
differentiation at day 8 treated with exogenous leptin 
Expression profile of PPARα in 3T3-L1 pre-adipocytes undergoing 
differentiation at day 8 treated with exogenous leptin 
Expression profile of GR in 3T3-L1 pre-adipocytes undergoing 
differentiation at day 8 treated with exogenous leptin 
Expression profile of 11βHSD2 in 3T3-L1 pre-adipocytes undergoing 
differentiation at day 8 treated with exogenous leptin 
 
 
124 
 
 
125 
 
127 
 
 
128 
 
 
 
129 
 
 
130 
 
132 
 
135 
 
136 
 
137 
 
138 
 
139 
 
140 
 
141 
 
142 
 
 
   xiii
Chapter 5 
IDENTIFICATION OF ALTERNATIVE PPARα TRANSCRIPTS AND 
CHARACTERISATION OF PROMOTER REGIONS 
Page 151-210 
 
Figure 5.1 
Figure 5.2 
Figure 5.3 
Figure 5.4 
 
Figure 5.5 
Figure 5.6 
Figure 5.7 
Figure 5.8 
 
Figure 5.9 
 
Figure 5.10 
 
Figure 5.11 
 
Figure 5.12 
Figure 5.13 
Figure 5.14 
Table 5.1 
 
Figure 5.15 
 
Table 5.2 
 
Table 5.3 
 
Figure 5.16 
Figure 5.17 
Figure 5.18 
 
Figure 5.19 
 
Figure 5.20 
The genomic organisation of the human and mouse PPARγ genes 
The genomic organisation of the human PPARδ gene 
The genomic organisation of the mouse PPARδ gene 
A comparison of the genomic organisation of the human, mouse and rat 
PPARδ genes 
The genomic organisation of the human PPARα gene 
The genomic organisation of the mouse PPARα gene 
The genomic organisation of the rat PPARα gene 
A comparison of the genomic organisation of the human, mouse and rat 
PPARα genes 
5’ RLM RACE PCR indicates that the liver expresses multiple PPARα 
transcripts whilst adipose tissue expresses just one PPARα transcript 
5’ RLM RACE PCR indicates that the kidney expresses multiple PPARα 
transcripts whilst muscle expresses just one PPARα transcript 
A schematic diagram showing the genomic organisation of the rat PPARα 
gene 
Sequence of exons at the 5’ end of the PPARα P2 and P3 transcripts 
Sequence of exons at the 5’ end of the PPARα P5 and P6 transcripts 
Sequence of exons at the 5’ end of the PPARα P1 and P4 transcripts 
Alternative PPARα 5’UTR exon/intron junctions conform to the GT-AG 
splice site rule 
A comparison of the rat PPARα 5’UTR genomic organisation with human 
and mouse 5’UTR before and after 5’ RLM RACE procedure 
Clustal 2.0.12 sequence alignment scores for rat PPARα 5’UTR exons 
with corresponding human and mouse 5’UTR exons 
Alternative PPARα transcript ATG initiation sites and surrounding kozak 
sequence 
PPARα P1 transcript has no alternative initiator codons within the 5’UTR 
PPARα P2 transcript has no alternative initiator codons within the 5’UTR 
PPARα P3 transcript has four possible alternative upstream initiator 
codons within the 5’UTR 
Use of PPARα P3 transcript uATG 1 codon results in termination after 
30bp 
Use of PPARα P3 transcript uATG 2 codon may produce a 5’ extended 
154 
156 
156 
157 
 
159 
160 
160 
161 
 
164 
 
164 
 
166 
 
167 
168 
169 
170 
 
172 
 
173 
 
175 
 
176 
177 
178 
 
179 
 
180   xiv
 
Figure 5.21 
 
Figure 5.22 
 
Figure 5.23 
Figure 5.24 
Figure 5.25 
Figure 5.26 
 
Table 5.4 
 
Figure 5.27 
 
Figure 5.28 
 
Figure 5.29 
 
Figure 5.30 
 
 
Figure 5.31 
 
 
Figure 5.32 
 
Figure 5.33 
 
Figure 5.34 
 
Figure 5.35 
 
Table 5.5 
transcript 
Use of PPARα P3 transcript uATG 3 codon results in termination after 
45bp 
Use of PPARα P3 transcript uATG 4 codon results in termination after 
21bp 
PPARα P4 transcript has no alternative initiator codons within the 5’UTR 
PPARα P5 transcript has no alternative initiator codons within the 5’UTR 
PPARα P6 transcript has no alternative initiator codons within the 5’UTR 
Two CpG islands are located in the P1/P2/P4/P6 upstream regulatory 
sequence 
Positions of core promoter elements within the P1/P2/P4/P6 regulatory 
region of PPARα as identified by MatInspector software 
Sequence of the PPARα P1/P2/P4/P6 upstream regulatory region showing 
potential transcription factor binding sites and core promoter elements 
Sequence of the PPARα P3 upstream regulatory region showing potential 
transcription factor binding sites and core promoter elements 
Sequence of the PPARα P5 upstream regulatory region showing potential 
transcription factor binding sites and core promoter elements 
Sequence of the overlapping PPARα P1 and P2 cloned promoter regions 
showing potential transcription factor binding sites and core promoter 
elements 
Schematic diagram showing relative locations of PPARα P1, P2 and P3 
cloned promoters and their positioning relative to Ensembl transcription 
start site and 5’UTR exons 
The PPARα P1 and P2 promoters are active in HepG2 cells, but the P3 
promoter is inactive 
Dexamethasone activates the PPARα P1 promoter and the P2 promoter, 
but not the P3 promoter in HepG2 cells 
Clofibric acid activates the PPARα P2 promoter, but not the P3 or P1 
promoters in HepG2 cells 
PPARα P2 promoter 5’ deletion constructs indicate locations of main basal 
activity 
Location of core promoter elements and transcription factor binding sites 
within the deletion constructs 
 
181 
 
182 
 
183 
184 
185 
187 
 
188 
 
189 
 
190 
 
191 
 
193 
 
 
194 
 
 
194 
 
196 
 
197 
 
198 
 
199 
 
 
   xv
Chapter 6 
II)  LEPTIN ACTIVATION OF THE PPARα PROMOTER 
II) METHYLATION STATUS OF THE PPARα PROMOTER IN ADULT RATS 
IN RESPONSE TO NEONATAL LEPTIN TREATMENT 
Page 211-240 
 
Figure 6.1 
Figure 6.2 
 
Figure 6.3 
 
 
 
 
Table 6.1 
 
Figure 6.4 
 
 
Figure 6.5 
 
Figure 6.6 
 
Figure 6.7 
 
Figure 6.8 
 
Figure 6.9 
 
 
Figure 6.10 
 
Leptin receptor signalling mechanisms 
Leptin activates the PPARα P2 promoter, but not the P1 or P3 promoters in 
HepG2 cells 
The expression of the P1 and P2 PPARα transcripts is not significantly 
altered by maternal diet or postnatal diet in the adipose tissue of adult 
female offspring.  The expression of the PPARα P2 specific transcript but 
not the P1 specific transcript is significantly altered by neonatal leptin 
treatment 
Table showing tests of between subject effects on the mRNA expression of 
PPARα P1 and P2 in the adipose tissue of female offspring 
The sequence of the “unique” region of the P2 promoter indicating the 
location of potential core promoter elements and transcription factor 
binding sites 
Stat3 inhibitor specifically prevents the activation of the PPARα P2 
promoter by leptin 
Mutation of the Sp1 response element present in the unique region of the 
liver specific P2 PPARα promoter prevents its activation by leptin 
Methylation of the P1 and P2 PPARα promoter constructs by HpaII 
methylase and CpG methylase prevents all promoter activity 
Location of the PPARα pyrosequencing region relative to P1 and P2 TSS, 
unique region of P2 promoter, MSP region and CpG islands 
Pyrosequencing analysis of CpGs 1-18 within the PPARα promoter in 
adipose tissue of adult female offspring fed a high fat diet confirms that all 
CpG’s are unmethylated in offspring given both saline or leptin treatment 
Pyrosequencing analysis of CpGs 19-30 within the PPARα promoter in 
adipose tissue of adult female offspring fed a high fat diet confirms that all 
CpG’s are unmethylated in offspring given both saline or leptin treatment 
214 
219 
 
221 
 
 
 
 
222 
 
224 
 
 
226 
 
228 
 
230 
 
232 
 
233 
 
 
234 
 
 
 
   xvi
Chapter 7 
DISCUSSION 
Page 241-247 
 
Figure 7.1 
 
Proposed effect of neonatal leptin treatment on adipocytes according to 
altered gene expression profiles 
245 
 
 
 
Appendix 1 
CLUSTAL 2.0.12 MULTIPLE SEQUENCE ALIGNMENT 
Page 248-251 
 
Figure 1 
Figure 2 
 
Figure 3 
 
Figure 4 
 
Figure 5 
 
Multiple sequence alignment of mouse, rat and human PPARα exon 3 
Multiple sequence alignment of mouse and rat PPARα exon 2 and human 
exon 1A 
Multiple sequence alignment of mouse PPARα exon 1B, rat PPARα exon 
1E and human PPARα exon X before 5’RACE 
Multiple sequence alignment of mouse PPARα exon 1B, rat PPARα exon 
1E and human PPARα exon X after 5’RACE 
Multiple sequence alignment of mouse PPARα exon 1A, rat PPARα exon 
1C and human PPARα exon A after 5’RACE 
248 
248 
 
249 
 
250 
 
251 
 
 
 
Appendix 2 
PPARα ALTERNATIVE 5’UTR PREDICTED SECONDARY STRUCTURES 
Page 252-257 
 
Figure 1 
Figure 2 
Figure 3 
Figure 4 
Figure 5 
Figure 6 
 
 
PPARα P1 5’UTR predicted secondary structure 
PPARα P2 5’UTR predicted secondary structure 
PPARα P3 5’UTR predicted secondary structure 
PPARα P4 5’UTR predicted secondary structure 
PPARα P5 5’UTR predicted secondary structure 
PPARα P6 5’UTR predicted secondary structure 
 
252 
253 
254 
255 
256 
257 
   xvii
DECLARATION OF AUTHORSHIP 
 
 
I, Emma Garratt declare that the thesis entitled Leptin and Peroxisome Proliferator Activated 
Receptor α: Understanding their contribution towards normalising the programmed phenotype in 
the peripheral tissues of IUGR Offspring, and the work presented in the thesis are both my own, 
and have been generated by me as the result of my own original research.  I confirm that: 
 
 
  this work was done wholly or mainly while in candidature for a research degree at this 
University; 
 
  where any part of this thesis has previously been submitted for a degree or any other 
qualification at this University or any other institution, this has been clearly stated; 
 
  where I have consulted the published work of others, this is always clearly attributed; 
 
  where I have quoted from the work of others, the source is always given. With the exception of 
such quotations, this thesis is entirely my own work; 
 
  I have acknowledged all main sources of help; 
 
  where the thesis is based on work done by myself jointly with others, I have made clear exactly 
what was done by others and what I have contributed myself; 
 
  Parts of this work have been published as: 
 
 Gluckman,  P.  et al. Metabolic plasticity during mammalian development is directionally 
  dependent on early nutritional status. Proc Natl Acad Sci U S A.104, 12796-12800 (2007).  
 
 
 
Signed: …Emma Garratt……………………………………….. 
 
Date:…… 13
th June 2010……………………………………….   xviii
ACKNOWLEGEMENTS 
 
 
I would like to thank the following people for all their support and encouragement during my PhD. 
 
Karen, thank you for giving me this great opportunity and for all the help and support you have 
given me along the way, it’s been a great experience that I am very thankful for.  To Graham and 
Howard, thank you for all your support and advice over the years.  To Sam, thank you for all your 
encouragement and the hours you have spent proof reading my thesis and to Abi, thank you for 
your constant support and encouragement.  Thank you to all my lab colleagues for their constant 
harassment to finish writing, without which I would probably still be writing in several months 
time…..  Finally to my ever patient and wonderful husband Simon, thank you for putting up with 
me and my ups and downs throughout this PhD. 
 
 
Thank you   xix
ABBREVIATIONS 
 
 
5’ RNA ligase mediated rapid amplification of cDNA ends    5’RLM RACE 
11  beta-hydroxysteroid  dehydrogenase        11βHSD      
Acetyl  coA  carboxylase        ACC 
Activator  protein  1        AP1 
Acyl-coA  oxidase          AOX 
Adenosine  triphosphate          ATP 
Ad libitum         A D  
Agouti-related  peptide          AgRP 
Alpha-melanocyte  stimulating  hormone      α-MSH 
Analysis  of  variance        ANOVA 
AMP-activated  protein  kinase         AMPK 
Arcuate nucleus of the hypothalamus          ARH 
ATP-citrate  lyase          ACL 
Beckwith  Wiedemann  syndrome        BWS 
Calf  Intestinal  alkaline  phosphatase      CIP 
cAMP response element binding protein         CREB 
Carnitine  palmitoyl  transferase-1        CPT-1 
CCAAT-enhancer-binding  proteins         C/EBP 
Chicken ovalbumin upstream promoter transcription factor     Coup TF 
Chromatin  immumoprecipitation        ChIP 
C l o f i b r i c   a c i d          C F A  
Cocaine and amphetamine-related transcript         CART 
Copy-deoxyribonucleic  acid       c-DNA 
Coronary  heart  disease          CHD 
CREB  binding  protein          CBP 
Cycle  threshold         Ct 
Cyclophillin         CYC 
Deoxyribonucleic  acid        DNA 
Developmental origins of health and disease         DOHaD 
D e x a m e t h a s o n e          D E X  
Differentially  methylated  region       DMR 
Dihydrofolate  reductase  gene         DHFR 
DNA  methyl  transferases         DNMT 
Downstream  promoter  element         DPE 
Dorsomedial  hypothalamic  nucleus      DMH 
E m b r y o n i c   s t e m           E S  
Enhancer  box         E-Box   xx
Fat  mass  and  obesity  associated         FTO 
Fatty  acid  synthesase          FAS 
GATA  binding  protein          GATA 
Global  undernutrition        UN 
Glucocorticoid  receptor        GR 
Glucocorticoid  response  elements        GRE 
Glucokinase         GK 
Heterochromatin  protein  1         HP1 
Hepatocyte  nuclear  factor       HNF 
H i g h   F a t          H F  
Histone  deacetylase          HDAC 
Histone  acetyl  transferase       HAT 
Hormone  sensitive  lipase       HSL 
Hypothalamic-pituitary-adrenal         HPA 
Initiator  element       INR 
Insulin-like  growth  factor       IGF 
I n t e r l e u k i n            I L  
Intracytoplasmic  sperm  injection        ICSI 
Internal ribosome entry site-dependent           IRES 
Intracisternal  A  particle          IAP 
Intrauterine  growth  retardation         IUGR 
In  vitro  fertilisation          IVF 
J a n u s   k i n a s e          J A K  
Lateral  hypothalamic  area       LHA 
L e p t i n           L  
Leptin  receptor         LR 
Ligand  independent  activation  domain        AF-1 
Lipoprotein  lipase        LPL 
Loss  of  imprinting          LOI 
L u r i a   b r o t h          L B  
M a l i c   e n z y m e            M E  
M a t e r n a l   l o w   p r o t e i n         M L P  
Methylation  sensitive  PCR       MSP 
M e t h y l   b i n d i n g   d o m a i n           M B D  
Methyl  CpG  binding  proteins         MBD 
M i c r o   R N A s            m i R N A  
Motif  ten  elements          MTE 
Neuropeptide  Y         NPY 
Nonesterified  fatty  acid          NEFA 
Nuclear  factor  1         NF-1   xxi
Nuclear factor kappa-light-chain-enhancer of activated B cells     NFкB 
Nucleosome remodelling and histone deacetylase       NuRD 
Obese  gene         OB 
O c t a m e r   1          O C T 1  
O p e n   r e a d i n g   f r a m e         O R F  
Paraventricular  nucleus        PVH 
Peroxisome proliferator activated receptor        PPAR 
Peroxisome proliferator response element         PPRE 
Perfluorodecanoid  acid          PFDA 
Phosphoenolpyruvate  carboxykinase      PEPCK 
Phosphoinositide  3-kinase         PI3K 
Polycomb  group  proteins       PcG   
Polymerase  chain  reaction       PCR 
P o s t n a t a l   d a y          P N D  
PPAR  gamma  coactivator  1         PGC-1 
Predictive  adaptive  response         PAR 
Primordial  germ  cells          PGCs 
Proliferating  cell  nuclear  antigen        PCNA 
Pro-opiomelanocortin        POMC 
Protein tyrosine phosphatase 1B           PTP1B 
Retinoic  acid  receptor          RAR 
Retinoid  X  receptor        RXR 
Ribonucleic  acid        RNA 
5’RNA ligase mediated rapid amplification of cDNA ends    5’RLM RACE 
s-adenosyl-L-homocysteine       SAH 
s-adenosyl-l-methionine        SAM   
SH-2  domain  containing  phosphatases        SHP2 
Signal transducer and activator of transcription        STAT 
Specificity  protein  1          P1 
Stat3  binding  element        SBE 
Sterol  regulatory  binding  protein        SREBP 
Suppressors  of  cytokine  signalling  3      SOCS3 
TATA  binding  protein          TBP   
TBP  associated  factor  4          TAF  4 
TFIIB  recognition  elements         BRE 
Thiazolidinedione        TZD 
Thyrotrophin  releasing  hormone       TRH 
Tissue inhibitor of metalloproteinase 1           TIMP-1 
Tobacco  acid  pyrophosphatase         TAP 
Transcriptional  repression  domain        TRD   xxii
Transcription  start  site        TSS 
Transcription  factor          TF 
T r i a c y l g l y c e r o l            T A G  
Trichostatin  A           TSA 
Tumour necrosis factor α         T N F - α   
T y r o s i n e          T Y R  
Tyrosine  aminotransferase         TAT 
Undernutrition         UN 
Untranslated  region        UTR 
U p s t r e a m   A T G          u A T G  
U p s t r e a m   O R F          u O R F  
White  adipose  tissue          WAT 
X  Core  promoter  element  1         XCPE1 
   1
 
 
 
Chapter 1 
 
Introduction   2
1.0 Introduction 
 
 
1.1  Origins of obesity  
 
Western society has an obesity epidemic.  Obesity is a disorder of energy balance associated with a 
cluster of disturbances termed the metabolic syndrome, which includes; insulin resistance, 
dyslipidemia and hypertension.  Thus obesity is a high risk factor for chronic disease, including 
type II diabetes and cardiovascular disease 
1,2.  The incidence of obesity has risen dramatically in 
recent years, for example in the US prevalence has increased nearly 8% in just 7 years, with 1 in 3 
Americans now being obese 
2 and worryingly, one third of pregnant women are now obese 
3.  
Statistics show that this increase in obesity is also reflected in children; in the US 9 million children 
between the ages of 6-19 are overweight and in the UK this figure reaches nearly 1 million.  This 
represents levels three times that of 1980 and the incidence in this age range is increasing by 1% 
each year, the adverse effects of which will manifest in later life 
4.  Startlingly, obesity related 
metabolic disturbances have even been identified in 5 year old children and the incidence of type II 
diabetes has increased dramatically in adolescents in recent years 
5.  Consequently, obesity has 
reached epidemic levels worldwide, in children as well as adults, with 300 million people thought 
to be obese and the levels still increasing.  
 
The rapid increase in obesity can not be exclusively due to genetic factors, but can also be 
attributed to changes in lifestyle factors due to the increasing prevalence of a westernised lifestyle.  
This includes increased energy intake due to larger portions and energy rich foods and reduced 
energy expenditure due to a more sedentary lifestyle.  Interestingly, evidence from human 
epidemiological studies and animal models has clearly shown that the origins of obesity and its 
associated metabolic disturbances can be programmed by the maternal environment in utero and 
this has led to the acceptance of the ‘developmental origins of health and disease’ hypothesis 
6-8.  
 
 
1.2  The developmental origins of health and disease hypothesis 
 
The basic concept of the developmental origins of health and disease (DOHaD) hypothesis is that 
environmental constraints such as poor maternal nutrition, acting during critical periods of early 
development, can induce metabolic disturbances in the developing offspring which result in an 
increased risk of non-communicable chronic diseases in adult life.  These diseases include type II 
diabetes and coronary heart disease (CHD).   
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1.2.1  Programming of the adult phenotype by maternal undernutrition 
 
Retrospective human epidemiological studies in the UK provided the first evidence for the DOHaD 
hypothesis.  In 1986, Barker and colleagues made the original observation that reduced fetal 
growth, as a result of adverse intrauterine environment such as maternal undernutrition, was 
associated with an increased risk of CHD in adulthood 
9-11.  This reduced fetal growth manifests as 
a smaller birth size 
12, but growth restriction does not need to be severe, as birth sizes within the 
normal range have been shown to have a continuous relationship with disease risk 
11,13.  Since these 
original studies by Barker, the association between maternal undernutrition and risk of CHD in 
adult life has been extensively replicated in other cohorts throughout the world, in both men and 
women, including the US 
14, India 
15 and Europe 
16. 
 
One important retrospective epidemiological study which has generated much information on the 
effect of maternal undernutrition on adult disease risk is the Dutch Hunger Winter 
17.  During the 
harsh winter of 1944-1945, a severe food shortage affected the west Netherlands as a result of 
German occupation and frozen waterways preventing the passage of food.  As a result, the scarce 
food supplies were rationed.  Consequently, at the height of the famine, daily calorie intake for 
adults was less than 1000 kcal per day, whereas both before and after the famine, the population 
was well nourished.  Individuals were classed as being exposed to the famine if they consumed less 
than 1000 kcal per day for a 13 week period, furthermore exposures were classed in to early, mid or 
late gestation.  As a result, this famine provided a unique opportunity to study the effects of 
maternal undernutrition at different periods of gestation on the health of adult offspring 
17.   
 
When exposure to the famine was during early gestation, an increased incidence of atherogenic 
lipid profiles was evident in men and women when compared to unexposed individuals.  This 
included; lower plasma HDL, lower apolipoprotein concentrations and higher total cholesterol, 
LDL-cholesterol and apolipoprotein B concentrations 
18.  There was also an increased incidence of 
abdominal obesity in 50yr old women, which is known to be associated with metabolic disease.  
Therefore, this indicated a disruption to bodyweight control, which could be due to either endocrine 
or adipocyte dysfunction 
6.  However, this increased prevalence of obesity was not found in 50yr 
old men, which indicates that the mechanisms underlying the predisposition to obesity were more 
likely to involve central endocrine abnormalities rather than peripheral dysregulation of adipocytes 
17.  Furthermore, abdominal obesity was not apparent in men or women exposed in mid or late 
gestation 
6,17.  An increase in the prevalence of CHD was also identified in those exposed to famine 
during early gestation 
19, which again was absent in those exposed during mid or late gestation 
19.  
Furthermore, as famine exposure during late gestation did not affect central obesity, lipid profiles 
or CHD, it is possible that the transition from the undernutrition to adequate nutrition in individuals 
exposed during early gestation played a role in the onset of these disturbances.  In addition, as 
individuals exposed to the famine in early gestation had a normal birth weight despite the   4
metabolic disturbances in adulthood, this indicated that size at birth was not always predictive of 
adult disease 
18.   
 
When exposure to the famine was during late gestation, an increased occurrence of impaired 
glucose tolerance was apparent, indicating alterations to insulin-glucose metabolism in these 
individuals.  Furthermore, in contrast to those subjected to famine in early gestation, those exposed 
during late gestation were found to be smaller at birth than unexposed individuals 
20.  Data also 
indicated that increased blood pressure in adults exposed to the famine was associated with this 
smaller size at birth 
21.  In addition, increased blood pressure also correlated with a low protein to 
carbohydrate ratio in the maternal diet during the third trimester, indicating that the balance of 
macronutrients may play a role in formation of disease 
21.     
 
Extensive studies into this cohort have therefore demonstrated that maternal undernutrition during 
gestation results in a variety of phenotypes associated with metabolic syndrome and that the adult 
phenotype varies according to the timing of the nutrient restriction during development 
17.  These 
studies have therefore informed us of the different organs and metabolic systems which are 
susceptible to maternal nutrition at differing periods of gestation.  In addition to this, analysis of 
many other epidemiological studies have led to the conclusion that a smaller birth size within the 
normal range is associated with an increased risk in adulthood of; obesity 
6,22, impaired insulin 
metabolism and non-insulin dependent diabetes 
23,24, dyslipidemia 
18 and hypertension 
25,26, which 
all contribute to an increased risk of coronary heart disease.  Furthermore, a study of males born in 
Helsinki has shown that the adverse long term effects of inadequate prenatal nutrition and 
subsequent small birth size are augmented by increased catch up growth during early childhood 
27.  
This finding has been replicated in other cohorts, for example, IUGR offspring whom experienced 
rapid catch up growth had an increased risk of obesity at the age of two 
28. 
 
 
1.2.2  Programming of the adult phenotype by maternal overnutrition 
 
In addition to maternal undernutrition, fetal overnutrition due to maternal adiposity is also 
associated with altered fetal growth and development, which results in an increased risk of chronic 
disease such as obesity in adult life 
3.  This has been termed the ‘fetal overnutrition’ hypothesis 
29.  
It is thought that maternal obesity programs alterations in metabolism, appetite or neuroendocrine 
function due to an increased nutrient transfer across the placenta 
5.  For example, in a prospective 
study of 7000 women in Australia, maternal BMI in pregnancy was found to have a positive 
association with offspring BMI at the age of 14 
29.  Furthermore, in a retrospective cohort from 
Finland, children born to mothers with high BMI were found to have higher BMI themselves 
throughout childhood than those children born to normal weight mothers.  In addition, offspring 
who were overweight at the age of 31 were more likely to be born from women whom were   5
overweight before pregnancy 
30.  This worrying fact indicates that obese women tend to produce 
obese offspring, thus amplifying the incidence of obese individuals throughout subsequent 
generations 
31. 
 
Therefore two opposing fetal environments; nutrient deficiency and nutrient surplus, converge 
towards a common phenotype, which may indicate similar underlying mechanisms.  Consequently, 
a U shaped curve can be used to describe the relationship between birth weight and the risk of 
chronic disease in adulthood
32, with those at risk being the smaller and larger babies.  All these 
findings from human epidemiological studies indicate that environmental constraints, which 
include both maternal undernutrition and overnutrition, can alter physiology and metabolism to 
induce an increased risk of chronic disease in postnatal life, including obesity, insulin resistance, 
dyslipidemia and hypertension.  In addition, adequate nutrition in postnatal life can augment this 
disease risk.  Furthermore, the timing and nature of the nutritional constraint can affect the 
resulting phenotype, indicating that different systems such as glucose metabolism and lipid 
metabolism are sensitive to maternal undernutrition at different periods of gestation. 
 
Although retrospective studies have been of utmost importance in identifying the consequences of 
maternal undernutrition, these studies are limiting for obvious reasons.  As a result, prospective 
studies are now emerging which investigate the effects of the maternal environment on the 
development of offspring and the association with adult disease risk.  These studies have the 
advantage of being able to overcome the short fallings of retrospective studies, such the inability to 
look at underlying mechanisms, absent or incomplete data and the lack of appropriate 
measurements and information on the maternal environment.  One such study is the Southampton 
women’s survey 
33.  This study was set up to determine the effects of the maternal environment 
before and during pregnancy on fetal growth throughout gestation, postnatal growth and also on 
risk factors for chronic disease such as type II diabetes and CVD.   Unlike the retrospective studies 
discussed in this report, this study benefits from pre-pregnancy maternal measurements, which can 
therefore be related to fetal growth, development and disease risk.  In addition, numerous samples 
and measurements are being taken throughout the study, including; anthropometric measurements, 
DXA scans for bone and body composition, blood and urine before and during pregnancy and 
buccal swabs from offspring at different stages of postnatal life.  Furthermore, a wealth of 
information is being collected on maternal diet, lifestyle and illnesses before and during pregnancy.  
However, a major disadvantage of this study and others like it is that they extend over a very long 
period of time; therefore a complete set of data will not be available until all children in the cohort 
have reached the study endpoint.  However, it is hoped that the outcomes from this unique 
experiment will enable the development of strategies to enable optimal growth and development of 
the offspring and thus minimise the risk of chronic disease in adult life 
33. 
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1.2.3  Developmental plasticity and predictive adaptive responses 
 
The term ‘Fetal Programming’ has been used to describe the developmental alterations which 
underpin the increased risk of disease in later life.  These ‘alterations’ are a consequence of the 
environmental cue, such as altered maternal nutrition or increased glucocorticoid exposure, acting 
during a sensitive window of early development 
13.  This developmental window extends 
throughout early development from conception to the neonatal period and is associated with 
developmental plasticity 
34.  Plasticity results from an increased vulnerability due to tissue growth 
and differentiation, which occurs at different times in different cells, tissues and organs.   
Subsequently those cells undergoing rapid growth are more at risk.  As a result, adverse 
environmental cues can alter physiology and metabolism and lead development down alternative 
and irreversible paths, resulting in the production of alternative phenotypes from one genotype 
12.  
The timing of plasticity can also differ according to species, for example in humans adipose tissue 
is formed during fetal life, whereas in rodents adipogenesis occurs after birth.  Subsequently, the 
effects of environmental constraints on programming will depend not only on the nature of the 
constraint, but also on the stage of gestation and species.  
 
The response an organism makes to the adverse environmental cue during this critical period of 
development is crucial for its future fitness. It has been proposed that organisms respond to such 
environmental constraints by making what has been termed a predictive adaptive response (PAR) 
12, whereby the organism predicts the future postnatal environment and makes changes in 
physiology and metabolism to adapt to this.  The PAR therefore leads the organism down an 
alternative developmental path which provides it with an increased chance of survival if the 
adverse conditions persist in the future.  If however, the postnatal environment doesn’t match that 
which it predicted, then there is an increased risk of disease (figure 1.1) 
12.  Therefore, appropriate 
PARs increase the chance of survival to reproduce, whereas inappropriate PARs carry an increased 
risk of disease in later life 
35. 
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Figure 1.1  The relationship between predictive adaptive responses and the risk of disease 
in later life.  The organism responds to an environmental cue (e.g. poor nutrition) during the 
plastic stage of development by predicting the future environment and altering its developmental 
trajectory to enable improved fitness in the predicted environment (i.e. poor nutrition).  When the 
future environment matches that which it predicted, it has maximal fitness and chance of survival 
and the PAR is said to be appropriate.  If the predicted environment does not match that predicted 
(i.e. high calorie diet), the developmental path undertaken leads the organism to reduced fitness and 
an increased risk of disease and the PAR is said to be inappropriate 
35. 
 
 
1.2.4  Animal models of programming 
 
Studying the molecular mechanisms underlying developmental programming in humans is limited 
due to obvious ethical considerations as well as social and environmental variations.  For these 
reasons, animal models of programming have been developed using animals such as mice and rats.  
These models enable subjects to be carefully chosen, environments controlled and diets 
manipulated, whilst tissues and measurements can be collected throughout gestation and beyond. 
As mechanisms which alter fetal growth play a main role in developmental programming, such as 
maternal nutrition or stress, these have therefore provided the main cue for inducing alternative 
phenotypes in these animals.  Applying these nutritional and endocrine insults during early 
development to rodents results in offspring with similar phenotypes to that identified in humans, 
such as; reduced birth weight, increased blood pressure, obesity and impaired glucose tolerance 
13 (figure 1.2).  These animal models have produced a wealth of data and have been invaluable in 
understanding the underlying mechanisms linking maternal nutrition to risk of obesity and 
metabolic disease in later life in the offspring.   
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Figure 1.2  The relationship of an altered fetal environment with adult disease.  Adapted 
from 
13.  Altered maternal nutrition is reflected in the fetal nutrition.  This can induce altered 
epigenetic regulation of genes which therefore affects gene transcription.   The effects of altered 
gene transcription will depend on the genes affected, but may include, for example, increased 
expression of genes of gluconeogenesis.  This can contribute to the development of diabetes, which 
is a risk factor for CHD. 
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1.2.5  Nutritional models of programming 
 
Many different nutritional models of programming have been developed and these can differ in 
both the content and timing of the altered diet.  A variety of different diet options are employed, 
some of which vary in the overall level of energy, such as undernutrition and overnutrition and 
some of which differ in the ratio of specific nutrients, such as a low protein or high fat.   
Furthermore, different postnatal diets, in particular high fat, are often employed to determine the 
effects of catch up growth at different stages of postnatal development.  Diets can also be 
supplemented with additional nutrients, to determine the effects on disease risk in an attempt to 
prevent or even reverse the effects of altered nutrition during development.  In addition, studies can 
also differ according to the timing of nutrient manipulation, which enables the effects on differing 
developing organs and metabolic or neuroendocrine systems to be determined.  Two contrasting 
models of programming include a model of global undernutrition and a well characterised maternal 
low protein diet (MLP), which program offspring with phenotypes displaying some similarities, but 
also some differences.  Furthermore, models of maternal overnutrition are now being investigated. 
 
 
1.2.5.1  Maternal global undernutrition 
 
A rat model employing a maternal global undernutrition (30% of ad libitum) throughout gestation 
was developed 
8 to produce offspring with a phenotype consistent with the metabolic disturbances 
of human intrauterine growth retardation (IUGR) 
6,25,26,36.  The resulting IUGR offspring were 
significantly smaller at birth compared to control offspring and adult offspring from dams fed this 
diet exhibited hyperinsulinemia, hyperleptinemia and increased systolic blood pressure compared 
to control offspring.  Offspring had significantly reduced locomotor behaviour 
37, were hyperphagic 
and consequently developed obesity 
8.  Furthermore, all these metabolic abnormalities were 
augmented by feeding a post weaning hypercaloric diet (30% fat), which supports human 
epidemiological data 
27,28 and indicates the importance of the postnatal environment in exacerbating 
disease risk.  The combination of obesity, hyperphagia and hyperleptinemia indicated that the 
offspring were leptin resistant, as normally leptin functions to decrease appetite, whilst the 
hyperinsulinemia indicated insulin resistance 
8.  It was hypothesised that the increased insulin and 
leptin concentrations mediated all the disturbances identified in these rats.  Currently, the 
mechanisms which underlie the alterations to development in these rats have not been determined, 
for example, no work has been undertaken to identify alterations in the expression of key genes 
involved in energy balance in metabolic organs, such as adipose or liver tissue. 
 
Similar models of global undernutrition have been utilised, which differ in both the severity and 
duration of maternal undernutrition; for example, in a model of 50% ad libitum maternal 
undernutrition during the first 2 weeks of gestation, adult female offspring exhibited marked   10
adiposity at postnatal day (PND) 53 despite similar food intake to controls 
38.  A mouse model 
employing a maternal diet 70% ad libitum from 18.5 post conception (p.c.) to delivery, produced 
offspring that were born small but exhibited rapid catch up growth by PND 10, developed 
increased adiposity, increased leptin concentrations, impaired glucose metabolism and abnormal 
lipid profiles compared to controls.  These offspring had increased weight gain on a high fat diet 
compared to controls despite a similar energy intake and therefore did not exhibit hyperphagia 
39.  
Thus variations on the extent of global undernutrition all seem to induce a similar phenotype prone 
to obesity and its metabolic disturbances, although some differences in phenotype are apparent.  All 
these features indicate that offspring from these rodent models of global undernutrition have 
adapted their metabolism to allow for a poor postnatal supply of nutrients by increasing their long 
term storage of energy and are thus predisposed to obesity upon a nutrient rich or even standard 
postnatal diet.   
 
 
1.2.5.2  Maternal low protein diet 
 
The maternal low protein (MLP) diet, in which there is a disproportionately low amount of protein 
compared to carbohydrate, results in offspring with low birth weight presenting with metabolic 
disorders in later life including dyslipidemia, impaired glucose homeostasis, insulin resistance, 
diabetes and hypertension 
40,41.  Abnormalities found in the adult offspring of dams fed a MLP diet 
include increased corticosteroid activity 
40 and altered hepatic glucose output 
42.  Studies have 
uncovered that the increased corticosteroid activity may induce the altered hepatic output in these 
offspring due to increased activity of the rate limiting enzyme of gluconeogenesis 
phosphoenolpyruvate carboxykinase (PEPCK) and reduced activity of glucokinase (GK), a key 
enzyme of glycolysis, in the liver of adult offspring 
43,44.  The MLP diet also results in reduced islet 
size and beta-cell proliferation in the pancreas of offspring 
45 and an impaired insulin response to 
glucose when fed a high sugar diet, which predisposes to later glucose intolerance 
46.  In agreement 
with human studies, obesity is heightened in programmed offspring who experience catch up 
growth 
7.  Furthermore, it has been shown that restricting nutrition between conception and 
implantation followed by a control diet can induce a programmed phenotype characterised by 
smaller size at birth and hypertension in adult offspring, thus emphasising the sensitivity of the 
periconceptual period 
47.  This confirms that the timing effects of nutrient restriction are important 
in determining later risk of disease 
7 and confirms findings in Dutch Hunger Winter studies 
17.  
However, the phenotype of MLP offspring can vary according to the exact composition of the diet 
48,49.  For example, the Southampton model produces offspring which develop hypertension that 
persists into adulthood 
48, whilst the Hope farm MLP model does not 
49.  This indicates that even 
small changes in similar diets can induce different programming effects and underlines the 
importance of the balance of nutrients on risk of adult disease 
50, which is in agreement with data 
from the Dutch Hunger Winter 
21.    11
  Much work has been undertaken in MLP offspring investigating the mechanisms underlying 
altered lipid and carbohydrate metabolism and the programming of hypertension.  Much of this 
work has involved looking at gene transcription, as persistent alterations in the expression of genes 
can provide a link between the environment, alterations in metabolic systems and the adult 
phenotype 
51.  As such, the MLP model has been extensively investigated for alterations in the 
transcription of genes in the liver, which could be playing a causative role in the altered metabolic 
systems.  This has generally involved a candidate gene approach, in which specific genes are 
targeted, such as transcription factors and their target genes involved in lipid metabolism and 
glucose metabolism.  As such, much work has focused on the glucocorticoid receptor (GR), 
peroxisome proliferator activated receptors (PPARs) and their target genes.  The role of PPARs in 
programming of lipid metabolism will be discussed later in this report.  
 
The evident role of glucocorticoids in programming both glucose intolerance and hypertension has 
instigated interest in determining expression levels of the glucocorticoid receptor (GR) in 
programmed offspring.  Glucocorticoids mediate their action through expression of the GR and 
glucocorticoid activity is determined by the level of GR expression.  Activated GR translocates to 
the nucleus to control expression of a wide variety of genes involved in glucose metabolism 
52, 
such as PEPCK, GK (involved in glycolysis) and Na/K-ATPase α1- and β1- subunits (involved in 
sodium reabsorption in the kidney) 
52.   In MLP offspring, expression of GR mRNA and protein 
levels were found to be twice that of controls in the brain, lung, liver and kidney in fetal and 
neonate tissue and this increased to 3 times that of controls in adult life.  Also increased was 
expression of Na/K-adenosine triphosphate α1- and β1-subunit mRNA.  In addition to this, GR 
expression was reduced in the hypothalamus, thus reducing negative feedback to the hypothalamic-
pituitary-adrenal (HPA) axis.  As such, alterations in GR expression may result in increased 
sensitivity to glucocorticoids and consequently increase the expression and activity of 
glucocorticoid sensitive enzymes in protein restricted offspring 
53. 
 
Another factor which controls glucocorticoid activity is the expression of the enzyme 11β 
hydroxysteroid dehydrogenase type 2 (11βHDS2).  This converts cortisol (corticosterone in the rat) 
into its inactive form, cortisone (11-dehydrocorticosterone in the rat) in aldosterone target tissues 
and prevents glucocorticoids activating the mineralocorticoid receptor in such tissues 
54.  11βHSD 
is found in fetal tissues such as lung, adrenal, colon, kidney and is expressed in high levels in the 
placenta 
54.  It plays a crucial role by limiting the amount of maternal glucocorticoids exposed to 
the fetus in the placenta 
55.  In the MLP model, 11βHSD2 expression 
52 and activity 
41 have been 
shown to be down-regulated by gestation d20 in the placenta.  This reduction in 11βHSD2 activity 
is thought to play a major role in the reduced growth, hypertension and glucose intolerance found 
in this model of programming, by permitting maternal glucocorticoids to cross the placenta.  The 
changes in 11βHSD2 and GR expression may therefore both contribute to increased glucocorticoid 
activity in specific tissues seen in programmed adult offspring 
52.     12
Work is also focusing on global changes in gene transcription, with gene expression arrays 
increasingly being employed to determine the global expression patterns within tissues.  This 
method enables the identification of specific sets of genes or pathways which have been altered by 
maternal or postnatal diet.  For example, in MLP offspring, an expression array of genes in the 
placenta identified both upregulated genes, such as negative regulators of cell growth and 
metabolism and those involved in epigenetic modifications, whilst it also identified genes which 
were downregulated, including genes of nucleotide metabolism.  This implicates both reduced 
growth and epigenetic alterations the placenta of PR offspring 
56. 
 
Most work in MLP offspring on energy metabolism has centred on the liver and little on adipose 
tissue despite the wealth of data implicating an increased risk of obesity and altered lipid profiles 
32,57.  However, one study 
58 has used an expression array to determine alterations in gene 
expression in adipose tissue in offspring of rats fed a protein restricted diet throughout pregnancy 
and lactation.  These offspring develop increased visceral adiposity in adult life, are insulin 
resistant, diabetic and are hypertensive in adult life compared to controls.  The array identified that 
the maternal diet altered gene expression of several genes associated with carbohydrate 
metabolism, adipocyte differentiation and lipid metabolism, such as upregulated genes of 
lipogenesis (fatty acid synthase (FAS) and stearoyl-CoA desaturase) and adipocyte differentiation 
(CCAAT-enhancer-binding protein β) 
58.  Contrastingly, another study has failed to identify any 
changes in the ability of preadipocytes isolated from MLP rats to store fat or divide 
59.  This is, 
however, in agreement with data from the Dutch Hunger Winter study 
6,17, which implies that 
changes seen in fat storage are not due to a programming effect on the adipocytes directly, but due 
to neuroendocrine changes 
59. 
 
 
1.2.5.3  Maternal and postnatal high fat diet 
 
Human epidemiological studies indicate that maternal obesity can induce an increased risk of 
chronic disease in offspring.  As such, animal models have been developed employing maternal 
overfeeding or obesity to induce an altered phenotype in the offspring.  The findings in these 
animal models support human data, for example, offspring from mice fed a high fat before and 
during pregnancy and lactation, which are fed a high fat diet from weaning, have an increased risk 
of non alcoholic fatty liver disease and obesity 
31.  At 7 weeks, offspring were heavier than controls 
despite similar calorie intake, whilst at 15 weeks abdominal fat mass was increased compared to 
control groups.  Furthermore, offspring from dams fed a HF diet, which were fed a HF postnatal 
diet or chow diet had increased expression of genes of fatty acid synthesis, such as sterol regulatory 
element binding transcription factor 1c (SREBP1c), Fas and ATP citrate lyase (Acl).  They also 
had increased expression of genes involved in TAG synthesis, such as diacylglycerol O-
acyltransferase (Dgat1).  The effects on gene expression were exacerbated by the high fat diet.    13
Given that these genes were also affected in the chow offspring, it follows that these gene 
expression profiles were set up prior to the commencement of the postnatal diet, therefore 
indicating a persistent effect on gene expression.  This study indicates that high fat nutrition during 
development and postweaning life exacerbates the effects of developmental HF feeding alone and 
thus contradicts the PAR hypothesis 
31.  In another study, mice fed an obesegenic diet before 
conception and during pregnancy and lactation, resulted in adult offspring which were hyperphagic, 
had decreased locomotor activity, increased adiposity, hypertension and diabetes indicates altered 
metabolic and cardiovascular function 
60.  Therefore, both an excess and lack of nutrients during 
the early stages of development result in adaptations which result in a similar phenotype, which 
favours obesity. 
 
 
1.2.6  Programming by excess glucocorticoid exposure 
 
IUGR infants have been shown to have elevated placental cortisol levels 
61 and glucocorticoids 
have been shown to have important roles in regulating fetal growth, promoting gluconeogenesis 
and increasing blood pressure 
52, all of which are altered in programmed humans and rats. 
Normally, exposure to glucocorticoids occurs during late gestation 
53.  It has been shown that 
administration of excess glucocorticoids using dexamethasone (dex) during late gestation, results in 
a similar adult phenotype to the nutrition models i.e. reduced size at birth, hyperglycaemia and 
hyperinsulinemia offspring 
62.  This indicates that programming by undernutrition and 
glucocorticoid exposure may involve similar mechanisms, mediated in part by glucocorticoids. 
 
In agreement with the MLP model, the offspring of rats administered dex during last week of 
pregnancy, have increased expression of GR and PEPCK mRNA and activity of PEPCK in the 
liver, thus leading to glucose intolerance 
62.  These alterations in gene expression are not seen if the 
dex administration was during the first stages of gestation 
62, in keeping with observations from the 
Dutch Hunger Winter of impaired glucose tolerance in individuals exposed to the famine during 
late gestation 
20.  These data could imply that exposure to glucocorticoids, be it due to maternal 
undernutrition/stress or glucocorticoid administration in utero, are responsible for impaired glucose 
tolerance in later life and that this is mediated by increased GR expression and reductions in 
11βHSD2 expression in the placenta 
52.  This in turn results in over expression of target genes, 
including PEPCK 
62, which may contribute to altered glucose metabolism.   
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1.3 PPARα, leptin and their role in developmental programming 
 
Evidence from human studies and animal models has clearly indicated that programmed offspring 
have an increased risk of developing dyslipidemia and obesity in adult life.  Two factors which 
play key roles in the regulation of energy balance are that of the nuclear hormone receptor PPARα 
and the adipokine leptin.  Evidence is emerging identifying alterations in PPARα and leptin 
regulation during development, which may account for some of the mechanisms underlying adult 
disease in programmed offspring, whilst leptin may also be employed as a potential mechanism for 
reversing disease.  Given the emphasis on PPARα and leptin in this report as a whole, the following 
sections will discuss their regulation, function and signalling.  Furthermore evidence of their role in 
development and their alteration in programmed offspring will be discussed. 
 
 
1.4  Peroxisome proliferator activated receptor alpha 
 
1.4.1  Nutritional programming and peroxisome proliferator activated receptors 
 
The finding that developmental programming can result in dyslipidemia in both humans 
18 and 
animal models 
57, implies that regulatory factors and/or key genes involved in lipid metabolism 
may be altered by environmental constraints during development, resulting in an altered 
metabolism and an inability to maintain lipid homeostasis in later life.  As a result of this, interest 
has developed in the potential role of peroxisome proliferator activated receptors (PPARs), a family 
of nuclear hormone receptors which control the expression of a variety of key genes involved in 
lipid metabolism, including those involved with transport, cellular uptake, catabolism and storage 
of fatty acids.  They include PPARα, PPARγ2 and PPARβ.     
 
 
1.4.2 PPAR  functions 
 
Knock out mice which lack functional PPARα protein were initially developed to study PPARα 
function.  These mice were found to be viable, of healthy appearance and fertile, thus arguing 
strongly against a role for PPARα in development 
63.  However, it was found that they were unable 
to respond to peroxisome proliferators, failed to induce several key enzymes of β-oxidation and 
subsequently accumulate lipid in the liver, thus implicating PPARα as a key mediator of lipid 
metabolism 
63.  Consequently, these mice have helped to confirm the role of PPARα in controlling 
the transcriptional regulation of many genes involved in lipid homeostasis, specifically genes 
involved in mitochondrial β-oxidation, peroxisomal β-oxidation, uptake of fatty acids and 
lipoprotein metabolism 
64-66.  Furthermore, the role of PPARα in inflammation has been discovered 
using these animal models 
67.  Contrastingly, PPARγ knock out mice die at E10, as it interferes   15
with the development of the trophoblast, indicating a crucial role for PPARγ in development 
68.  
However, adipose specific disruption of PPARγ results in mice with reduced white adipose tissue 
(WAT) mass due to the presence of hypertrophic adipocytes in reduced numbers.  These mice also 
have reduced plasma leptin, increased plasma free fatty acids and triglycerides, have a fatty liver 
and are insulin resistant 
69. 
 
It has since been established that PPARα and PPARγ have key roles in directing either the 
oxidation or storage of fatty acids to maintain plasma lipid profiles.  PPARα functions to promote 
fatty acid uptake and β-oxidation in liver 
70, by regulating the expression of key rate limiting 
enzymes of fatty acid oxidation, including acyl-coA oxidase (AOX) 
71, which catalyses the rate 
limiting step of peroxisomal β-oxidation and carnitine palmitoyl transferase-1 (CPT-1) 
72, an 
enzyme which controls the transport of fatty acids into mitochondria for oxidation.  PPARγ on the 
other hand promotes adipocyte differentiation, the uptake of fatty acids and their storage in adipose 
tissue 
73.  PPARγ achieves this by up regulating the expression of genes such as lipoprotein lipase 
(LPL), which hydrolyses lipids in lipoproteins to release fatty acids for uptake 
74, PEPCK, which is 
involved in glycerolneogenesis and stearoyl-CoA desaturase-1 (SCD-1), which catalyzes the rate-
limiting step in the synthesis of monounsaturated fatty acids.  Interestingly, PPARγ has been shown 
to mediate the actions of the insulin sensitizing thiazolidinediones (TZD’s).  These actions include 
increasing the lipid storing potential of adipocytes to protect against lipotoxicity of liver and 
muscle, increasing the expression of insulin sensitising adipokines such as adiponectin and 
inhibiting the expression of insulin desensitizing adipokines such as TNFα 
75.  Less is known about 
the functions of PPARβ, however it appears to have roles in fatty acid catabolism, adaptive 
thermogenesis and embryo implantation 
76. 
 
 
1.4.3  PPAR expression in programmed offspring 
 
Interestingly, a study has revealed that the expression of two of these PPARs is altered in the liver 
and adipose tissue of offspring from dams fed a low protein diet throughout gestation 
57.  PPARα 
expression was found to be up regulated by 69% in the liver, whereas PPARγ2 expression was 
shown to be 59% lower in the adipose tissue of these offspring and this was associated with 
increased plasma triacylglycerol (TAG) and nonesterified fatty acid (NEFA) concentrations 
57.  
Since this initial study, altered PPAR expression has been repeatedly found in similar models of 
programming 
77-79.  Thus, given the functions of these proteins, reduced PPARγ expression implies 
reduced fatty acid uptake and TAG synthesis for storage within adipocytes, whilst increased 
hepatic PPARα expression would lead to increased fatty acid uptake and β-oxidation in the liver.  
This implies a causative role for both PPARα and PPARγ in the dyslipidemia found in these 
programmed offspring.   
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1.4.4  PPAR expression during development and in the adult 
 
The 3 PPAR isotypes possess distinct expression patterns during development and in the adult, 
which is consistent with their physiological function 
80,81.  In the rat expression of PPARα is 
detected late in development around day E13.5 in all the tissues in which it will be expressed in 
adult life. In the adult, expression of PPARα is consistent with tissues required for fatty acid 
oxidation i.e. the liver, heart, kidney, intestine and skeletal muscle 
80.  Similar expression profiles 
are found for PPARα in developing and adult mice 
82, whilst in humans, PPARα is predominantly 
expressed in the liver kidney, heart, skeletal muscle and large intestine 
83.  Expression of PPARγ in 
the developing embryo can be detected in brown adipose tissue from E18.5 when tissues are 
beginning to form.  In agreement with its role in lipid storage, PPARγ expression in adult rodents is 
predominantly in adipose tissue, however it is also found in brown adipose tissue, the intestine, 
liver and lymphoid tissues 
80.  In humans, PPARγ expression is found in adipose tissue, liver and 
heart 
84.  PPARβ is expressed from an early stage in the developing embryo with expression as 
early as E8.5 peaking at E13.5 then decreasing to adult levels 
81.  In contrast to PPARα and PPARγ, 
the expression of PPARβ is ubiquitous, with transcripts present in most tissues in the adult, often at 
high levels with particular abundance in the NS 
80.  In humans, PPARβ also has a ubiquitous 
expression, with high expression in the placenta 
85.   
 
The expression of PPARs is therefore initiated at a time of intense tissue differentiation in the 
developing embryo, making each isoform susceptible to the effects of maternal undernutrition 
during pregnancy.  It is therefore possible that maternal undernutrition could somehow cause a 
reprogramming of PPAR regulation, which impacts on their control of lipid homeostasis in 
postnatal life leading to dyslipidemia. 
 
 
1.4.5  Regulation of PPAR expression  
 
To understand how PPARs may be involved in the mechanisms underlying programming it is 
important to understand the factors dictating their regulation.  Given the emphasis on PPARα in 
this report, a detailed focus is therefore directed predominantly to this specific isoform. 
 
One mechanism which could account for the increased expression of PPARα in programmed 
offspring, is an increase upstream signaling mechanisms.  Several diverse factors have been found 
to alter the expression of PPARα, including; positive regulation by glucocorticoids, peroxisome 
proliferators, fatty acids and other nuclear hormone receptors and negative regulation by insulin, 
growth hormone and the cytokine interleukin 6 (IL6).  In addition, PPARα has also been shown to 
positively regulate its own expression.  Interestingly, several of these factors have been found to be 
altered by maternal undernutrition and thus provide a plausible mechanism for altered PPARα   17
expression in these offspring.  However, in most cases, the exact mechanisms underlying the 
regulation of the PPARα promoter have not been studied. 
 
The effects of glucocorticoids on PPARα expression are well documented.  In primary rat 
hepatocytes, mRNA levels of PPARα are increased by both natural and synthetic glucocorticoids 
and this increase is prevented upon use of a glucocorticoid antagonist 
86.  In conjunction with the 
finding that the mineralocorticoid aldosterone has no effect on PPARα expression, this implies that 
the effects of glucocorticoids on PPARα expression are mediated specifically by GR, not the 
mineralocorticoid receptor.  Furthermore, the use of the protein synthesis inhibitor cyclohexamide 
and an inhibitor of RNA synthesis actinomycin D, indicate that the effects on PPARα mRNA levels 
are at the transcriptional level of control, using pre-existing GR protein 
86.  The stimulatory effect 
of the synthetic glucocorticoid dex on PPARα expression has also been confirmed in vivo in male 
rats 
87.  Furthermore, dex induction of PPARα is inhibited if insulin is added at the same time and 
conversely increased if fatty acids are added to the dex 
87.  Another group has shown that hepatic 
PPARα expression is rapidly increased in the rat after immobolisation stress.  It was demonstrated 
that glucocorticiods mediated this response as specific antagonists inhibited their action 
88.   
 
All these results clearly indicate that glucocorticoids play a key role in the regulation of PPARα 
expression in rodents, although the exact mechanisms are unknown.  Given that both 
glucocorticoids 
40 and hepatic GR 
77 are increased in programmed rodents, they therefore provide a 
mechanism which could account for the induction of hepatic PPARα expression and thus a means 
of linking glucocorticoids with altered lipid metabolism in protein restricted offspring.   In addition, 
reduced actions of insulin in the programmed offspring as a result of insulin resistance could also 
contribute to the increased levels of PPARα mRNA.  
 
PPARα has been found to exhibit diurnal rhythmic expression.  It was originally proposed that 
glucocorticoids mediated this effect, as PPARα mRNA levels follow normal diurnal variations in 
corticosterone at both the mRNA and protein level 
88.  However, the use of adrenalectomised mice 
has shown that this circadian rhythm of PPARα is not due to glucocorticoids, but instead mediated 
by CLOCK, as the circadian rhythm of PPARα expression in the liver was absent in CLOCK 
mutant mice.  This was further verified by showing direct activation of PPARα by CLOCK via an 
EBOX located within the second intron of the PPARα gene 
89.  
 
It is well established that PPARα expression is induced by its own ligands, i.e. fatty acids and 
peroxisome proliferators.  For example, treatment of rats with the strong peroxisome proliferator 
fenofibrate results in increased PPARα at both the mRNA and protein levels 
90.  Using a rat 
hepatoma cell line, it was shown that oleic acid and the peroxisome proliferators perfluorodecanoid 
acid (PFDA) and Wy14,643 all cause a rapid increase in PPARα mRNA.  Treating cells with 
actinomycin D before Wy14,653 prevented the induction of PPARα, indicating that effects were at   18
the transcriptional level 
91.  Furthermore, the use of cyclohexamide did not prevent upregulation by 
Wy14,643, indicating therefore that the upregulation was independent of protein synthesis and thus 
PPARα mediated.  Consequently, this is thought to be a form of positive autoregulation of 
transcription by PPARα.  This is a common feature of nuclear hormone receptors and has been 
shown for the androgen receptor 
92, thyroid receptor β1 and retinoic acid receptor β2 
93. 
 
Interestingly, it has been shown that hPPARα can regulate its own expression through an 
alternative nuclear hormone response element, namely the hepatocyte nuclear factor-4 response 
element (HNF-4) instead of via a PPRE 
94.  In addition to positive autoregulation, PPARα 
expression can also be regulated by other nuclear hormone receptors, including negative regulation 
by chicken ovalbumin upstream promoter-transcription factor II (coup TFII) 
94 and positive 
regulation by a key mediator of lipid metabolism, HNF-4, via a HNF-4RE within the human 
PPARα promoter 
94.  This effect has been confirmed using an HNF-4 overexpression microarray 
95 
and an HNF-4 knock out mouse model 
96.     
 
Under normal conditions, PPARα maintains lipid homeostasis by controlling fatty acid uptake and 
peroxisomal β-oxidation in tissues such as the liver.  As glucocorticoids and fatty acids play key 
roles in regulating the expression and activation of PPARα, it stands to reason that the expression 
of PPARα is altered under conditions of stress and altered nutrition, such as found in programmed 
offspring, fasting or consuming a high fat diet.  Thus, under conditions of stress, the hypothalamic-
pituitary-adrenal axis (HPA axis) is activated, resulting in the release of glucocorticoids from the 
adrenal cortex, which functions to mobilize energy.  In addition, activation of the sympathetic 
nervous system results in the release of catecholamines which stimulate fatty acid mobilization 
from adipose tissue 
88.  The increased glucocorticoid thus induces PPARα in the liver to increase 
expression of enzymes involved in fatty acid β-oxidation.  Consequently, it has been shown in the 
fasting state that PPARα is needed in order to provide energy from released fatty acids from 
adipose tissue, as PPARα null mice which have been fasted for 24hr exhibit lipid accumulation in 
the liver due impaired β-oxidation of fatty acids 
97.  Likewise PPARα knockout mice fed a high fat 
diet exhibit a similar phenotype 
97.   
 
In contrast to dex, fatty acids and CLOCK, which all act in a positive manner on PPARα 
expression, growth hormone (GH) exposure has been shown to cause a 50% reduction in PPARα 
basal levels in primary rat hepatocytes 
98.  Furthermore, regulation of PPARα in inflammation by 
C/EBP has been shown to be involved in the transcriptional repression of human PPARα by the 
cytokine Il-6 in HepG2 cells as part of its role in mediating the acute phase response 
99. 
 
Given the role of PPARγ in adipose differentiation and fatty acid storage, it is unsurprising that like 
PPARα, the expression of PPARγ is controlled by both hormonal and nutritional status.  As such, it 
is up regulated in the presence of a high fat diet 
100, obesity, insulin and glucocorticoids 
101 and   19
reduced upon fasting and insulin resistance.  Thus both PPARα and PPARγ are; controlled by 
insulin and glucocorticoids, are sensitive to alterations in environmental stimuli, such as 
availability of food and stress and all these have all been shown to be affected in offspring 
programmed by maternal nutrition.   
 
 
1.4.6  The structure and activation of PPARs 
 
In order for PPARs to regulate the transcription of downstream target genes, they must first be 
activated.  Activation of PPAR and target genes is mediated by specific structural domains, which 
share a similar structure to that of other members of this nuclear hormone receptor superfamily.  
PPARs are composed of 3 domains derived from 6 translated exons; 1 exon encodes an NH3-
terminal A/B domain, 2 exons encode a highly conserved DNA binding domain (DBD), one 
encodes a hinge region and finally two exons encode the ligand binding domain (LBD) 
102,103.   
 
The NH terminal domain possesses little sequence identity between the PPAR isotypes and is 
considered to be the domain responsible for the various PPAR functions.  This domain can function 
as a ligand independent activation domain and can be subjected to post translational modifications 
which alter PPAR activity, such as phosphorylation 
104.   
 
In keeping with their central role in lipid metabolism, PPARs act as lipid sensors activated by the 
very molecules whose fate they control.  The natural ligands of PPARs are therefore fatty acids and 
their derivatives, which activate PPARs via the LBD.  The LBD is not as conserved as the DBD 
between isotypes, so whilst some ligands are able to activate all 3 PPAR isoforms to varying 
degrees, many are isotype specific.  Medium and long chain unsaturated fatty acids such as such as 
arachidonic acid (C20:4) and linoleic acid (C18:2) can activate all 3 PPAR isoforms, whereas 
saturated fatty acids such as lauric acid (C12:0) are poor activators of PPAR generally 
105.  
Derivatives of fatty acids which can activate PPARs include eicosanoids (derived from arachidonic 
acid) which can form both prostaglandins and leukotreines.  These can be specific to particular 
isotypes of PPAR, for example the prostaglandin15-Deoxy-Δ12,14-PGJ2 is specific to PPARγ and 
Leukotriene B4 (LTB4), which is involved in inflammation is a specific ligand for PPARα 
106.  
Synthetic PPAR ligands have also been identified and for PPARα these were identified as 
chemicals which cause peroxisome proliferation in the rat liver 
107.  This process results in 
increased peroxisome size and number, induction of peroxisomal and non peroxisomal enzymes 
and consequently increased peroxisomal β oxidation.  Such chemicals include fibrates 
(hypolipidemic drugs), herbicides and phthalate plasticizers.  For PPARα, activators include the 
hypolipidemic agents fenofibrate 
90, clofibric acid (CFA) and Wy-14643 
105.  Synthetic activators 
of PPARγ include the hypoglycaemic agents thiazolidinediones (TZD), which include the 
antidiabetic drugs rosiglitazone and troglitazone.     20
The PPAR DBD is highly conserved in PPARs.  It is composed of 2 zinc fingers, each encoded by 
one exon.  These zinc fingers recognise and bind to a specific hexanucleotide sequence (AGGTCA) 
in target gene promoters.  However, as with other nuclear receptors, binding to the specific DNA 
response element requires binding as dimers and in the case of PPAR, binding is as a heterodimer 
with the 9-cis-retinoic acid receptor (RXR) 
108.  Consequently, PPAR:RXR  has been shown to bind 
a DR1 element 
109, which is composed of  ‘a direct repeat of 2 core recognition motifs AGGTCA 
spaced by 1 nucleotide’ 
108.  However, other steroid receptors including thyroid hormone receptor 
(TR), all-trans-retinoic acid receptor (RAR) and vitamin D receptor (VDR) are able to 
heterodimerise with RXR and bind to DR1 elements and thus may compete with PPARs.   
However, the peroxisome proliferator response element (PPRE) definition as a DR1 was further 
defined to have 3 main properties which discriminate it from other DR1 response elements; firstly 
an imperfect core DR1 sequence, adenylate as the spacer nucleotide and finally an extended 5’ half 
site (AACT).  In addition to this, it has been shown that PPAR binds the 5’ extended half site and 
hexamer, whilst RXR binds the 3’ hexamer.  It is these characteristics that permit selectivity for 
PPAR:RXR binding as opposed to other RXR heterodimers 
110.  Thus the consensus sequence of 
PPRE is 5’-AACTAGGNCAAAGGTCA-3’. 
 
As PPARs are often co-expressed in the same tissues 
80 and can be activated by the same ligands, 
other factors must determine isotype selectivity.  PPREs can be strong, intermediate or weak and it 
is the conformity of consensus and the 5’ extension which aids isotype selectivity by determining 
which PPAR can bind a given PPRE.  For example, an unconserved 5’ extension is unimportant for 
PPARγ binding and it can therefore bind strongly to weak PPREs.  On the other hand, PPARα 
binding requires a conserved 5’ extension, i.e. a strong PPRE.  A second level of isoform 
selectivity is determined by the RXR binding partner and PPAR’s can heterodimer with RXRα, 
RXRβ and RXRγ.  Weak PPREs to which PPARγ can preferentially bind, favour RXRα binding 
and strong PPREs to which PPARα can bind favour RXRγ binding.  Therefore, ability of a given 
PPAR isotype to bind a PPRE depends on both the DNA sequence of PPRE and the RXR isoform 
present in that cell type 
108.  However, generally the differing RXR isoforms are all expressed in the 
tissues in which PPARs are expressed 
80. 
 
In the inactive state, PPARα:RXR heterodimers are bound to co-repressors such as the nuclear co-
repressor (N-CoR).  Ligand binding induces a conformational change within the LBD which causes 
co-repressors to disassociate and allows PPARα to interact with co-activator proteins, such as 
steroid receptor co-activator-1 (SRC1), CREB binding protein (CBP)/p300 and PPAR Gamma co-
activator 1 (PGC-1) 
111.  These co-activator proteins are able to modify chromatin structure due to 
their intrinsic histone acetylation activity and thus direct transcription of target genes (figure 1.3).  
 
PPAR activation of target genes and thus impact on lipid metabolism may therefore be affected by 
several factors involved in the regulation and activation of PPARα, some of which have been found to be altered in animal models of programming; such as regulation of mRNA transcription by 
hormonal factors such as glucocorticoids and the availability of ligand by stress and diet.  In 
addition to this, the presence of accessory molecules (repressors and activators), RXR isoforms, of 
competitors for RXR binding and finally posttranslational modifications, such as phosphorylation 
may also influence PPARα activity.  It is possible that these factors may be altered in programmed 
offspring, but this is currently unknown.  However, as PPAR target genes have also been shown to 
be upregulated alongside increased PPARα in programmed offspring 
57, it is probable that the 
alterations to PPARα expression alone are responsible and not those affecting activity, such as 
availability of accessory proteins and binding partner.  The influence of epigenetic factors on 
transcription of PPARs is discussed later in this report.   
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Figure 1.3  Mechanisms of PPARα expression and activation.  1) Stress, for example due to 
maternal undernutrition, fasting or a high fat diet, brings about in an increase in plasma free fatty 
acids.  2) Stress results in increased glucocorticoid levels and consequently GR expression.   3) 
Several factors are known to upregulate (+) or downregulate (-) PPARα gene expression by 
interacting with as yet undetermined response elements within the promoter region, resulting in 
altered levels of PPARα protein within the nucleus.  4, 5) Fatty acids bind to the LBD to activate 
PPARα and induce a conformational change in LBD.  6) Accessory proteins bind which facilitate 
an active chromatin conformation.  7) Altered transcription of PPARα target genes, e.g. AOX.  8) 
The end result is altered lipid metabolism, e.g. an increased rate of fatty acid peroxisomal and 
mitochondrial β-oxidation. 
  21  22
1.5 Leptin   
 
1.5.1  Leptin function in bodyweight regulation 
 
Over the past 14 years, evidence has accumulated implicating a central role for the hormone leptin 
in the regulation of bodyweight and studies using both ob/ob and db/db mice have been central to 
understanding this role.  ob/ob mice have a complete lack of leptin, they are infertile, obese and 
present with hyperinsulinemia and hyperglycemia.  However, when these mice are administered 
leptin, glucose and insulin concentrations are normalised and they lose weight as a result of a 
reduction in food intake and increased energy expenditure 
112,113.  Similarly, the db/db mouse is 
obese and diabetic and in this model, mutations in the leptin receptor render it non-functional.  
Therefore an inability to propagate the leptin signal is responsible for the adverse phenotype in the 
db/db mouse 
114.  Thus it has emerged that leptin is an anti obesity hormone, which is involved in 
the regulation of bodyweight and energy expenditure 
112,113.   
 
Central and peripheral administration of leptin to both ob/ob and db/db/ mice have revealed that 
leptin exerts its effects on feeding and energy balance by acting through leptin receptor signalling 
on the hypothalamus 
115.  The hypothalamus acts as the feeding centre of the central nervous 
system, which receives signals from the periphery relating to the nutritional, energy and 
environmental status via satiety and adiposity signals.  Leptin is an adipokine produced mainly in 
adipose tissue 
116 and leptin concentrations correlate with adipose tissue mass; the more adipose 
tissue present, as occurs in obesity, the higher the circulating leptin levels 
117.  Therefore the 
circulating leptin acts as a peripheral sensor of fat mass and signals to the hypothalamus the 
nutritional status of the body.  Leptin prevents the excess storage of adipose tissue by acting on 
long form receptors within the arcuate nucleus of the hypothalamus (ARH) 
118,119.  These receptors 
act predominantly by a janus kinase / signal transducer and activator of transcription (Jak/Stat) 
pathway and alter activity within these neurons which relay the signal to reduce food intake and 
increase energy expenditure (figure 1.4) 
112.  However, leptin receptors (LR) are also found in 
peripheral tissues including adipose tissue and pancreatic β cells, indicating that they are also direct 
targets of leptin 
120,121.  In both humans and rodents, leptin levels are often elevated in obesity 
indicating they have become leptin resistant 
117,122.   This is thought to be due to either receptor or 
post receptor defects which prevent the transmission of the leptin signal, or the inability of leptin to 
be transported across the blood brain barrier.   Adipocyte
IR
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Figure 1.4  Central and peripheral actions of leptin on energy balance.  Leptin is able 
transverse the BBB via a transport mechanism using the short form of the leptin receptor.  Leptin 
induces a negative energy balance by acting on leptin receptors on two populations of neurones 
within the ARH 
123; the pro-opiomelanocortin (POMC) and cocaine and amphetamine-related 
transcript (CART) containing neurons and the neuropeptide Y (NPY) and agouti related protein 
(AgRp) containing neurons.  Leptin induces an increase in the expression of CART and POMC 
which inhibit appetite (anorexigenic) and decreases the expression of the appetite enhancing 
peptides NPY 
123 and AgRP (orexigenic) 
124.  Therefore in the absence of leptin, the appetite 
enhancing peptides dominate.  These first order neurons relay the leptin signal to second order 
neurons involved in bodyweight regulation, including the paraventricular nucleus (PVN), the 
lateral hypothalamic area (LHA) and the dorsomedial hypothalamic nucleus (DMH) 
124.  For 
example, alpha-melanocyte stimulating hormone (α-MSH) is a melanocortin derived from the 
cleavage of POMC, which activates MC3/4 receptors in PVN to relay its inhibitory effect on 
feeding by inducing thyrotropin releasing hormone (TRH) and corticotrophin releasing hormone 
(CRH) 
123.  AgRP blocks effect of αMSH on MC4 receptors resulting in increased feeding, 
therefore the balance of the two peptides determines the overall outcome.  NPY acts on Y1/5R in 
the second order neurons to exert its effects on appetite 
2.  NPY and AgRP suppress sympathetic 
output to decrease energy expenditure, whereas αMSH stimulate sympathetic output.  This is 
mediated by the effects of catecholamines on adrenergic receptors of peripheral cells.   24
1.5.2  Leptin, insulin and the adipoinsular axis  
 
Given their important roles in maintaining an energy balance, it is not surprising that a close 
relationship exists between leptin and insulin.  Adipocytes possess insulin receptors on their 
surface, whilst pancreatic β cells express the functional long form of the leptin receptor 
125.  A 
feedback loop exists between leptin produced by adipocytes and insulin produced by pancreatic 
islets and this interaction has been termed the adipoinsular axis (figure 1.4) 
120.  Within this 
feedback loop, leptin expression is induced by the action of insulin on adipocytes to increase fat 
mass as part of its anabolic role 
126,127 and increasing leptin levels in response to this signal 
suppresses insulin secretion from β cells in a form of negative feedback 
125,128.  In addition, leptin 
levels also follow that of insulin in response to food intake; fasting normally results in reduced 
leptin mRNA which permits feeding, whilst food intake increases leptin mRNA to inhibit feeding.  
Furthermore, fasting rats given an insulin injection have increased leptin mRNA, indicating that the 
increased leptin found after food intake is due to the action of insulin on adipocyte 
126.  Thus the 
adipoinsular axis is thought to maintain a set point for adipose stores, i.e. if adipose stores are low, 
reduced leptin facilitates increased insulin synthesis and secretion, whilst if adipose stores are high, 
the increased leptin synthesis exerts a negative feedback on insulin secretion.  Thus alterations in 
the levels either of these hormones as occurs in programmed offspring may influence the activity of 
the other.  For example, it has been proposed that the hyperinsulinemia identified in programmed 
offspring may be due to dysregulation of this adipoinsular axis as a result of leptin resistance 
120.   
 
 
1.5.3  Leptin in early development  
 
It is well known that IUGR induced by maternal undernutrition is associated with an increased risk 
of obesity in later life in both humans and rodents 
8,22,28,39.  As leptin plays a key role in the 
regulation of bodyweight, this could indicate altered leptin function in IUGR offspring.  In support 
of this hypothesis, expression profiles indicate that leptin is expressed throughout gestation and 
early postnatal life and in addition, evidence suggests that leptin plays an important role in early 
growth and development of both rodents and humans throughout this important time.  Furthermore, 
alterations in leptin levels have been identified in both human and rodent IUGR offspring.   
Interestingly, administration of leptin during specific phases of early development has been shown 
to have beneficial effects on the regulation of bodyweight in adult offspring.  Consequently, these 
studies all indicate that alterations in leptin levels during early development could therefore play a 
key role in the mechanisms underlying fetal programming of obesity and its associated metabolic 
disturbances.   
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1.5.3.1  Leptin concentrations in early development in humans  
 
The importance of leptin function during early development in humans can be inferred by its 
expression profile in both the placenta and fetal tissues.  In the human placenta, leptin enhancer 
elements specific to the placenta enhance the transcription of leptin 
129.  This source probably 
contributes greatly to fetal leptin levels during gestation, as the high leptin levels in the offspring 
drop after birth 
130.  Furthermore, placental leptin may contribute to maternal levels during 
gestation, as maternal fat mass does not correlate with leptin during pregnancy.  It is thought that 
this placental source of leptin may function to mobilise fat to sustain growth of the fetus 
131.  Serum 
leptin can be detected from 18 weeks gestation, a time which coincides with the start of adipose 
development 
132.  At 34 weeks gestation, leptin levels rise dramatically, a period of exponential 
adipose development 
132 after which levels drop around birth.  This large increase in maternal leptin 
alongside an increased requirement for nutrients indicates either maternal leptin resistance or an 
alternative and unknown role.  Leptin is also expressed in the mammary epithelium and therefore 
leptin is found in human breast milk 
133.  Furthermore it is found at levels associated with maternal 
plasma leptin levels and thus reflects maternal obesity 
134.  Interestingly, epidemiological studies 
indicate that breast feeding may be associated with a reduced risk of obesity in later life 
135 and this 
may be in part due to the presence of leptin in breast milk.   
 
Leptin levels in the cord blood of newborns correlate positively with birth weight 
136,137.  IUGR 
newborns therefore have significantly reduced serum leptin compared to normal and this correlates 
with fat mass 
132,138.  This indicates that fetal growth relates to circulating leptin levels 
137.  
However, other studies have shown that leptin levels are associated with reduced placental leptin, 
as leptin levels drop after birth 
130.  Interestingly, although leptin is reduced in IUGR offspring at 
birth, in later life these individuals develop hyperleptinemia compared to normal birth weight 
individuals of the same obesity 
139,  i.e. low birth weight individuals have higher leptin levels in 
adulthood than would be expected by their obesity, implying some leptin resistance or adipocyte 
dysfunction 
139. 
 
 
1.5.3.2  Leptin concentrations in early development in rodents 
 
Similarly to humans, both leptin and leptin receptor have been identified in murine fetal tissues and 
the placenta, indicating a key role for leptin in growth and development 
140.  For example, 
administration of leptin to pregnant rats in the second trimester of gestation results in reduced 
skeletal muscle growth and adipose tissue mass in adult offspring, which is unrelated to altered 
food intake 
141.  In addition, fetal pancreatic islet cells are stimulated to proliferate by leptin, 
indicating that islet cell mass may be partly determined by leptin at birth 
142.  Leptin is also present 
in the maternal milk, indicating that maternal milk is important for neonatal leptin concentrations   26
133.  Furthermore, the placenta may also have a role in leptin transport as it expresses a short 
isoform of the leptin receptor 
143.  Interestingly, expression of this leptin receptor is markedly 
upregulated in the 3
rd trimester of gestation in the rat and accordingly placental passage of leptin 
from the dam to the fetus increases ten fold during this time.  This is therefore a significant source 
of leptin for the fetus 
143.  Thus rodents experience a similar increase in leptin during the last stage 
of pregnancy as has been identified in humans.   
 
Interestingly, dex induced growth retardation in the rat prevents the increase in transplacental leptin 
passage 
143.  This indicates that programmed offspring which exhibit upregulated glucocorticoids 
40 
may be hypoleptinemic at birth due to reduced passage of leptin from the mother to the fetus.  In 
agreement with this, IUGR induced by maternal glucocorticoids in the 3
rd trimester has been found 
to cause fetal hypoleptinemia, although in this study, this was due to reduced placental expression 
of leptin.  Placental transport of leptin was not measured.  These offspring like human IUGR 
offspring, went on to develop hyperleptinemia, hyperinsulinemia and developed hypertension in 
later life 
144.  Hypoleptinemia in IUGR rodents agrees with findings in humans 
132.  It is possible 
that some of the metabolic and physiological disturbances which occur during fetal programming 
may be in part due to this hypoleptinemia 
122.  The leptin resistance that results from 
hypoleptinemia could be interpreted as an adaptive resistance programmed from the intrauterine 
environment to maximise catch up growth.  Leptin resistance in combination with an improved 
nutritional status would therefore play a causative role in the development of obesity, by altering 
the regulation of systems involved in growth and bodyweight regulation. 
 
Unsurprisingly, treating programmed offspring with leptin can have beneficial effects on adult 
phenotype.  For example, offspring from dams fed a maternal low protein diet have reduced 
placental 11βHSD2 activity 
41,52.  This reduction in 11βHSD2 activity is thought to play a major 
role in the reduced growth, hypertension and glucose intolerance found in this model of 
programming, by permitting maternal glucocorticoids to cross the placenta.  It has been shown that 
leptin treatment during the 3
rd trimester of gestation and lactation can prevent this down regulation 
of 11βHSD2 and suggests that leptin may reduce fetal exposure to corticosterone 
145.  These leptin 
treated offspring have a reduced susceptibility to weight gain and insulin resistance when fed a 
high fat postnatal diet 
145.   
 
Evidence has also shown that postnatal overnutrition alone can induce alterations in the regulation 
of bodyweight 
146.  As both the hypothalamus and adipose tissue are still plastic in the postnatal 
phase in rodents, it is possible that altered leptin signalling could affect the development of these 
organs during this time.  For example, postnatal overfeeding has been shown to induce disturbances 
to hypothalamic leptin signalling which persist into adult hood 
147.  Giving normal rat offspring five 
times the normal concentration of leptin found in breast milk throughout lactation (pnd1-20) altered 
leptin signalling in PND 84 adult offspring, which afforded some protection against weight gain   27
during adulthood.  Leptin treated offspring ate fewer calories, weighed less and had a lower fat 
content than controls, regardless of whether they were fed high fat or a normal fat postnatal diet.  
These leptin treated offspring fed a high fat diet had increased POMC signalling compared to 
control offspring fed a high fat diet.  Furthermore, leptin treatment in offspring fed a high fat diet 
prevented the reduction in hypothalamic OB-Rb found in control rats fed a high fat diet.  In 
addition, Socs-3 mRNA was reduced in all leptin treated offspring.  Both these features indicate an 
increase in leptin sensitivity in leptin treated offspring and indicates that the leptin treatment 
resulted in a PAR, which provided some protection to high fat induced leptin resistance in later life 
147.    
 
 
1.5.4  The neonatal leptin surge  
 
The extent of leptins role in the development of energy balance systems in rodents has been 
revealed following the discovery that there is a significant, but transient surge in plasma leptin 
during early postnatal development (PND 7-10), with levels reaching up to ten times that of normal 
148,149. This is a period of development in rodents where food intake is maximised for growth and 
development.  As such, studies indicate that during this period rodents exhibit increased feeding 
148 
and increase their bodyweight whilst maintaining a low fat mass 
148,149.  The presence of these 
features in combination with increased leptin concentrations is therefore contrary to its 
anorexigenic role and was originally thought to imply leptin resistance 
148.  However, emerging 
studies have revealed that unlike in adults, leptins role at this time is not in energy balance 
150.  For 
example, in adult rats, leptin challenge induces normal hypothalamic signalling, however leptin 
challenge between PND 7-21 fails to influence NPY POMC and AgRP and CART mRNA 
150.  In 
fact, leptin is unable to have an effect on energy balance until the 3
rd postnatal week, indicating that 
during this early postnatal period, leptin has a role which differs to that in adults 
150.  It is now 
known that this surge in leptin is in fact a developmental signal 
124. 
 
The source of the leptin surge is still controversial.  Two options have been proposed, both of 
which have supporting evidence; increased expression of leptin in adipose tissue or the maternal 
milk supply.  Several studies have found that adipose leptin mRNA increases up to ten times 
normal levels during the surge period 
148,149.  However, if adipose tissue is the source, it is unknown 
what induces this transient change.  It is known that insulin and glucocorticoids have a positive 
effect on leptin expression, but it is unlikely they are the source of the surge as insulin levels were 
unchanged during one study and adult corticosteroid levels were not yet in place 
149.   On the other 
hand, plasma leptin concentration in pups is greatly reduced when they are removed from their 
mothers for more than 24 hours 
151, however, in another study, depriving neonatal mice of food did 
not affect the leptin surge 
149. 
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1.5.5  The role of leptin in the formation of hypothalamic feeding circuits 
 
Further studies into the significance of the leptin surge have uncovered an exciting role for leptin.  
Rather than the hypothalamus being insensitive to leptin during the first two weeks of life as first 
thought, it appears that leptin has a neurotrophic role instead.  Experiments have shown that the 
period of the leptin surge coincides exactly with the formation of feeding/bodyweight circuits in the 
arcuate nucleus of the hypothalamus and that these centres remain immature in the absence of 
leptin 
124.  In ob/ob mice, ARH projections are permanently disrupted and have a reduced density 
of fibres innervating the PVH, DMH and LHA.  However, if these mice are given leptin treatment 
to replicate the normal surge, fibre innervation is permanently restored to normal levels.  Thus the 
neonatal leptin surge acts as a peripheral developmental signal’ 
124 for the formation of the 
hypothalamic feeding circuits which it goes on to regulate in adult life.  This concept of hormones 
acting as signals to direct hypothalamic development and activity is well established 
152.  
Interestingly, if leptin is given to given to adult ob/ob mice, projections remain disrupted, 
indicating that leptins neurotrophic role is restricted to a specific period in early postnatal life 
124.  
Therefore, the timing of formation of these circuits is restricted to a critical period which coincides 
with a surge in leptin concentrations 
124.  Furthermore, maturation of feeding circuits in the 3
rd 
week of life coincides with the ability of leptin to resume its normal role in the regulation of food 
intake and bodyweight 
153.   
 
 
1.5.6  Alterations to the leptin surge and hypothalamic circuitry in programmed offspring 
 
Given the inherent link between leptin and nutrition, it was hypothesised that maternal 
undernutrition and postnatal nutrition may affect the leptin surge.  As such, alterations in leptin 
levels during development would therefore have long lasting consequences on the formation of 
feeding circuits in the hypothalamus, which impact the regulation of energy balance in adults.  This 
would therefore implicate developmental leptin concentrations in the development of adult obesity.  
Several key studies have explored this hypothesis and identified alterations in the leptin surge in 
response programmed offspring 
39,151.  They have identified changes to the leptin surge and to 
specific hypothalamic wiring and gene expression as a result of maternal undernutrition, thus 
providing a link between maternal undernutrition, leptin and a propensity towards an obese 
phenotype in adulthood. 
 
In a mouse model of maternal undernutrition (50% ad libitum), a postnatal high fat diet induces 
marked weight gain in adult mice despite the same calorie intake as controls.  These mice exhibit 
hyperleptinemia, impaired glucose metabolism, hyperinsulinemia and dyslipidemia 
39.  It has been 
shown in these neonates that the leptin surge has premature onset and peak, which appears to stem 
from alterations in adipose leptin expression.  It was proposed that this increase in adipose leptin   29
was a result of the undernutrition induced hyperinsulinemia.  Interestingly, control mice given 
leptin administration to match the premature surge also exhibited marked increased weight gain 
from weaning when fed a high fat diet, despite a similar calorie intake to controls.  They also 
exhibited hyperleptinemia levels at 17 weeks age.   Therefore in this study, maternal undernutrition 
induced a premature leptin surge, which was coupled to the development of obesity and its 
associated metabolic disturbances upon feeding a high fat postnatal diet.  This study therefore 
indicates that the timing of the surge is critical for bodyweight regulation 
39.  
 
In a second study, it has been shown that maternal undernutrition during gestation and lactation 
(50% ad libitum) also affects the postnatal leptin surge in rats 
151.  In these offspring, growth is 
reduced in UN offspring until PND 30.  In contrast to the study in mice, the leptin surge in these 
offspring is not premature, but is instead severely blunted.  This reduced leptin surge is associated 
with a subsequent reduction in hypothalamic neuropeptide expression specific to POMC from PND 
14-30.  In addition, hypothalamic projections specific to POMC are affected from the ARC to PVN 
at PND 21.  Normal levels of leptin and POMC levels were resumed by PND 30 in all offspring.  
Despite these changes, offspring in this study do not become overweight on a chow diet, indicating 
that a combination of both maternal undernutrition and postnatal over nutrition may be required to 
induce an obese phenotype.  However, it may also be that these offspring at PND 30 are too young 
to exhibit the effects of maternal undernutrition.  Therefore, this study indicates that the strength of 
the leptin surge is affected by maternal undernutrition, which induces alterations in hypothalamic 
wiring 
151. 
 
These studies therefore indicate that both the timing and size of the leptin surge may be affected by 
maternal undernutrition, although it is not known if the different effects on the leptin surge are 
species or diet specific.  However, it could be implied from these data that the early leptin surge 
and blunted leptin surge seen in these studies result in inadequate leptin levels at a critical period of 
development.  Clearly in both models, early life nutrition affects the leptin surge and the formation 
or regulation of hypothalamic feeding circuits and thus impacts on the regulation of body weight in 
adult life.  It is not currently known if the leptin surge has affects on the peripheral organs involved 
in bodyweight regulation such as adipose tissue. 
 
The human brain in neonates is more mature than that of the neonate rodent.  Information on 
human brain development is limited, but work with non human primates has indicated that the 
development of hypothalamic feeding projections occurs in the last trimester of gestation 
154.  
Therefore the development of hypothalamic feeding circuits is likely to occur during the last 
trimester of gestation in humans as opposed to neonatal life.  As a consequence, development 
would be under direct control of the maternal environment.  This finding indicates that leptin levels 
at the end of gestation may play a role in circuit formation, rather than postnatal leptin 
concentrations 
153.  This is consistent with the finding that in humans, leptin concentration is   30
increased at the later stages of gestation and is reduced at birth, which could be equivalent to the 
rodent neonatal leptin surge 
132. 
 
 
1.5.7  Neonatal leptin treatment and the reversal of developmental programming  
 
One study has illustrated the importance of leptin in fetal programming using the previously 
described model of maternal undernutrition (30% ad libitum) 
8.  The aim of the study was to 
determine if neonatal leptin treatment could prevent the postnatal obesity and its associated 
metabolic disturbances found in programmed offspring fed a high fat postnatal diet.  These 
offspring were given neonatal leptin treatment during the proposed timing of leptin surge (d3-13) 
and its effects investigated in adult female offspring.  Results showed that the leptin administration 
normalised all the phenotypic and metabolic features of the programmed offspring, i.e. it abolished 
the hyperphagia, reduced fat mass and body weight, normalised insulin and leptin concentrations 
and normalised locomotor behaviour 
122.  The outcome of the study therefore indicates that the 
phenotype induced by programming may be “reversed” by leptin treatment given during the later 
stages of developmental plasticity.   
 
Previous studies have shown that maternal undernutrition induces alterations in the neonatal leptin 
surge 
39,151.  Unfortunately, in this study it is unknown if the neonatal leptin surge or hypothalamic 
wiring were altered in the programmed or leptin treated offspring.  It is, however possible that the 
undernutrition in these offspring induced neonatal hypoleptinemia.  If this were the case, the 
restoration of the leptin surge with neonatal leptin treatment would be interpreted as a high 
nutritional state, thus enabling the offspring to readjust from their earlier adverse developmental 
trajectory 
122.  In support of this data, it has been shown that giving leptin deficient mice neonatal 
leptin treatment induces a long term decrease in food consumption 
124.  Interestingly, not all leptin-
induced fat mass reduction is a result of reduced feeding; leptin-induced weight loss in ob/ob mice 
results in both reduced fat mass and feeding, but pair fed ob/ob mice do not lose as much weight.  
Therefore leptin treatment has effects on adipocyte mass other than by reducing feeding 
155, 
indicating that other systems may also be altered as a result of the neonatal leptin treatment in this 
study.  Furthermore, offspring subjected to maternal undernutrition in this study were cross 
fostered onto ad libitum fed dams.  This indicates that the maternal milk supply is not enough to 
prevent the development of obesity and its associated metabolic abnormalities and strengthens the 
argument that favours adipose leptin expression as the source of leptin surge. 
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1.6  Epigenetics and developmental programming 
 
Epigenetic modifications affect the control of gene expression by altering the structure of DNA 
without altering the genetic code.  They are also heritable due to their ability to be passed on 
through cell division.  Epigenetic systems include DNA methylation, histone modifications and 
micro RNA (miRNA), which work cooperatively with the overall effect of exposing or shielding 
regulatory regions of genes (promoters) to factors which control and direct transcription.  Thus 
epigenetic modifications which expose these regions allow transcription to occur if the correct 
regulatory complexes are available, whilst those which shield these regions inhibit transcription by 
sterically preventing regulatory proteins from binding.   
 
As the epigenome is set up in early development, during the window in which environmental 
constraints such as maternal diet are able to influence developmental trajectories, altered epigenetic 
regulation is therefore one mechanism which could underpin the persistent changes in gene 
expression identified in programmed offspring.  It is therefore important to understand the nature of 
epigenetic modifications to recognise how early life constraints may impact on them.  
 
 
1.6.1 Methylation  of  DNA 
 
DNA Methylation is the most common covalent modification of DNA found in vertebrate animals 
and is stably inherited through cell division.  It is an epigenetic event in which the dinucleotide 5’-
Cytosine-p-Guanine-3’ has a methyl group (CH3) added at the carbon 5 position of the cytosine.  
Although 60-90% of dinucleotides are methylated 
156, their distribution throughout the genome is 
uneven and two percent of the genome comprises short (1000-1500bp) CpG rich stretches of DNA 
termed CpG islands which are located within the regulatory regions of genes.   
 
The main function of DNA methylation is to silence transcription (table 1.1) and as such, 
regulatory DNA which is unmethylated is associated with transcription and that which is 
methylated with a lack of transcription.  CpG islands are usually unmethylated and therefore 
associated genes have the ability to be expressed.  As such, these CpG islands are usually found at 
regulatory regions of constitutively expressed genes such as house keeping genes 
157.  Exceptions to 
this occur for some tissue specific genes, for example the POMC gene whereby methylation of the 
regulatory CpG islands is tissue specific 
158 and imprinted genes whereby methylation of CpG 
islands ensures transcriptional silencing of the associated parental allele 
159.  However, 
hypomethylation of a gene promoter does not guarantee that it will be expressed, just that it has the 
ability to be expressed, as gene expression is dependent on multiple factors such as chromatin 
conformation and the availability of transcription factors.  In agreement with this, some tissue 
specific genes with CpG islands are hypomethylated in all tissues.   32
Table 1.1  Main functions of DNA methylation.  The main repressive functions of DNA 
methylation are indicated. 
 
 
Process 
 
 
Description 
 
Gene repression 
 
X chromosome 
inactivation 
 
 
Genomic imprinting 
 
 
 
 
Silencing of retroviruses 
 
 
Silencing transposons 
 
 
 
Repress expression of mRNA 
77 and miRNA 
160 
 
Methylation of CpG islands ensures silencing of X linked genes in 
female embryos 
161 e.g. phosphoglycerate kinase 1 (PGK-1) 
(together with genomic imprinting, accounts for <10% CpG in genome) 
 
Only the paternal or maternal allele of a gene is expressed.  The CpG 
island of the non expressing gene is heavily methylated thereby 
irreversibly silencing the gene 
159.  e.g. H19 is maternally expressed and 
IGF-2 is paternally expressed. 
 
8% of genome is composed of endogenous retroviruses (junk DNA) 
which have integrated into human genome  
 
Silencing promoters of these GC rich mobile genetic elements 
contained within introns (>40% of genome) accounts for the majority of 
methylated CpG 
162.  
 
 
Unsurprisingly, given the role of epigenetics in gene regulation, aberrant epigenetic modifications 
(epimutations) have been implicated in several disorders, including ageing, cancer and congenital 
disorders.  For example, loss of imprinting (LOI) can result in the silencing of both parental alleles 
or biallelic expression of imprinted genes, such as occurs in Angelman’s syndrome, Prader-Willi 
syndrome and Beckwith Wiedemann syndrome (BWS) 
159.  In addition a gradual loss of global 
methylation is a feature of cellular senescence and when this occurs in gene promoters it may result 
in aberrant gene transcription and lead to cancer 
163.  Contrastingly, de novo DNA 
hypermethylation at CpG islands of tumour suppressor genes will repress their expression and also 
lead to cancer, as has been identified for the breast cancer 1 (BRCA1) gene 
164. 
 
  1.6.2 DNA  methyltransferases 
 
Methyl groups, which are largely supplied by the diet, are transferred to nucleotides by a group of 
enzymes called DNA methyltransferases (Dnmts) using the donor s-adenosyl-l-methionine (SAM) 
(figure 1.5).  Three families of Dnmt have been identified, Dnmt1 (comprised of Dnmt1o, Dnmt1s 
and Dnmt1p), Dnmt2 and Dnmt3 (comprised of Dnmt3a, Dnmt3b and Dnmt3l).  They are classed 
as either de novo Dnmts, which methylate unmethylated DNA and therefore involved in 
establishing methylation patterns, or maintenance Dnmts, which methylate hemi-methylated DNA 
and function to propagate established methylation patterns through mitosis.   
 
 
O
CH3
NH 2
H
NH 2
O
S-adenosylmethionine
(SAM)
S-adenosylhomocystine
(SAH)
DNA Methyltransferases
Cytosine
5-Methylcytosine
N
N
N
N
 
Figure 1.5  Formation of 5-methylcytosine.  The methyl group is covalently added to the 
carbon 5 position of cytosine of CpG by a family of enzymes called DNA methyltransferases, 
resulting in 5-me-Cytosine.  It is an active process and requires the donor SAM which is recruited 
by the methyl transferase.  The products of the reaction are methylated cytosine and s-adenosyl-L-
homocysteine (SAH). 
 
 
1.6.3 Maintenance  methylation 
 
In somatic cells, the methylation status of DNA is maintained by Dnmt1s, which acts 
predominantly as a maintenance DNA methyltransferase due to its 5-30 fold preference for hemi-
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methylated DNA 
165.  This enables methylation patterns to be faithfully replicated on the daughter 
strand during mitosis, thus maintaining the heritability of the methylation blueprint laid down 
during development.  The role of Dnmt1s has been confirmed using Dnmt1 null embryonic stem 
(ES) cells, which can grow normally until stimulated to differentiate whereby they undergo 
apoptosis 
166 and mice embryos with mutant Dnmt1 which lose 95% of methylation and die mid 
gestation 
166.  Furthermore, in these mutant embryos, inactive X chromosomes become reactivated 
and LOI occurs 
167.  Dnmt1 also has sex specific promoters, resulting in an oocyte specific isoform 
(Dnmt1o), which is also expressed in the early embryo and an isoform specific to spermatocytes 
(Dnmt1p) 
168.  Deletion of Dnmt1o results in loss of imprinting, suggesting that it maintains 
methylation of imprinted loci 
169.   
 
 
1.6.4  Epigenetic reprogramming and de novo methylation  
 
DNA methylation patterns are established early in development and during this time the dynamic 
epigenome undergoes two major phases of reprogramming, throughout which epigenetic 
modifications are erased and reset 
159.  This is therefore a sensitive period for the epigenome which 
can be highly susceptible to dysregulation by environmental factors such as maternal 
undernutrition.   
 
The first event which occurs is the demethylation of primordial germ cells (PGCs), which is 
followed by remethylation during gametogenesis whereby parental imprinting patterns are reset 
170.  
This reprogramming of the epigenome also serves to reset any epimutations that have developed in 
parental genomes and therefore prevents their transmission to the subsequent generation.   
Secondly, after fertilisation of the egg, the epigenome undergoes a wave of demethylation to 
produce a pluripotent zygote, followed by locus specific de novo methylation after the fifth 
division 
171.  One exception to the second wave of reprogramming are the imprinted genes whose 
methylation is set up during gametogenesis and do not undergo demethylation 
172.  The methylation 
status of the genome is therefore resumed by implantation.   
 
 
1.6.5  Demethylation of the parental genomes in the embryo 
 
Demethylation of the maternal and paternal genomes in the zygote during preimplantation 
development occurs by contrasting mechanisms.  Maternally derived chromosomes show a gradual 
reduction in methylation over several cell divisions, due to a lack of maintenance methylation 
following DNA replication, therefore indicating a passive demethylation 
173,174.  This is proposed to 
be due to exclusion of Dnmt1o from the nucleus in the initial three divisions 
170.  Conversely, it has 
been shown that demethylation of the paternally derived genome after fertilization precedes any   35
replication, thus inferring an active mechanism 
174,175.  In agreement with this, immunofluorescence 
studies have provided evidence that completion of demethylation of the male derived genome is 
within 4hr of fertilization 
176.  It is not known why demethylation of the male and female genome 
differs, but it has been hypothesised that demethylases are unable to access the maternal genome 
175.   
 
Exact mechanisms of active demethylation are currently under debate, but 3 potential mechanisms 
have been speculated; the complete removal of the methyl-CpG, removal of the methyl group and 
its subsequent substitution with hydrogen and finally the excision of the methylated cytosine base 
177.  The search is on to identify the demethylase(s) and once this is achieved the mechanism will 
become clearer.  One potential demethylase, identified as methyl CpG binding protein 2 (MBD2), 
was claimed to demethylate DNA 
178, but this has been contested 
177, as it has been found that 
demethylation of the paternal genome occurred normally in fertilized oocytes deficient in MBD2 
176. 
 
 
1.6.6  De novo methylation 
 
The highly coordinated remethylation of the genome is performed largely by the de novo DNA 
methyl transferases Dnmt3a and Dnmt3b using unmethylated DNA as their substrate 
179.  In mice, 
Dnmt3a and Dnmt3b knockouts block de novo methylation and are lethal to the early embryo 
179.  
In contrast, deletion of these genes does not effect maintenance methylation, thus providing 
evidence they are the main de novo DNA methyltransferases crucial for early development 
179.  In 
addition, Dnmt3b is also mutated in patients with ICF syndrome, in which satellite DNA of 
pericentric regions loses its methylation 
168.  Furthermore, loss of Dnmt3b causes demethylation of 
X inactivated CpG islands.  Normally, these regions are methylated shortly following implantation, 
thus indicating a role for Dnmt3b in this particular de novo methylation 
168.  Another member of 
this family, Dnmt3l has no methyltransferase activity, but is instead involved in recruiting other 
members of the Dnmt3 family to promoters.  It has been shown that this isoform is necessary for 
establishing maternal imprints in the female germ line 
180. 
 
Further changes to the methylation status of genes also occur later in development during tissue 
differentiation 
181.  This involves the do novo methylation and demethylation of specific genes 
which creates cells with their own epigenetic fingerprint, thus permitting a gene expression profile 
appropriate for the particular cell type and time of development.  These epigenetic alterations 
therefore occur at different times depending on the tissue involved and the role of the gene.  For 
example, genes may be demethylated during tissue differentiation such as leptin 
182, whilst others 
may undergo methylation during the later stages of development, such as the Hox genes 
183.   
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1.6.7  What directs de novo methylation? 
 
A major unanswered question in the field of epigenetics is what directs de novo methylation to 
specific sequences during development.  Several theories exist, including both the exclusion and 
targeting of Dnmt and the direction of methylation by non coding RNA.  For example, sequence 
specific targeting of Dnmt to DNA could occur by sequence specific protein repressor complexes 
such as transcription factors and histone modifying enzymes 
184.   Alternatively, it has been 
hypothesised that the accessibility of response elements at critical periods of development leaves 
them exposed and accessible to Dnmts, which would result in de novo methylation, whereas steric 
hindrance due to presence of protein factors such as transcription factors may exclude Dnmt from 
the DNA and therefore prevent methylation 
185.  In agreement with this theory, Sp1 response 
elements, which are normally present in multiple copies in CpG islands have been hypothesized to 
play a role in directing the hypomethylation of CpG islands 
186.  It has been revealed that Sp1 
response elements at the periphery of a CpG island in the promoter of the housekeeping gene 
adenine phosphoribosyltransferase are crucial in order to maintain its hypomethylation, thus 
providing protection from methylation 
186.  Using transgenic mice and embryonic stem cells, 
mutation and deletion of Sp1 sites in the CpG island were shown to prevent Sp1 binding, which led 
to the methylation of the CpG island 
186.   
 
 
1.6.8 Histone  modifications 
 
Collectively the complex of DNA and its associated histone proteins are termed chromatin and the 
structure of chromatin around promoter regions of genes affects the ability of the gene to be 
transcribed.  Modifications to amino acids on the N-terminal tails of histones protruding from the 
nucleosome core can induce both an open or closed chromatin structure and these affect the ability 
of transcription factors to access promoter regions to activate transcription.  These covalent 
modifications include; acetylation, methylation, phosphorylation and ubiquitination and the 
combination of histone modifications have been collectively termed the histone code 
187 (figure 
1.6).  Methylation of some residues is associated with transcriptional repression, such as 
methylation of histone 3 lysine 9 (H3 K9) 
188 and others with transcriptional activation, such as 
methylation of histone 3 lysine 4 (H3 K4) 
189.  Methylation is performed by histone 
methyltransferases (HMTs), which can transfer up to three methyl groups to lysine residues with 
differing effects on gene activity; for example, tri methylation of H3 K9 is associated with silent 
heterochromatin and monomethylated H3 K27 is found throughout euchromatin.  Acetylation, 
which occurs solely at lysine residues such as H3 K9 is associated with transcriptional activation 
190.  This modification is performed by histone acetylases (HATs) and histone deacetylases 
(HDAC) can remove the acetylation mark.   
 Other important regulators of chromatin conformation include the polycomb group (PcG) and 
trithorax group (trxG) proteins, which have key roles in developmental gene regulation 
191.  They 
are recruited to response elements near proximal promoters to direct histone modifications, which 
induce both an active chromatin structure (trxG) and an inactive chromatin structure (PcG).   
Trithorax group proteins methylate H3 K4 to induce an active chromatin conformation 
191, whilst 
PcG proteins direct the methylation of H3 K27 to induce a repressive chromatin conformation.  The 
effects of PcG proteins are however reversible, as removal of PcG during development leads to 
gene activation.  PcG proteins have been implicated in regulation of developmental transcription 
factors, genomic imprinting and X chromosome inactivation 
161.   
 
Thus in addition to DNA methylation recruiting protein complexes to induce histone modifications, 
modifications to histones themselves may also induce alterations to DNA methylation, owing to 
their interaction with protein complexes such as HDAC, HMT and MBD which may recruit Dnmts.  
Thus DNA methylation can bring about histone modifications and histone modifications can 
influence DNA methylation 
192.  However, as histone modifications generally can be viewed as 
more short term and dynamic, the additional brace of DNA methylation serves to stabilise gene 
silencing. 
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Figure 1.6  Common modifications of histone 3 Common histone modifications to lysine 
tails of histone 3 are shown, indicating both modifications associated with a repressive chromatin 
structure and those associated with an active chromatin structure. 
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1.6.9  DNA methylation and repression of gene expression 
 
Methyl-CpG can lead to the repression of gene transcription by one of two contrasting 
mechanisms; firstly a direct mechanism in which the methyl group physically prevents 
transcription factor access to its target DNA sequence and secondly from providing a binding site 
for methyl CpG binding proteins (MBDs), which in turn recruit repressive protein complexes that 
facilitate a closed chromatin structure.  It is considered that the latter indirect method is the most 
prevalent mechanism 
157.   
 
 
1.6.9.1  DNA methylation and transcription factor binding 
 
Many transcription factor response elements possess CpGs within their response elements and the 
methylation status of these CpGs may affect transcription factor binding and therefore influence 
gene transcription.  As such, increasing examples of DNA methylation physically interfering with 
transcription factor binding are emerging.  For example, binding assays have shown that 
methylation of CpGs within the DNA binding site for the transcription factor MLTF can prevent its 
binding at the adenovirus major late promoter and inhibit gene expression in vitro and this is effect 
is dependent on the exact position of the CpG within the response element 
193.  Methylation of an 
E2F response element in the POMC promoter prevents its binding and contributes its tissue specific 
expression 
158.  CpG methylation within the specificity protein 1 (sp1) response element has also 
been shown to reduce protein binding by 95% 
194 and it has even been found that methylation just 
outside its response element can prevent Sp1 binding and thus inhibit transcription 
195.  Clearly the 
effects of methylation of CpGs within response elements vary for the same transcription factor 
within different promoters and therefore need to be characterised on an individual basis to 
determine if and how DNA binding is affected by cytosine methylation. 
 
 
1.6.9.2  DNA methylation and methyl DNA binding proteins 
 
MBD proteins are a family of proteins expressed in most somatic tissues which can bind me-CpG.  
To date they include; MeCP1, MeCP2, MBD2 and Kaiso.  They serve to mediate the methylation 
signal by linking DNA methylation to alterations in chromatin structure 
196 and exert their 
repressive natures by specifically binding me-CpG via their methyl CpG binding domain (MBD) 
and recruiting histone modifying proteins via their transcriptional repression domain (TRD).  The 
histone modifying proteins recruited include both histone deacetylases (HDAC) and histone 
methyltransferases (HMT). 
 The most extensively studied methyl DNA binding protein is MeCP2, which can bind to a single 
me-CpG via its MBD 
197.  MeCP2 is composed of a single polypeptide chain which contains a both 
a MBD and a TRD.  The TRD recruits a co-repressor complex which includes mSin3A, HDAC1 
and HDAC2 
198, which enable the deacetylation of H3 and H4, the formation of a more closed 
chromatin structure and thus transcriptional repression (figure 1.7).  Although deacetylase 
inhibitors such as trichostatin A (TSA) remove most repression 
199, some repression remains, thus 
indicating other factors are involved.  Subsequently, chromatin immumoprecipitation (ChIP) and 
co-immumoprecipitation studies have provided evidence that MeCP2 also recruits a HMT which 
add methyl groups specifically to H3 K9, a repressive modification, therefore adding a further 
brace to the closed chromatin structure 
200. 
 
MeCP1 is a protein complex which requires at least 12 me-CpGs to bind DNA 
201.  As such, it can 
repress heavily methylated promoters, but its suppression of poorly methylated promoters is weak 
196.   MeCP1 complex contains MBD2 which facilitates the DNA binding activity of this complex 
202 and the nucleosome remodelling and histone deacetylase (NuRD) co-repressor complex 
203.  
Conversely, Kaiso binds methylated DNA via zinc finger motifs to repress transcription.  It has 
also been identified as part of the MeCP1 protein complex and requires two adjacent methyl-CpGs 
to bind methylated DNA 
204. 
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Figure 1.7  Mechanism of repressive action by MeCP2.  The MeCP2 MBD binds to me-
CpG, whereas the TRD recruits a co-repressor complex which includes mSin3A, HDAC1 and 
HDAC2, which enable the deacetylation of histones, the formation of a more closed chromatin 
structure and transcriptional repression (adapted from 
205). 
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1.6.10  Micro RNA and epigentics 
 
Recently, interest has also arisen in micro RNAs (miRNA) as an epigenetic mechanism with the 
potential to be implicated in programming.  miRNA are small untranslated RNAs about 22bp long 
involved in posttranscriptional repression of target genes by translational repression and mRNA 
degradation 
160.  Over 1000 human miRNAs exist and each miRNA may regulate in the region of 
100 target genes, thus these molecules are an important determinant of the transcriptome.   
Intriguingly, miRNAs may be both controlled by epigenetic mechanisms 
160 and induce epigenetic 
alterations in target genes 
206.  Using a Dnmt1 and Dnmt3b double knock out cell line, it has been 
shown that DNA methylation has an important role in the regulation of around 10% of miRNA 
160.  
Furthermore, the use of HDAC inhibitors has revealed that histone modifications can regulate 
miRNA expression 
206.  The ability of miRNA to induce epigenetic modifications is owing to their 
regulation of factors involved in the processes of DNA methylation 
207 and histone modification 
(e.g. HDAC4) to induce a closed chromatin conformation 
206.  These recent findings imply that like 
normal genes, miRNA have the potential to be affected by environmental constraints during 
development, however due to their ability to regulate 100s of target genes and their ability to 
induce epigenetic modifications, any alterations in miRNA expression during development could 
have profound effects on numerous biological systems.   
 
 
1.7  Evidence implicating epigenetic alterations in developmental programming 
 
Each cell type possesses its own epigenetic “fingerprint” which is laid down in early development 
to determine the array of genes which will be expressed.  There is a growing body of evidence 
giving substance to the hypothesis that an adverse environment during critical periods of 
development, which stretch from the periconceptual period to postnatal life, may induce aberrant 
epigenetic marks which alter this epigenetic fingerprint and underpin the gene expression changes 
identified in programmed offspring.  Thus, the stable propagation of these epimutations contributes 
to the altered phenotype and associated metabolic disorders.   
 
Emerging studies in rodents are discovering that throughout early life, the epigenome is vulnerable 
to environmental insults including not only maternal diet, but also postnatal diet, social behaviour 
and stress.  Furthermore, despite the main body of work focusing on rodents, data is now emerging 
identifying alterations in human epigenome as a result of similar developmental constraints.  These 
studies are unravelling the complex epigenetic alterations which bring about the potential for 
altered gene expression.  They include altered expression of Dnmts, altered DNA methylation of 
specific CpGs, altered transcription factor binding or binding of MBD and altered histone 
modifications.  These elegant studies show that the epigenetic alterations induced can occur in 
genes involved in a variety biological processes, include both imprinted and non imprinted genes,   41
occur in a variety of tissues and may be induced at different time points throughout gestation and 
postnatal life.  Interestingly, it is emerging that these marks may be reversible, thus providing a 
means to develop therapies to intervene and prevent the onset of adult disease.  The following 
studies represent some key landmarks that have contributed to the current knowledge of epigenetic 
programming. 
 
 
1.7.1  Evidence of altered epigenetic regulation in rodents 
 
1.7.1.1  Epigenetic alterations arising from maternal behaviour and stress 
 
Interest in the role of epigenetic modifications in programmed offspring arose from one key paper.  
In rodents, maternal care during the first week of life is associated with an altered stress response in 
adult offspring.  Weaver and colleagues provided evidence that the ability of maternal behavior to 
alter this stress response was due to altered epigenetic regulation of the GR promoter in the 
hippocampus 
208.  It was shown that offspring subjected to high levels of maternal care had 
increased expression of GR.  This was found to be due to hypomethylation of a CpG within an 
NGF1-A response element in the promoter.  Furthermore, the alteration in methylation was shown 
to be specific, as the methylation status of an alternative CpG within the NGF1-A response element 
remained unchanged.  In line with the reduced methylation, increased binding of NGF1-A and 
increased acetylation of H3K9 were also found, consistent with inducing a transcription competent 
chromatin conformation.  Thus the increased GR expression which resulted from these alterations 
acted as a negative feed back on the HPA axis to dampen the response to stress in the offspring.  
Weaver and colleagues therefore provided evidence that specific and permanent epigenetic changes 
can occur through maternal behavioral programming which affect the stress response of adult 
offspring 
208.  Interestingly, later studies showed that all the epigenetic alterations identified in 
offspring subjected to high levels of maternal care could be reversed by methionine 
supplementation to adult offspring, indicating that the epigenetic marks are reversible even in 
terminally differentiated cells of the hippocampus 
209.  
 
 
1.7.1.2  Epigenetic alterations arising from maternal nutrition  
 
The first evidence to show that maternal diet can affect the epigenetic status of genes in the 
offspring was that of the agouti mouse model.  In A
vy/a mice, the phenotype of the mouse is altered 
depending on the expression of the agouti gene, which regulates production of fur colour.  These 
phenotypes range from yellow mice which are obese, through a range of mottled mosaics, to black 
pseudo agouti mice which are lean and healthy.  Expression of the agouti gene in these mice is 
controlled by an intracisternal A Particle (IAP) promoter and maximal expression results in mice   42
with yellow fur and an unhealthy obese phenotype.  However, expression of the agouti gene is 
affected by methylation status of the IAP promoter and when methylated, agouti gene expression is 
switched off resulting in a black pseudoagouti fur colour and mice which are lean and healthy.  
Further studies indicated that giving methyl supplements to the mother throughout pregnancy 
induced hypermethylation of the IAP promoter in offspring, resulting in reduced gene expression 
and offspring which displayed the pseudoagouti phenotype 
210.  Although this study is not relevant 
to natural conditions due to control of the agouti gene by a foreign promoter, it is a good model 
system in which the effects of maternal factors such as diet on epigenetic status can be studied. 
 
Another example which showcases the ability of nutrition to modify developmental fate via 
modification of the epigenome is that of the honeybee 
211.  Development of the honeybee into a 
queen is determined by prior nutrition; royal jelly fed female larva become queens, whereas those 
fed a lesser substance become sterile workers.  siRNA directed knockdown of Dnmt3 in hatched 
larvae was shown to have effects similar to that of royal jelly feeding, i.e. induced an altered 
developmental trajectory such that the honeybee became a fertile queen rather than a sterile worker, 
thus implicating altered de novo methylation in the honeybee development.  By analysing the 
methylation status of specific genes, it was shown that average methylation levels were higher in 
control larvae than siRNA treated larvae or queens.  Furthermore, alterations to DNA methylation 
were found to be specific to particular CpGs rather than a global effect.  In agreement with altered 
methylation, an expression array identified altered gene expression in siRNA knockdown larvae 
and queens compared to control larvae.  Thus here, the fertile queen, induced by natural royal jelly 
feeding or laboratory induced Dnmt3 knockdown, is associated with reduced capacity to methylate 
specific genes during a critical period of larval development, facilitating altered gene expression 
and an alternative phenotype 
211.  The honeybee example although not relevant to humans, is a 
good example of the mechanism of early nutrition affecting epigenetics and altering the adult 
phenotype.  
 
  
1.7.1.3  Epigenetic alterations to GR and PPARs arising from maternal nutrition  
 
Evidence is accumulating implicating altered DNA methylation in nutritional models of 
programming in rodents.  Interest in epigenetic modification has concentrated on genes whose 
expression has previously been shown to be altered in these offspring, such as GR and PPARα.  For 
example, in the liver of day 34 MLP offspring, the PPARα promoter was found to be 
hypomethylated 
77, consistent with previous reports of increased expression in this tissue 
57.  In 
addition, methylation of the GR exon 110 promoter was also shown to be reduced and corresponded 
to an increase in gene expression.  Furthermore, this hypomethylation was also shown to be gene 
specific and not a general effect, as methylation of the PPARγ promoter remained unchanged in 
response to maternal diet.  Interestingly, this work also identified that supplementing the MLP diet   43
with folic acid specifically prevented the methylation and expression changes in PPARα and GR, 
thus implicating a reduced supply of folic acid and subsequent altered 1-carbon metabolism to 
alterations in DNA methylation in programmed offspring 
77.   
 
Further to this, a more detailed analysis of the methylation status of the PPARα promoter in the 
same offspring has since been undertaken.  Pyrosequencing of 16 CpGs in the promoter region 
showed that the hypomethylation seen in PR offspring was specific to individual CpGs rather than 
a global effect, as the methylation of many CpGs remained unchanged by maternal diet.  Mean 
methylation of all these 16 CpG was shown to be 26% lower in PR compared to control and 
feeding a PRF diet prevented all individual CpG methylation changes seen in PR offspring.   
Furthermore, the individual changes in methylation were also found in day 80 offspring, indicating 
that the changes were persistent.  Further to this, CpGs with altered methylation were shown to 
coincide with potential binding sites for transcription factors such as Sp1 whose DNA binding 
ability has previously been found to be affected by methylation and could therefore play a key role 
in altered PPARα gene expression 
212.  However, although DNA methylation levels in the PPARα 
promoter were found to be low overall, they had a negative correlation with gene expression, 
indicating that these subtle changes were enough permit changes in gene expression.   
 
To understand how the altered methylation of the GR promoter results in altered transcriptional 
activity, a detailed investigation was undertaken to characterise the mechanisms involved and this 
elegant study uncovered a series of alterations which could facilitate a chromatin structure 
permissive for increased gene expression 
213.  Lillycrop and colleagues identified reduced 
methylation of the GR exon 110 promoter in day 34 offspring from dams fed a MLP diet, which 
corresponded to an 84% increase in GR expression and a 16% increase in the expression of its 
target gene PEPCK.  Evidence was provided that this reduction in methylation was linked to altered 
maintenance methylation, as Dnmt1 expression was also reduced by 17% indicating a reduced 
maintenance methylation in these cells and consequently binding of Dnmt1 to the GR promoter 
was reduced.  In contrast, Dnmt3a and Dnmt3b expression were unchanged indicating alterations in 
de novo methylation were not involved.  The MLP offspring were also found to have reduced 
expression of MeCP2 and reduced binding of MeCP2 to the GR promoter, providing a link to 
histone structure.  Unsurprisingly, chromatin immunoprecipitation (ChIP) studies indicated 
increased amount of histone modifications associated with open chromatin structure and reduced 
histone modifications involved with the repression of transcription.  Thus a complete picture of the 
mechanisms underlying altered GR expression was uncovered.  Interestingly, it was shown that 
supplementing the maternal diet with folic acid prevented the reduction in Dnmt1 expression 
213.  
This supports the theory that Dnmt1 expression is reduced due to impaired carbon-1 metabolism 
and suggests that the protein restricted diet causes a reduction in Dnmt1 expression during 
development which is associated with reduced maintenance methylation of specific genes in 
specific tissues 
213.  Interestingly, evidence to support the gene specificity of altered Dnmt1   44
methylation has emerged, indicating that it represses transcription in promoters with E2F binding 
sites 
184, which explains why methylation of all genes is not altered.  Furthermore, this study also 
shows that when epimutations affect the expression of transcription factors, effects can be relayed 
on to target genes which affect the metabolic activity of a cell therefore influencing the adult 
phenotype.   
 
 
1.7.1.4 Epigenetic alterations to other genes implicated in acquisition of the programmed 
 phenotype   
 
Other biological aspects of programming have been investigated for epigenetic alterations, such as 
the mechanisms underlying the programming of hypertension.  For example, activation of the AT1b 
receptor in the adrenal gland stimulates aldosterone production which results in increased blood 
pressure.  In the adrenal gland of MLP offspring, bisulfite sequencing and pyrosequencing have 
confirmed that there is significant under-methylation of 3 CpG sites within the AT1b Angiotensin 
receptor proximal promoter.  Interestingly, 1 of these CpG sites falls within Sp1 consensus site and 
may therefore affect protein binding.  This altered methylation is accompanied by increased 
expression of the AT1b gene prior to the 1
st week of life which persists at least to week 12.  Thus 
increased expression of this receptor due to reduced methylation may contribute to the formation of 
hypertension in later life 
214.   
 
The IUGR rat is also associated with an increased risk of hypertension in later life and IUGR 
offspring in both rat and humans have decreased glomeruli number and therefore impaired renal 
function.  A study has found that the p53 promoter is hypomethylated in the kidney of IUGR 
neonates in the rat, specifically methylation of regions which have previously been shown to affect 
levels of p53 mRNA.  Again hypomethylation was specific to certain CpGs and led to increased 
expression of its protein and apoptotic target genes, resulting in increased apoptosis.  As apoptosis 
has a fundamental role in nephrogenesis which peaks late gestation (when the IUGR was induced), 
it is probable that the altered methylation of p53 contributed to the reduced glomeruli number and 
the reduced glomerular filtration rate found in these offspring 
215.  
 
Pdx1 is a transcription factor involved in β cell differentiation and reductions in Pdx1 can result in 
type II diabetes.  One interesting study has tracked the sequence of epigenetic modifications which 
occur over time to repress the expression of the Pdx1 gene in the β-cells of a rodent model of IUGR 
216.  It has shown that the course of development was associated with a cascade of epigenetic 
modifications which led to the permanent silencing of Pdx1 in adult offspring.  In the fetus, 
repressive protein complexes were recruited to the Pdx1 promoter resulting in the deacetylation of 
histones.  This was associated with reduced binding of the transcription factor USF-1, an activator 
of Pdx1 gene transcription, to the Pdx-1 promoter compared to controls.  After birth, this was   45
followed by alterations in histone methylation associated with gene repression and deterioration of 
glucose homeostasis.  At this point, no DNA methylation is apparent in the Pdx1 promoter.  In 
adulthood, when offspring have developed type II diabetes, the Pdx1 promoter is methylated and 
the Pdx1 gene permanently silenced.  Thus the progressive silencing of this gene by a “self 
propagating epigenetic cycle” 
216, plays a causative role in the onset of diabetes in this IUGR rodent 
model 
216.   
 
 
1.7.1.5  Epigenetic alterations arising from postnatal nutrition 
 
In addition to programming of the epigenome by maternal undernutrition, studies have identified 
that neonatal overnutrition can alter the epigenome in the hypothalamus and adipose tissue of 
rodents.  For example, rats from small litters bred to develop obesity exhibit hyperinsulinemia, 
hyperglycemia and hyperleptinemia and have hypermethylation of the POMC promoter compared 
to controls.  Activity of the POMC promoter has previously been shown to be affected by DNA 
methylation 
217.  It has been shown that overnutrition induced increased methylation of two CpGs 
in the POMC promoter, one of which is located in an NFкB response element and the other just 
upstream a Sp1 binding site which has previously been shown to be crucial for leptin mediated 
activation of POMC.  It is known that methylated CpG upstream of Sp1 response elements can 
effect Sp1 binding to DNA 
195 and methylation of this CpG was found to be inversely associated 
with POMC expression 
185.  As a result, POMC expression was not increased in these rats despite 
hyperleptinemia.  It explains the inability of the hyperleptinemia to prevent obesity, as the 
increased leptin would normally increase POMC expression to reduce feeding.  The alterations in 
methylation were also gene specific, as methylation of the hypothalamic NPY promoter was 
unaffected by overnutrition.  Thus this study has shown that overfeeding can specifically induce 
hypermethylation of the POMC gene in the hypothalamus during a period of plasticity and thus 
induce hypothalamic leptin resistance which contributes to the altered phenotype 
185.   
 
Furthermore, it has recently been shown that the leptin promoter is subject to altered DNA 
methylation by postnatal high fat feeding.  Rats fed a high fat diet for 11 weeks become obese with 
associated hyperleptinemia.  Analysis of the leptin promoter from adipose tissue in these rats found 
hypermethylation of a specific CpG in the leptin promoter, which was associated with reduced 
leptin expression 
218.  As leptin is an adipokine which mediates its effects body wide, alterations in 
its methylation and therefore expression could have effects on many biological processes, with a 
particular emphasis on bodyweight regulation.   
 
Thus these two studies indicate that the postnatal environment is still able to alter the epigenome in 
tissues which maintain some developmental plasticity, such as adipose tissue and the   46
hypothalamus, implicating postnatal life as a mediator of an altered adult phenotype, with 
particular relevance to obesity and its related metabolic disorders. 
 
 
1.7.2  Evidence of altered epigenetic regulation in humans 
 
1.7.2.1  Epigenetic alterations arising from childhood abuse 
 
In rodents, maternal behaviour is able to induce epigenetic alterations to the promoter of GR in 
offspring, which induces an altered HPA response to stress that persists throughout life.   
Intriguingly, recent work in humans has uncovered similar epigenetic alterations to the GR 
promoter in the hippocampus of suicide victims with a history of childhood abuse. In these 
individuals, reduced GR expression was found specific to the 1F splice variant and this was 
associated with increased methylation of specific CpGs in the GR promoter.  Furthermore, ChIP 
and patch methylation reporter gene experiments indicated that CpG methylation which mimicked 
that identified in child abuse suicide victims, resulted in reduced NGF1-A binding to its response 
element and a reduced ability to induce GR transcription.  These experiments therefore imply that 
mechanisms underlying HPA stress responses in rodents and humans as a result of care in early life 
share a common pathway, based around epigenetic modification and expression of GR in the 
hippocampus 
219.   
 
 
1.7.2.2  Epigenetic alterations arising from maternal nutrition  
 
Evidence is now emerging in humans implicating altered DNA methylation as a consequence of 
nutritional constraints during development. The first evidence of altered DNA methylation in 
humans as a result of altered nutrition came from the Dutch Hunger Winter cohort in which 
alterations in both imprinted 
220,221 and non imprinted genes 
221 were identified 60 years after the 
initial famine exposure.  For example, 5 CpGs within the DMR of the maternally imprinted insulin-
like growth factor II (IGF2) gene were analysed using Sequenom technology and found to have 
reduced methylation compared to controls.  Although differences were small (5.2% average of all 5 
CpGs), they were significant 
220.  Furthermore, this effect was shown to be specific to famine 
exposure in the periconceptual period, a period in which the epigenome is especially susceptible to 
environmental effects.  Interestingly these individuals had a normal birth weight.  Contrastingly, 
alterations in DNA methylation were not found in those individuals of low birth weight exposed in 
late gestation, indicating that the effect on DNA methylation was specific to the timing of exposure 
220.  These results also indicate that birth weight is not a reliable indicator of altered epigenetic 
regulation.  A later study using the same cohort, found that alterations in DNA methylation induced 
by famine exposure were not specific to imprinted genes, but also found in non imprinted genes   47
involved in growth and metabolism including; leptin, interleukin 10, tumor necrosis factor (TNF) 
and the fat mass and obesity associated gene (FTO) 
221.  Here, alterations in the methylation status 
were found to be dependent on the timing of exposure and in some cases the sex of the individual.  
For example, both hypomethylation (IGF2) and hypermethylation (IL10, leptin) were associated 
with periconceptual exposure, whereas leptin hypermethylation was also identified in men exposed 
during late gestation.  Again, changes in methylation status were small (<3%), but significant 
221.   
 
 
1.7.2.3  Epigenetic alterations arising from assisted reproductive technologies  
 
Children who are conceived by assisted reproductive technologies (ART) including in vitro 
fertilisation (IVF) and intracytoplasmic sperm injection (ICSI) account for 1-3% of births in the 
western world 
222.  These children have an increased risk of congenital disorders arising from LOI 
of imprinted genes 
223.  For example, ART is associated with increased incidence of; Angelman 
syndrome, Prader-Willi syndrome and Beckwith Wiedemann syndrome (BWS) 
223.  This indicates 
that the procedures associated with these technologies, such as gonadotrophin treatment, embryo 
retrieval, embryo culture and embryo replacement may induce epigenetic alterations in imprinted 
genes.  For example, BWS LOI occurs due to hypermethylation of the H19 gene (which is 
normally maternally transcribed) and leads to aberrant activation of IGF2 (which is normally 
paternally transcribed).  In addition to this, hypomethylation of Lit1 DMR has been identified, 
which is normally methylated on the maternal allele 
224.  These findings in ART children, which 
indicate the vulnerability of the periconceptual period, are consistent with studies culturing mouse 
embryos in which both culture and embryo transfer were found to be associated with aberrant 
expression of imprinted genes in day 9.5 concepti, in particular that of H19 and the biallelic 
expression of Lit1 due to hypomethyalation of the maternal allele 
225.  Furthermore, analysis of 700 
genes covering 1536 CpG in children conceived from both ART and natural conception showed 
that IVF was associated with higher average DNA methylation in cord blood and reduced overall 
methylation in the placenta compared to controls, with associated alterations in gene expression.  
Furthermore, these differences were identified in not only imprinted genes, but also non imprinted 
genes.  Thus, like the differences in methylation identified in the Dutch Hunger Winter, changes in 
DNA methylation were small but statistically significant 
222.   
 
Results from all these studies clearly indicate that the periconceptual period is most susceptible 
period for the induction of epigenetic alterations, especially in humans.  In addition, overwhelming 
evidence indicates that the alterations in CpG methylation are specific to particular CpGs and not a 
global effect.  These studies therefore raise the question as to how methylation changes are not only 
targeted to specific genes during development, but also to specific cytosines.  As such, the 
mechanisms by which alterations in epigenetic modifications are targeted needs to be elucidated. 
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Two mechanisms have been proposed for how the environment may lead to alterations in DNA 
methylation during development 
226; the first mechanism is by modifying the availability of methyl 
donors or the activity of Dnmt1, resulting in an inability to faithfully replicated methylation 
blueprint onto the daughter strand.  An example of the maternal environment potentially effecting 
Dnmt1 is that of altered GR and PPARα DNA hypomethylation, which is prevented by increasing 
maternal folic acid 
77.   The second theory concerns preventing de novo methylation.  If signalling 
pathways are activated during development as a result of an environmental constraint, this would 
result in regulatory factors binding to promoter regions, thus protecting the promoter area from 
DNA methylation.  This region would therefore remain unmethylated with the ability to be 
expressed if stimulated to do so in later life.  An example of this could involve the effects of 
increased GR signalling as a consequence of maternal behaviour 
208.   
 
 
1.8  Methods for measuring DNA methylation 
 
Many methods are available to measure DNA methylation levels and these differ in the cost, ease 
of use, sensitivity, scale and level of throughput.  As such, these methods range from the simple, 
which measure average DNA methylation over a stretch of DNA, to methods which look at 
individual CpG methylation of the ‘whole genome’.  Therefore the method chosen will depend on 
the cost, level of detail and throughput required.  The simple methods are useful for an initial look 
at DNA methylation of a known region of DNA.  For example, methylation sensitive PCR is a 
semi-quantitative method which utilises methylation sensitive restriction enzymes to differentiate 
between methylated and unmethylated sequences in DNA.  Subsequent real time PCR will only 
amplify amplicons containing undigested methylated DNA, whilst digested unmethylated DNA is 
unable to be amplified.  Alternatively, more sensitive quantitative methods are available which can 
look at the methylation status of individual CpGs within a stretch of DNA, for example 
Pyrosequencing or Sequenom analysis.  Although more costly, these methods are highly sensitive 
and thought to be the gold standard for measuring DNA methylation of specific CpGs within a 
short stretch of DNA.  Pyrosequencing, for example, uses bisulfite converted DNA and PCR of the 
region of interest to introduce a C-T SNP which depends on the methylation status of the CpG; 
methylated C remains a ‘C’, whereas unmethylated C becomes a ‘T’.  This SNP is accurately 
quantified in a sequencing by synthesis reaction.  On a larger scale, whole genome technology now 
exists which can determine the methylation status of the “whole genome”, although it is very costly 
to use.  For example, ChIP-ChIP can be performed in which antibodies (e.g. for methylated 
cytosine) or protein complexes (e.g. MBD2) are used to capture methylated DNA from sonicated 
chromatin, whilst the unmethylated DNA is washed away.  The captured methylated DNA can then 
be applied to an array for samples to be identified.  Alternatively, enriched methylated samples 
may be sequenced and then mapped (ChIP-Seq), for example using the Illumina Genome Analyzer 
and Solexa sequencing.     49
1.9 Thesis  aims 
 
There are two main aims to this report: 
 
i)  In a rat model of programming induced by a maternal global undernutrition, offspring have a 
reduced birth weight compared to controls and adult offspring present with; hyperphagia, reduced 
locomotor behaviour, high blood pressure, hyperleptinemia, hyperinsulinemia and are obese.   
These disturbances are all augmented by a calorie rich postnatal diet and reversed by neonatal 
leptin treatment 
122.  The molecular mechanisms underlying the metabolic disturbances in these 
IUGR offspring are not known, but it is hypothesised that they may involve similar mechanisms to 
those found in the PR offspring, i.e. altered DNA methylation and mRNA expression of key 
transcription factors and enzymes involved in carbohydrate and lipid metabolism.  Furthermore, it 
is hypothesised that the leptin treatment may act during the neonatal period to prevent the 
programmed phenotype of IUGR offspring by altering the regulation of key genes involved in 
energy balance.   
 
AIM:  To investigate the DNA methylation and gene expression of key genes involved in energy 
  balance in the adipose tissue and liver of IUGR offspring in response to maternal diet, 
  postnatal high fat diet and neonatal leptin treatment using real time PCR and methylation 
 sensitive  PCR 
 
ii)  Previous work within this laboratory has identified altered PPARα mRNA expression in the 
liver of PR offspring in response to a protein restricted maternal diet.  Furthermore, these changes 
have been associated with alterations in DNA methylation of the PPARα promoter 
77,212.  However, 
exact mechanisms underlying these changes in gene expression and methylation are unknown.  
Furthermore, mechanisms underlying regulation of PPARα by factors such as glucocorticoids and 
leptin at the promoter level have been largely unexplored.  Nuclear hormone receptors such as the 
PPARs have been shown to possess multiple tissue specific transcripts and this has been shown to 
be the case for both the mouse and human PPARα orthologues.  However, to date, it is not known 
if such variant transcripts are present in the rat.  It is hypothesised that the rat PPARα gene may 
also possess alternative transcript variants, which may play a key role in the tissue specific 
regulation of PPARα gene expression and may therefore be differentially regulated by maternal 
undernutrition. 
 
AIM:  To identify the structure of the rat PPARα gene using 5’RLM RACE 
  To characterise the structure of the rat PPARα promoter 
To use a reporter gene strategy to investigate the mechanisms underlying the regulation of 
PPARα transcription by factors known to induce its expression, including leptin. 
  To analyse the methylation status of the PPARα promoter(s) using pyrosequencing   50
 
 
 
Chapter 2 
 
Materials and Methods 
 
 
 
 
 
 
 
 
   51
2.0  Materials and methods 
 
2.1 Materials 
 
Table 2.1  Reagents and chemicals used in experiments 
 
 
Reagent/Chemical 
 
 
Supplier 
 
3-isobutyl-1-methylxanthine 
1 Kb DNA ladder 
AciI restriction enzyme and buffer 
Agar 
Ampicillin, sodium salt 
Annealing buffer (Pyrosequencing) 
Binding buffer (Pyrosequencing) 
Calcium chloride 
Chloroform 
Clofibric acid 
CG methyltransferase (M.SssI) and buffer 
Denaturation solution (Pyrosequencing) 
Deoxynucleotide triphosphates (dNTP’s) 
Dexamethasone 
Diethyl pyrocarbonate (DEPC) 
Dulbecco’s modified Eagle’s medium 
EcoRI restriction enzyme 
Ethanol 
Ethylenediaminetetraacetic acid disodium salt (EDTA) 
Ficoll 400 
Fetal calf serum 
GC solution 
Glacial acetic acid 
Glucose 
HEPES (Salt free) 
HindIII restriction enzyme 
HinP1I restriction enzyme 
HotStar Taq 
HpaII methyltransferase and buffer 
 
Sigma-Aldrich, Dorset, UK 
Invitrogen, Paisley UK 
New England Biolabs, Herts, UK 
Sigma-Aldrich, Dorset, UK 
Sigma-Aldrich, Dorset, UK 
Biotage AB, Kungsgatan, Sweeden 
Biotage AB, Kungsgatan, Sweeden 
Sigma-Aldrich, Dorset, UK 
Fisher, Leicestershire, UK 
Sigma-Aldrich, Dorset, UK 
New England Biolabs, Herts, UK 
Biotage AB, Kungsgatan, Sweeden 
Promega, Southampton, UK 
Sigma-Aldrich, Dorset, UK 
Sigma-Aldrich, Dorset, UK 
Sigma-Aldrich, Dorset, UK 
Promega, Southampton, UK 
Fisher, Leicestershire, UK 
Sigma-Aldrich, Dorset, UK 
Sigma-Aldrich, Dorset, UK 
Sigma-Aldrich, Dorset, UK 
Roche, Burgess Hill, UK 
Fisher, Leicestershire, UK 
Sigma-Aldrich, Dorset, UK 
Sigma-Aldrich, Dorset, UK 
Promega, Southampton, UK 
New England Biolabs, Herts, UK 
Qiagen, West Sussex, UK 
New England Biolabs, Herts, UK   52
HpaII Restriction enzyme and buffer 
Insulin from porcine pancreas 
Isopropanol 
IPTG 
Leptin (Recombinant Murine) 
L-Glutamine 
Luria broth (LB) base 
Lysozyme (from chicken egg white) 
M-MLV reverse transcriptase 
Orange G 
Penicillin streptomycin 100× Solution 
Pfu DNA polymerase 
Phenol 
Phosphate buffered saline (PBS) 
Poly(ethylene glycol) 6000 (PEG) 
Potassium acetate (KAc) 
Propan-2-ol 
Proteinase K 
Random primers 
RNAse A 
SacI restriction enzyme 
Sodium acetate (NaAc) 
Sodium chloride (NaCl) 
Sodium dodecyl sulfate (SDS) 
Sodium hydroxide (NaOH) 
Sodium phosphate dibasic (Na2HPO4) 
Stat3 inhibitor 
Streptavidin sepharose HP beads 
Sucrose 
SYBR Green JumpStart taq ready mix 
T4 DNA ligase 
Taq DNA polymerase – Hot Start 
TRIReagent 
Tris 
Triton
® X-100 
Trypsin-EDTA 
Wash buffer (Pyrosequencing) 
X-Gal 
XhoI restriction enzyme 
Promega, Southampton, UK 
Sigma-Aldrich, Dorset, UK  
Fisher, Leicestershire, UK 
Melford Laboratories, Ipswich, UK  
Insight Biotech, Wembley, UK 
Sigma-Aldrich, Dorset, UK  
Sigma-Aldrich, Dorset, UK  
Sigma-Aldrich, Dorset, UK 
Sigma-Aldrich, Dorset, UK 
Sigma-Aldrich, Dorset, UK 
Sigma-Aldrich, Dorset, UK 
Promega, Southampton, UK 
Fisher, Leicestershire, UK 
Oxon, UK 
Sigma-Aldrich, Dorset, UK 
Sigma-Aldrich, Dorset, UK 
Fisher, Leicestershire, UK 
Promega, Southampton, UK 
Promega, Southampton, UK 
Sigma-Aldrich, Dorset, UK 
Promega, Southampton, UK 
Sigma-Aldrich, Dorset, UK 
Fisher, Leicestershire, UK 
Sigma-Aldrich, Dorset, UK 
Sigma-Aldrich, Dorset, UK 
Sigma-Aldrich, Dorset, UK 
Merck Chemicals Ltd, Notts, UK 
GE Healthcare Life Sci, Bucks, UK 
Sigma-Aldrich, Dorset, UK 
Sigma-Aldrich, Dorset, UK 
Promega, Southampton, UK 
Promega, Southampton, UK 
Sigma-Aldrich, Dorset, UK 
Fisher, Leicestershire, UK 
Sigma-Aldrich, Dorset, UK 
Sigma-Aldrich, Dorset, UK 
Biotage AB, Kungsgatan, Sweeden 
Melford Laboratories, Ipswich, UK 
Promega, Southampton, UK   53
2.1.1 Sterilization 
 
Water 
All water used in experiments was obtained from a Purite Neptune (Purite Ltd Oxon, UK) and 
autoclaved at 3 bar, 121
oC for 15 minutes. 
 
DEPC treated water 
DEPC treated water was used for all RNA/cDNA related work.  DEPC was added to a final 
concentration of 0.1% in deionised water (Purite Neptune, Purite Ltd Oxon, UK) and left 16hr.  
The solution was subsequently autoclaved to degrade DEPC at 3 bar, 121
oC for 15 minutes. 
 
Sterilization of solutions 
Where mentioned, all solutions were autoclaved at 3 bar, 121
oC for 15 minutes.  Heat labile 
solutions including calcium chloride and antibiotics were filter sterilized using Millipore 0.2µM 
filters. 
 
 
2.1.2  Bacterial cell culture 
 
Luria broth culture medium 
20g LB base/ litre dH2O, sterilized by autoclaving.  
 
LB agar 
20g LB base/litre dH2O, 1.5% Agar, sterilized by autoclaving.  LB Agar plates were prepared by 
pouring 25ml of cooled autoclaved LB agar into 90mm Petri dishes and allowed to cool.  Plates 
were then dried at 37
oC, sealed and stored at 4
oC until use. 
 
Media supplements / antibiotics 
Ampicillin stocks were made to a concentration of 100mg/ml and filter sterilized through a 0.2µM 
filter.  Stocks were aliquoted and stored at -20
oC.  These stocks were used to inoculate culture 
media (LB and LB Agar) after autoclaving, at a final concentration of 100µg/ml. 
 
To prepare agar supplemented with ampicillin for blue / white colour screening plates, 5% w/v X-
Gal in Di-methyl Formamide was prepared and used to supplement the autoclaved agar to a final 
concentration of 0.02% and 100µM IPTG was prepared and filter sterilized and added to a final 
concentration of 0.5µM. 
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2.1.3 DNA  purification 
 
TNES 
50mM Tris pH 7.5, 400mM NaCl, 100mM EDTA, 0.5% SDS, stored room temperature 
 
RNAse A (DNAse free) 
RNAse A 1mg/ml in 10mM Tris pH7.5, 15mM NaCl, boiled for 15 minutes and cooled slowly to 
room temperature.  Stocks are aliquoted and stored at -20
oC. 
 
Mini prep solution I 
50mM glucose, 25mM Tris.Cl pH 8.0, 10mM EDTA pH 8.0.  Autoclaved, stored 4
oC. 
 
Mini prep solution II 
0.2N NaOH freshly diluted from 10N stock, 1% SDS.  Stored at room temperature. 
 
Mini prep solution III 
60ml 5M KAc, 11.5ml glacial acetic acid, 28.5ml dH2O, resulting in a solution that is 3M with 
respect to potassium and 5M with respect to acetate.  Stored at room temperature. 
 
Maxi prep sucrose-tris buffer 
25% sucrose, 50mM Tris pH 8.0, stored room temperature 
 
Maxi prep 3×triton buffer 
1.5ml Triton X-100, 7.5ml 1M Tris pH 8.0, 18.75ml 0.5M EDTA, 22.5ml dH2O.  Stored at room 
temperature. 
 
Maxi prep peg buffer 
10mM Tris pH 8.0, 1mM EDTA, 1M NaCl, 20% PEG 6000.  Autoclaved and stored at room 
temperature. 
 
 
2.1.4  Agarose gel electrophoresis 
 
1×Tris acetate EDTA buffer (TAE) 
0.04M Tris Acetate, 0.001M EDTA 
 
Agarose gel 
0.8%, 1% or 1.5% in 1×TAE 
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DNA loading solution 
20% Ficoll 400, 0.25% Orange G in 1×TAE buffer 
 
 
2.1.5 Cell  culture 
 
Phosphate buffered saline 
Prepared from tablets according to manufacturers instructions and autoclaved at 3 bar, 121
oC for 15 
minutes. 
 
3T3-L1 media 
10% foetal calf serum, 2mM L-Glutamine in Dulbecco’s modified Eagle’s medium (DMEM). 
 
3T3-L1 differentiation media 
3T3-L1 media supplemented with 0.5mM 3-isobutyl-1-methylxanthine, 0.25µM dex, 175nM 
insulin. 
 
HepG2 complete media 
DMEM supplemented with 10% fetal bovine serum, 2mM glutamine, 10U/ml penicillin and 
100ug/ml streptomycin. 
 
No adds media 
DMEM only. 
 
2×HBS 
A stock solution of 10×HBS (8.18% NaCl, 5.94% Hepes, 0.2% Na2 HPO4) was diluted to 2× with 
dH2O.  The 2× solution was then adjusted to pH 7.12 exactly using NaOH.  This was then filter 
sterilized and stored at 4
oC. 
 
HepG2 cell treatments 
Leptin stock solution 1mg/ml in dH2O, aliquoted and stored -20
oC.  Diluted in HepG2 complete 
media for appropriate concentration. 
 
CFA stock solution 100mM in 100% ethanol, made fresh.  Diluted in HepG2 complete media for 
appropriate concentration. 
 
Dex stock solution 1mg/ml in 100% ethanol, stored -20
0C.  Diluted in HepG2 complete media for 
appropriate concentration. 
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Stat3 Inhibitor 500µM in dH2O, stored -20
oC.  Diluted in HepG2 complete media for appropriate 
concentration. 
 
 
2.2 Methods 
 
2.2.1 Animal  methods 
 
All rat work was performed by the Liggins Institute, University of Auckland, New Zealand.  Rats 
used in the study were from an established model of fetal programming by maternal undernutrition 
227.   
 
Virgin Wistar rats age 100 ± 5 days were time mated and after mating housed in the same room in 
individual cages with free access to water, 12 hour light 12 hour dark cycle at a constant 
temperature of 25
oC.  Animals were allocated to either the undernutrition group (UN) (diet 30% of 
ad libitum) throughout gestation or the standard diet ad libitum (AD) throughout gestation.   
Recordings were made of maternal weight and food intake until pregnancy ended.  At birth all pups 
were weighed.  To ensure standardised nutrition of pups until weaning, litter size was adjusted to 8 
pups per litter.  Pups from the UN group were cross-fostered onto dams from the AD group.  At 
postnatal day 3 female pups from both AD and UN groups were randomly selected to receive either 
saline or recombinant rat leptin (L) (2.5µg/g/day) for a total of 10 days by subcutaneous injection 
(n=16/group).  From treatment period and until weaning, all animals were maintained on ad libitum 
diet.   At weaning, saline or leptin treated AD and UN offspring were weight matched and placed 
on either standard rat chow (C) or a high fat (HF) diet (Research Diets Inc no 12451, 45% kcal as 
fat).  At postnatal day 170, rats were fasted overnight and killed by halothane anaesthesia followed 
by decapitation, resulting in 8 treatment groups with 8 female adult offspring per group (figure 
2.1).   
 
All animal work was approved by the Animal Ethics Committee of the University of Auckland.  
Samples of liver and adipose tissue were provided snap frozen.   Maternal
Diet
(Throughout Gestation)
Neonatal
Treatment
(D3-D12)
Postnatal
Diet
(From Weaning)
Offspring
Group
(D170) (n=8)
Chow
Ad-libitum Fed
(AD)
Saline
Leptin
Chow
High Fat
High Fat
AD
AD HF
AD Leptin
AD Lep HF
30 % Ad-libitum Fed
(UN)
Saline
Leptin
Chow
High Fat
High Fat
UN
UN HF
UN Leptin
UN Lep HF
Chow
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1  Design of rat study.  Maternal and postnatal diet groups, treatments and timings 
are shown. 
 
 
2.2.2  Isolation and digestion of genomic DNA 
 
High salt genomic DNA isolation from liver tissue 
30mg of snap frozen tissue was ground under liquid nitrogen and incubated with 500µl TNES and 
2.5µl 20mg/ml proteinase K at 55
oC for 16 hours. 500µl 2.6M NaCl was added to make a final 
concentration of 1.5M and shaken vigorously for 15 seconds.  Samples were centrifuged at 
12,000rpm for 5 min and the supernatant removed to a new tube.  An equal volume of ethanol was 
added to the supernatant.  Precipitated genomic DNA was spooled into 500µl sterile water.  Quality 
and quantity of genomic DNA was checked on the NanoDrop ND-1000 (NanoDrop Technologies, 
Wilmington, USA.  All DNA had a 260/280 ratio of >1.7.  Genomic DNA was stored at -20
oC. 
 
Isolation of genomic DNA from adipose tissue 
30mg of snap frozen adipose tissue was ground under liquid nitrogen.  Isolation of DNA was then 
performed using the Wizard SV Genomic DNA Purification System according to manufacturer’s 
instructions (Promega, Southampton, UK).  DNA was eluted in sterile water.  Quality and quantity 
of genomic DNA was checked on the NanoDrop ND-1000 (NanoDrop Technologies, Wilmington, 
USA).  All DNA had a 260/280 ratio of >1.7.  Genomic DNA was stored at -20
oC. 
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Digestion of genomic DNA 
All genomic DNA for use in methylation sensitive real time PCR was cut with the methylation 
sensitive restriction endonucleases AciI (5’-C▼CGC) and Hinp1I (G▼CGC).  500ng genomic 
DNA was incubated with 5U of each enzyme at 37
oC for 24 hours in a total volume of 25µl.  The 
DNA was then analysed for digestion on a 0.8% agarose gel and then stored at -20
oC. 
 
 
2.2.3  Agarose gel electrophoresis of DNA/RNA 
 
All DNA/RNA used in experiments was checked for integrity, or for analysis of digestion on a 
0.8% agarose gel (genomic DNA), a 1% agarose gel (plasmid DNA/RNA) or a 1.5% agarose gel 
(PCR product) in 1× TAE buffer at 100v for 40 minutes. 
 
 
2.2.4  Isolation of RNA from liver, adipose, muscle and kidney tissue 
 
50-100mg of snap frozen tissue was ground under liquid nitrogen and 1ml TRI Reagent added.  
Samples were then spun 12,000rpm at 4
oC 10 minutes and supernatant removed to a clean tube.  
The lipid layer was also removed from adipose samples.  Extraction of total cellular RNA was then 
performed according to manufacturer’s instructions. All RNA was resuspended in DEPC treated 
water. Quality and quantity of RNA was checked on the NanoDrop ND-1000 (NanoDrop 
Technologies, Wilmington, USA) and diluted to 500ng/µl.  All RNA had a 260/280 ratio of >1.7.  
RNA was stored at -70
oC. 
 
 
2.2.5 cDNA  synthesis 
 
1µg total RNA was used as a template for cDNA synthesis and incubated with 500ng random 
primers, 1µl 10mM dNTP’s and 200U M-MLV Reverse Transcriptase according to manufacturer’s 
instructions.  cDNA was stored at -70
oC until use. 
 
 
2.2.6  Real time PCR 
 
Primers for real time PCR 
Real time PCR primers (table 2.2) were designed using Beacon Designer 2.0 software (Premier 
Biosoft, CA, USA).  For expression, primers were designed to span intron-exon boundaries or 
exons and for methylation specific PCR primers were designed within CpG islands (figure 2.2).    59
All primers were supplied by Invitrogen (Paisley, UK), made to a concentration of 100µM and 
stored at -20
oC. 
  
Real time PCR 
cDNA was amplified for quantification using 12.5µl SYBR Green JumpStart Taq Ready Mix, 1µl 
cDNA and forward and reverse primers to a final concentration of 0.2µM and made to a final 
volume of 25µl with DEPC treated water.  For methylation sensitive real time PCR, 25ng digested 
genomic DNA was used instead of cDNA.  Real time PCR was performed using the DNA Engine 
Opticon 2 Real Time PCR Detection System (MJ Research, MA, USA).  Cycling conditions were 
as follows; initial denaturation of 94
0C 2 minutes, followed by 40 cycles of 94
oC 30s, anneal at a 
primer specific temperature (table 2.2) 1 minute and extension at 72
oC 1 minute.  DNA samples 
were normalised to PPARγ2 which contains no AciI or HinP1I restriction sites and cDNA samples 
were normalised to either 18s (adipose tissue samples) or cyclophillin (Cyc) (liver tissue samples) 
and quantified using the ΔCt method 
228.   
 
Statistical analysis of real time PCR 
Statistical comparisons of gene expression between data groups were by a general linear model 
using maternal diet, leptin treatement and post-weaning diet as fixed factors with Bonferonni’s post 
hoc analysis.  For female and male liver expression analysis, a retrospective statistical power 
calculation was performed unsing an online statistical power calculator tool: 
www.dssresearch.com/toolkit/spcalc/power_a2.asp. 
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Table  2.2  Sequence and anneal temperatures of methylation sensitive PCR and real 
time PCR primers 
 
 
Gene 
 
Forward Primer (5’3’) 
 
Reverse Primer (5’3’) 
 
 
Temp 
 
Methylation-Sensitive PCR 
 
LR 
AOX 
Leptin 
PPAR  
PPAR 2 
GR 
11βHSD2 
PPAR γ1 
 
CATTTCCCACATCTGCTGCTG 
ACAATGAACCCTTTCCCGAACG 
GACCCGTCCTTAAACTACC 
TGTGTCTCGTTCTGAACCG 
GTCTCTGCTCTGGTAATTC 
CGTCTTGTTCCACCCACT 
GCGTGCCAATAGGCTCACA 
CGACTGTGAGGAGCAAGG 
 
CCCGAATGTCCTGCGTCCTG 
AGGAGAGCAAGGTAGAAGGTCAAG 
TGCCTGCCCCTCTTATAG 
TCCACCCACCTCACTGTC 
AAGGCTTGTGGTCATTGAG 
CCTTGCAGTTGCCGACAG 
TGGCTAGATCCGCTTTCGAA 
CCCAGGTCTCTTCTTCAG 
 
68.1 
60 
60 
52.9 
60 
61 
60 
60 
 
mRNA Expression 
 
Cyc 
CPT-1 
LPL 
LR 
18S 
AOX 
Leptin 
PPAR 
PPARαP1 
PPARαP2 
PPAR2 
GR 
11βHSD2 
GR 1 10 
Dnmt1 
Dnmt3a 
PEPCK 
IR 
HSL 
 
TTGGGTCGCGTCTGCTTCGA 
ACCACTGGCCGAATGTCAAG 
ACTCGCTCTCAGATGCCCTAC 
ATGCTGTGCAGTCACTCAGTG 
GTAACCCGTTGAACCCCATT 
CCAATCACGCAATAGTTCTGG 
CACACACGCAGTCGGTATCC 
CGGGTCATACTCGCAGGAAAG 
CGCAGCCTCAGCCAAGAC 
CTGGGTCCTCTGGTTGTC 
TATGCTGTTATGGGTGAAAC 
GGAGAATTATGACCACACTCAAC 
TGGCCACTGTGTTGGATTT 
TGACTTCCTTCTCCGTGACA 
QIAGEN Quantitect primer assay 
QIAGEN Quantitect primer assay 
AGCTGCATAATGGTCTGG 
ATGCCACCAATCCTTCCGTTCC 
ACGGAGATTGAGGTGCTATC 
 
GCCAGGACCTGTATGCTTCA 
AGCGAGTAGCGCATGGTCAT 
ATGTCCACCTCCGTGTAAATCAAG 
CAACTCCTTCCATAAATACTGGG 
CCATCCAATCGGTAGTAGTAGCG 
CGCTGTATCGTATGGCGAT 
AGGTCTCGCAGGTTCTCCAG 
TGGCAGCAGTGGAAGAATCG 
CTCTGTGTCCACCATGTTGAATG 
GCCTTGAACTTCAGTCTTGG 
TGGTAATTTCTTGTGAAGTGCTC 
GCAGTAGGTAAGGACATTCTCAA 
ATCGGCCACTACCATGTTG 
GGAGAATCCTCTGCTGCTTG 
QT00493577 
QT00429380 
GAACCTGGCGTTGAATGC 
GTCCTCCGCCTGCCTCTCC 
AGGTGAGATGGTAACTGTGAG 
 
60 
60 
60 
60 
60 
60 
60 
60 
60 
60 
60 
58 
60 
65 
55 
55 
53 
52.5 
52.5 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
+944 +1032
Exon 1
-609 -1037
-122 -471
+1 +252
-537 +259
PPAR α Exon 2
+8808 +8909
-247 -417
-195 -594
+1 +342
-196
+223
AOX Exon 2 Exon 1
+21670 +21736
+200 -107
+1 +414
-128
+267
PPAR γ1 Exon 1 Exon 2
+9270 +9447
-188 -325
-14 -297
+1 +29
-563 -400
Leptin Exon 2 Exon 1
+199 +517
-188 -325
-14 -297
+1 +97
-563 -400
LR Exon 2 Exon 1
-2207
1 10 1 9 1 8 1 7 1 6 1 5 1 4
+1 +1249 -2547 -1698 -2407 -1805 -2469 -2831 -2731 -2924 -2976 -3264 -3317 -3533 -3587 -4005 -4213
Exon 2 GR
-4186
-2455 -2758
-3173 -1750 -3268 -3577 -3878
1 11
-4056
+3393 +3605
-110 -270
+21 -358
+1 +390
+39 +419
11βHSD2 Exon 2 Exon 1
 
Figure 2.2  A schematic diagram showing the location of MSP amplicons relative to CpG 
islands for all MSP amplicons.  The first 2 exons are shown for each gene in red.  The position of 
methylation sensitive PCR amplicons and CpG islands relative to exons are shown by pink arrows 
and black dashed arrows respectively. 
 
 
2.2.7 Gene  cloning 
 
Ligation 
Insert DNA was ligated to vector DNA at a insert:vector molar ratio of 3:1 using 3U T4 DNA 
ligase in a total volume of 10µl.  Ligations were incubated at 4
oC overnight.  Ligations without 
insert DNA were included as a negative control. 
 
Preparation of competent DH5α cells 
DH5α cells were made competent just prior to transformation to enhance their ability to take up 
DNA.  A single colony of DH5α cells was picked from an LB agar plate and used to inoculate 
10ml LB.  This was incubated for 16hrs at 37
oC with agitation to bring cultures to the stationery 
phase.  An aliquot of cells were then removed and diluted 1:100 with fresh LB and incubated at 
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37
oC with agitation until cultures had reached an OD600 of 0.6 whereby cells had reached the 
exponential phase.  Cultures were then centrifuged at 3,000rpm 5 min at 4
oC and pellets were 
resuspended in 5ml ice cold filter sterile 100mM CaCl2.  Cells were then centrifuged again at 
3,000rpm for 5 min and resulting cell pellets resuspended in 500µl ice cold filter sterile 100mM 
CaCl2.  Competent DH5α cells were kept on ice until needed. 
 
Transformation into DH5α bacterial cells 
All plasmid constructs prepared were transformed into competent DH5α cells.  2µl ligated plasmid 
DNA or 0.5µl complete plasmid DNA were added to pre-chilled eppendorf tubes and kept on ice.  
Next, 100µl competent DH5α cells were added to the DNA and samples mixed well.  DNA/cell 
mixtures were incubated on ice for 30 minutes and then subjected to a heat shock 2 minutes at 42
oC 
to allow the cells to take up the DNA.  Cells were then subjected to a further incubation on ice for 
20 minutes.  Next 400µl LB was added to the samples which were subsequently incubated at 37
oC 
for 60 minutes with shaking.  Cells were then centrifuged at 3,000rpm 5 minutes and all but the last 
100µl supernatant discarded.  Cell pellets were then resuspended in the remaining LB and spread 
over LB agar plates supplemented with 100µg/ml ampicillin.  The use of ampicillin in the medium 
enables transformants to be distinguished from non-transformants, as only the cells which have 
successfully taken up plasmids containing the Amp
r gene will survive.  Plates were incubated 
overnight inverted at 37
oC and then sealed and stored at 4
oC until needed.   
 
Preparation of glycerol stocks 
Single colonies were picked from agar plates and used to inoculate 10ml LB.  This was incubated 
at 37
oC overnight with agitation.  500µl of LB was then added to 500µl of a 50% LB/50% Glycerol 
solution and mixed well.  Glycerol stocks were stored at -80
oC. 
 
Purification of plasmid DNA 
Glycerol stocks were streaked out onto agar plates containing 100µg/ml ampicillin.  Colonies were 
allowed to grow overnight at 37
oC.  Single colonies were then picked and used to inoculate 10ml 
LB containing 100µg/ml ampicillin.  For small scale plasmid preparations, cultures were grown 
overnight at 37
oC with agitation.  For large scale plasmid preparations, cultures were grown to an 
DO600 of 0.6, then used to inoculate 500ml LB containing 100µg/ml ampicillin and allowed to grow 
overnight at 37
oC with agitation. 
 
For small scale plasmid DNA preparations, 10ml cultures were centrifuged at 3,500 rpm for 10 min 
at 4
oC.  Cell pellets were resuspended in 100µl of solution I and incubated at room temperature for 
5 minutes.  Next, 200µl of solution II was added, mixed well and incubated on ice for 5 minutes.  
150µl solution III was then added, mixed well and incubated on ice for 15 minutes.  Cell lysates 
were then centrifuged at 12,000 rpm for 10 minutes and the supernatant removed to a clean 
microfuge tube.  500µl of a 50:50 phenol:chloroform mix was added to the supernatant and mixed   63
well.  This was then centrifuged at 12,000 rpm 5 minutes and the top aqueous layer removed.  The 
DNA was then precipitated using 1/10
th volume of 3M NaAc pH5.2 and 2 volumes of ethanol.  
This was incubated at -20
oC for 20 minutes and then centrifuged at 12,000 rpm for 15 minutes.  
The resulting DNA pellet was resuspended in 50µl dH2O.  To remove RNA from manual DNA 
preparations, RNAse A was added to a final concentration of 10µg/ml and incubated at 37
oC for 60 
minutes.  DNA was then cleaned again using the phenol-chloroform and ethanol precipitation 
procedure.  When DNA was needed for DNA sequencing submission, plasmid DNA was purified 
using QIAprep Spin Miniprep Kit (Qiagen, Crawley, UK) according to manufacturer’s instructions. 
 
Large scale preparations of plasmid DNA were prepared for cell culture experiments.  500ml cell 
cultures were centrifuged at 3,000 rpm at 4
oC for 20 minutes.  Cell pellets were resuspended in 4ml 
sucrose tris buffer and 100µl of 40 mg/ml lysozyme and incubated on ice for 15 minutes.   Next, 
EDTA was added to a final concentration of 10mM and incubated on ice for 15 minutes.  ½ volume 
of 3×triton buffer was then added to the cell lysate, mixed well and incubated on ice for 60 
minutes.  This was then centrifuged at 18,000 rpm for 90 minutes at 4
oC.  The supernatant was 
removed to a clean tube and NaCl added to a final concentration of 0.5M.  Next, an equal volume 
of phenol:chloroform mixture added, mixed well and then centrifuged at 4,000 rpm for 10 minutes.  
The top aqueous layer was then removed to a clean tube and an equal volume of chloroform added 
and mixed well.  This was then centrifuged at 3,500 rpm for 10 minutes and the top aqueous layer 
removed.  PEG was added to a concentration of 10% w/v and this was dissolved at 37
oC for 20 
minutes.  This solution was then incubated at 4
oC overnight.  The next day, this was centrifuged at 
12,000 rpm for 20 minutes and the resulting pellet re-dissolved in 500µl 0.1M tris pH 8.0 and 
RNase.  This was incubated at 37
oC for 30 minutes.  Next, 500µl PEG buffer was added and 
incubated on ice for 60 minutes.  This was then centrifuged at 12,000 rpm for 15 minutes and the 
resulting pellet re-dissolved in 400µl of 10mM tris pH 8.0, 0.5M NaCl.  The resulting DNA 
solution was then subjected to phenol:chloroform extraction and ethanol precipitation as previously 
described.  All DNA preparations were checked for integrity on a 1% agarose gel and for 
concentration and purity 2µl was measured on the NanoDrop. 
 
 
2.2.8  5’ RNA ligase mediated rapid amplification of cDNA ends (5’ RLM RACE) 
 
RACE procedure 
5’ ends of RNA were amplified using a 5’RLM RACE kit (Ambion, Austin, USA) according to 
manufacturer’s instructions.  Briefly, 10µg total RNA from liver, adipose, muscle and kidney were 
incubated with calf intestinal alkaline phosphatase (CIP) for 1hr at 37
oC to remove free 5’ 
phosphates from any degraded / fragmented RNA or contaminating DNA.  RNA was then cleaned 
by adding 15µl ammonium acetate, 115µl nuclease free water and 150µl phenol:chloroform.  This 
was vortexed and centrifuged at 12,000rpm for 5 minutes.  The top aqueous layer containing the   64
RNA was precipitated by adding 150µl isopropanol and then chilled on ice for 10 minutes.  The 
RNA was pelleted by centrifuging at 12,000rpm for 20 minutes and the resulting pellet washed in 
70% ethanol.  The RNA pellet was next resuspended in 11µl nuclease free water and incubated 
with tobacco acid pyrophosphatase (TAP) for 1hr at 37
oC to remove the CAP structure from all the 
intact RNA.    The TAP treated RNA was then incubated with 5’ RACE adapter and T4 RNA 
ligase for 1hr at 37
oC.  2µl of ligated RNA was used in a standard reverse transcriptase reaction. 
 
PCR 
In order to amplify the 5’ region of PPARα mRNA generated from the 5’RLM RACE, nested gene 
specific reverse primers for PPARα were designed to use with the standard forward 5’ RACE 
primers.  These primers were designed so that the 5’ end of the transcript would be amplified 
without giving too large a product (figure 2.3).  A forward gene specific primer was also designed 
to ensure that the mRNA population being investigated contained the transcript of interest.  Primers 
were evaluated using Netprimer software (Premier Biosoft Int, Palo Alto, USA).  All primers were 
supplied by Invitrogen (Paisley, UK), made to a concentration of 100µM and stored at -20
oC.  For 
primer sequences, see (table 2.3).   
 
2µl liver 5’RLM RACE cDNA and 5µl of adipose, kidney and muscle 5’RLM RACE cDNA were 
amplified using 1.25U Promega Taq DNA polymerase with MgCl2 to a final concentration of 
1.5mM, forward and reverse primers to a final concentration of 0.4µM and dNTP’s at a final 
concentration of 0.2µM each in a total volume of 50µl.   2µl or 5µl outer PCR product was used as 
template for the nested PCR with the same conditions.  PCR was performed using the PCR Express 
PCR machine DNA (Thermo Fisher Scientific, Epsom UK).  Cycling conditions for both outer and 
nested PCR were as follows; initial denaturation of 94
0C 3 minutes, followed by 35 cycles of 94
oC 
30s, anneal at a 60
oC 30 sec and extension at 72
oC 1 minute 30 sec.  Resulting PCR products from 
the inner PCR reaction were gel extracted using QIAquick Gel Extraction Kit (Qiagen, Crawley, 
UK) and 2µl measured on the NanoDrop.  Purity of bands was checked by agarose gel 
electrophoresis. 
 
Cloning RACE PCR products using Promega pGEM T-Easy vector system 
25ng of each purified Liver (P2 and P3) and Adipose (P1) RACE PCR product was ligated with 
50ng pGem T-Easy cloning vector (Promega, Southampton, UK) for a 3:1 insert:vector molar ratio.  
This cloning vector has single 3’-T overhangs (figure 2.4) and PCR products generated by Taq 
DNA Polymerase have a single deoxyadenosine added to the 3’-ends, allowing easy ligation to the 
pGem T-Easy vector.  In addition, the vector contains the Amp
r gene.  Ligations were transformed 
into competent DH5α cells and plated out onto XGal-IPTG-ampicillin agar plates.  Successful 
ligation of inserts into this vector interrupts the coding region of β-galactosidase and this allows 
recombinants to be identified by colour screening; positive colonies are white, whilst negative 
colonies blue.  Positive white colonies were picked and grown in 10ml LB supplemented with 100µG/ML ampicillin at 37
oC overnight with agitation.  These cultures were used to prepare small 
scale plasmid preparations.  The pGem T-Easy vector has EcoRI restriction sites either side of the 
cloned insert within the multiple cloning region (figure 2.4).  To confirm presence of the RACE 
insert in the vector, 500ng of all DNA preparations were digested with 12U of the restriction 
endonuclease EcoRI in a total volume of 10µl at 37
oC for 60 minutes (figure 2.5).  Positive clones 
for liver and adipose samples were sequenced by university of Dundee sequencing service using a 
T7 sequencing primer (Dundee, UK).  The muscle and kidney RACE PCR products were 
sequenced directly by the University of Dundee sequencing service using the gene specific reverse 
inner primer.  In addition to this, a PPARα heart RACE PCR product prepared by Dr Jo Slater-
Jefferies using the same primers was also sequenced directly by the University of Dundee. 
 
 
 
 
 Table 2.3  Gene specific primer sequences for PPARα  5’ RLM RACE 
 
 
Primer 
 
                                          Sequence (5’ → 3’) 
  
 
 
Gene Specific Forward 
Gene Specific Reverse Outer 
Gene Specific Reverse Inner 
TTCGTGGAGTCCTGGAACTGAA 
AGCCTTCACATGCGTGGACT 
TGACTGAGGAGGGGCTGGAA 
 
   
 
 
 
 
 
 
 
 
 
 
   
 
  500bp 
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Figure 2.3  Locations of primers for PPARα 5’ RLM RACE.  (A) 5’ RLM Race Nested 
PCR Design.  (B) First 5 exons of PPARα mRNA Transcript (Ensembl Transcript ID: 
ENSRNOT00000030082) showing location of gene specific RACE primers.  Exons 1-5 are 
indicated in alternating blue and black.  Forward GS primer is shown in green highlight, reverse GS 
primers in yellow highlight.  Primers were designed to give as small a product as possible, but far 
enough into sequence to ensure that RACE products would amplify.  EcoRI restriction enzyme site 
is shown in blue highlight. 
 
 
 
5’ RACE Adapter PPARα mRNA Transcript
5’ RACE 
Outer Primer
5’ RACE 
Inner Primer
Gene Specific
5’ Primer
5’ RACE Gene 
Specific Inner Primer
5’ RACE Gene 
Specific Outer Primer
Around
150bp
B 
A 
 GAACTGTCCGCTACTTCGAGTCCCCTTGAGCGCCGTGTGCCGGCTCTGAACATTGGCGTT   
 
 Exon 1  CGCAGCTGTTTTGTGGGCTGGAGGGTTCGTGGAGTCCTGGAACTGAAGCGACGCTGGGTC 
  
 CTCTGGTTGTCCCCTTGAGGGGAGGGCACACGAGCGGGGACATCGGGGCGCTCCCTTCCC   
  
 ACAGCGTGGTGCATTTGGGCGTAACTCACCGGGAGGCGTTTCCTGAGACCCTCGGGGATC   
  
 TTAGAGGCGAGCCAAGACTGAAGTTCAAGGCCCTGCCTTCCCTGTGAACTGACATTTGTG  
 
 Exon 2  ACTGGTCAAGCTCAGGACACAAGACGTTGTCATCACAGATTGGTGCTCTGTGGCCCGCCT  
 
 GGCCACAACCATTCAACATGGTGGACACAGAGAGCCCCATCTGTCCTCTCTCCCCACTTG   
 
 Exon 3  AAGCAGATGACCTGGAAAGTCCCTTATCTGAAGAATTCTTACAAGAGATGGGAAACATTC  
 
 AAGAGATTTCTCAGTCCCTCGGAGAGGAGAGTTCCGGAAGCTTTAGTTTTGCGGACTACC   
 
 AGTACTTAGGGAGCTGTCCAGGCTCGGAGGGCTCTGTCATCACAGACACCCTCTCTCCAG  
 
 Exon 4  CTTCCAGCCCCTCCTCAGTCAGCTGCCCTGCTGTCCCCACCAGTACAGATGAGTCCCCTG  
 
 GCAATGCACTGAACATCGAGTGTCGAATATGTGGGGACAAGGCCTCAGGATACCACTATG   
 
 GAGTCCACGCATGTGAAGGCTGCAAGGGCTTCTTTCGGCGAACTATTCGGCTAAAGCTGG  
 
 Exon 5  CGTACGACAAGTGTGATCGAAGCTGCAAGATTCAGAAAAAGAACCGGAACAAATGCCAGT  
 
 ACTGCCGTTTCCACAAGTGCCTGTCCGTCGGGATGTCACACAATGCAATCCGTTTTGGAA  
B  C 
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A 
B 
 
Figure 2.4  Circular map and multiple cloning region of the pGem T-Easy plasmid.  (A) 
pGem T-Easy vector circle map showing ampicillin resistance, β- Galactosidase coding region and 
multiple cloning region. (B)  Detailed view of multiple cloning region including 3’-T overhangs, 
T7 promoter and location of EcoRI restriction sites.   
 
 
 
 
 
 
 
 
 
 
     1Kb 
 
 
  500bp 
1Kb           Neg              Neg              P2             P2               P3             P3               P1              P1                P1               P1 
Ladder    Uncut          EcoRI       Clone 4     Clone 4      Clone 6     Clone 6      Clone 3      Clone 3      Clone 5      Clone 5 
                                                        Uncut        EcoRI        Uncut        EcoRI        Uncut         EcoRI        Uncut         EcoRI    
 
Figure 2.5  Digests of PPARα liver and adipose 5’ RACE PCR - pGEM T-Easy clones 
with EcoRI.  A selection of RACE product-pGEM T-Easy clones were digested with EcoRI, 
whereby successful recombinants will drop out the appropriate sized insert (Liver P2 800bp, Liver 
P3 450bp and Adipose P1 450bp).  Digests are shown for each clone without and with EcoRI.  As 
each insert also contains an EcoRI site, approximate sizes of insert fragments are; P2 550bp+ 
250bp, P3 250bp+200bp, P1 250bp+200bp. 
 
 
2.2.9 pGL3  Basic  constructs 
 
PPARα promoter constructs 
Primers were designed to amplify 1-1.5Kb of upstream sequence from the transcription start site 
for the adipose specific transcript (P1), liver specific transcript (P2) and the liver specific transcript 
(P3).  Primers were designed to contain a SacI/XhoI restriction site at the 5’ end of the forward 
primer and a HindIII restriction site at the 5’ end of the reverse primer (figure 2.6) to allow cloning 
of PCR fragments into the pGL3 Basic reporter vector (Promega, Southampton, UK)  (figure 2.7).  
Use of 2 different restriction sites allows easy cloning into the pGL3 reporter vector in the correct 
orientation.  In addition, primers contained an extra 2 bases at the 5’ end of each primer to permit 
efficient digestion of amplified promoters for cloning.  Primers were evaluated using Netprimer 
software (Premier Biosoft Int, Palo Alto, USA).  All primers were supplied by Invitrogen (Paisley, 
UK), made to a concentration of 100µM and stored at -20
oC.  For primer sequences see (table 2.4).   
 
The pGL3 basic reporter vector contains a modified gene for firefly luciferase, but lacks any 
functional promoter or enhancer sequences.  Presence of the Amp
r gene within the vector allows 
transformants to be identified from non-transformants.  Firefly luciferase catalyses a 
bioluminescent reaction, in which luciferin is converted to oxyluciferin, producing light in the 
process.  Insertion of PPARα regulatory DNA into the multiple cloning region of the vector allows 
its activity to be assessed in transfected eukaryotic cells by measuring luminescence.   
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5µg of the pGL3 Basic vector was digested with 25U each of either XhoI and HindIII or SacI and 
HindIII in a total volume of 50µl at 37
oC for 60 minutes.  Digested vector was checked on an 
agarose gel for completion and gel extracted using QIAquick Gel Extraction Kit (Qiagen, Crawley, 
UK).  DNA was quantified using the NanoDrop. 
 
100ng rat genomic DNA (female liver sample 1.0.0) was used as a template for PPARα promoter 
PCR.  DNA was amplified using 1.25U Pfu DNA polymerase (P1, P2) and Taq DNA polymerase 
(P3) with and forward and reverse primers to a final concentration of 0.4µM and dNTP’s at a final 
concentration of 0.2µM each and 10µl GC solution, in a total volume of 50µl.   PCR was 
performed using the PCR Express PCR machine DNA (Thermo Fisher Scientific, Epsom UK).  
Cycling conditions for PCR were as follows; initial denaturation of 94
0C 2 minutes, followed by 40 
cycles of 95
oC 45s, anneal at a 60
oC 45 sec and extension at 72
oC 5 minutes.  Resulting PCR 
products were gel extracted using QIAquick Gel Extraction Kit (Qiagen, Crawley, UK).   
 
All gel extracted PCR products were digested with 10U each of either XhoI and HindIII, or SacI 
and HindIII in a total volume of 25µl at 37
oC for 60 minutes.  Digested PCR product was cleaned 
using QIAquick PCR Cleanup Kit (Qiagen, Crawley, UK).  Purity of products was checked by 
agarose gel electrophoresis (figure 2.8) and 2µl product was measured on the NanoDrop. 
 
Digested pGL3 Basic vector was ligated with the digested PPARα promoter fragments at a molar 
ratio of 1:3.  These ligations were then transformed into DH5α cells.  Individual colonies were 
picked and grown in 10ml LB supplemented with 100µg/ml ampicillin at 37
oC overnight with 
agitation.  These cultures were used to prepare small scale plasmid preparations.  To confirm 
presence of the PPARα promoter inserts in the pGL3 Basic vector, 500ng of all DNA preparations 
were digested with 6U each of either XhoI and HindIII or SacI and HindIII in a total volume of 
10µl at 37
oC for 60 minutes (figure 2.9).  Positive clones were sequenced by university of Dundee 
sequencing service using a pGl3 Basic sequencing primer (GL primer 2 see figure 2.8B).   
Subsequent reporter constructs were named P1- pGL3 (adipose specific), P2-pGL3 (liver P2 
specific) and P3-pGL3 (liver P3 specific).  
 
 
 
 
 
 
 
 
P1 Promoter 1019bp HindIII SacI
P3 Promoter 1456bp HindIII XhoI
P2 Promoter 1189bp HindIII SacI
Figure 2.6  Pictorial representation of the PPARα promoter constructs showing the 5’ 
and 3’ restriction sites for cloning.  The P2 promoter construct (1189bp) and P1 promoter 
construct (1019bp) have a 5’ SacI restriction site (GAGCTC) and a 3’ HindIII restriction site 
(AAGCTT).  The P3 promoter construct (1456bp) has a 5’ XhoI restriction site (CTCGAG) and a 
3’ HindIII restriction site (AAGCTT). 
 
 
 
Table 2.4  Sequences of the PPARα promoter cloning primers 
 
 
Primer 
 
Forward Primer 
Sequence 5’→3’ 
 
Reverse Primer 
Sequence 5’→3’ 
 
P1, P2 
P1  
P2  
P3  
 
 
ATGAGCTCAGCAGCGTCCTGAGGCGTT 
 
 
ATAAGCTTGGAGTCTTCCTTCTGGTT 
 
 
ATAAGCTTACCTGAGGCTGCGCTCCG 
ATAAGCTTGTGCCCTTCCTAGCGTGT 
ATACTCGAGTCTGCGTGGGTGTCTAAT 
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Figure 2.7  Circular map and multiple cloning region of the pGL3 basic reporter vector.  (A)  
Circular map showing location of multiple cloning region, luciferase gene and Amp
r.  (B) Detailed 
view of pGL3 Basic multiple cloning region showing location of the GL primer 2 and cloning 
restriction sites. 
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         1Kb                    pGL3                   pGL3                  P1                        P2                        P3  
    Ladder                  Basic                    Basic               HindIII              HindIII                HindIII 
                                   H+S                     H+X                  SacI                     SacI                    XhoI 
   1.6Kb 
 
 
     1Kb 
 
 
 
 
   500bp 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  2.8  Digested and gel extracted pGL3 basic vector and PPARα promoter 
fragments.  Digested gel extracted DNA is shown for pGL3 Basic (4818bp) and the PPARα 
promoter fragments; P1 (1019bp), P2 (1189bp), P3 (1456bp). 
 
 
 
 1 Kb          pGL3                 P1                 P1                   P2                   P2                     P3                  P3 
 Ladder      Basic                pGl3            pGL3              pGL3             pGL3               pGL3            pGL3 
                  Uncut               Uncut             H+S              Uncut               H+S                Uncut             H+X 
 
 
 
 
 
 
 
   
 
 
 
  1.5Kb 
 
     
    1KB 
 
 
 
 
 
 
 
 
 
Figure 2.9  Digests of PPARα promoter-pGL3 basic clones to drop out promoter insert.  
Clones for P1-pGL3, P2-pGL3, P3-pGL3 are shown with and without restriction enzymes to drop 
out insert (P1+P2 HindIII and SacI, P3 HindIII and XhoI).  Correct size inserts are shown for P1 
1019bp, P2 1189bp and P3 1456bp. 
  72PPARα promoter-pGL3 5’ deletion mutants 
PPARα promoter-pGL3 5’ deletion constructs were generated using exactly the same procedure as 
the normal PPARα promoter-pGL3 constructs, except 50ng PPARα P2-pGL3 construct was used 
as the DNA template for PCR.  Primers were designed to amplify the P2 promoter using the same 
reverse primer, but using forward primers which generated products which progressively lost 
200bp from the 5’ end of the promoter (figure 2.10, 2.11, table 2.5).   Primers were evaluated using 
Netprimer software (Premier Biosoft Int,  Palo Alto, USA).  All primers were supplied by 
Invitrogen (Paisley, UK), made to a concentration of 100µM and stored at -20
oC.  Subsequent 
constructs were named according to their size; A 198bp, B 462bp, C 598bp, D 845bp, E 1096bp 
(figures 2.12, 2.13).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
P2- pGL3 1189bp
+42 -1147
“E” 1096bp
+42 -1054
”D” 845 bp
+42 -803
“C” 598 bp
+42 -556
“B” 462 bp
+42 -420
“A” 198 bp
+42 -156
Luciferase
Luciferase
Luciferase
Luciferase
Luciferase
P1- pGL3 1019bp
-128 -1147
Luciferase
Luciferase
CpG Island
+1 +319 -131 -191
P1 Exon 1 P2 Exon 1
-970 -542 -470 +326 CpG Island
Sp1
CpG Island
Figure 2.10  Schematic representation of the PPARα promoter 5’ deletion mutant pGL3 
Basic constructs.  PPARα deletion promoter constructs are shown relative to the P2 transcription 
start site (+1).  The red bars represent the promoter deletion mutant and the yellow bars represent 
pGL3 Basic.  Location of promoters is also shown relative to P2 exon 1, P1 exon 1, CpG islands 
and Sp1 consensus sequence within region of P2 promoter which is not present in P1 promoter. 
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For AGCAGCGTCCTGAGGCGTTGGCACCCCGGGGGCTATGTGCATTCCGTGATCAGA   
 
 GATCCAGGGGTGAAGCAAACAAAGCGGTTGCTCCCAGTCGCAGCCTGCCCCCTGCGCTGT 
                                                          GCTGT  
 CAGTTGGCAGAGTCCCAGTGCCTGAGCTGGACATAGTCAGCCCCTCAACTTCCCCCTTCC 
 CAGTTGGCAGAGT  For E Primer (1096bp) 
 CCCAGCGTACACAGAGGGGCCGCAGCCCGGGGCGGGGCAGAGGCGGAGGGTCGAAGCGGC 
 
  CGCGCCTCCCCGCGACCGTCCTCGATGCCCTTCAGCCTCTGCCTTCCCCGCCCGCCACAC 
 
  CCACCCTGGCACCTCCGACACCTGTTGCCGCGTGCCCCAGCTCGCTCTTCCTTTCTCCCC 
 
  ATTTCGCATCCTGGGGCTCTGAAGATCAGATCCCGCCTGCCCGCCCGCCACCCCACGAAG  
             CATCCTGGGGCTCTGAAG For Primer D (845bp)
  TCCCGGGACTCGGGGCACGCGCTCCACGATCTAGACCAGTTCACCGAGGGCACCCGGTGG 
 
  GAAGCTCTACCAGACCCGCAGCCTTGAACTTCAGTTCTGGCCGGTGCGCGGGGCTGGGAG 
 
  CAGAAAGGCGCGCTCGCCCAGGCGCGCCCTTCCCACAGGGCTGTCTCGCCCGTCGGGTGA 
 
  CCTTGGGCAGTCCCTTCACCTAGCCAGCCTCAGTTTACCAACAGATGCCCGAGCCCCGAG  
               CTTCACCTAGCCAGCCTC For Primer C (598bp) 
 GCACTAAATGGGCATCGAGGAGAACTGCCCAGGGCCTCTTAGGCCCCGCCCTCACAGCAG 
 
  CGGCCAATCAGATGCTGCCGTCCGGGGGGTGTGTCTCGTTCTGAACCGCGGCCCGGGCCT  
                           (462bp)TGTGTCTCGTTCTGAAC For Primer B 
  AGAGGGCGGGGTTTCCGGGGCGGTCACCTCGCCGCGGGACCCCGCAGGGGACGTCCGAGG 
 
  GGCGGCGCGTGTCGTGGGGGCGCGGCTGGCACGGGCGCGCGTAGGCGGTGCCGGGCAGGG 
 
  GCCCCGGACGCTGCGGCCCCACGACAGGGGTGACGGGGGCGGAGACAGCCGCTCGAGCCC 
 
P1 Rev  CTCCTGGCGCCGCCTACCCGGGCGGGCTGGCCCTGCGGACCCGCAGGCGGAGCGCAGCCT  
                                                             GCAGCCT 
  CAGGTGCCCAGGGGCGGGAGGGCACGCGCGAGGACGGGAGCCAGGCGTCCCCCGTCCCGG 
    CAGGTGCCCAG For A Primer (198bp) 
  GACAGTGAGGTGGGTGGACAGGGAGGGGAGGGGCTCGGTGGCGCATGCGCGTGGACCAGG  
    GACAGTGAGGTGGGTGGA  For Primer F (114bp)
P2 Rev  GGCGCGGGTCTGGAGACCCACAGCCACTGGCGAGGGCACACGCTAGGAAGGGCAC    
                 Rev Primer      ACACGCTAGGAAGGGCAC  
 
 
Figure  2.11  Location of primers used for PPARα promoter 5’ deletion mutants.  The 
original PPARα promoter cloning primers are shown in yellow highlight.  The reverse primer for 
PPARα promoter 5’ deletion mutants is shown in blue highlight and is the same as the original P2 
reverse primer.  Forward primers for deletion mutants are shown in red and the size of the PCR 
product is indicated.  P2 transcription start site is shown in green and P1 start site is shown in pink.  
The 2 CpG islands are shown in bold and underlined. 
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Figure  2.12  Gel extracted PPARα promoter 5’ deletion mutant PCR products.  Gel 
extracted PCR products of the correct size are shown for deletion mutant A (198bp), B (462bp), C 
(598bp), D (845bp), E (1096bp) and F (115bp). 
 
 
 
 
 
 
 
 
 
 
 
 
    1Kb 
 
  
 500bp 
        1Kb                “A”                  “B”                 “C”                    “D”                  “E”                   “F” 
      Ladder            198bp              462bp             598bp                 845bp              1096bp              115bp 
   
    1.5Kb 
 
    1Kb 
 
 
     1Kb         “A”         “A”          “B”        “B”         “C”        “C”          “E”        “E”               “D”          “D”         1Kb 
   Ladder     pGL3     pGL3      pGL3     pGL3      pGL3     pGL3       pGL3     pGL3           pGL3       pGL3     Ladder 
                    Uncut       H+S      Uncut      H+S       Uncut       H+S       Uncut      H+S            Uncut       H+S 
 
 
  
 1.5Kb 
 
    1Kb 
 
 500bp 
Figure 2.13  Digests of PPARα promoter 5’ deletion mutant-pGL3 basic clones to drop out 
the promoter insert.  Clones for the deletion mutants A-E are shown with and without HindIII + 
SacI restriction enzymes to drop out the promoter insert.  Correct size inserts are shown for 
Deletion mutant A (198bp), B (462bp), C (598bp), D (845bp) and E (1096bp). 
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Table 2.5   Sequences of the PPARα promoter deletion mutant primers 
 
  
Primer 
 
Primer Sequence 5’→3’ 
 
PPARα Del Mut A For  
PPARα Del Mut B For 
PPARα Del Mut C For 
PPARα Del Mut D For 
PPARα Del Mut E For 
PPARα Del Mut F For 
 
GCAGCCTCAGGTGCCCAG 
TGTGTCTCGTTCTGAAC 
CTTCACCTAGCCAGCCTC 
CATCCTGGGGCTCTGAAG 
GCTGTCAGTTGGCAGAGT 
GACAGTGAGGTGGGTGGA 
 
Production of P2-pGL3 Sp1 mutants 
Primers were designed to mutate the Sp1 consensus site within the unique region of the PPARα P2 
promoter.  Two sets of mutagenic primers were designed; the first set to change the internal CG of 
the Sp1 consensus sequence GGGCGG to an AT and the second to change it to an EcoRI 
restriction site (GAATTC).  Primers were designed using the QuikChange® Primer Design 
Program (Stratagene, Texas, USA).  All primers were supplied by Invitrogen (Paisley, UK), made 
to a concentration of 1µg/μl and stored at -20
oC.  For primer sequences see table 2.6. 
 
The Stratagene QuikChange method of mutagenesis was used to mutate the Sp1 site.  30ng and 
50ng of the PPARα P2-pGL3 construct was used as a template for Sp1M QuikChange PCR.  DNA 
was amplified using 1.5U Pfu DNA polymerase with and forward and reverse primers to a final 
concentration of 0.4µM, dNTP’s at a final concentration of 0.2µM each and 10µl GC solution in a 
total volume of 50µl.   PCR was performed using the PCR Express PCR machine DNA (Thermo 
Fisher Scientific, Epsom UK).  Cycling conditions for PCR were as follows; initial denaturation of 
95
0C 2 minutes, followed by 18 cycles of 95
oC 30s, anneal at a 60
oC 1 min and extension at 72
oC 4 
minutes, followed by a final extension at 72
oC for 5 minutes.  Resulting PCR products (figure 2.14) 
were digested with the restriction enzyme DpnI at 37
oC for 1 hour.  This enzyme digests the 
sequence G
meA
▼TC found on the parental strands of the plasmid, leaving the newly formed strands 
intact.  Next, 4μl of digested PCR product was used to transform competent DH5α cells.   
Individual colonies were picked from the plates and grown in 10ml LB supplemented with 
100µg/ml ampicillin at 37
oC overnight with agitation.  These cultures were used to prepare small 
scale plasmid preparations.  To confirm mutation of the Sp1 site in the EcoRI mutant, 500ng of 
plasmid was digested with 6U of EcoRI at 37
oC for 60 minutes. As the pGL3 vector does not 
contain an EcoRI restriction site, the Sp1M AT mutants should not cut with the restriction enzyme, 
whereas the EcoRI positive mutants should (figure 2.15).  Sp1M RI and Sp1M AT clones were 
sequenced by university of Dundee sequencing service using the GL primer 2 pGl3 Basic Reverse 
Sequencing Primer (5’CTTTATGTTTTTGGCGTCTTCCA-3’).  Table 2.6  Sequences of PPARα P2 SP1 mutagenesis primers.  EcoRI site is shown in blue 
highlight and mutated sequence is in bold and underlined. 
 
 
Primer 
 
Primer Sequence 5’→3’ 
 
SP1M AT For 
SP1M AT Rev 
SP1M RI For 
SP1M RI Rev 
 
CAGGTGCCCAGGGATGGGAGGGCACGCG 
CGCGTGCCCTCCCATCCCTGGGCACCTG 
GCCTCAGGTGCCCAGGAATTCGAGGGCACGCGCGAGG 
CCTCGCGCGTGCCCTCGAATTCCTGGGCACCTGAGGC 
 
 
 
 
 
 
  NTC         SP1M                 SP1M                      NTC                    SP1M                    SP1M                       1Kb 
                      “AT”                  “AT”                                                    “RI”                      “RI”                     Ladder 
                    30ng                    50ng                                                     30ng                       50ng 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.14   PPARα P2 SP1M PCR products.  PCR products are shown for PPARα P2 
SP1M PCR, for the “AT” mutant and “RI” mutant, both 30ng and 50ng PCR reactions. 
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     1Kb                 P2                     P2                     P2                 Sp1M               Sp1M               Sp1M             Sp1M 
   Ladder           pGL3               pGL3                pGL3              ”AT”                “AT”                “RI”               “R1” 
                          Uncut              HindIII               SacI              Uncut                EcoRI              Uncut              EcoR1 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.15  Digests of PPARα P2 Sp1M-pGL3 basic clones.  Sp1M AT and R1 are shown 
with and without EcoRI restriction enzyme.  P2-pGl3 has no EcoRI restriction sites.  “AT” mutant  
is unable to cut with EcoRI, but the Sp1M RI construct, which has an EcoRI site instead of Sp1 site 
is able to be cut, indicating that mutagenesis has been successful.   
 
 
Methylation of PPARα promoter-pGL3 constructs with CpG and HpaII methyltransferases 
The PPARα P1-pGL3, P2-pGL3, P3-pGL3 and pGL3 Basic constructs were all methylated using 
CpG methyltransferase (M.SssI) which methylates the cytosine within the dinucleotide 5'-CG-3' 
and HpaII methyltransferase which methylates the internal cytosine of the sequence 5’-CCGG-3’.  
Briefly 5µg of promoter construct were methylated with either 4U of SssI methyltransferase, 4U of 
HpaII methyltransferase or 1µl water (mock methylated).  These were incubated with 160µM SAM 
and either 1× NEB buffer 2 (M.SssI methyltransferase), or 1×NEB HpaII Methylase buffer (HpaII 
methyltransferase).  Reactions took place in a total volume of 100µl for 3 hours at 37
oC, after 
which enzymes were heat inactivated at 65
oC for 15 minutes.   
 
The differentially methylated constructs were then cleaned by phenol chloroform extraction and 
ethanol precipitation as previously described.  2µl of each construct was measured on the 
NanoDrop, made to a concentration of 500ng/µl and then 500ng of this was digested with HpaII 
restriction enzyme in Promega buffer A buffer at 37
oC for 30 minutes.  This methylation sensitive 
restriction enzyme cuts the sequence 5’-C
▼CGG-3’ only if it is unmethylated.  If methylated (5’-
CC
meGG-3’) it will not cut.  After digestion, all differentially methylated and digested constructs 
were analysed for methylation by agarose gel electrophoresis against an equivalent amount of 
uncut plasmid (figure 2.16).   
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   1Kb    pGL3   pGL3   pGL3  pGL3     P1        P1         P1         P1       P2       P2         P2         P2        P3         P3       P3        P3 
              Uncut   Mock     CG    HpaII   pGL3  pGL3   pGL3   pGL3  pGL3  pGL3   pGL3   pGL3   pGL3   pGL3  pGL3   pGL3 
                            Meth    Meth  Meth    Uncut  Mock    CG      HpaII  Uncut Mock    CG      HpaII   Uncut   Mock    CG     HpaII  
                                                                              Meth    Meth    Meth               Meth    Meth   Meth                  Meth   Meth    Meth 
+HpaII RE  +HpaII RE  +HpaII RE  +HpaII RE 
 
Figure 2.16  Digests of methylated PPARα-pGL3 constructs.  P1-pGL3, P2-pGL3, P3-pGL3 
and pGL3 Basic were methylated with either M.SssI or HpaII methyltransferase and then digested 
with the HpaII methylation sensitive restriction enzyme.  As expected, all mock methylated 
constructs were digested to completion with the HpaII restriction enzyme, whereas the CG and 
HpaII methylated constructs were completely protected from digestion by methylation. 
 
 
2.2.10 Cell  culture 
 
Maintenance of murine 3T3-L1 pre-adipocyte cells 
Mouse 3T3 L1 cells were cultured in 3T3-L1 media in 75cm
2 tissue culture flasks (Greiner Bio 
One, Glos, UK) at 37
oC with 5% CO2 in a humidified atmosphere.  80% confluent cultures were 
washed in PBS, 1ml trypsin-EDTA added and incubated 2-5minutes to detach cells from base of 
flask.  10ml DMEM was then added to neutralise trypsin and cells diluted 1:50 and added to a new 
flask. 
 
Differentiation of murine 3T3-L1 pre-adipocyte cells 
3T3-L1 cells at passage 6-9 were stimulated to differentiate into adipocytes as follows.  Cells were 
detached as described above and added in 3T3 media to 9.6cm
2 6 well culture plates (Greiner Bio 
One, Glos, UK).  At 2 days post confluence (day 0), 3T3-L1 media was replaced with 3T3-L1 
differentiation media.  48 hours later (day 2) media was removed and replaced with 3T3-L1 media 
containing 175nM insulin.  Another 48 hours later (day 4), media was again removed and replaced 
with 3T3-L1 media containing 175nM insulin.  At day 6 media was removed and replaced with 
3T3-L1 media. 
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Treatment of 3T3 cells 
3T3 cells undergoing differentiation were treated with murine leptin at either 0ng/ml or 10ng/ml in 
3T3-L1 media at both day 2 and day 8 and incubated for 0hr, 2hr, 6hr, 24hr and 48hr at 37
oC 5% 
CO2.  All samples were performed in duplicate.  At each time point cells were washed in PBS and 
scraped into 1ml ice cold PBS, spun at 3,000 rpm 5 minutes and supernatant removed.  Cell pellets 
were either stored at -70
oC or used to prepare RNA straight away. 
 
Maintenance of HepG2 cells 
The human hepatoma cell line HepG2 were cultured in HepG2 complete media in 75cm
2 tissue 
culture flasks at 37
oC with 5% CO2 in a humidified atmosphere.  80% confluent cultures were 
washed in PBS, 1ml trypsin-EDTA added and incubated 2-5minutes to detach cells from base of 
flask.  10ml DMEM was then added to neutralise trypsin and cells diluted 1:50 in HepG2 complete 
media and added to a new flask. 
 
Preparation of DNA for cell culture 
For cell culture, plasmid DNA was precipitated in 1/10
th volume of 3M NaAc pH5.2 and 2 volumes 
of 100% ethanol.  This was incubated at -20
oC for 20 minutes and then centrifuged at 12,000rpm 
for 15 minutes.  The DNA pellet was then resuspended under sterile conditions in dH2O to a 
concentration of 1µg/µl and stored at -20
oC.  For use in transfection experiments, DNA was diluted 
to 500ng/µl. 
 
Transfection of HepG2 cells 
Transfection of HepG2 cells with PPARα promoter fragments was by the calcium phosphate 
method 
229.  All transfections were performed in triplicate.  The day before transfection, cells were 
seeded onto 6 well culture plates at a density of 2×10
5 cells / well.  On the day of transfection, 1μg 
of promoter-pGL3 construct was added to 12.4μl CaCl2 and made to 100μl with dH2O.  This was 
added drop wise to an eppendorf containing 100μl 2×HBS and then incubated at room temperature 
for 20 minutes.  After incubation samples were then added drop wise to the cells.  Cells were 
incubated for 5 hours then washed twice in no adds media.  2ml complete DMEM was then added 
to cells with or without treatments and incubated for a further 24 hours (see below).  
 
Transfection of HepG2 cells - treatments 
Cells transfected with PPARα P1-pGL3, P2-pGL3, P3-pGL3 and pGL3 basic were initially treated 
with concentration gradients of CFA, leptin and dex as follows; i) CFA treatment, 20µM, 40µM, 
60µM, 80µM, 100µM. ii) leptin treatment 10ng/ml, 50ng/ml, 100ng/ml, 500ng/ml, 1000ng/ml. iii) 
dex 1nM, 10nM, 100nM, 1µM, 10µM.   
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Cells transfected with the PPARα P2-pGL3, P1-pGL3 and pGL3 basic were treated with Stat3 
inhibitor as follows; 1nM, 10nM, 100nM, 1µM, 10µM.  1 hour after Stat3 inhibitor treatment leptin 
was added to cells (1000ng/ml).  Cells were then incubated for 24hours. 
 
Cells transfected with the PPARα Sp1M were treated with 1000ng/ml leptin. 
 
Luciferase assay 
Luciferase assays were performed on all cells transfected with pGL3 Basic-promoter constructs, 
using the luciferase assay system (Promega, Southampton, UK).  Media was aspirated from 
transfected cells and then washed in 2ml ice cold PBS.  PBS was removed and cells scraped into 
100μl 1× reporter lysis buffer using a cell scraper and removed to an eppendorf tube.  Cells were 
subjected to 2 freeze thaw cycles by submerging in liquid nitrogen and thawing at 37
oC in a 
waterbath.  Cells were then centrifuged at 12,000rpm for 30 seconds to pellet cell debris and 
supernatant transferred to a new tube.  Samples and luciferase assay reagent were allowed to reach 
room temperature before use in the assay.  To measure luminescence of samples, 50μl of luciferase 
assay reagent was transferred to a luminometer tube and 5μl of sample added and mixed well.  The 
tube was then placed in the luminometer (Turner Designs 20-20, Promega, UK) and a reading 
initiated. For all assays, the luminometer was set to 100% sensitivity, a 2 second delay before 
reading and a 10 second measurement read for luciferase activity.  Each sample was measured 3 
times in succession. 
 
Protein assay 
Protein levels within transfected cell lysates were determined using BioRad protein assay reagent 
(BioRad, Hemel Hempstead, UK) according to manufacturer’s instructions.  All samples were 
measured in duplicate.  Briefly, 2µl sample was added to a microtitre plate, followed by 250µl 1× 
protein assay reagent.  In addition, BSA was added to separate wells to create a standard curve.  
Protein concentrations of samples and standards were read at 570nm and absolute amounts of 
protein in unknown samples calculated.  Results from luciferase assays were normalized to protein 
levels within cell lysates. 
 
Statistical analysis of transfections 
All samples were transfected in triplicate. Statistical comparisons of luciferase activity between 
promoter constructs and treatments were determined by 1 way or 2 way ANOVA (as appropriate) 
followed by Bonferroni post hoc analysis using the PRISM software package. 
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2.2.11  Methylation analysis by pyrosequencing 
 
Bisulfite conversion of DNA 
Bisulfite conversions were performed using the EZ DNA methylation gold Kit (Cambridge 
Biosciences, Cambridge, UK) according to manufacturers instructions.  2µg of genomic DNA was 
used in all bisulfite conversions.  Resulting bisulfite DNA was stored at -20
oC and used within 2 
months.  
 
Primer design for bisulfite PCR 
Prior to designing PCR primers for bisulfite PCR, the sequence of the region of interest was first 
changed for assay design purposes; all CpGs within the sequence were converted to YG, then all 
C’s were converted to T.  This represents the changes which would have occurred to the DNA 
during the bisulfite conversion process.  Bisulfite PCR primers and sequencing primers (table 2.7) 
were then designed using PSQ Assay Design software version 1.0.6 (Biotage AB, Kungsgatan, 
Sweden).  Primers were designed to cover as much of the CpG island within the PPARα promoter 
as possible (without themselves containing a CpG within their sequence) (figure 2.17-2.20).  All 
standard primers were supplied by Invitrogen (Paisley, UK) and 5’-biotin labelled primers by 
Biomers (Ulm, Germany). Primers were made to a concentration of 100µM and stored at -20
oC.   
 
Bisulfite PCR 
2µl Bisulfite DNA was amplified using 1.25 units HotStar Taq, 200µM of each dNTP, 0.2µM of 
forward and reverse primers (one of which is 5’ biotin labelled) and made to a final volume of 50µl 
with DEPC treated water.  PCR was performed using the PCR Express PCR machine DNA 
(Thermo Fisher Scientific, Epsom UK).  Cycling conditions were as follows; initial denaturation of 
95
oC 15 minutes, followed by 45 cycles of 94
oC 30s, anneal at a previously optimised primer 
specific temperature (table 2.7) 1 minute and extension at 72
oC for 1 minute.  This was followed by 
a final extension at 72
oC for 10 minutes. 
   10µl of all PCR products were run on a 1.5% agarose gel 
to confirm the presence of a single band of the correct size. 
 
Pyrosequencing 
All solutions were allowed to reach room temperature before starting the pyrosequencing 
procedure.  First, the biotinylated PCR Products were immobilized to Streptavidin beads.  To 
achieve this, 10µl of PCR product (previously optimized) was added to a 96-well plate and the 
volume made up to 40μl with dH2O.  Next, 38µl binding buffer and 2µl Streptavidin beads were 
added to each well, the plate sealed and mixed for 5 minutes on a plate shaker.  Next, the PCR 
product was made single stranded and cleaned.  To accomplish this, the PCR plate was placed onto 
the plate holder of a vacuum prep workstation (Biotage AB, Kungsgatan, Sweden).  The beads 
were then captured onto the vacuum prep tool ensuring that all solution was removed.  The 
captured beads were next washed in 70% ethanol and then the strands separated in denaturation solution.  The beads were subsequently washed in wash buffer then the vacuum was switched off 
and the beads were released into a PSQ plate (Biotage AB, Kungsgatan, Sweden) containing 12µl 
of 0.3µM sequencing primer in annealing buffer.  To anneal the primers to the newly single 
stranded biotin labeled PCR product, the plate was heated with the samples at 80˚C for 2 minutes 
then allowed to cool slowly to room temperature.  Nucleotides, enzymes and substrate were added 
to nucleotide and reagent dispensing tips which were loaded into the tip holder and a tip test 
performed.  Samples were then analyzed by pyrosequencing using the Pyromark MD 
Pyrosequencer (Biotage AB, Kungsgatan, Sweden).  To check that the bisulfite conversion had 
gone to completion, a quality control was included in the pyrosequencing assay which checks that 
any cytosine not followed by a guanine had been 100% converted to thymine. 
 
 
Table 2.7  Sequences of the PPARα pyrosequencing PCR and sequencing primers 
 
 
Primer 
 
                                          Sequence (5’ → 3’) 
  
Anneal 
 
290-475 Forward 
290-475 Reverse (5’-Biotin)  
290-380 Sequencing 
395-475 Sequencing 
 
475-540 Forward (5’- Biotin) 
475-540 Reverse 
475-540 Sequencing 
 
GAGAATTGTTTAGGGTTTTTTAGG 
CCCTATCCACCCACCTCACTA 
AGGGATTTAGTAGGGGA 
GGTTTTAAGATAGGGGTGA 
 
GGGTGATTTTGGGTAGTTTTT 
TCCCTATCCACCCACCTCACTA 
CCACCCACCTCACTAT 
  58.5 
 
 
 
 
56.4 
 
 
 
+1 +319 -131 -191
P1 Exon 1 P2 Exon 1
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Figure 2.17  Diagram showing the location of the PPARα pyrosequencing amplicons.  The 
pyrosequencing amplicon is shown relative to the P1 and P2 transcription start sites, MSP primers 
and the CpG islands found within the PPARα promoter.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     TAGAAAGGYGYGTTYGTTTAGGYGYGTTTTTTTTATAGGGTTGTTTYGTTYGTYGGGTGA 60 
 
                                                       
     TTTTGGGTAGTTTTTTTATTTAGTTAGTTTTAGTTTATTAATAGATGTTYGAGTTTYGAG 120 
 
 
     GTATTAAATGGGTATYGAGGAGAATTGTTTAGGGTTTTTTAGGTTTYGTTTTTATAGTAG 180 
 
      
     YGGTTAATTAGATGTTGTYGTTYGGGGGGTGTGTTTYGTTTTGAATYGYGGTTYGGGTTT 240 
                                                 
                                         GGATTTYGTAGGGGA1   2 
     AGAGGGYGGGGTTTTYGGGGYGGTTATTTYGTYGYGGGATTTYGTAGGGGAYGTTYGAGG 300 
 
       3  4 5    6       7 8        9   101112    13    14  
     GGYGGYGYGTGTYGTGGGGGYGYGGTTGGTAYGGGYGYGYGTAGGYGGTGTYGGGTAGGG 360 
 
         15  16   17      18           
     GTTTYGGAYGTTGYGGTTTTAYGATAGGGGTGAYGGGGGYGGAGATAGTYGTTYGAGTTT 420 
 
 
     TTTTTGGYGTYGTTTATTYGGGYGGGTTGGTTTTGYGGATTYGTAGGYGGAGYGTAGTTT 480 
 
                    
     TAGGTGTTTAGGGGYGGGAGGGTAYGYGYGAGGAYGGGAGTTAGGYGTTTTTYGTTTYGG 540 
           GGGYGG 
                                         
     GATAGTGAGGTGGGTGGATAGGGAGGGGAGGGGTTYGGTGGYGTATGYGYGTGGATTAGG 600 
 
        
     GGYGYGGGTTTGGAGATTTATAGTTATTGGYGAGGGTATAYGTTAGGAAGGGTATAYGYG 660 
 
        
     TGYGATTTTYGGGGTTTTTGGAATTGTTYGTTATTTYGAGTTTTTTTGAGYGTYGTGTGT 720 
 
      
     YGGTTTTGAATATTGGYGTTYGTAGTTGTTTTGTGGGTTGGAGGGTTYGTGGAGTTTTGG 780 
 
Figure 2.18  PPARα promoter sequence showing the location of the 290-380 
pyrosequencing amplicon.  Diagram shows the location of the PPARα 290-380 PCR amplicon 
and sequencing primers on bisulfite converted DNA.  Forward and reverse primers are shown in 
blue highlight and sequencing primer in pink highlight.  The region to be sequenced is indicated by 
pink text.  CpG islands are underlined, whilst CpGs are highlighted in green and numbering of the 
CpGs is shown above the sequence.  The Sp1 consensus within the “unique region” is shown in red 
highlight.  The P2 transcription start site is highlighted in grey and the P1 transcription start site is 
highlighted in yellow. 
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     TAGAAAGGYGYGTTYGTTTAGGYGYGTTTTTTTTATAGGGTTGTTTYGTTYGTYGGGTGA 60 
 
                                                       
     TTTTGGGTAGTTTTTTTATTTAGTTAGTTTTAGTTTATTAATAGATGTTYGAGTTTYGAG 120 
 
                     
     GTATTAAATGGGTATYGAGGAGAATTGTTTAGGGTTTTTTAGGTTTYGTTTTTATAGTAG 180 
 
      
     YGGTTAATTAGATGTTGTYGTTYGGGGGGTGTGTTTYGTTTTGAATYGYGGTTYGGGTTT 240 
                                           
            
     AGAGGGYGGGGTTTTYGGGGYGGTTATTTYGTYGYGGGATTTYGTAGGGGAYGTTYGAGG 300 
 
        
     GGYGGYGYGTGTYGTGGGGGYGYGGTTGGTAYGGGYGYGYGTAGGYGGTGTYGGGTAGGG 360 
 
                   GGTTTTAYGATAGGGGTGA19              20  21 
     GTTTYGGAYGTTGYGGTTTTAYGATAGGGGTGAYGGGGGYGGAGATAGTYGTTYGAGTTT 420 
               
            22 23      24  25           26    27    28   29 
     TTTTTGGYGTYGTTTATTYGGGYGGGTTGGTTTTGYGGATTYGTAGGYGGAGYGTAGTTT 480 
 
                   30         
     TAGGTGTTTAGGGGYGGGAGGGTAYGYGYGAGGAYGGGAGTTAGGYGTTTTTYGTTTYGG 540 
                GGGYGG 
 
     GATAGTGAGGTGGGTGGATAGGGAGGGGAGGGGTTYGGTGGYGTATGYGYGTGGATTAGG 600 
 
        
     GGYGYGGGTTTGGAGATTTATAGTTATTGGYGAGGGTATAYGTTAGGAAGGGTATAYGYG 660 
 
        
     TGYGATTTTYGGGGTTTTTGGAATTGTTYGTTATTTYGAGTTTTTTTGAGYGTYGTGTGT 720 
 
      
     YGGTTTTGAATATTGGYGTTYGTAGTTGTTTTGTGGGTTGGAGGGTTYGTGGAGTTTTGG 780 
 
Figure 2.19  PPARα promoter sequence showing the location of the 395-475 
pyrosequencing amplicon.  Diagram shows the location of the PPARα 395-475 PCR amplicon 
and sequencing primers on bisulfite converted DNA.  Forward and reverse primers are shown in 
blue highlight and sequencing primer in pink highlight.  The region to be sequenced is indicated by 
pink text.  CpG islands are underlined, whilst CpGs are highlighted in green and numbering of the 
CpGs is shown above the sequence.  The Sp1 consensus within the “unique region” is shown in red 
highlight.  The P2 transcription start site is highlighted in grey and the P1 transcription start site is 
highlighted in yellow. 
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3.1 Introduction 
 
 
3.1.1  Liver function in energy homeostasis  
 
The liver is a complex metabolic organ composed not only of hepatocytes (80%), but also of a 
variety of cells, including Kupffer cells, stellate cells and endothelial cells.  Hepatocytes are central 
to energy homeostasis and perform many vital metabolic processes involving carbohydrate, protein 
and lipid metabolism.  All these processes are under the strict control of either the anabolic 
hormone insulin or the catabolic hormone glucagon depending on the metabolic status.  However, 
in addition to insulin and glucagon, catecholamines and glucocorticoids can also exert metabolic 
control of the liver in response to stress.   
 
One of the main functions of the liver is to maintain blood glucose concentrations within strict 
parameters.  In the fed state, insulin synthesis is stimulated to promote the storage of energy.  As a 
consequence, excess dietary glucose is removed from the blood and converted to glycogen for 
storage in the liver until needed (glyconeogenesis) and fatty acids are synthesized and esterified 
with glycerol for storage as TAG in adipose tissue (lipogenesis).  Conversely in times of energy 
demand such as during fasting, glucagon synthesis is stimulated which opposes the effects of 
insulin.  Here, catabolic processes are stimulated along with the production of glucose in order to 
supply vital glucose to the brain and fatty acids and ketones are produced for tissues which do not 
rely on glucose.  Glucagon achieves this by increasing the production of glucose in the liver by 
promoting glycogen breakdown (glycogenolysis) and converting non-carbohydrate sources into 
glucose (gluconeogenesis).  Glucagon also stimulates the production of fatty acids and ketones by 
stimulating fatty acid oxidation and ketogenesis (figure 3.1).  In addition during times of stress or if 
glycogen stores have been depleted, the HPA axis is activated to release glucocorticoids which 
have an anti-insulin effect, thereby promoting gluconeogenesis, lipolysis and fatty acid oxidation in 
the liver.  Furthermore, the catecholamine epinephrine is also stimulated by stress and directly 
stimulates catabolic processes to increase blood glucose levels. 
 
Alterations in carbohydrate and lipid metabolism occur in metabolic disorders such as insulin 
resistance.  When insulin signaling is defective, glucagon becomes the predominant active hormone 
as it is unopposed by insulin and therefore inappropriately promotes catabolic processes and 
glucose production, which can lead to hyperglycemia.  If untreated, this can also lead to 
ketoacidosis and hypertriglyceridemia (figure 3.1).  In a rat model of programming, protein 
restricted offspring have been shown to be insulin resistant with an altered hepatic glucose output, 
indicating that the regulation of hepatic metabolic processes is disturbed 
42.  These offspring also 
have increased corticosteroid activity, which may have a causative role in the altered carbohydrate 
metabolism and indicates a “stressed” phenotype 
40.  Normally, gluconeogenesis only occurs during fasting when glycogen stores have run out, however in PR offspring there is increased expression 
of hepatic GR and its target gene PEPCK 
57.  It is probable that these gene expression changes may 
result in increased gluconeogenesis and contribute to the altered hepatic glucose output.   
Furthermore, these offspring also exhibit increased PPARα expression in the liver along with 
increased expression of its target genes AOX and CPT1, resulting in inappropriate fatty acid β-
oxidation.  It has been shown that the changes in gene expression of the transcription factors GR 
and PPARα are due to alterations in the methylation status of CpG dinucleotides in their promoter 
77.  Evidence is now accumulating which indicates that epigenetic alterations in gene promoters in 
programmed offspring may underpin the relationship between early life environment and an altered 
phenotype in adult life.   
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Figure 3.1  The effect of a reduced insulin:glucagon ratio on energy metabolism.  The 
effect of a reduced insulin:glucagon ratio on the control of metabolic processes in the liver is 
shown along with the disturbances which may occur if left untreated.    
 
 
3.1.2 Aims 
 
In rodents, the PR model of programming results in offspring with low birth weight presenting with 
metabolic disorders in later life including insulin resistance, diabetes and hypertension 
48.  This 
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model has been intensively studied for alterations in the epigenetic regulation of transcription 
factors and enzymes which may affect glucose and lipid metabolism in the liver.  As a result, such 
studies have identified specific epigenetic changes and alterations in gene expression of important 
hepatic transcription factors and enzymes associated with gluconeogenesis and fatty acid oxidation, 
including GR, PPARα and their target genes 
77,213.   
 
Another animal model of programming by maternal nutrition is the IUGR rat 
227.  The offspring 
have low birth weight and present with hyperphagia, high blood pressure, hyperleptinemia, 
hyperinsulinemia (indicating they are insulin resistant) and become obese.  Furthermore, all these 
disorders are augmented by a calorie rich postnatal diet and reversed by neonatal leptin treatment 
122.  Currently, knowledge of the molecular mechanisms underpinning the metabolic disturbances 
have not been investigated in the IUGR rat, but may involve similar mechanisms to those found in 
the liver of PR offspring, i.e. altered carbohydrate and lipid metabolism.  In addition, the 
mechanism of leptin action in the reversal of metabolic disturbances is unknown, but may also 
involve peripheral effects on key hepatic transcription factors and enzymes involved in energy 
metabolism. 
 
To gain a better understanding of the programming of energy balance in the IUGR rats and the 
effect of neonatal leptin treatment, this study uses liver tissue from the same rat model of global 
undernutrition used by Vickers and colleagues 
122 to investigate the expression and methylation 
status of several key genes in the liver associated with glucose and lipid metabolism.  Effects are 
investigated in response to maternal diet, postnatal diet and neonatal leptin treatment in both male 
and female offspring using real time PCR and methylation sensitive real time PCR.   
 
Data presented in this chapter shows that the mechanisms underlying altered carbohydrate 
metabolism in the livers of PR offspring are not present in the liver of IUGR offspring and that 
leptin treatment has largely no effect on expression of these genes.  Results indicate that 
programming occurs by alternative mechanisms in the IUGR rat.   90
3.2 Results 
 
 
3.2.1  The expression of genes involved in energy balance in the liver of adult female 
offspring differ in their response to maternal diet, postnatal diet and neonatal leptin 
treatment.   
 
In order to ascertain if the expression of genes involved in energy balance in the liver of female 
offspring are affected by maternal diet, postnatal diet or neonatal leptin treatment, total RNA was 
prepared from the liver of adult female offspring from the IUGR rat study (n=8 / diet-treatment 
group) and used to prepare copy DNA (cDNA).  Real time polymerase chain reaction (PCR) was 
performed with validated gene specific primers using the cDNA as a template.   
 
Genes studied included those involved in gluconeogenesis; GR, PEPCK and 11βHSD-2 and also 
key genes involved in fatty acid metabolism; PPARα, AOX, CPT-1 and LPL.  Resulting gene 
expression data were normalised to CYC cDNA and analysed by the ΔCT method 
228.  Results for 
each group were converted to % of the control group (AD Chow 100%) and a one way analysis of 
variance (ANOVA) performed followed by Bonferroni’s post hoc test.  Graphs showing 
differences in mRNA expression for each gene with statistical analysis can be found in figures 3.2 
to 3.4.  All results are described relative to the control group only.  In addition, a 3 way ANOVA 
was performed for all genes measured to analyse single factor and interaction effects on gene 
expression.  The results of the 3 way ANOVA are shown in table 3.1. 
 
Analysis of PPARα expression by real time PCR demonstrated that its expression was significantly 
reduced by maternal diet and this effect was dependent on offspring being fed a chow diet (39.76% 
p=0.001) (figure 3.2a).  This reduction in expression was prevented if the offspring were given 
neonatal leptin treatment.  There were no other effects of neonatal leptin treatment, maternal diet or 
postnatal diet on PPARα expression.  The expression of the PPARα target genes AOX and CPT-1 
differed to that of PPARα.  For AOX gene expression, there a significant effect of neonatal leptin 
treatment on AD offspring and this was dependent on their being fed a HF diet (151.0%, p=0.05).  
There were no other effects of neonatal leptin treatment, maternal diet or postnatal diet on AOX 
expression (figure 3.2b).  For CPT-1, there was no effect of any diet or neonatal leptin treatment on 
gene expression (figure 3.2c).  These data show that differences in PPARα gene expression are not 
passed onto its target genes in the liver of these offspring. 
 
The expression of LPL was not altered by maternal diet, postnatal diet or neonatal leptin treatment 
(figure 3.3).  Conversely, examination of GR and its target gene PEPCK revealed that they were 
both significantly affected by maternal diet, but the response depended on the postnatal diet.  For 
GR expression, there was a significant effect of maternal diet on offspring fed a chow diet (45.53%   91
p=0.001) (figure 3.4a), whereas for PEPCK expression, the effect was only evident in offspring fed 
a high fat diet (50.81% P=0.05) (figure 3.4b).  This effect was not evident if the offspring were 
given neonatal leptin treatment.  There were no other effects of diet or neonatal leptin treatment on 
the expression of GR or its target gene PEPCK.  There was also no significant effect of any 
treatment on the expression of 11βHSD-2 (figure 3.4c).  
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Figure 3.2  The expression of PPARα and its target genes CPT-1 and AOX in the liver of 
adult female offspring differ in their response to maternal diet, postnatal diet and neonatal 
leptin treatment.  Real time PCR data for expression of PPARα (A), CPT-1 (B), AOX (C) are 
shown  in response to maternal diet (ad libitum [AD] and undernutrition [UN]), postnatal diet 
(Chow [C] and High Fat [HF]) and neonatal leptin treatment (leptin [L]) (n=8/group). Values with 
different letters are significantly different (p<0.05) by Bonferroni’s post hoc test. 
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Figure 3.3  The expression of LPL in the liver of adult female offspring is not altered by 
maternal diet, postnatal diet or neonatal leptin treatment.  Real time PCR data for expression 
of LPL are shown  in response to maternal diet (ad libitum [AD] and undernutrition [UN]), 
postnatal diet (Chow [C] and High Fat [HF]) and neonatal leptin treatment (leptin [L]) (n=8/group). 
Values with different letters are significantly different (p<0.05) by Bonferroni’s post hoc test. 
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Figure 3.4  The expression of GR and its target gene PEPCK and 11βHSD-2 in the liver 
of adult female offspring differ in their response to maternal diet and postnatal diet, but are 
not altered by neonatal leptin treatment.  Real time PCR data for expression of GR (A), PEPCK 
(B), 11βHSD-2 (C), are shown in response to maternal diet (ad libitum [AD] and undernutrition 
[UN]), postnatal diet (Chow [C] and High Fat [HF]) and neonatal leptin treatment (leptin [L]) 
(n=8/group). Values with different letters are significantly different (p<0.05) by Bonferroni’s post 
hoc test. 
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Table 3.1  Table showing tests of between subject effects on the mRNA expression of 
genes measured in the liver of female offspring.  Single factor effects (MD, T, PND) and 
interaction effects (MD*T, MD*PND, T*PND, MD*T*PND) are shown.  Significant effects 
(P<0.05) are indicated in red.  There were significant single factor effects for all genes except 
11βHDS2.  There were significant effects of MD for PPARα, CPT-1, GR and PEPCK.  There were 
significant effects of T for PPARα and LPL.  There were significant effects of PND for PPARα, 
AOX and LPL.  There were significant interaction effects for PPARα (MD*T, MD*PND, 
MD*T*PND), CPT-1 (MD*PND), AOX (MD*PND), GR (MD*PND, MD*T*PND), PEPCK 
(MD*T) and 11βHDS2 (MD*T, MD*PND).  There were no significant interaction effects for LPL. 
 
 
 
Variable 
 
 
Anova 
 
Maternal 
Diet 
(MD) 
 
Treatment 
(T) 
 
Postnatal 
Diet 
(PND) 
 
MD*
T 
 
MD* 
PND 
 
T* 
PND 
 
MD* 
T* 
PND 
 
 
PPARα 
CPT-1 
AOX 
GR 
PEPCK 
11BHSD2 
LPL 
 
 
0.000 
0.039 
0.006 
0.002 
0.006 
0.000 
0.013 
 
0.019 
0.018 
0.589 
0.001 
0.005 
0.313 
0.119 
 
0.003 
0.109 
0.186 
0.580 
0.231 
0.654 
0.003 
 
 
0.027 
0.289 
0.002 
0.430 
0.369 
0.456 
0.010 
 
0.001 
0.273 
0.856 
0.901 
0.005 
0.000 
0.765 
 
0.042 
0.033 
0.017 
0.013 
0.092 
0.030 
0.340 
 
0.122 
0.907 
0.788 
0.264 
0.979 
0.567 
0.874 
 
0.010 
0.615 
0.067 
0.015 
0.702 
0.973 
0.933   96
3.2.2  The methylation of GR and PPARα in the liver of adult female offspring is not altered 
  by maternal diet or postnatal diet.  The methylation status of GR but not PPARα is 
  affected by neonatal leptin treatment. 
 
In order to ascertain if the methylation status of the promoter regions of key mediators of energy 
balance in the liver of female offspring is affected by maternal diet, postnatal diet or neonatal leptin 
treatment, methylation sensitive PCR (MSP) was performed.  Genomic DNA was prepared from 
the liver of female offspring from the IUGR rat study (n=8 / diet-treatment group).  This DNA was 
digested with methylation sensitive restriction enzymes (AciI or Hinp1I) and real time PCR was 
performed with validated gene specific primers using the digested genomic DNA as a template.  
Resulting data were normalised to PPARγ2 which has no AciI or Hinp1I sites.  Results were 
converted to % of the control group (AD Chow 100%) and a 1 way ANOVA performed followed 
by Bonferroni’s post hoc test.  Graphs showing differences in methylation for both genes with 
statistical analysis can be found in figure 3.5.  All results are described relative to the control group 
only.  In addition, a 3 way ANOVA was performed for both genes to analyse single factor and 
interaction effects on DNA methylation.  The results of the 3 way ANOVA are shown in table 3.2. 
 
MSP was performed on the PPARα and GR promoters.  Resulting data showed that there were no 
significant differences in DNA methylation for the PPARα promoter, however, there was a trend 
for increased methylation in AD offspring irrespective of postnatal diet, but this failed to reach 
significance (figure 3.5a).  For GR there was a significant increase in promoter methylation in 
leptin treated AD offspring which was dependent on offspring being fed a chow diet (285.3% 
p=0.05) (figure 3.5b).  There was also a trend for increased methylation in AD offspring fed a HF 
diet, but this failed to reach significance.  For both GR and PPARα, leptin treatment and postnatal 
diet had no effect on methylation in UN offspring.    
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Figure 3.5  The methylation status of the PPARα and GR promoters in the liver of adult 
female offspring is not altered by maternal diet or postnatal diet, but GR methylation is 
altered by neonatal leptin treatment.  Real time PCR data for methylation of PPARα (A) and GR 
(B) are shown in response to maternal diet (ad libitum [AD] and undernutrition [UN]), postnatal 
diet (Chow [C] and High Fat [HF]) and neonatal leptin treatment (leptin [L]) (n=8/group). Values 
with different letters are significantly different (p<0.05) by Bonferroni’s post hoc test. 
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Table 3.2  Table showing tests of between subject effects on DNA methylation for genes 
measured in liver of female offspring.  Single factor effects (MD, T, PND) and interaction effects 
(MD*T, MD*PND, T*PND, MD*T*PND) are shown.  Significant effects (P<0.05) are indicated in 
red.  For PPARα, there were no significant single factor effects, whereas for GR there were single 
factor effects (MD).  For both PPARα and GR, there were significant interaction effects (MD*T).  
 
 
Gene 
 
 
Anova 
 
Maternal 
Diet 
(MD) 
 
 
Treatment 
(T) 
 
Postnatal 
Diet 
(PND) 
 
MD*
T 
 
MD* 
PND 
 
T* 
PND 
 
MD* 
T* 
PND 
 
PPARα 
GR 
 
 
0.215 
0.006 
 
0.966 
0.011 
 
0.484 
0.054 
 
0.957 
0.315 
 
0.011 
0.005 
 
0.916 
0.559 
 
0.312 
0.193 
 
0.230 
0.399   99
3.2.3  The expression of genes involved in energy balance in the liver of adult male offspring 
  is not altered by maternal diet or postnatal diet.  The effect of neonatal leptin 
  treatment is gene specific and dependent on maternal and postnatal diet. 
 
In order to ascertain if the expression of genes involved in energy balance in the liver of male 
offspring are affected by maternal diet, postnatal diet or neonatal leptin treatment, total RNA was 
prepared from the liver of adult male offspring from the IUGR rat study (n=8 / diet-treatment 
group) and used to prepare cDNA.  Real time polymerase chain reaction was performed with 
validated gene specific primers using the cDNA as a template.   
 
Genes studied were the same as those studied in the liver of female offspring; GR, PEPCK, 
11βHSD-2, PPARα, AOX, CPT-1 and LPL.  Resulting gene expression data were normalised to 
CYC cDNA and analysed by the ΔCT method 
228.  Results were converted to % of the control 
group (AD Chow 100%) and a 1 way analysis of variance (ANOVA) performed followed by 
Bonferroni’s post hoc test.  Graphs showing differences in mRNA expression for each gene with 
statistical analysis can be found in figures 3.6 to 3.8.  All results are described relative to the 
control group only.  In addition, a 3 way ANOVA was performed for all genes measured, to 
analyse single factor and interaction effects on gene expression.  The results of the 3 way ANOVA 
are shown in table 3.3. 
 
Results showed that there was no effect of a maternal diet or postnatal diet on the expression of any 
of the genes studied in the liver of male offspring.  In addition, the majority of genes tested were 
not significantly altered by neonatal leptin treatment.  However, there was a significant effect of 
neonatal leptin treatment for 2 of the genes tested.  For PEPCK, there was a significant effect of 
leptin treatment in UN offspring fed a chow diet (42.0% p=0.05) (figure 3.6b).  Conversely for 
CPT-1, leptin treatment significantly affected UN offspring given a HF diet (49.91% p=0.05) 
(figure 3.7c).  These data indicate that an effect of leptin treatment on gene expression in this tissue 
is dependent on maternal UN diet.   
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Figure 3.6  The expression of GR110, PEPCK and 11βHSD-2 in the liver of adult male 
offspring is not altered by maternal diet or postnatal diet.  Expression of PEPCK is altered by 
neonatal leptin treatment and the effect is dependent on both maternal and postnatal diet.  
Real time PCR data for expression of GR110 (A), PEPCK (B) and 11βHSD-2 (C) are shown in 
response to maternal diet (ad libitum [AD] and undernutrition [UN]), postnatal diet (Chow [C] and 
High Fat [HF]) and neonatal leptin treatment (leptin [L]) (n=8/group). Values with different letters 
are significantly different (p<0.05) by Bonferroni’s post hoc test. 
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Figure 3.7  The expression of PPARα and its target gene AOX in the liver of adult male 
offspring is not altered by maternal diet, postnatal diet or neonatal leptin treatment.     
Expression of CPT-1 is altered by neonatal leptin treatment and the effect is dependent on 
both maternal and postnatal diet.  Real time PCR data for expression of PPARα (A) and AOX 
(B) and CPT-1 (C) are shown in response to maternal diet (ad libitum [AD] and undernutrition 
[UN]), postnatal diet (Chow [C] and High Fat [HF]) and neonatal leptin treatment (leptin [L]) 
(n=8/group). Values with different letters are significantly different (p<0.05) by Bonferroni’s post 
hoc test. 
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Figure 3.8  The expression of LPL in the liver of adult male offspring is not altered by 
maternal diet, postnatal diet or neonatal leptin treatment.  Real time PCR data for expression 
of LPL are shown  in response to maternal diet (ad libitum [AD] and undernutrition [UN]), 
postnatal diet (Chow [C] and High Fat [HF]) and neonatal leptin treatment (leptin [L]) (n=8/ 
group).  
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Table 3.3  Table showing tests of between subject effects on the mRNA expression of 
genes measured in the liver of male offspring.  Single factor effects (MD, T, PND) and 
interaction effects (MD*T, MD*PND, T*PND, MD*T*PND) are shown.  Significant effects 
(P<0.05) are indicated in red.  There were no significant single factor or interaction effects for 
PPARα.  There were significant single factor effects for CPT-1 (MD), AOX (PND), LPL (MD), 
GR110 (MD,T) and 11βHSD2 (PND).  There were significant interaction effects for LPL 
(MD*PND), GR110 (MD*PND), 11βHSD2 (MD*T) and PEPCK (MD*PND). 
 
 
Variable 
 
 
Anova 
 
Maternal 
Diet 
(MD) 
 
Treatment 
(T) 
 
Postnatal 
Diet 
(PND) 
 
MD*
T 
 
MD* 
PND 
 
T*P
ND 
 
MD* 
T*P
ND 
 
PPARα 
CPT-1 
AOX 
LPL 
GR110 
11βHSD2 
PEPCK 
 
0.637 
0.047 
0.082 
0.030 
0.000 
0.001 
0.036 
 
0.464 
0.015 
0.445 
0.010 
0.012 
0.394 
0.250 
 
0.204 
0.076 
0.084 
0.268 
0.001 
0.212 
0.026 
 
0.178 
0.175 
0.009 
0.455 
0.351 
0.005 
0.782 
 
 
0.818 
0.116 
0.648 
0.190 
0.161 
0.000 
0.460 
 
0.634 
0.899 
0.810 
0.032 
0.000 
0.464 
0.015 
 
 
0.426 
0.754 
0.421 
0.746 
0.923 
0.320 
0.110 
 
0.546 
0.224 
0.203 
0.334 
0.085 
0.298 
0.354 
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3.3 Discussion 
 
The regulation of energy metabolism in the liver is under strict hormonal control.  This hormonal 
action is mediated by specific transcription factors which regulate the expression of key enzymes 
involved in metabolic pathways such as glucose metabolism.  For example, under conditions of 
stress glucocorticoids mediate their catabolic effects via the glucocorticoid receptor.  GR in turn 
regulates the expression of key enzymes such as PEPCK and this in turn could alter the rate of 
gluconeogenesis, which will impact blood glucose levels.  Alterations in the regulation of 
transcription factor expression will therefore impact on their respective metabolic pathways and 
have consequences on overall energy homeostasis.    
 
In offspring programmed by a protein restricted maternal diet, metabolic control mechanisms are 
disturbed, as indicated by the presence of disorders such as impaired glucose tolerance and 
dyslipidemia 
40,42.  In the liver of PR offspring, studies have shown that energy metabolism favours 
gluconeogenesis and fatty acid β-oxidation, as a result of reduced gene expression of 11βHSD2, 
increased expression of GR, PPARα and their target genes.  In addition to this, methylation 
changes have been identified in the promoters of PPARα and GR in these offspring which favour 
the altered gene expression 
77,213.  Differential methylation of key transcription factors in the liver is 
therefore implicated in the altered metabolic state of these offspring.  In agreement with this, 
emerging evidence has indicated the causative role of alterations in the expression of other genes in 
programmed rats due to altered DNA methylation 
214,215.   
 
In another established model of programming, the IUGR rat, it has been shown that neonatal leptin 
treatment can prevent all metabolic abnormalities, i.e. hyperphagia, high blood pressure, 
hyperinsulinemia, hyperleptinemia and obesity 
122.  If mechanisms of programming are similar to 
that identified in PR offspring and aberrant methylation of key transcription factors underwrites the 
metabolic abnormalities, this may imply that leptin treatment is able to prevent or counteract the 
methylation changes.  The aim of this study was to determine if there were similar changes in the 
expression and methylation of key genes involved in energy metabolism in the liver of male and 
female IUGR offspring as identified in PR offspring and in addition to determine if neonatal leptin 
treatment could prevent any gene expression and methylation changes.  To answer these questions 
we measured the expression and methylation status of genes involved in energy balance in the liver 
from the IUGR offspring 
122 using real time PCR.   
 
The work in this chapter demonstrated that in the liver of both male and female offspring, the 
expression of key transcription factors and enzymes involved in gluconeogenesis and fatty acid β-
oxidation were not generally altered by maternal undernutrition, a postnatal high fat nutrition or by 
neonatal leptin treatment.  In keeping with this, there was little evidence of any altered DNA 
methylation in the promoters of the transcription factors GR and PPARα.     105
In female offspring, gene expression was mostly unchanged by maternal diet, postnatal diet and 
neonatal leptin treatment.  However, for most of the genes tested, data had a large spread which 
could potentially mask the presence of any significant changes.  However, despite this, a few 
significant changes in gene expression were identified, namely of PPARα, GR and PEPCK.  For 
these genes, expression was reduced by UN maternal diet and this reduction was dependent on the 
postnatal diet.  Interestingly, these changes were prevented by neonatal leptin treatment.   
Furthermore, any significant changes which were identified in the transcription factors PPARα and 
GR were not passed onto their target genes.  For example, the effect of maternal diet on GR gene 
expression in offspring fed a chow diet was not passed on to PEPCK.  In fact alterations occurred 
in PEPCK gene expression, which were independent of GR.  In addition, alterations in PPARα 
expression were not passed onto AOX and again, AOX had alterations in gene expression which 
were independent of PPARα.  This implies that alternative signalling mechanisms were affecting 
PEPCK and AOX expression, for example the alterations in PEPCK could have been mediated by 
glucagon, whilst alterations in AOX could be a result of leptin receptor signalling.  Alternatively, it 
is possible that the methylation of their own promoter regions was altered, thus affecting gene 
expression and this warrants further investigation.  In male offspring, significant differences in 
gene expression were found for only 2 of the genes studied; PEPCK and CPT-1.  These alterations 
in gene expression were dependent on maternal diet (UN), postnatal diet and neonatal leptin 
treatment, but as shown in females, were not associated with changes in the expression of the 
transcription factors GR and PPARα.  This implies again that either alternative signaling 
mechanisms were causing the differences in gene expression or differential methylation of their 
own promoter regions.  The failure of transcription factor gene differences to be passed on to their 
target genes in both males and female offspring is contrasting to that found in PR offspring in 
which target gene expression mirrored that of GR and PPARα.  The lack of significant changes in 
gene expression was not due to low sample numbers, as a retrospective statistical power calculation  
confirmed that an N of 8 per dietary group provided statistical power of at least 70% for detecting a 
50% difference between groups, with a probability of P<0.05 for all of the genes measured.   
 
Methylation of the PPARα and GR promoters were investigated in the female offspring.  The 
amplicons used were the same as those used to measure methylation in the PR offspring.   
Unsurprisingly, no methylation changes were identified for PPARα and GR in offspring groups 
where gene expression had not changed.  However, the few significant alterations in gene 
expression found in PPARα and GR were not accompanied by methylation changes, in fact, no 
methylation changes were identified what so ever for PPARα.  The only significant alteration in 
methylation identified was an increase in methylation of the GR promoter in AD offspring given 
neonatal leptin treatment.  Although this change corresponded to a small decrease in corresponding 
gene expression, as would be expected, this did not reach significance.  Overall, trends in 
methylation between the different offspring groups were not representative of gene expression 
changes.  However, the MSP amplicons do not cover the whole promoter regions of PPARα and   106
GR.  It is therefore possible that methylation is altered in different locations of the PPARα and GR 
promoters to that measured. 
 
Overall, none of the gene expression and methylation changes seen in the liver of PR offspring 
were found in the same genes in the liver of IUGR offspring.  These results indicate that alternative 
mechanisms may exist in the programming by severe maternal nutrition as opposed to a protein 
restriction.  This could be expected, as the 70% diet reduction in the IUGR rat represents a much 
more extreme situation than the mild protein restriction of PR offspring.  It is therefore plausible 
that in IUGR rats different metabolic pathways within the liver and other tissues types are affected 
compared to those altered in the PR offspring.  This would therefore involve epigenetic alterations 
in different transcription factors and enzymes.  The metabolic disturbances found in PR offspring 
are consistent with altered hepatic glucose production by gluconeogenesis and increased fatty acid 
β-oxidation.  Given the role of adipose tissue in the metabolic processes associated with IUGR 
disturbances, in particular obesity and the ability of the adipokine leptin to reverse these 
disturbances, it is therefore possible that in IUGR offspring, metabolic disturbances may be a 
consequence of altered lipid metabolism in adipose tissue.  
 
Research into the effect of leptin treatment on genes involved in energy balance in peripheral 
tissues in adult rats may give clues as to the genes which are affected by maternal diet in the IUGR 
rat.  It has been shown that leptin given to ob/ob mice not only depletes adipose lipid, but also 
depletes liver lipid indicating that fat metabolism is affected in both tissue types 
230.  A hepatic 
microarray on leptin treated ob/ob mice has identified lipogenic genes which are down regulated by 
leptin including fatty acid synthase (FAS), ATP-citrate lyase (ACL) and stearoyl CoA desaturase-1 
(SCD1) 
230.  Furthermore leptin was also shown to regulate genes involved with carbohydrate 
metabolism including glucose-6-phosphatase and fructose bisphosphatase 1, two gluconeogenic 
enzymes 
230.  In addition to this, it has also been shown that leptin treatment in adult rats also 
effects gene expression in adipose tissue.  For example, leptin has been found to suppress the 
adipogenic expression of the lipogenic enzymes ACL and FAS 
231, whilst in another study it 
increased expression of PPARα and its target genes, CPT-1 and AOX within adipose tissue 
232.   
 
Findings in this report have not identified how neonatal leptin treatment may act to reverse 
metabolic disturbances in programmed offspring, however data indicates that leptin may act by 
normalising the expression of genes involved in energy balance which are affected by 
undernutrition.  The finding that leptin regulates several other genes of lipid metabolism in both the 
liver and adipose tissue of adult rats 
230,231, indicates which genes may be altered by neonatal leptin 
treatment and possibly by maternal undernutrition in the IUGR rat.   It would therefore be 
interesting to determine if regulation of any of these lipid and carbohydrate metabolism genes were 
altered not only by neonatal leptin treatment but also by maternal undernutrition in the IUGR 
offspring.   107
 
 
 
Chapter 4 
 
Gene Expression and Methylation in 
Adipose Tissue of Female IUGR 
Rats   108
4.1 Introduction 
 
 
4.1.1  Adipose tissue, obesity and developmental programming 
 
White adipose tissue (WAT) is the body’s largest endocrine organ.  It is composed predominantly 
of adipocytes (33-66%), however a variety of cells are also present including fibroblasts, vascular 
cells, macrophages, preadipocytes and monocytes 
233.  Like the liver, adipose tissue plays a 
fundamental role in whole body energy homeostasis.  As such, it has three main roles; it houses the 
major energy reserve of the body TAG, it releases fatty acids and glycerol according to energy 
demands and it secretes adipokines which have autocrine, paracrine and endocrine effects on 
carbohydrate and lipid metabolism.   
 
An excessive increase in WAT mass results in obesity, which is associated with metabolic 
disorders such as dyslipidemia, insulin resistance, glucose intolerance and hypertension 
233.  These 
disorders are also found in IUGR offspring whom have experienced rapid catch up growth during 
early life 
27,28,39,122 and collectively are associated with an increased risk of type II diabetes and CV 
disease.  An understanding of adipose tissue metabolic function and formation is therefore 
necessary in order to recognise which pathways could be altered in the developmental 
programming of obesity and its related disorders and elucidate how they could be intervened.   
 
 
4.1.2  Storage and mobilisation of energy stores 
 
WAT maintains an overall energy balance by sensing and responding to external signals, which 
result in the storage of excess energy in the form of TAG during times of nutritional affluence, or 
by the mobilisation of energy during times of nutritional deprivation.  The size of WAT mass is 
therefore determined by the balance between storage and mobilisation, i.e. lipogenesis and 
lipolysis, which are predominantly under strict hormonal control by the regulatory hormones 
insulin and glucagon 
234.   
 
In the fed state, high blood glucose levels stimulate insulin secretion which binds to its receptor on 
adipocytes to induce lipogenesis and the storage of excess energy as TAG.  This is achieved in a 
number of ways.  Firstly, insulin signalling increases glucose transporters in the adipocyte cell 
membrane which stimulate glucose uptake into the adipocytes.  The glucose is needed to provide 
glycerol-3-phosphate from glycolysis for the synthesis of TAG, as adipose tissue does not express 
glycerol kinase.  In addition, the glucose can also be oxidised to acetyl CoA for fatty acid synthesis 
and insulin increases the expression and activation of several key enzymes central to this process, 
including fatty acid synthetase (FAS) and acetyl CoA carboxylase (ACC).  Insulin also increases   109
LPL activity, which facilitates the hydrolysis of triglycerides in lipoproteins, allowing FA to be 
taken up into the adipocyte.  Fatty acids can then be esterified to form TAG for storage until 
needed.  In addition to these roles, the increased insulin to glucagon ratio also results in the 
dephosphorylation and inactivation of a major enzyme of lipogenesis, hormone sensitive lipase 
(HSL), thereby inhibiting lipolysis and the release of FA from adipocytes.   
 
Conversely, during times of energy demand such as fasting, lipogenesis is inhibited by an increased 
glucagon to insulin ratio and lipolysis takes place.  Glucagon inhibits lipogenesis by inactivating 
ACC by phosphorylation, whereas it stimulates lipolysis by phosphorylating and activating HSL 
which cleaves TAG.   The end result is the mobilisation of TAG to fatty acids and glycerol, which 
can be transported to the liver whereby fatty acids are oxidised for energy and glycerol can be used 
in gluconeogenesis 
235.  The action of glucagon on adipocytes therefore results in net lipolysis in 
adipose tissue, providing FA to other metabolic tissues in times of energy demand.  Furthermore, in 
times of stress such as exercise and cold, glucocorticoids and epinephrine are also able to stimulate 
lipolysis within adipocytes.   
 
If energy intake exceeds expenditure over a long period of time, it results in the excessive growth 
of adipose tissue and obesity develops, which is associated with a loss of adipocyte function.  Here, 
adipocytes become enlarged and insensitive to external signals, with altered regulation, expression 
and activation of key transcription factors and enzymes involved in the metabolic pathways, 
resulting in inappropriate lipogenesis and lipolysis 
235.  For example, in obesity, excess FA are 
inappropriately released from adipocytes and taken up in tissues such as the liver and muscle 
resulting in lipotoxicity and the stimulation of gluconeogenesis which can both lead to insulin 
resistance.  As the activating effects of glucagon on HSL are unopposed in insulin resistance, this 
only serves to worsen the condition. 
 
 
4.1.3  Adipokines and obesity 
 
Adipose tissue functions as an important endocrine organ by producing an array of adipokines 
(hormones and cytokines).  Important adipokines secreted by WAT include leptin, adiponectin, 
retinol binding protein 4 (RBP4), resistin and the pro-inflammatory cytokines TNFα and IL6.  They 
can act not only on adipose tissue but also on other key metabolic organs such as the liver, muscle, 
pancreas and brain and have varying functions in these tissues, including modulating carbohydrate 
and lipid metabolism and the immune response 
235.   Unsurprisingly, adipokine profiles are altered 
in obesity and this can have profound effects on carbohydrate and lipid metabolism and thus the 
insulin sensitivity of the organs they target 
236.  
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Some of these adipokines, such as leptin and adiponectin have insulin sensitising roles.   
Adiponectin, for example, is thought to enhance insulin sensitivity due to several key roles in 
carbohydrate and lipid metabolism; It decreases hepatic gluconeogenesis, activates AMPK in liver 
and muscle to increase FA oxidation, reduces TAG storage, enhances insulin signalling by 
phosphorylating IRS in the liver and muscle 
235 and also increases adipose and muscle glucose 
uptake 
236.  Adiponectin release is stimulated by insulin, but is also increased in response to the 
insulin sensitising thiazolidinediones (TZD’s) indicating that it is in part regulated by PPARγ.    As 
such, adiponectin levels are reduced in insulin resistance, glucose intolerance, hyperlipidemia, type 
2 diabetes and obesity 
236.   
 
The expression of some adipokines, however, is associated with insulin resistance.  For example, 
RBP4 decreases insulin sensitivity by modulating glucose homeostasis and levels are increased in 
HF feeding, obesity and the metabolic syndrome.   Resistin acts on adipose tissue and skeletal 
muscle to antagonise insulin actions, e.g. by increasing gluconeogenic enzymes and reducing 
AMPK activity 
235, resulting in glucose intolerance and insulin resistance.  Furthermore, the pro-
inflammatory cytokines such as tumour necrosis factor α (TNF-α) and interleukin 6 (IL6) are 
proposed to increase insulin resistance in obesity, in part by increasing the release of FFA from 
adipocytes and by reducing adiponectin synthesis 
236.  
 
 
4.1.4 Adipogenesis 
 
Initiation of adipogenesis during development occurs at different periods in humans and rodents.  
In humans, WAT is not produced until the third trimester and is subsequently present at birth, 
whereas in rodents WAT is not detected until after birth 
233.  WAT mass is dynamic and can vary in 
humans and rodents according to the global energy status due to its ability to increase not only 
adipocyte size by increasing TAG storage (hypertrophy), but also by increasing cell numbers 
(hyperplasia).   As a result, in addition to early development, adipogenesis can occur continuously 
throughout adult life and WAT has the novel capacity for unlimited growth.    
 
In vitro models of adipocyte differentiation such as the pre-adipocyte cell line 3T3-L1 derived from 
17-19 day old Swiss 3T3 mouse embryos have been central to deciphering the process of 
differentiation and the main factors involved in the process.  Pre-adipocytes are derived from 
mesenchymal precursors and adipogenesis occurs when these fibroblastic pre-adipocytes are 
stimulated to differentiate by hormones, the effects of which are mediated by a cascade of 
transcription factors in a highly coordinated process 
233.      
 
Prior to differentiation, pre-adipocytes in culture first undergo cell contact inhibition and growth 
arrest.  Next, upon hormonal stimulation with factors including insulin, glucocorticoids and cAMP,   111
clonal expansion occurs, whereby cells re enter the cell cycle and go through at least two rounds of 
cell division.  This is then followed by growth arrest and terminal differentiation.  Three main 
classes of transcription factors play fundamental roles in orchestrating adipose differentiation; 
CCAAT-enhancer-binding proteins (C/EBP), PPARγ2 and sterol regulatory binding protein 
(SREBP) (ADD-1 in rodents) 
234 (figure 4.0).  PPARγ2 plays a particularly important role in 
differentiation and has been termed “the master regulator”.  Its expression is induced early in 
differentiation, whereby it induces exit from cell cycle and in combination with C/EBPα induces 
transcription of adipose specific genes, for example LPL, FAS, fatty acid binding protein 
234.  In all, 
around 100 proteins are altered at the transcriptional level during terminal differentiation 
233, 
leading the adipocyte to take on the spherical, lipid filled characteristics of a terminally 
differentiated mature adipocyte 
234.   
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Figure  4.0  The involvement of adipogenic transcription factors in adipocyte 
differentiation (adapted from 
233).  Fibroblastic, proliferative, pre-adipocytes express preadipocyte 
factor-1 (Pref-1), which is markedly down regulated upon initiation of differentiation.  During 
clonal expansion, the first transcriptional event known is induction of C/EBPδ and β, which in vitro 
are induced by hormones such as glucocorticoids, cAMP and insulin.  SREBP1 is also expressed 
early during differentiation and this coordinates transcription of genes of lipid, fatty acid and 
cholesterol metabolism.  In addition, Stats are implicated during the early stages of differentiation; 
Stat’s 1,3 and 5 are induced strongly and this is probably due to the effect of cytokines and peptide 
hormones such as GH on cytokine receptors found on adipocytes.  C/EBPβ, C/EBPδ and SREBP1 
all subsequently induce expression of the master regulator of adipose differentiation, PPARγ2.  In 
addition GR can also induce PPARγ2 expression indirectly via C/EBP’s and secondly by inducing 
PPARγ2 directly.  PPARγ2 induces the expression of key adipocyte genes such as LPL, fatty acid 
synthetase (FAS), acyl CoA synthesase and PEPCK, all of which facilitate uptake and storage of 
fatty acids. C/EBPα is induced in later stages of differentiation (by C/EBP β and δ) and it functions 
to stabilize the mature phenotype in part by maintaining PPARγ expression and also by inducing 
other adipose specific genes 
234.   
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4.1.5 De-differentiation  of  adipocytes 
 
An interesting and useful feature of adipocytes is that anti-adipogenic factors can inhibit or even 
reverse differentiation.  Such factors include TNFα which can induce de-differentiation via down 
regulating PPARγ and C/EBPα expression 
237 and retinoic acid which can inhibit the early stages of 
differentiation 
235.  A key paper has indicated that leptin can exert fat reducing effects in adult 
rodents via inducing adipocyte de-differentiation.  Hyperleptinemia was induced in normal adult 
rats which resulted in the rapid disappearance of all visible body fat within 7 days owing to a 95% 
reduction in adipocyte TAG content and the gene profile of a de-differentiated adipocyte 
232.   
However, as the rats regained weight two months after leptin levels returned to normal, this ability 
to de-differentiate the adipocyte was not permanent 
238.  Normally, calorie reduction results in the 
reduction of fat in adipocytes through lipolysis, providing FA for oxidation in the liver, as occurs in 
sympathetic mediated lipolysis.  However, in leptin treated rats there was no corresponding release 
of free fatty acid or ketones alongside glycerol as would be expected.  It further was shown in 
isolated adipocytes that the leptin treatment caused a significant reduction in the mRNA of leptin, 
PPARγ2 and FAS, key adipogenic genes.  Contrastingly they found an increase in the mRNA of 
PPARα and its target genes, CPT-1 and AOX, enzymes of fatty acid β-oxidation not normally 
expressed in adipocytes 
232.  Furthermore, in hyperleptinimic rats, researchers also found increased 
UCP-1 and UCP-2 mRNA, indicating that the energy from oxidation of FA was released as heat 
238 
and down regulated adipocyte markers, including ACC, TNFα and leptin, whilst the preadipocyte 
specific gene pref-1 was up regulated 
238.  It was therefore concluded that the leptin treatment had 
reduced the expression of key adipogenic factors and induced fatty acid oxidation within the 
adipocytes, resulting in their transformation from fat storing cells into de-differentiated fat burning 
cells, with the PPAR’s playing a key regulatory role 
232,238.   
 
Subsequent studies have shown that the oxidative effects of leptin were not centrally mediated on 
the adipocyte (sympathetic stimulation), as norepinephrine stimulated lipolysis resulted in normal 
FFA release from adipocytes 
232.  The leptin receptor (OB-Rb) is expressed on adipocytes 
121 and 
evidence indicates that the effects of leptin were mediated directly on the adipocyte, as the lipolytic 
effects were shown to be absent in adipocytes from OB-Rb deficient fa/fa rats 
232.  It was also 
shown that PPARα is absolutely required to facilitate this novel form of lipolysis, as in PPARα null 
mice, hyperleptinemia reduced food intake, but not fat pad weight.  Furthermore CPT-1 expression 
did not increase, indicating the need for PPARα to facilitate the oxidative effects of 
hyperleptinemia in these adult mice 
239. 
 
This novel oxidation function of leptin has also been identified in liver, skeletal muscle and the 
pancreas 
240.  For example, in the pancreas fatty acid oxidation was shown to be increased due to 
upregulated AOX and CPT1 and a reduction in the enzymes of lipogenesis including ACC.  These 
alterations in gene expression did not occur in islets from OB-Rb deficient fa/fa rats indicating a   114
direct effect 
241.  The role of leptin in these tissues was proposed to be anti-diabetic by preventing 
non-adipocyte lipotoxicity 
240 and to maintain the TAG content of these cells within a strict range 
73.   
 
 
4.1.6 Aims 
 
Interest in the developmental programming of disease by altered epigenetic regulation has focused 
predominantly on pathways involved in programming of hypertension, energy metabolism and 
glucose intolerance in the metabolically active liver tissue.  These studies have identified specific 
DNA methylation and gene expression changes of important transcription factors, such as GR and 
PPARα, which are involved in key metabolic pathways such as gluconeogenesis and fatty acid 
metabolism respectively 
77,213.  Little work has focused on the programming of energy balance in 
adipose tissue, which could play a central causative role in the development of adult obesity and its 
associated metabolic disturbances commonly found in IUGR rodents and humans. 
 
It has been shown in a rat model of global undernutrition that neonatal leptin treatment to 
reproduce the natural leptin surge during development reverses the metabolic disturbances found in 
programmed IUGR offspring, including obesity 
122.  Work in this thesis has not identified any 
relevant changes in the expression or methylation of genes involved in energy balance in the liver 
due to maternal diet or neonatal leptin treatment.  It is possible that the mechanisms underlying 
programming and reversal by leptin involves alterations in key adipocyte genes, such as 
transcription factors involved in adipogenesis and lipid metabolism.  Interestingly, recent work has 
shown that leptin can induce de-differentiation of adipose cells in adult rats as a result of down-
regulating key adipocyte genes including PPARγ and upregulating genes of lipolysis such as 
PPARα 
232.   Taken together, these two studies imply that leptin may act during the later stages of 
developmental plasticity to reverse the programmed phenotype of offspring from undernourished 
dams in part by altering the regulation of key genes involved in energy balance to prevent the 
storage of excess adipose tissue.  This, however, has not yet been tested. 
 
To gain a better understanding of the programming of energy balance in adipose tissue and the 
molecular mechanisms induced by neonatal leptin treatment at the level of the adipocyte, this study 
uses adipose tissue from the same rat model of global undernutrition used by Vickers and 
colleagues 
122.  It investigates the expression and methylation status of several key genes associated 
with adipocyte function and energy balance in response to maternal diet, postnatal diet and 
neonatal leptin treatment using real time PCR and methylation sensitive real time PCR.   
Furthermore, it investigates the impact of the timing of leptin treatment in differentiating 
adipocytes on the expression of several key genes involved in energy balance. 
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Data presented in this chapter shows that there is no effect of maternal diet or postnatal diet on the 
expression of any of the genes tested.  There was, however a significant effect of neonatal leptin 
treatment, which increased the expression of many of the genes involved in energy balance tested. 
Results indicate that neonatal leptin treatment may induce a novel form of lipolysis in adipocytes 
which persists into adult hood to protect against HF feeding.  However, unlike mechanisms 
underlying altered gene expression in the livers of PR offspring 
77,213 methylation sensitive PCR 
indicates that methylation changes in the regions measured were not responsible for the leptin-
induced changes in gene expression.  Furthermore, work with 3T3-L1 adipocytes indicates that 
leptin treatment is able act on the adipocyte to alter gene expression of key genes involved in 
energy balance during differentiation. 
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4.2 Results 
 
 
4.2.1  The expression of genes involved in energy balance in the adipose tissue of adult 
female offspring is not altered by maternal diet or postnatal diet, but is altered by 
neonatal leptin treatment 
 
In order to ascertain if the expression of genes involved in energy balance in adipose tissue of 
female offspring is affected by maternal diet, postnatal diet or neonatal leptin treatment, total RNA 
was prepared from adipose tissue of adult female offspring from the IUGR rat study (n=8 / diet-
treatment group) and used to prepare cDNA.  Real time PCR was performed with validated gene 
specific primers using the cDNA as a template.  Genes studied were those involved in adipocyte 
differentiation and fatty acid storage (IR, GR, 11βHSD2, PPARγ2 and LPL), lipolysis (PPARα, 
AOX, CPT-1 and HSL) and body weight regulation (Leptin and its receptor).  Resulting gene 
expression data were normalised to 18s cDNA and analysed by the ΔCT method 
228.  Results were 
converted to % of the control group (AD Chow 100%) and a 1 way ANOVA performed followed 
by Bonferroni’s post hoc test.  Graphs showing differences in mRNA expression for each gene with 
statistical analysis can be found in figures 4.1 to 4.5.  All results are described relative to the 
control group only.  In addition, a 3 way ANOVA was performed for all genes measured, to 
analyse single factor and interaction effects on gene expression.  The results of the 3 way ANOVA 
are shown in table 4.1. 
 
Results showed that there were no significant differences in gene expression between AD and UN 
offspring, or between AD and UN offspring fed a chow diet or a high fat diet in any of the genes 
measured. There was therefore no significant effect of a maternal diet or postnatal diet on the 
expression of genes involved in energy balance in the adipose tissue of female offspring.   
 
Analysis of PPARα expression by real time PCR demonstrated that its expression was significantly 
increased by neonatal leptin treatment in offspring fed a chow diet from both AD dams (303.8% 
p=0.05) and UN dams (317.3% p=0.05).   In addition, PPARα expression was significantly 
increased by neonatal leptin treatment in offspring fed a high fat diet from both AD dams (478.5% 
p=0.001) and UN dams (391.6% p=0.001) (figure 4.1a).  The expression of PPARα’s target genes 
AOX and CPT-1 were affected by neonatal leptin treatment in a similar manner.  AOX expression 
was increased in leptin treated offspring fed a chow diet from both AD dams (530.2% p=0.01) and 
UN dams (466.5% p=0.05) (figure 4.1c).   In addition to this, AOX expression was increased in 
leptin treated offspring fed a high fat diet from AD dams (728.6% p=0.001) and UN dams (565.2% 
p=0.001).  For CPT-1, the increase in gene expression was limited to leptin treated offspring fed a 
high fat diet from both AD dams (350.6% p=0.001) and UN dams (248.8% p=0.01).  Although 
there was a trend for increased CPT-1 expression in leptin treated offspring fed a chow diet in AD   117
and UN offspring, this did not reach significance (figure 4.1b).  These data indicate that PPARα 
may be responsible for the changes in CPT-1 and AOX expression. 
 
Analysis of PPARγ2 by real time PCR demonstrated that its expression was significantly increased 
in all offspring given neonatal leptin treatment; for those offspring fed a chow diet from both AD 
dams (324.5% p=0.01) and UN dams (349.7% p=0.001) and also for offspring fed a high fat diet 
from both AD dams (340.1% p=0.001) and UN dams (279.2% p=0.5) (figure 4.2a).  The 
expression of PPARγ2’s target gene LPL was also affected by neonatal leptin treatment, but only in 
those offspring fed a high fat diet from both offspring from AD dams (441.9% p=0.001) and UN 
dams (414.6% p=0.01) (figure 4.2b).  Although there was a trend for increased expression of LPL 
in offspring fed a chow diet, this did not reach significance.  Like PPARα, these data indicate that 
PPARγ2 may be responsible for the changes seen in the expression of its target gene, LPL. 
 
For GR, there was a trend for increased expression in all leptin treated offspring, however this only 
reached significance in offspring fed a chow diet from AD dams (1412% p=0.05) and those fed a 
high fat diet from UN dams (1954% p=0.001) (figure 4.3a).  However, expression of the GR 
exon110 specific transcript was significantly increased in all leptin treated offspring.  Expression 
was increased in leptin treated offspring fed a chow diet from both AD dams (420.7% p=0.05) and 
UN dams (309.6% p=0.05) and leptin treated offspring fed a high fat diet from both AD dams 
(408.4% p=0.001) and UN dams (328.8% p=0.01) (figure 4.3b).  For 11βHSD2, expression was 
also increased in offspring given neonatal leptin treatment (figure 4.3c).  Expression was 
significantly increased in leptin treated offspring from AD dams fed both a chow (452.4% 
p=0.001) and high fat (579.2% p=0.001) diet, but for UN offspring the increase was only 
significant in leptin treated offspring fed a high fat diet (352.4% p=0.05).  Expression of 11βHSD2 
was increased in leptin treated UN offspring fed a chow diet, but this failed to reach significance.  
 
The expression of HSL was not significantly altered by neonatal leptin treatment in any of the 
offspring groups (figure 4.4a).  There was however, a trend for reduced expression of HSL in AD 
offspring regardless of postnatal diet but this failed to reach significance.  For IR, there was a trend 
for reduced expression in all leptin treated offspring, but this only reached significance in AD 
offspring fed a HF diet (51.5% p=0.05) (figure 4.4b). 
 
Analysis of the effects of neonatal leptin treatment on leptin expression revealed that there was a 
trend for increased leptin expression in all offspring when compared to the control group, but this 
only reached significance in offspring from AD dams fed a high fat diet (723.1% p=0.001) (figure 
4.5a).  For leptin receptor there was also a trend for increased expression in all leptin treated 
offspring, but this only reached significance in UN offspring fed a high fat diet (766.1% p=0.001) 
(figure 4.5b). 
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Figure 4.1  The expression of PPARα and its target genes CPT-1 and AOX in adipose 
tissue of adult female offspring is altered by neonatal leptin treatment but not maternal diet 
or postnatal diet.  Real time PCR data for expression of PPARα (A), CPT-1 (B), AOX (C) are 
shown  in response to maternal diet (ad libitum [AD] and undernutrition [UN]), postnatal diet 
(Chow [C] and High Fat [HF]) and neonatal leptin treatment (leptin [L]) (n=8/group). Values with 
different letters are significantly different (p<0.05) by Bonferroni’s post hoc test. 
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Figure 4.2  The expression of PPARγ2 and its target gene LPL in adipose tissue of adult 
female offspring is altered by neonatal leptin treatment but not maternal diet or postnatal 
diet.  Real time PCR data for expression of PPAR γ2 (A) and LPL (B) are shown in response to 
maternal diet (ad libitum [AD] and undernutrition [UN]), postnatal diet (Chow [C] and High Fat 
[HF]) and neonatal leptin treatment (leptin [L]) (n=8/group). Values with different letters are 
significantly different (p<0.05) by Bonferroni’s post hoc test. 
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Figure 4.3  The expression of GR, GR 110 and 11βHSD2 in adipose tissue of adult female 
offspring is altered by neonatal leptin treatment but not maternal diet or postnatal diet.  Real 
time PCR data for expression of GR (A), GR 110 (B) and 11βHSD2 (C)are shown in response to 
maternal diet (ad libitum [AD] and undernutrition [UN]), postnatal diet (Chow [C] and High Fat 
[HF]) and neonatal leptin treatment (leptin [L]) (n=8/group). Values with different letters are 
significantly different (p<0.05) by Bonferroni’s post hoc test. 
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Figure 4.4  The expression of HSL in adipose tissue of adult female offspring is not 
affected by maternal diet, postnatal diet or neonatal leptin treatment.  The expression of 
Insulin Receptor is effected by leptin treatment and this effect is dependent on maternal diet 
and postnatal diet.  Real time PCR data for expression of HSL (A) and Insulin Receptor (B) are 
shown in response to maternal diet (ad libitum [AD] and undernutrition [UN]), postnatal diet 
(Chow [C] and High Fat [HF]) and neonatal leptin treatment (leptin [L]) (n=8/group). Values with 
different letters are significantly different (p<0.05) by Bonferroni’s post hoc test. 
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Figure 4.5  The expression of leptin and its receptor in adipose tissue of adult female 
offspring is altered by neonatal leptin treatment but not maternal diet or postnatal diet.   
effect of leptin treatment is dependent on maternal diet.  Real time PCR data for expression of 
leptin (A) and leptin Receptor (B) are shown in response to maternal diet (ad libitum [AD] and 
undernutrition [UN]), postnatal diet (Chow [C] and High Fat [HF]) and neonatal leptin treatment 
(leptin [L]) (n=8/group). Values with different letters are significantly different (p<0.05) by 
Bonferroni’s post hoc test. 
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4.2.2  The expression of DNA methyl transferases in the adipose tissue of adult female 
  offspring in programmed rats is not significantly altered by maternal diet, postnatal 
  diet or  neonatal leptin treatment 
 
In order to determine if the expression of the DNA methyltransferases 1 and 3a are affected by 
maternal diet, postnatal diet or neonatal leptin treatment in adipose tissue of female offspring, total 
RNA was prepared from adipose tissue of female offspring from the IUGR rat study (n=8 / diet-
treatment group) and used to prepare cDNA.  Real time PCR was performed with validated primers 
specific for Dnmt1 and Dnmt3a using the cDNA as a template.  Resulting gene expression data 
were normalised to 18s cDNA and analysed by the ΔCT method 
228.  Results were converted to % 
of the control group (AD Chow 100%) and a 1 way ANOVA performed followed by Bonferroni’s 
post hoc test.  Graphs showing differences in mRNA expression with statistical analysis can be 
found in figure 4.6.  All results are described relative to the control group only.  In addition, a 3 
way ANOVA was performed to analyse single factor and interaction effects on gene expression.  
The results of the 3 way ANOVA are shown in table 4.1. 
 
Analysis of Dnmt1 expression revealed that its expression was not significantly altered by maternal 
diet, postnatal diet or neonatal leptin treatment (figure 4.6a).  However, some trends were evident 
in leptin treated offspring; there was a trend for increased expression in AD offspring, but this 
failed to reach significance and similarly there was a trend for reduced expression in UN offspring 
but again this failed to reach significance.  Dnmt3a expression was also not significantly altered by 
maternal diet, postnatal diet or neonatal leptin treatment, although there was a trend towards 
reduced Dnmt3a expression in all UN offspring (figure 4.6b).   
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Figure 4.6  The expression of DNA methyltransferases in adipose tissue of adult female 
offspring is not significantly altered by neonatal leptin treatment, maternal diet or postnatal 
diet.  Real time PCR data for expression of Dnmt1 (A) and Dnmt3a (B) are shown in response to 
maternal diet (ad libitum [AD] and undernutrition [UN]), postnatal diet (Chow [C] and High Fat 
[HF]) and neonatal leptin treatment (leptin [L]) (n=8/group).  
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Table 4.1  Table showing tests of between subject effects on the mRNA expression of 
genes measured in the adipose tissue of female offspring.  Single factor effects (MD, T, PND) 
and interaction effects (MD*T, MD*PND, T*PND, MD*T*PND) are shown.  Significant effects 
(P<0.05) are indicated in red.  There were significant single factor effects for all genes.  There were 
significant effects of MD for 11βHDS2, HSL, leptin, Dnmt1 and Dnmt3a.  There were significant 
effects of T for all genes except HSL, Dnmt1 and Dnmt3a.  There were significant effects of PND 
for PPARα, CPT-1, LPL, IR, HSL and leptin.  There were significant interaction effects for CPT-1 
(T*PND, MD*T*PND), 11βHSD2 (MD*T), HSL (MD*T), leptin (MD*T) and Dnmt1 (MD*T).  
 
 
Variable 
 
 
Anova 
 
Maternal 
Diet 
(MD) 
 
Treatment 
(T) 
 
Postnatal 
Diet 
(PND) 
 
MD*
T 
 
MD* 
PND 
 
T* 
PND 
 
MD* 
T* 
PND 
 
 
PPARα 
CPT-1 
AOX 
PPARγ2 
LPL 
GR 
GR110 
11βHSD2 
IR 
HSL 
Leptin 
LR 
Dnmt1 
Dnmt3a 
 
 
0.000 
0.000 
0.000 
0.000 
0.000 
0.000 
0.000 
0.000 
0.030 
0.006 
0.000 
0.000 
0.035 
0.198 
 
0.298 
0.540 
0.231 
0.451 
0.905 
0.439 
0.059 
0.010 
0.601 
0.016 
0.043 
0.304 
0.004 
0.008 
 
0.000 
0.000 
0.000 
0.000 
0.000 
0.000 
0.000 
0.000 
0.003 
0.358 
0.000 
0.000 
0.262 
0.296 
 
0.006 
0.000 
0.146 
0.809 
0.008 
0.355 
0.734 
0.114 
0.018 
0.053 
0.007 
0.238 
0.864 
0.679 
 
0.847 
0.543 
0.339 
0.965 
0.587 
0.498 
0.152 
0.013 
0.794 
0.003 
0.044 
0.231 
0.025 
0.793 
 
0.223 
0.152 
0.704 
0.287 
0.392 
0.078 
0.971 
0.908 
0.421 
0.637 
0.528 
0.946 
0.576 
0.808 
 
0.184 
0.043 
0.176 
0.396 
0.657 
0.499 
0.644 
0.338 
0.993 
0.468 
0.431 
0.350 
0.653 
0.568 
 
0.642 
0.009 
0.568 
0.522 
0.770 
0.091 
0.554 
0.480 
0.564 
0.456 
0.247 
0.912 
0.884 
0.348 
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4.2.3  The methylation of genes involved in energy balance in the adipose tissue of adult 
  female  offspring in programmed rats is not altered by maternal diet, postnatal diet or 
  neonatal leptin treatment 
 
In order to ascertain if the methylation status of promoter regions of genes involved in energy 
balance is affected by maternal diet, postnatal diet or neonatal leptin treatment in adipose tissue of 
female offspring, genomic DNA was prepared from adipose tissue of female offspring from the 
IUGR rat study (n=8 / diet-treatment group).  This DNA was digested with methylation sensitive 
restriction enzymes (AciI or Hinp1I) and real time PCR was performed with validated gene specific 
primers using the digested genomic DNA as a template.  Promoters studied were those from genes 
involved in adipocyte differentiation and fatty acid storage (GR, 11βHSD2 PPARγ1), fatty acid 
metabolism (PPARα, AOX) and body weight regulation (Leptin and its receptor).  Resulting data 
were normalised to PPARγ2 which has no AciI or Hinp1I sites.  Results were converted to % of the 
control group (AD Chow 100%) and a 1 way ANOVA performed followed by Bonferroni’s post 
hoc test.  Graphs showing differences in methylation for each gene with statistical analysis can be 
found in figures 4.7 to 4.9.  All results are described relative to the control group.  In addition, a 3 
way ANOVA was performed for all genes measured, to analyse single factor and interaction effects 
on DNA methylation.  The results of the 3 way ANOVA are shown in table 4.2. 
 
There were no significant effects of maternal diet or postnatal diet on the methylation status of any 
of the genes studied.  There were also no significant effects of neonatal leptin treatment on the 
methylation of any of the genes except for an increase in methylation of the PPARα promoter in 
UN offspring fed a high fat diet (109.27% p=0.001) (figure 4.8a).  Furthermore, no trends in 
methylation status were apparent with any of the treatment groups. 
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Figure  4.7  The methylation of the GR, PPARγ1 and 11βHSD2 promoters in adipose 
tissue of adult female offspring are not altered by maternal diet, postnatal diet or neonatal 
leptin treatment.  Real time PCR data for methylation of GR (A), PPARγ1 (B) and 11βHSD2 
(C)are shown in response to maternal diet (ad libitum [AD] and undernutrition [UN]), postnatal 
diet (Chow [C] and High Fat [HF]) and neonatal leptin treatment (leptin [L]) (n=8/group). Values 
with different letters are significantly different (p<0.05) by Bonferroni’s post hoc test. 
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Figure  4.8  Methylation of the PPARα promoter in adipose tissue of adult female 
offspring is affected by neonatal leptin treatment but not maternal diet or postnatal diet.  the 
methylation of the AOX promoter is not altered by maternal diet, postnatal diet or neonatal 
leptin treatment.  Real time PCR data for methylation of PPARα (A) and AOX (B) are shown in 
response to maternal diet (ad libitum [AD] and undernutrition [UN]), postnatal diet (Chow [C] and 
High Fat [HF]) and neonatal leptin treatment (leptin [L]) (n=8/group). Values with different letters 
are significantly different (p<0.05) by Bonferroni’s post hoc test. 
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Figure 4.9  Methylation of the leptin and leptin receptor promoters in adipose tissue of 
adult female offspring are not altered by maternal diet, postnatal diet or neonatal leptin 
treatment.  Real time PCR data for methylation of leptin (A) and LR (B) are shown in response to 
maternal diet (ad libitum [AD] and undernutrition [UN]), postnatal diet (Chow [C] and High Fat 
[HF]) and neonatal leptin treatment (leptin [L]) (n=8/group).   
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Table 4.2  Table showing tests of between subject effects on DNA methylation for genes 
measured in adipose tissue of female offspring.  Single factor effects (MD, T, PND) and 
interaction effects (MD*T, MD*PND, T*PND, MD*T*PND) are shown.  Significant effects 
(P<0.05) are indicated in red.  There were no significant single factor or interaction effects for GR, 
LR or PPARγ1.  For PPARα, there were significant single factor effects (MD, T) and interaction 
effects (T*PND, MD*T*PND).  For AOX and 11βHSD2, there were only significant single factor 
effects (T).  For leptin, there were significant interaction effects (MD*T, MD*T*PND).  
 
 
Variable 
 
 
Anova 
 
Maternal 
Diet 
(MD) 
 
Treatment 
(T) 
 
Postnatal 
Diet 
(PND) 
 
MD*
T 
 
MD* 
PND 
 
T* 
PND 
 
MD* 
T* 
PND 
 
 
PPARα 
AOX 
GR 
11βHSD2 
Leptin 
LR 
PPARγ1 
 
 
0.000 
0.359 
0.669 
0.026 
0.049 
0.147 
0.812 
 
0.001 
0.437 
0.146 
0.970 
0.681 
0.312 
0.493 
 
0.009 
0.044 
0.711 
0.001 
0.216 
0.163 
0.712 
 
0.133 
0.224 
0.598 
0.866 
0.317 
0.703 
0.524 
 
0.564 
0.364 
0.935 
0.989 
0.045 
0.189 
0.459 
 
0.368 
0.888 
0.900 
0.200 
0.067 
0.053 
0.544 
 
0.038 
0.708 
0.499 
0.054 
0.322 
0.275 
0.255 
 
0.037 
0.882 
0.194 
0.307 
0.046 
0.190 
0.550 
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4.2.4  Leptin undergoes a surge in expression during differentiation of 3T3-L1 pre-
 adipocytes 
 
In order to determine if leptin treatment to differentiating 3T3-L1 adipocytes is able to induce the 
expression of genes found to be upregulated in response to neonatal leptin treatment in IUGR 
offspring and to determine if the effect of leptin treatment differs according to the phase of the 
leptin surge, the period of the leptin surge during the differentiation of 3T3-L1 cells first needs to 
be determined.  Therefore 3T3 cells were stimulated to differentiate and total RNA prepared from 
3T3-L1 cells at different stages of differentiation (day 0 to day 13), which was used to prepare 
cDNA.  Real time PCR was then performed with validated primers specific for leptin using the 
cDNA as a template.  Resulting expression data were normalised to CYC cDNA and analysed by 
the ΔCT method 
228.   Data at each time point was expressed as a percentage of treatment day 0, 
which was set to 100%.  A graph showing leptin expression alongside the appearance of the 
adipocytes throughout the stages of differentiation is shown in figure 4.6.   
 
Results indicated that leptin expression did not alter between differentiation day 0 and 6 (figure 
4.10a).  By day 9, leptin levels had increased to levels 400% that of undifferentiated cells.  Leptin 
expression then further increased dramatically up to day 13 resulting in levels 6000% that of 
undifferentiated cells, at which point the adipocytes showed morphological features of fully 
differentiated adipocytes (figure 4.10b). 
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Figure  4.10  Appearance of 3T3-L1 adipocytes and expression profile of leptin mRNA 
during differentiation.  A) Endogenous leptin expression in 3T3-L1 pre-adipocytes undergoing 
differentiation from undifferentiated (Day 0) to fully differentiated (Day 13) B) Appearance of 
adipocytes during the same differentiation period. 
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4.2.5  Endogenous leptin treatment alters the expression of specific genes involved in energy 
  balance before and during the differentiation of 3T3-L1 adipocytes 
 
In order to ascertain if leptin treatment can induce an increase in the expression of key genes 
involved in energy balance in differentiating adipocytes, 3T3-L1 pre-adipocytes were stimulated to 
differentiate into adipocytes and treated with leptin (10ng/ml).  Leptin treatment was given in two 
separate experiments at differentiation day 2 (prior to the leptin surge) and day 8 (start of the leptin 
surge), to determine if the timing of treatment relative to the leptin surge in adipocytes was 
important for the gene response.  mRNA expression was measured in 4 genes; PPARα, leptin, GR 
and 11βHSD2.  Therefore, to determine the effect of leptin treatment on the expression profile of 
these genes, total RNA was prepared from 3T3-L1 cells at different timepoints after the onset of 
leptin treatment for both day 2 and day 8 (0, 2, 6, 24, 48hr) and used to prepare cDNA.  Real time 
PCR was performed with validated primers using the cDNA as a template.  Resulting gene 
expression data were normalised to CYC cDNA and analysed by the ΔCT method 
228.   Data from 
each timepoint is expressed as a percentage of day 0, which was set to 100%.  Graphs showing 
representative replicates of gene expression profiles for all genes can be found in figures 4.11 to 
4.18.  Results are described as a mean of 2 replicates. 
 
At differentiation day 2, endogenous leptin expression showed a slight dip in expression over the 
following 48 hours (figure 4.11).  Up to this time point, there was no effect of exogenous leptin 
treatment on the expression of leptin.  However, after 48 hours, mean leptin levels in control cells 
remained dipped at 88% compared to time 0, whereas in leptin treated cells, mean expression 
increased to 173%.  PPARα expression in the untreated cells underwent a steady increase in 
expression throughout the 48 hour period from day 2, reaching a mean of 2468% compared to 0hr 
(figure 4.12).  The effect of leptin treatment on PPARα gene expression was only apparent at 24 
hours after treatment, reaching a mean of 2933% compared to untreated (2009%) at 24hr.   
However this increase in expression was lost at 48 hours, returning to mean levels of 1613% at 48 
hours compared to 2468% in controls.  Mean GR gene expression showed a steady increase to 
225% and 302% original levels in untreated cells over the 24 and 48 hours respectively.  Leptin 
treated cells showed a similar expression profile and GR gene expression was only mildly 
increased at 24 and 48 hrs after treatment with leptin compared to untreated, with mean values of 
295% at 24hr and 335% at 48hr (figure 4.13).  Expression of 11βHSD2 in untreated cells showed 
no variation in expression throughout the time course, except for a spike in expression at 6hrs to a 
mean of 750% compared to untreated value of 106%.  At the end of the 48 hours, the expression of 
11BHSD2 in untreated cells was 196% compared to time 0, whereas for leptin treated cells, this 
mean was slightly higher at 217% (figure 4.14). 
 
Expression profiles were next measured in the same genes undergoing differentiation from day 8.  
Untreated cells showed a dip in leptin expression over the 24hr period with mean values of 54%   134
compared to time 0.  After this leptin expression increased over the next 24hr with levels reaching a 
mean of 250% compared to 0hr at 48hr (figure 4.15).  In leptin treated cells, again, there was a dip 
in expression but only over the first 6 hours.  After this, mean leptin expression increased reaching 
187% at 24hr and 1061% at 48hr post treatment.  Mean PPARα expression at day 8 remained fairly 
constant over the first 24hr and then increased to 815% at 48hr in untreated cells (figure 4.16).  In 
the leptin treated cells, this increase in expression occurred earlier at 24hrs with mean levels of 
700% compared to time 0, which dropped off to 74% at 48hr.  Contrastingly, mean GR expression 
in untreated differentiating cells remained constant for the first 6hr and then showed a reduction in 
expression at 24hr to 15% original levels, then dropping further to a mean of 8% at 48 hr (figure 
4.17).  The leptin treated cells followed a similar pattern of expression, but expression dropped at 
an earlier time point, dropping at 6hr to mean levels of 18% and then dropping further to 3% at 48 
hours.  For 11βHSD2 expression untreated cells showed a steady increase in mean 11βHSD2 
expression over the time course resulting in levels of 434% compared to 0hr at 48hr (figure 4.18).  
Treatment with leptin resulted in a similar steady increase in gene expression, but with overall 
higher levels at all time points, resulting in mean expression levels of 280% at 24hr and 634% at 
48hr. 
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Figure  4.11  Expression profile of leptin in 3T3-L1 pre-adipocytes undergoing 
differentiation at day 2 treated with exogenous leptin.  Real time PCR data for expression of 
leptin are shown  in response to leptin treatment at 0ng/ml and 10ng/ml.  Treatment starts at 
differentiation day 2 (0hr) and results are taken over a 48 hour time course.  Replicates are shown 
in separate graphs (A and B). 
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Figure  4.12  Expression profile of PPARα in 3T3-L1 pre-adipocytes undergoing 
differentiation at day 2 treated with exogenous leptin.  Real time PCR data for expression of 
PPARα are shown in response to leptin treatment at 0ng/ml and 10ng/ml.  Treatment starts at 
differentiation day 2 (0hr) and results are taken over a 48 hour time course.  Replicates are shown 
in separate graphs (A and B). 
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Figure 4.13  Expression profile of GR in 3T3-L1 pre-adipocytes undergoing differentiation 
at day 2 treated with exogenous leptin.  Real time PCR data for expression of GR are shown in 
response to leptin treatment at 0ng/ml and 10ng/ml.  Treatment starts at differentiation day 2 (0hr) 
and results are taken over a 48 hour time course.  Replicates are shown in separate graphs (A and 
B). 
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Figure 4.14  Expression  profile  of  11βHSD2 in 3T3-L1 pre-adipocytes undergoing 
differentiation at day 2 treated with exogenous leptin.  Real time PCR data for expression of 
11βHSD2 are shown in response to leptin treatment at 0ng/ml and 10ng/ml.  Treatment starts at 
differentiation day 2 (0hr) and results are taken over a 48 hour time course.  Replicates are shown 
in separate graphs (A and B). 
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Figure  4.15  Expression profile of leptin in 3T3-L1 pre-adipocytes undergoing 
differentiation at day 8 treated with exogenous leptin.  Real time PCR data for expression of 
leptin are shown  in response to leptin treatment at 0ng/ml and 10ng/ml.  Treatment starts at 
differentiation day 8 (0hr) and results are taken over a 48 hour time course.  Replicates are shown 
in separate graphs (A and B). 
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Figure  4.16  Expression profile of PPARα in 3T3-L1 pre-adipocytes undergoing 
differentiation at day 8 treated with exogenous leptin.  Real time PCR data for expression of 
PPARα are shown in response to leptin treatment at 0ng/ml and 10ng/ml.  Treatment starts at 
differentiation day 8 (0hr) and results are taken over a 48 hour time course.  Replicates are shown 
in separate graphs (A and B). 
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Figure 4.17  Expression profile of GR in 3T3-L1 pre-adipocytes undergoing differentiation 
at day 8 treated with exogenous leptin.  Real time PCR data for expression of GR are shown in 
response to leptin treatment at 0ng/ml and 10ng/ml.  Treatment starts at differentiation day 8 (0hr) 
and results are taken over a 48 hour time course.  Replicates are shown in separate graphs (A and 
B). 
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Figure 4.18  Expression  profile  of  11βHSD2 in 3T3-L1 pre-adipocytes undergoing 
differentiation at day 8 treated with exogenous leptin.  Real time PCR data for expression of 
11βHSD2 are shown in response to leptin treatment at 0ng/ml and 10ng/ml.  Treatment starts at 
differentiation day 8 (0hr) and results are taken over a 48 hour time course.  Replicates are shown 
in separate graphs (A and B). 
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4.3 Discussion 
 
Evidence is accumulating which implicates altered DNA methylation and expression of key 
transcription factors and their target genes as causative factors underlying the metabolic 
disturbances associated with developmental programming 
77,213,216.  For example, alterations in the 
epigenetic regulation of genes involved with energy homeostasis such as GR and PPARα have 
been identified in the liver of MLP offspring 
77,213.  These mechanisms have not been investigated 
in an alternative animal model, the IUGR rat, an established model of programming involving a 
maternal 30% global undernutrition.  These offspring are born small for their gestational age with 
reduced body fat, indicating altered adipose tissue development.  They are also predisposed to 
become obese in adulthood upon nutritional affluence, have hyperphagia, increased systolic blood 
pressure and present with hyperinsulinemia and hyperleptinemia 
122.   
 
Work in the previous chapter of this report failed to identify any of the gene expression and 
methylation changes found in the liver of PR offspring 
57,77 in the liver of IUGR offspring.  It is 
therefore probable, that different genes, pathways or tissues are affected by maternal undernutrition 
in the IUGR rat, resulting in the altered capacity to store fat and the associated metabolic 
disturbances.  Given the key role of adipocytes in the altered metabolism and the role of adipokines 
such as leptin in fetal growth, adipose tissue is strongly implicated as a causative factor in the 
development of obesity in the IUGR offspring.  This would indicate that in IUGR rats, adipocyte 
function may be lost and this could be a result of altered methylation and expression of adipokines, 
transcription factors and their target genes involved in energy metabolism.   
 
Previous work using this IUGR rat model of undernutrition has found that neonatal leptin treatment 
can prevent all the metabolic and physiological effects found in programmed offspring, by reducing 
weight gain 
122.  Work in the previous chapter of this report could not find any relevant alterations 
in hepatic transcription factors and their target genes in IUGR offspring which could account for 
these changes induced by leptin.  However, it has been shown in normal adult rats that leptin 
treatment can induce weight loss by directly acting on adipocytes to alter the expression of key 
genes involved with lipid metabolism, such as PPARα and its target genes 
232.  Therefore, given 
that in adipose tissue, leptin has previously been shown to affect the expression of genes of 
lipogenesis 
231 and lipolysis 
232, it is possible that neonatal leptin treatment acts to alter signaling 
pathways to reduce lipogenesis and increase lipolysis in adipose tissue, to normalise the 
programmed phenotype. 
 
The aim of this chapter was to determine if maternal or postnatal diet altered the expression and 
methylation of key genes of lipid metabolism in the adipose tissue of adult offspring from the 
IUGR rat study and to determine if leptin treatment was able to prevent any associated gene 
expression and methylation changes.  To address these questions, the expression and methylation   144
status of a variety of genes involved in lipid metabolism were measured in the adipose tissue from 
IUGR offspring using real time PCR.    
 
This study demonstrated in adipose tissue that the expression of key genes involved in energy 
homeostasis, including PPARα, PPARγ2 and their target genes, were not altered by maternal diet 
or postnatal nutrition.  In agreement with this, the DNA methylation status of their respective 
promoters was also unchanged by diet.  In contrast, neonatal leptin treatment resulted in a 
persistent increase in mRNA expression for many of the genes studied and this effect tended to be 
amplified in response to a HF postnatal diet, consistent with reduced weight gain in these offspring.  
There was, however, no evidence of altered DNA methylation in the promoters of offspring given 
neonatal leptin treatment.  Analysis of the effect of leptin treatment on differentiating 3T3-L1 
adipocytes in vitro conformed that leptin could increase the expression of several of these genes by 
acting directly on the adipocyte. 
 
Unlike the MLP model which found increased GR and PPAR Alpha expression in liver of MPL 
offspring 
57,77, there were no significant effects of maternal diet on the expression or methylation of 
any of the genes measured in adipose tissue.  This may well be due to the timing effects of maternal 
undernutrition, because in rats, adipose tissue undergoes differentiation after birth.  As these 
offspring were cross fostered onto AD dams at birth, the nutritional constraint may be outside the 
plastic stage of adipocytes, which would therefore be unaffected by maternal diet.  It is also 
possible however, that different pathways and therefore genes were modified by maternal diet 
compared to MLP offspring.  However, despite this, some interesting alterations in gene expression 
were apparent in the leptin treated offspring. 
 
The expression of PPARα and its target genes AOX and CPT-1 were increased in response to 
neonatal leptin treatment and this increase was heightened in response to a high fat diet.  As fatty 
acids are known to regulate PPARα expression by auto-regulation, it follows that PPARα would be 
up-regulated by HF feeding.  Furthermore, the similar expression profiles of these three genes 
mean it is likely that PPARα is responsible for the differences in expression of CPT-1 and AOX.  
Thus in adipose tissue, the effect of neonatal leptin treatment in offspring fed a high fat diet is the 
permanent increase in expression of key genes involved in fatty acid metabolism not normally 
highly expressed in adipocytes.  This could indicate an increase in fatty acid oxidation within 
adipose tissue and is in agreement with a previous report on the transient effects of leptin treatment 
in the adipose tissue of adult rats 
232.  However, in this rat model the effects of neonatal leptin 
treatment are persistent and this is most likely to be due to the epigenetic plasticity which is still 
present in the neonate. 
 
There was also a strong effect of leptin treatment on the expression of PPARγ2 in offspring fed 
both a chow and high fat postnatal diet, with increased expression compared to control offspring.    145
The expression of its target gene LPL had a similar expression profile, with a significant effect of 
leptin on offspring fed a high fat diet.  As PPARγ2 controls the expression of LPL, this indicates 
that it may well be responsible for its changes in expression.  Thus the leptin treatment resulted in a 
permanent increase in the expression of key adipocyte genes which function in adipogenesis, 
lipogenesis and transport of fatty acids into adipocytes.  A previous report of leptin treatment in 
adult rats found reduced expression of PPARγ2, LPL and other adipogenic genes which contributed 
towards the de-differentiation of adipocytes 
232.  This study did not find a reduction in PPARγ2 or 
LPL expression in response to leptin treatment, but this may be a consequence of the timing of 
leptin administration, as in this study the first two weeks of neonatal life is a critical time for the 
development of adipose tissue.  Furthermore, GR expression was vastly increased in all leptin 
treated offspring and as GR can both directly and indirectly induce PPARγ2 expression 
234, this 
could be responsible for preventing PPARγ2 down regulation.   
 
GR is known to have at least 11 transcript variants which have tissue specific expression, but it is 
not known which transcripts are expressed in the adipose tissue of rats 
242.  Results from this study 
indicated that there were differences in the expression of GR transcript variants in response to the 
treatments.  The expression of GR110, which is thought to be expressed in most tissues, was 
increased in all leptin treated offspring, whereas the expression of total GR was more strongly 
induced by leptin treatment, indicating an alternative transcript(s) may be responsible for the 
increase in total GR in adipose tissue.  The increase in GR expression in all leptin treated offspring 
could also contribute to the increase in PPARα and 11βHDS-2 expression seen in the same 
offspring.  Increased 11βHDS-2 expression in leptin treated offspring is consistent with the finding 
that in MLP rats, leptin treatment can prevent the placental reduction in 11βHSD-2 to increase 
conversion of cortisone to inactive corticosterone 
145.   
 
Leptin treatment resulted in a trend towards a reduction in the expression of IR.  This would be 
consistent with a reduction in insulin signaling in the leptin treated adipose tissue and could 
potentially result in the reduction in expression of lipogenic genes.  It has been found in other 
studies that leptin can reduce the expression of key lipogenic genes in adipose tissue such as FAS 
and ACL 
231.  It is therefore possible that these genes are suppressed in neonatal leptin treated 
offspring.   It would therefore be invaluable to look at the expression of such genes in future 
experiments.  
 
The expression of leptin receptor was increased in all leptin treated offspring, but due to the 
variability in data, this did not reach significance, apart from UN offspring fed a high fat diet.  An 
increase in leptin receptor signalling would be consistent with effects of leptin being peripherally 
mediated on the adipocyte and would implicate increased leptin sensitivity and thus increased 
signalling mechanisms such as Jak/Stat on target genes in leptin treated offspring.  Several lines of 
evidence indicate that the expression of leptin receptor could play a key role in the programming of   146
obesity, with reduced expression contributing to leptin resistance and increased expression 
protecting from postnatal HF induced obesity.   
 
Firstly, leptin receptor expression in the hypothalamus is reduced in normal offspring fed a 
postnatal HF diet, indicating HF diet induced central leptin resistance.  However, there is no effect 
of a HF diet in these offspring given leptin treatment from PND1-20 and in these offspring OB-Rb 
expression is increased 
147.  This indicates that at the hypothalamic level neonatal leptin treatment 
helps prevent HF induced leptin resistance, by restoring OB-Rb expression and therefore leptin 
sensitivity 
147.  This has also found to be the case in adipose tissue 
243.  It has been shown that 
adipocyte specific OB-Rb is down regulated to virtually undetectable levels in the DIO rat, with an 
associated reduction in Stat3 activation and an increase in SOCS3 expression.  All these features 
imply adipose specific leptin resistance.  Reintroduction of adipocyte specific OB-Rb into these 
rats normalises Stat3 signalling and prevents obesity 
243.   
 
Furthermore, in a separate study it has been shown that adipose specific disruption of leptin 
signalling is responsible for increased weight gain in HF feeding even in the presence of normal 
hypothalamic leptin signalling.  Mice with adipose specific knockout of OB-Rb have increased fat 
mass due to hypertrophy and associated metabolic disturbances particularly upon HF feeding, as 
found in IUGR offspring.  This obesity occurs in the presence of normal hypothalamic OB-Rb 
expression and pair matched food intake to wild type mice.  In addition, these rats have altered 
adipose gene expression, including that of FAS TNFα and leptin.  This study indicates the 
importance of adipose specific leptin receptor signalling on the regulation of bodyweight and that 
leptin resistance at the adipocyte is important for onset of obesity and associated metabolic 
disturbances 
244.   
 
Interestingly, it is possible that insulin could mediate the down regulation of adipose specific OB-
Rb in the programmed offspring, as in rats, DIO can be prevented by blocking insulin signalling 
243.  
In agreement with this hypothesis, leptin treated IUGR offspring had a trend for down regulated 
insulin receptor compared to saline treated offspring, implying reduced insulin signalling in leptin 
treated offspring.  
 
In this study, IUGR rats have hyperleptinemia in conjunction with obesity, implying leptin 
resistance.  Collectively, all the above studies on OB-Rb imply that leptin resistance at the 
adipocyte due to reduced OB-Rb signalling is a causative factor in HF induced obesity and that by 
restoring OB-Rb, such as occurs with neonatal leptin treatment, obesity resulting from HF diet can 
be prevented.  This theory is consistent with results from this study, whereby leptin receptor 
expression is up regulated in the adipocytes of leptin treated offspring whom have reduced weight 
gain compared to saline treated offspring, particularly on a HF postnatal diet.  Therefore increased 
OB-Rb signalling in the adipose tissue and not the hypothalamus may play the main role in   147
preventing the diet induced obesity found in these offspring, by increasing leptin sensitivity at the 
adipocyte.  Increased OB-Rb expression may also be responsible for the other changes seen in gene 
expression in adipose tissue of IUGR rats, such as the PPAR’s.  It should be mentioned, however, 
that OB-Rb expression was not reduced in the saline treated IUGR offspring.  However, it may be 
that in these offspring signalling downstream of OB-Rb may have been affected, such as altered 
Socs-3 expression.  It would therefore be interesting to determine if Socs-3 was altered in 
adipocytes, or if OB-Rb and other factors such as Socs-3 were affected in the hypothalamus of the 
programmed IUGR rat. 
 
The expression of leptin was also increased in all leptin treated offspring, but did not reach 
significance apart from in AD offspring fed a high fat diet.  Increased leptin expression without 
leptin resistance could indicate increased leptin action in these offspring and could be in part 
responsible for reversing some of the metabolic disturbances in IUGR offspring.  For example, 
leptin reduces insulin expression as part of the adipoinsular axis 
125 and through central 
mechanisms.  Increased leptin action could therefore facilitate the reduction in insulin 
concentrations found in leptin treated IUGR offspring. 
 
It would have been of value to determine if the expression of leptin was altered in adipose tissue 
throughout the first two weeks of life, in particular if leptin expression was reduced in UN 
offspring.  Previous reports have shown that the neonatal leptin surge originates from leptin 
expression in adipose tissue 
148,149 and that the surge is responsible for the formation of 
hypothalamic feeding circuits which are central to whole body energy balance in adult life 
124.  
Furthermore, in the DIO rat, disrupted projections are associated with an increased propensity 
towards an obese phenotype 
245 and leptin treatment during the neonatal period can restore the 
formation of feeding circuits in leptin deficient Ob/Ob mice 
124.  Therefore, if leptin expression was 
absent or blunted in adipose tissue of UN offspring compared to controls, with associated 
alterations in plasma leptin concentration, this would indicate neonatal hypoleptinemia and 
probable altered hypothalamic appetite circuitry and would be consistent with previous reports that 
a 50% maternal undernutrition results in a blunted leptin surge and immature hypothalamic 
projections 
151.  Unfortunately, the neonatal leptin concentrations were not measured in the IUGR 
rat study and it is unknown if hypothalamic feeding circuits were affected.  However, it is possible 
that the neonatal leptin treatment prevented the effects of programming by acting at the level of the 
hypothalamus to maintain a leptin surge in UN offspring, possibly blunted in UN offspring due to 
reduced adipose leptin expression, thereby ensuring protection against later obesity and its 
complications.   Clearly additional rat studies would be needed to answer these questions.   
 
Evidence has indicated that alterations in the expression of genes in programmed rats are in part 
due to altered epigenetic regulation, for example GR and PPARα 
77,213-215.   Therefore it was 
speculated that this could be the mechanism by which leptin treatment causes long term changes in   148
gene expression in this study.  For example, it is possible that the alterations in leptin expression 
could be due to altered methylation, because it is known that the leptin promoter is sensitive to 
alterations in methylation status 
246,247 and in adipose tissue, the leptin promoter has been shown to 
be hyper methylated in response to HF feeding, with an associated with reduction in leptin 
expression 
218.  This study did not, however, find any relevant alterations in DNA methylation of 
the genes tested in response to neonatal leptin treatment.  Despite this, it may well be that a change 
in the methylation status had occurred in the leptin treated offspring in genes such as GR, PPARα 
and leptin, but was not observed due to technical limitations of the MSP assay.  Methylation 
primers are optimal at 150-200bp and some CpG islands span up to 2000bp, therefore in many 
cases, such as for PPARα and GR, only a small proportion of the CpG island could be studied 
(figure 2.2).  There are also limitations as to where MSP primers can work efficiently, for example 
primers must avoid areas of secondary structure and this is common in CpG islands.  It was 
therefore not possible to cover complete CpG islands with one set of primers, leaving areas outside 
the amplicons which have not been studied, which may be epigenetically altered.  In addition, MSP 
is a crude method to assess DNA methylation.  For example, just one unmethylated CpG within a 
highly methylated amplicon could prevent a PCR product and thus be classed as unmethylated.   It 
would therefore be useful to employ additional methods such as pyrosequencing to investigate 
DNA methylation of promoter regions, as this can determine the methylation status of individual 
CpGs.  Another explanation for the lack of change in DNA methylation is that upstream signaling 
factors may be epigenetically modified instead.  
 
The timing of the neonatal leptin treatment in the IUGR rat study was designed to mimic the 
normal leptin surge, which is crucial for the formation of hypothalamic feeding circuits and thus 
energy regulation in later life 
124.  Results showed that the neonatal leptin treatment resulted in a 
persistent increase in the expression of several genes involved in energy balance in the adipose 
tissue of female IUGR offspring, which was associated with reduced weight gain upon HF feeding.  
Evidence from other rodent studies suggest that this effect of leptin could be the result of a direct 
effect on the adipocytes, rather than an indirect effects via the hypothalamus 
121,232.  Interestingly, 
studies with mice subjected to maternal undernutrition have found that the neonatal leptin surge has 
a premature onset in programmed offspring compared to controls 
39.  Thus alterations in the timing 
of the natural leptin surge may have long term consequences on energy metabolism.  In order to 
confirm that the neonatal leptin treatment could have acted peripherally on adipocytes to alter the 
expression of genes involved in energy balance in the IUGR rat study, pre-adipocytes undergoing 
differentiation were treated with leptin and gene expression measured.  Furthermore, to determine 
if the timing of leptin treatment relative to the stage of differentiation affected the response of the 
same genes, the effect of leptin treatment was assessed following treatment before differentiation 
(day 2) and at the start of differentiation (day 8).   
 
In normal 3T3 cells undergoing differentiation, leptin was shown to undergo a surge in expression 
from day 6, peaking at day 13, consistent with previous reports that leptin undergoes a surge in   149
expression throughout differentiation 
248.  The genes tested for responsiveness to leptin treatment 
were PPARα, GR, 11βHSD-2 and leptin, which were found to be increased in response to neonatal 
leptin treatment in the adipose tissue of adult female offspring from the IUGR rat study.  Leptin 
treatment to adipocytes in vitro resulted in increased expression of leptin and PPARα at both day 2 
and day 8, whereas a small increase in GR expression was only found when the cells were treated 
with leptin on day 2 and a small increase in 11βHSD-2 when cells were treated with leptin on day 
8.  In addition, the effects on PPARα dropped off at 48hrs, indicating that the cells may need 
continual treatment with leptin, which has a short half life in order to mimic the effects found in the 
rat study.  These experiments therefore indicate that the effects of neonatal leptin treatment could 
have occurred by direct effects on adipocytes, with both neonatal leptin treatment and leptin 
treatment to differentiating adipocytes resulting in increased gene expression of the same genes.  
Furthermore, results indicate that apart from GR and 11B-HSD-2, the timing of leptin treatment to 
differentiating adipocytes did not affect the pattern of gene expression.  However, the strength of 
all gene responses in 3T3 cells at the later time points may have been strengthened with daily leptin 
treatment.  It remains to be determined the exact mechanisms by which leptin is able to alter 
expression of these genes.   
 
Work in this chapter has failed to identify any significant alterations in gene expression as a result 
of maternal diet in IUGR offspring and therefore none of the gene expression changes previously 
identified in MLP offspring.  Investigations were focused on key lipolytic and genes of β-oxidation 
due to their history being epigenetically altered in MLP offspring and the ability of leptin to induce 
their expression in adipocytes of adult rats.  However, it is likely that the genes altered by maternal 
diet may be involved in lipogenesis.  For example, in a similar nutritional model to this study, 
utilising a 50% maternal undernutrition, it has been shown in 9mth male rats, that SPEBP1c, LPL, 
FAS were all up-regulated by maternal diet, indicating a propensity towards increased fatty acid 
uptake and lipogenesis 
249.  Evidence from leptin treated adult rats 
232 and leptin treated DIO rats 
243, indicates that leptin treatment not only increases FA oxidation, but also reduces lipogenesis 
within the adipocyte.  Therefore, due to the finding that leptin can down-regulate some of these 
lipogenic genes e.g. FAS 
232, SREBP 
249, ACC 
243, it would be worthwhile to measure the 
expression of more key adipocyte genes such as Pref-1, C/EBP, SREBP, FAS as well as 
adipokines, as this would help to give a broader representation of the metabolic state of the 
adipocytes in response to maternal undernutrition.  Leptin is also known to increase UCP-1 and 
UCP-2 mRNA 
243.  It would therefore be interesting to see if UCP-2 was increased in this rat study 
which could facilitate dissipation of energy from β-oxidation as heat as found in islets 
241. 
 
In conclusion, it could be hypothesised that in the IUGR rat, neonatal leptin treatment acts directly 
on the adipocyte resulting in reduced insulin signalling, increased leptin signaling and consequently 
an increased uptake of fatty acids and β-oxidation of fatty acids within the adipocyte.  It is likely 
that leptin treatment also down-regulates key enzymes of lipogenesis, but this has not yet been   150
demonstrated in this study.  As the effects of leptin treatment were only transient in adult rats 
232 
and long term in this study, results indicate that it was the specific period of leptin treatment 
responsible for these differences.  This may be due to not only central hypothalamic effects, but 
also direct peripheral effects on the adipocyte.  It remains to be elucidated if epigenetic alterations 
are responsible for the persistent changes in gene expression and which genes in the signalling 
cascade are affected.  For example, are epigenetic alterations responsible for the changes in PPARα 
expression itself, or is the altered leptin receptor signalling responsible for the many changes in 
gene expression?  It is therefore important to determine how leptin effects the expression of these 
genes and identify how the effects could persist through to adulthood.   
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Chapter 5 
  
Identification of Alternative PPARα 
Transcripts and Characterisation of 
Promoter Regions   152
5.1 Introduction 
 
 
5.1.1  Nuclear hormone receptors and their regulation 
 
Nuclear hormone receptors such as PPAR’s, which are activated by hormones, control the 
expression of specific sets of genes within specific cell types, at specific times.  For example, 
PPARα directs the expression of an array of genes involved in fatty acid oxidation in tissues such 
as the liver and skeletal muscle and this activity is up regulated during times of stress.  The 
expression and activation of such receptors can therefore significantly impact the biochemical 
properties of the cell in which they are expressed.  Gene expression of nuclear receptors must 
therefore be under tight control in order to ensure that they are transcribed in correct tissues and 
that the timing is appropriate.  Many different factors are involved in determining when and where 
a gene is transcribed and also at what level the gene is expressed.  These factors can act at the 
transcriptional, post transcriptional or translational level.   
 
As a consequence of their tissue specific expression profiles, nuclear hormone receptors frequently 
have a complex genomic organisation, as this enhances their capacity for both transcriptional and 
translational regulation.  The step with most regulatory control is gene transcription, i.e. 
determining which genes are ‘switched on’ in a given cell type at a given time and this is controlled 
primarily by the gene promoter and regulatory elements within it.  Nuclear hormone receptors tend 
to have multiple promoters and thus transcriptional start sites, which increases the capacity for 
tissue specific transcriptional regulation by providing diversity in the factors they respond to 
250.  
Quite often these promoters have a complex secondary structure due to a high GC content, have 
multiple Sp1 response elements and lack a recognizable TATA box.  Furthermore, as a result of 
alternative promoter usage and alternative splicing, these genes commonly produce multiple 
transcript variants which differ in the 5’untranslated region (UTR).  Some nuclear hormone 
receptor genes may possess many 5’UTR variants, for example GR 
242, whilst others may have just 
a few such variants, such as PPARγ 
84.  The 5’UTR of these transcripts may differ in length, GC 
content, secondary structure, the presence of upstream AUG (uATG) initiation codons and 
upstream open reading frames (uORF).  All these features can affect selection of translation 
initiation codon and translation efficiency and represent another important component of gene 
regulation 
251.   
 
 
5.1.2  Genomic organisation of nuclear receptors 
 
A classic example of a nuclear hormone receptor with a complex expression profile is the 
glucocorticoid receptor (GR type II) which mediates the effects of the steroid hormone cortisol and   153
is involved in controlling physiological processes such as metabolism, differentiation and the stress 
response.  GR is expressed in most tissues at vastly differing levels, with both basal and stimulated 
expression in these tissues under tight control.  Subsequently, this receptor has a complex genomic 
structure to provide the additional levels of gene regulation to accommodate these needs 
250.   
 
For example, rat GR levels in a given tissue are a result of the differential expression of 11 
transcript variants which differ solely in the 5’UTR, specifically the first exon as a result of 
alternative promoter use.  All these different first exons lie within a large CpG island rich in Sp1 
sites 
242 and differ in the response elements present, providing the variety to cope with the many 
factors involved in the basal and stimulated tissue specific GR expression 
250.  As a result, some of 
these variants have broad patterns of expression, whilst some are more tissue specific.   Similarly, 
the mouse orthologue of GR has at least 4 promoters and variant first exons in the 5’UTR, whilst 
the human GR has 7 alternative first exons.  These alternative first exons exhibit high homology 
with those in the rat, indicating that it is probable that transcriptional regulation mechanisms are 
similar between species 
250.   
 
Other examples of nuclear hormone receptors with an array of alternative transcripts include the 
retinoic acid receptor (RAR) γ 
252 and the growth hormone receptor 
103.  The RARγ gene has 7 
alternative transcripts, 5 of which differ in the 5’UTR and 2 which differ in protein coding region 
252, whilst the human growth hormone receptor has 8 variants all of which differ in their 5’UTR 
103.  
Clearly, alternative 5’UTR transcripts are common to nuclear hormone receptors and represent an 
important feature of their complex regulation. 
 
 
5.1.3  Genomic organisation of PPARγ gene in humans and mice 
 
The PPARγ gene has been fully characterised in humans and mice, but not in the rat.  Like other 
nuclear hormone receptors, it has been revealed that the PPARγ gene produces tissue specific 
variant transcripts as a result of alternative promoter usage and splicing of the 5’UTR.  In addition, 
for the PPARγ isoform this not only results in 5’UTR transcript variants but also in a fully 
functional variant protein.  Furthermore, the mouse and human orthologues of PPARγ demonstrate 
remarkable similarity in their promoter and 5’UTR as well as their coding regions, indicating that 
regulation at the level of gene transcription may be similar in both species.  
 
Alternative promoter usage and splicing of the human PPARγ gene, produces 3 5’UTR variants; 
PPARγ1, PPARγ2 
84 and PPARγ3 
253 (figure 5.1).  Two of these variants, PPARγ1 and PPARγ3, 
differ solely in the 5’UTR, whilst the hPPARγ2 transcript, which harbors an in-frame upstream 
initiation codon in its 5’UTR, produces a variant protein which is 28 amino acids longer at the N-
terminal end.  As all 3 PPARγ transcripts share the same coding exons 1-6, the remainder of the protein has the same structural organisation in all 3 transcripts.  The hPPARγ gene has distinct 
promoters which are responsible for tissue specific gene expression.  The hPPARγ1 promoter is 
GC rich, containing multiple Sp1 sites but no TATA box.  Its corresponding transcript is the 
predominant form and is most widely expressed, found mainly in adipose tissue, the large intestine 
and to a lesser extent in the liver, kidney and macrophages.  In contrast, the structure of both the 
hPPARγ2 and γ3 promoters differs to that of γ1 such that they contain a potential TATA like 
element and are not GC rich 
84,253.  Furthermore, hPPARγ2 and γ3 have similar expression profiles 
with hPPARγ2 expression found in adipose tissue 
84 and hPPARγ3 in adipose tissue and the large 
intestine 
253.  
 
For the mPPARγ gene, only 2 variants have been identified so far, PPARγ1 and PPARγ2 and these 
differ in both their 5’UTR and coding region, exactly like their human orthologues.  As the 
PPARγ2 protein is 30 amino acids longer at the 5’end due to a uATG in the 5’UTR, PPAR γ1 and 
γ2 result in different, but fully functional proteins.  The mPPARγ1 promoter region, like that of 
hPPARγ1 is very GC rich with a CpG island containing several Sp1 sites. Again, similar to that of 
hPPARγ2, the mPPARγ2 promoter is not CG rich and has an upstream TATA like element near the 
transcription start site 
254.   
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Figure 5.1  The genomic organisation of the human and mouse PPARγ genes (adapted 
from 
253).  Differential use of promoters and alternative splicing mechanisms give rise to 3 hPPARγ 
variants (hPPARγ 1-3) and 2 mPPARγ variants (mPPARγ1-2).  5’UTR exons are shown in red, 
coding exons in blue and 3’UTR exons in pink.  Human and mouse PPARγ show remarkable 
homology in their promoter, 5’UTR and coding regions.  PPARγ2 results in a longer protein at the 
N terminal for both human and mouse forms due to an upstream in frame initiation codon. 
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5.1.4  Genomic organisation of PPARδ in different species 
 
In contrast to PPARγ, the expression profile of PPARδ is ubiquitous and similar to GR, total 
transcript levels vary between the many tissues in which it is expressed.  Detailed investigations 
into the structure of the mouse, human and rat PPARδ have been undertaken 
76,85,255 and in all 
except the rat, multiple 5’UTR variants have been identified.  Interestingly, studies have uncovered 
that translational control may be an important part of regulation of both the human and mouse 
PPARδ due to the structural complexity of the 5’UTR.  It has been proposed that this form of 
translational regulation may be responsible for the ‘temporal and spatial’ fine tuning of PPARδ 
protein levels.   
 
hPPARδ has a very complex genomic organisation (figure 5.2).  Differential promoter usage and 
alternative splicing of the hPPARδ gene result in 11 different transcripts which vary solely in the 
5’UTR.  Many of these variants share the same starting exon and these transcripts are expressed at 
higher levels than the others.  The promoter region for this major starting exon is CG rich and 
contains a CpG island and consistent with this no TATA box is present 
85.  Interestingly, all the 
transcript variants differ in both their length and the amount of uORF in their 5’UTR, with amounts 
varying from 4-14 uORF in total.  Coupled transcription / translation in a reticulocyte system has 
uncovered that both those transcripts with long 5’UTRs and those with more uORF had a reduced 
translational efficiency compared to those with shorter simpler 5’UTR, indicating an extra level of 
gene regulation for PPARδ compared to PPARγ.  In addition to the 5’UTR variants, researchers 
have also identified a further hPPARδ variant, which differs in the coding region.  This is a 3’ 
truncated splice variant which lacks some of the LBD and consequently is non functional 
85.   As 
such, expression of this variant protein may be another level of gene regulation which effects the 
overall expression of functional protein. 
 
 
mPPARδ has a similar genomic organisation to that of hPPARδ (figure 5.3).  Four variant 
transcripts have been identified which differ in the 5’UTR as a result of differential promoter usage 
and alternative splicing.  The major variant, expressed in most tissues, has high homology with the 
main human transcript, as does the upstream regulatory region which contains a CpG island.  This 
main transcript has a long 5’UTR containing multiple Kozak compatible uORF and like the human 
orthologue was shown to have a reduced translation efficiency compared to other less complex 
transcripts.  Being the predominantly expressed transcript, a possible IRES mode of transcriptional 
initiation was speculated 
76.  A
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Figure  5.2  The genomic organisation of the human PPARδ gene.  Differential use of 
promoters and alternative splicing mechanisms give rise to 11 hPPARγ variants (hPPARδ A-K).  
5’UTR exons are shown in red, coding exons in blue and 3’UTR exons in pink.  Transcripts differ 
in their 5’UTR, but not the coding region. 
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Figure  5.3  The genomic organisation of the mouse PPARδ gene.  Differential use of 
promoters and alternative splicing mechanisms give rise to 4 mPPARγ variants (Variant 1a-1c).  
5’UTR exons are shown in red, coding exons in blue and 3’UTR exons in pink.  Transcripts differ 
in their 5’UTR, but not the coding region. 
  156In contrast to human and mouse PPARδ, only 1 transcript has been identified so far for the rat 
orthologue.  This work was however limited to a rat brain cDNA library and as such more tissue 
specific transcripts may exist 
255.  Both the rat 5’UTR and regulatory regions are very similar to the 
predominant transcripts and promoters of the human and mouse PPARδ genes and like the other 
PPAR isoforms, the coding exons are conserved in all species (figure 5.4).  However, work to 
examine the structure of the 5’UTR has not been not undertaken and therefore it is not known if 
like the mouse and human orthologues, translational efficiency impacts rat PPARδ protein levels 
255.   
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Figure  5.4  A comparison of the genomic organisation of the human, mouse and rat 
PPARδ genes.  Human, mouse and rat PPARδ have similar organisation of their promoter and 
predominant 5’UTR exons.  5’UTR exons are shown in red, coding exons in blue and 3’UTR exons 
in pink.  All coding exons are shared between species.   
 
 
5.1.5  Genomic organisation of PPARα gene in different species 
 
PPARα has a tissue specific expression profile and levels of receptor vary according to metabolic 
needs of the cell.  As such, it is probable that gene regulation of PPARα will be complex.   
Unsurprisingly, studies into the genomic organisation of the PPARα gene indicate the presence of 
multiple 5’UTR variants in both the human and mouse orthologues and data indicates that these 
may play a role in not only the transcriptional regulation of gene expression but possibly the 
translational control as well.  The rat PPARα gene, however, has not been studied since its 
identification.  Despite this, data gathered confirms that all 3 species share not only the same 
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coding exons, but some 5’UTR exons also.  Furthermore, all 3 PPARα genes have 5’ regulatory 
regions which are highly GC rich and contain large CpG islands, indicating that regulation of 
transcription may be similar between species. 
 
Initially, the human PPARα gene was shown to be composed of 8 exons which formed just 1 
transcript.  The 5’UTR was composed of 3 exons; exon 1a, exon 2a and the 5’end of exon 3, the 
coding exons were composed of the remainder of exon 3 and exons 4-8, whilst the 3’UTR was 
composed of the 3’end of exon 8 
256.  Subsequent to this, a further study has revealed that human 
PPARα has a much more complex genomic organisation 
103.  This study demonstrated that PPARα 
is composed of 12 exons due to the identification of an extra 4 exons within the 5’UTR.   
Consequently it was revealed that 7 exons form the 5’UTR; exons A, 1A, B, 1B, 2A, 2B and the 
5’end of exon 3, whilst the remainder of the gene was exactly as previously reported 
103 (figure 
5.5).  Interestingly, Ensembl indicates the presence of a further 2 exons in the human PPARα 
5’UTR (gene ID: ENSG00000186951), one of which is conserved in both the mouse and rat 
PPARα 5’UTR (exon X).  However, in total a further 6 transcripts have been identified which 
differ purely in the 5’UTR, due to the use of 4 distinct promoter regions, several transcriptional 
start sites and alternative splicing.  Furthermore like PPARδ, the regulatory region for the 
predominant transcript was shown to be TATAless, GC rich and contain several putative Sp1 sites.  
It was found to contain putative response elements for transcription factors such as such as 
activator protein 1 (AP1), Stat, OCT1, TCF II,GATA binding protein 2 (Gata2), Coup II, CEBPβ, 
HNF3, CCAAT, CREB and NF1 
103.   
 
One other splice variant of human PPARα has been identified in which exon 6 is spliced out.  This 
results in a premature stop codon and consequently a truncated hPPARα protein which has no LBD 
(termed PPARα2).  Akin to the PPARδ truncated variant, this PPARα variant does not code a 
functional receptor protein 
257. It was further shown that PPARα2 also exists in other human tissues 
in which PPARα is normally expressed including the kidney, muscle and heart.  Furthermore, 
PPARα2 was found to represent 30% of all human PPARα in liver samples and therefore thought 
to contribute towards reduced functional PPARα expression 
258.  Further to this, this truncated 
version of PPARα was also found in mouse and rat, but at extremely low levels which were barely 
detectable 
257. 
 
The mouse PPARα gene extends over 30kb and is composed of 9 exons.  Four comprise the 
5’UTR; exon 1a, 1b, 2 and the 5’end of exon 3, the coding exons, like the human orthologue are 
composed of the 3’end of exon 3 and exons 4-8, whilst the 3’ UTR is composed of the 3’end of 
exon 8.  Initially, just 2 transcripts were identified in the mouse which differed solely in the 3’ end 
of exon 1b.  This exon was shown to harbor 2 major and 2 minor transcription start sites all within 
a 10bp range 
102.  Subsequent to this a second variant (variant 2 NM_001113418) has been 
identified which differs in the 5’UTR, specifically the use of an alternative first exon (exon 1a) (figure 5.6).  Therefore, in contrast to hPPARα, there is not considerable diversity in the mouse 
PPARα 5’UTR.  However, the exons present in the mouse 5’UTR are all present in the human 
PPARα 5’UTR.  Furthermore, like the human version of PPARα, the 5’ flanking promoter region 
has no TATA box or CCAAT sequences and is very GC rich, containing several putative Sp1 sites 
102, indicating that regulatory mechanisms may be similar between species.   
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Figure  5.5  The genomic organisation of the human PPARα gene.  Differential use of 
promoters and alternative splicing mechanisms give rise to 7 hPPARα variants (hPPARα 1-6).  
5’UTR exons are shown in red, coding exons in blue and 3’UTR exons in pink.  Transcripts differ 
in the 5’UTR, but not the coding region.  Exons marked X and Y represent the additional exons 
identified in Ensembl PPARα gene (ENSG00000186951). 
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Figure 5.6  The genomic organisation of the mouse PPARα gene.  Differential use of 2 
promoters and alternative splicing mechanisms give rise to 2 mPPARα variants (Variant 1 and 2).  
5’UTR exons are shown in red, coding exons in blue and 3’UTR exons in pink.  Transcripts differ 
in their 5’UTR, but not the coding region. 
 
Since its identification in 1992, the genomic organisation of the rat PPARα gene has not been 
investigated.  Rat PPARα was identified from a Sprague-Dawley rat liver cDNA library (accession 
M88592).   The 77 Kb gene was shown to comprise 8 exons, resulting in just 1 transcript of 
2020bp.  Three exons were shown to form the 5’UTR; exon 1, 2 and the 5’ end of exon 3, the 
coding regions were found to be composed of the 3’ end of exon3 and exons 4-8 and the 3’UTR 
contained the 3’ end of exon 8 
105 (figure 5.7).  In common with the other isoforms, coding regions 
of rat PPARα have high homology with the human and mouse orthologues (figure 5.8) and the 
exons present in the 5’UTR are present in both the human and mouse orthologues.  The promoter 
region of PPAR in the rat has not been characterised, but in common with human and mouse 
promoters, the upstream regulatory sequence of the rat gene is highly GC rich.   
 
 
 
 
 
 
 
 
 
2
ATG
1
rPPARα
gene
Promoter
5’ UTR 3’ UTR
Exons 3-8
Protein Coding Exons
 
Figure 5.7  The genomic organisation of the rat PPARα gene.  Genomic organisation of the 
rat PPARα gene, showing the untranslated and coding region organisation.  5’UTR exons are 
shown in red, coding exons in blue and 3’UTR exons in pink.  
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Figure  5.8  A comparison of the genomic organisation of the human, mouse and rat 
PPARα genes.  Human PPARα currently has a more complex 5’UTR organisation than mouse and 
rat.  5’UTR exons are shown in red, coding exons in blue and 3’UTR exons in pink.  Some 5’UTR 
exons are conserved between species.  All coding exons are shared between species.   
 
 
5.1.6 Aims 
 
Previous work within this laboratory and also that identified in this report has indicated that PPARα 
mRNA expression can be modified by maternal diet, postnatal diet, or neonatal leptin treatment and 
that this altered regulation is tissue dependent.  Furthermore, some of these changes have been 
associated with alterations in DNA methylation of the PPARα promoter 
77,212.  However, exact 
mechanisms underlying these changes in gene expression and methylation have not been 
elucidated.  In addition to this, although it is known that factors such as glucocorticoids may 
regulate the expression of PPARα, the mechanisms underlying regulation at the promoter level 
have been largely unexplored.   
 
Nuclear hormone receptors such as the PPAR’s have been shown to possess complex genomic 
organisations which create additional means of transcriptional and translational regulation to cope 
with their varied expression profiles.  Characterisation of PPARα gene in humans has already been 
undertaken and multiple transcripts with diversity in the 5’UTR have been identified.  However, to 
date, it is not known if such variant transcripts are present in the rat.  As the recent work with 
human PPARα uncovered more transcripts than originally identified, this may also be true for the 
rat orthologue.   
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It is therefore important to identify the structure of the rat PPARα gene to understand not only the 
basic tissue specific regulation of PPARα gene expression, but also to provide a basis for further 
understanding its role in programming and subsequent disease risk, by identifying regulatory 
regions and response elements which are important for basal and stimulated gene transcription.  For 
example, identification and characterisation of the complex GR gene structure has helped to clarify 
the exact mechanisms by which maternal grooming leads to altered stress response in pups, i.e. via 
specific methylation differences within response elements of tissue specific GR promoters. 
 
To address these PPARα issues and further our understanding of the mechanisms contributing to 
PPARα gene regulation, the PPARα gene and its 5’ regulatory region needed to be characterised.  
Work in this chapter identifies and characterises the 5’UTR of PPARα in the rat.  Six alternatively 
spliced variants were identified which differ in their 5’UTR due to tissue specific differential 
promoter usage.  Five novel exons were identified and flanking promoter regions of adipose and 
liver specific transcripts were identified, cloned and characterised.   
 
 
 
 
 
 5.2 Results 
 
5.2.1  5’ RLM RACE indicates that rat PPARα has multiple tissue specific transcript 
 variants 
 
In order to fully characterise the rat PPARα gene, a 5’RLM RACE was initially performed to 
enable identification of any 5’UTR transcript variants and their transcription start sites.  This would 
in turn enable potential promoter regions to be located.  Gene specific RACE primers were 
designed against exon 4 of the rat PPARα gene which is located downstream of the ATG initiation 
codon in exon 3 (ensemble gene ID ENSRNOG00000021463) (figure 2.3).  This positioning of the 
GS RACE primers thus ensures that any 5’UTR variants would be included in the results.  To 
determine if PPARα has tissue specific transcripts and promoters, the 5’RLM RACE was 
performed on tissue from liver, kidney, heart and muscle in which PPARα expression is high and 
adipose tissue where expression is low.  All tissues used for this procedure were taken from control 
offspring from the IUGR rat study. 
C 
 
7 PCR products of varying size were successfully identified from the RACE procedure in total 
(figures 5.9-5.10); 2 different sized PCR products from the liver (723bp and 463bp), 1 from 
adipose tissue (465bp), 2 from kidney (591 and 473bp), 1 from muscle (400bp) and 1 from the 
heart (approx 481bp data not shown).   A third faint band of ~1.2kb was also present in the liver 
PCR reaction, but as it disappeared with a temperature gradient, it was therefore presumed non-
specific.  As the size of the PCR product represents the length of the 5’UTR up to the GS reverse 
primer in the coding region of exon 4, the difference in PCR product size indicates the presence of 
variant transcripts which may differ in all or part of their 5’UTR sequence and possibly part of their 
coding sequence.   
 
The presence of multiple PCR products of different sizes in both the liver and kidney indicates the 
presence of multiple PPARα transcripts in these tissues, whilst the presence of just 1 PCR product 
in adipose tissue, muscle and heart indicates that PPARα transcription in these tissues primarily 
arises from one start site.  However, it is possible that variant RACE transcripts of the same size are 
present as a single band in these tissues.   
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Figure  5.9  5’ RLM RACE PCR indicates that the liver expresses multiple PPARα 
transcripts whilst adipose tissue expresses just one PPARα transcript.  Agarose gel showing 
PPARα RACE PCR results: (A) Positive control (mouse thymus RNA with control primers) 
indicates that both the 5’RACE and PCR have been successful, whilst the –TAP control indicates 
that the RACE products are specific to de-capped RNA.  The 5’RACE performed on liver indicates 
2 different PCR products (723bp and 463bp).  (B) Adipose 5’RACE indicates just 1 PCR product 
(465bp).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  5.10  5’ RLM RACE PCR indicates that the kidney expresses multiple PPARα 
transcripts whilst muscle expresses just one PPARα transcript.  Agarose gel showing PPARα 
RACE PCR results: (A) 5’RACE performed on the kidney indicates 2 different PCR products 
(591bp and 473bp).  (B) Muscle 5’RACE indicates just 1 PCR product (400bp).  
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5.2.2  Sequencing of the PPARα 5’ RLM RACE products identifies multiple novel 5’UTR 
  exons and six tissue specific 5’UTR variant transcripts    
 
To identify the sequence of the 7 alternative PPARα 5’RLM RACE transcripts, PCR products were 
either cloned into the pGEM T-easy vector and the resulting clones sequenced (2 clones for adipose 
and 1 clone for the liver), or the PCR products were sequenced directly (heart, kidney and muscle).  
All the transcript sequences were then compared to the published genomic sequence of rat PPARα 
(Ensemble gene ID ENSRNOG00000021463) to identify the exact genomic location of exons.  All 
sequences were analysed up to exon 4 which contained the gene specific reverse 5’RACE PCR 
primer.   
 
Prior to this study, the rat PPARα 5’UTR was reported to be composed of exon 1, exon 2 and the 
5’end of exon 3 (accession M88592), however none of the transcripts identified by 5’RLM RACE 
matched this sequence exactly.  All transcripts were, however found to contain Ensembl exon 3 and 
4 at the 3’ end, confirming that all PCR products were specific to PPARα.  Unfortunately, although 
a PCR product was generated for PPARα in the muscle, the corresponding sequence could not be 
matched to the PPARα genomic sequence, therefore no further work was undertaken on the muscle 
RACE transcript.  
 
All 6 transcripts differed from each other at the 5’ end and comparisons to the genomic sequence 
revealed that they had different transcription start sites owing to the presence of unique first exons.  
The PPARα transcripts were subsequently termed P1-6 and a schematic diagram indicating the 
genomic location of the PPARα 5’UTR exons, the organisation of the alternative 5’UTR and their 
sequences can be found in figures 5.11-5.14.  In total 8 exons were found to encode the PPARα 
5’UTR covering a genomic region of 45,000bp.  Exons were named according to their genomic 
location (1A, 1B, 1C, 1D, 1E, 2, 2A and 3).  Five of these exons were novel (1A, 1B, 1C, 1D, 2A), 
2 were a modified version of exon 1 (now termed 1E) and the remainder were exactly the same 
sequence as identified by Ensembl (exons 2 and 3).   
 
The 5’UTR of the adipose specific transcript (P1) is encoded by exons 1C, 2 and 3.  The 
transcription start site for the this transcript is 257bp upstream of the Ensembl published start site 
and gave rise to a distinct unique first exon of 60bp termed exon 1C.  This exon is spliced onto the 
published Ensembl exon 2, which is subsequently spliced onto Ensemble exon 3.    The liver 
specific transcripts were termed P2 and P3.  P2 is exactly the same as the Ensembl published 
sequence, except the first exon 1E (previously exon 1) is 67 bp longer than the original exon 1 at 
the 5’ end resulting in a 318bp exon.  This exon is spliced onto Ensembl exon 2, which is spliced 
onto Ensembl exon 3.  For P3, the first exon is a 145bp novel exon located several Kb downstream 
from exon 2 and has been termed exon 2A.  This exon is spliced directly onto Ensembl exon 3 and 
is the only transcript to be absent of exon 2.  The heart specific variant P4 is similar to P2 such that it contains exon 1E, 2 and 3.  However, the transcription start site is located 262bp downstream of 
the P2 TSS within exon 1E.  The P5 and P6 transcripts were identified in the kidney.  P5 is 
composed of exons 1A, 1B, 2 and 3.  This is the only transcript to have 2 novel exons identified 
within its 5’UTR.  Exon 1A is located 3068bp upstream of the Ensembl published TSS and forms a 
short 94bp exon.  This exon is spliced on to novel exon 1B another short exon of 92bp which is 
2015bp upstream of the Ensembl TSS.  Exon 1B is spliced to Ensembl exon 2.  Finally, P6 is 
composed of exons 1D, 2 and 3. This novel first exon is located at the 3’ end of exon 1C and is a 
short exon of 68bp which ends just upstream of exon 1E.  Exon 1D is spliced to Ensembl exon 2. 
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Figure 5.11  A schematic diagram showing the genomic organisation of the rat PPARα 
gene.  Location of PPARα 5’UTR Exons on the genomic sequence are shown for the original 
Ensembl PPARα transcript and the updated transcripts; the adipose specific transcript (P1), liver 
specific transcripts (P2 and P3), the heart specific transcript (P4) and the kidney specific transcripts 
(P5 and P6).  All exon positions are indicated relative to the Ensembl transcription start site.   
Ensembl exon 3 which contains the translation ATG start codon
105 is present in all transcripts.  
Non-coding 5’UTR exons are shown in red, coding exons in blue and 3’UTR exons in pink.   
Transcripts differ in the 5’UTR. 
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   AGACCCACAGCCACTGGCGAGGGCACACGCTAGGAAGGGCACACGCGTGCGACTTTCGGGGCCCCTG 
   GAACTGTCCGCTACTTCGAGTCCCCTTGAGCGCCGTGTGCCGGCTCTGAACATTGGCGTTCGCAGCT 
   GTTTTGTGGGCTGGAGGGTTCGTGGAGTCCTGGAACTGAAGCGACGCTGGGTCCTCTGGTTGTCCCC 
   TTGAGGGGAGGGCACACGAGCGGGGACATCGGGGCGCTCCCTTCCCACAGCGTGGTGCATTTGGGCG 
   TAACTCACCGGGAGGCGTTTCCTGAGACCCTCGGGGATCTTAGAGGCGAGgtaactcga……………gtt 
   ctatagCCAAGACTGAAGTTCAAGGCCCTGCCTTCCCTGTGAACTGACATTTGTGACTGGTCAAGCT 
   CAGGACACAAGACGTTGTCATCACAGgtaagaggg……………ctcctacagATTGGTGCTCTGTGGCCC 
   GCCTGGCCACAACCATTCAACATGGTGGACACAGAGAGCCCCATCTGTCCTCTCTCCCCACTTGAAG 
   CAGATGACCTGGAAAGTCCCTTATCTGAAGAATTCTTACAAGAGATGGGAAACATTCAAGAGATTTC 
   TCAGTCCCTCGGAGAGGAGAGTTCCGGAAGCTTTAGTTTTGCGGACTACCAGTACTTAGGGAGCTGT 
   CCAGGCTCGGAGGGCTCTGTCATCACAGgtaagggct……………ctttctctgtagACACCCTCTCTCC 
   AGCTTCCAGCCCCTCCTCAGTCAGCTGCCCTGCTGTCCCCACCAGTACAGATGAGTCCCCTGGCAAT 
   GCACTGAACATCGAGTGTCGAATATGTGGGGACAAGGCCTCAGGATACCACTATGGAGTCCACGCAT 
   GTGAAGGCTGCAAG 
 
 
 
       B   Liver P3 
 
   AGAGACTTGGAGACGCGGGAACCAGAAGGAAGACTCCCGGCAGGACTTCCTTGACTGAGAAAGTACAA 
   TCCTACAATGAATTGTGACCTTTGGAGGAATGAATGAACTTAGAGGGGGCTTTCCGGATGGGAGAAAG 
   CATCTTCTGgtaggtatt……………ctcctacagATTGGTGCTCTGTGGCCCGCCTGGCCACAACCATTC 
   AACATGGTGGACACAGAGAGCCCCATCTGTCCTCTCTCCCCACTTGAAGCAGATGACCTGGAAAGTCC 
   CTTATCTGAAGAATTCTTACAAGAGATGGGAAACATTCAAGAGATTTCTCAGTCCCTCGGAGAGGAGA 
   GTTCCGGAAGCTTTAGTTTTGCGGACTACCAGTACTTAGGGAGCTGTCCAGGCTCGGAGGGCTCTGTC 
   ATCACAGgtaagggct……………ctttctctgtagACACCCTCTCTCCAGCTTCCAGCCCCTCCTCAGTC 
   AGCTGCCCTGCTGTCCCCACCAGTACAGATGAGTCCCCTGGCAATGCACTGAACATCGAGTGTCGAAT 
   ATGTGGGGACAAGGCCTCAGGATACCACTATGGAGTCCACGCATGTGAAGGCTGCAAG 
 
 
       A    Liver P2 
Figure 5.12  Sequence of exons at the 5’ end of the PPARα P2 and P3 transcripts.  The 
sequences of 5’RLM RACE transcripts are shown for (A) Liver P2 and (B) Liver P3.  Exons are 
shown in differing colours; red indicates alternative first exons for each transcript.  Partial introns 
are shown in lower case, with GT-AG donor and acceptor splice sites bold and underlined.   
Published ATG translation start codon is shown in yellow highlight
105.  The original Ensembl TSS 
is indicated by grey highlight within the P2 first exon.  The outer GS RACE primer is underlined. 
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      A   Kidney P5 
 
   ACACAATAGGAAGCTTTGCAGATCAGCAGAGGGCAAGCCAGTGACCCTCAGAGGCCTTGGGTGGTTCC 
   TGGAGAGGACTTACATAAGTCACGAGgtaaacata……………gtctggtagACCTGAGTTAGCAGCAGAA 
   CACTCTGAATAAGGAGGCAACATTCCTGCACGTGGACTCTGGTCTTTGGAGCTTGGGACCTGCTGTAC 
   GCCAGgtaactaag……………gttctatagCCAAGACTGAAGTTCAAGGCCCTGCCTTCCCTGTGAACTG 
   ACATTTGTGACTGGTCAAGCTCAGGACACAAGACGTTGTCATCACAGgtaagaggg……………ctcctac 
   agATTGGTGCTCTGTGGCCCGCCTGGCCACAACCATTCAACATGGTGGACACAGAGAGCCCCATCTGT 
   CCTCTCTCCCCACTTGAAGCAGATGACCTGGAAAGTCCCTTATCTGAAGAATTCTTACAAGAGATGGG 
   AAACATTCAAGAGATTTCTCAGTCCCTCGGAGAGGAGAGTTCCGGAAGCTTTAGTTTTGCGGACTACC 
   AGTACTTAGGGAGCTGTCCAGGCTCGGAGGGCTCTGTCATCACAGgtaagggct……………ctttctctg 
   tagACACCCTCTCTCCAGCTTCCAGCCCCTCCTCAGTCAGCTGCCCTGCTGTCCCCACCAGTACAGAT 
   GAGTCCCCTGGCAATGCACTGAACATCGAGTGTCGAATATGTGGGGACAAGGCCTCAGGATACCACTA 
   TGGAGTCCACGCATGTGAAGGCTGCAAG 
 
 
       B   Kidney P6 
 
 
   AGGTGCCCAGGGGCGGGAGGGCACGCGCGAGGACGGGAGCCAGGCGTCCCCCGTCCCGGGACAGTGAG 
   gtgggtgga……………gttctatagCCAAGACTGAAGTTCAAGGCCCTGCCTTCCCTGTGAACTGACATT 
   TGTGACTGGTCAAGCTCAGGACACAAGACGTTGTCATCACAGgtaagaggg……………ctcctacagATT 
   GGTGCTCTGTGGCCCGCCTGGCCACAACCATTCAACATGGTGGACACAGAGAGCCCCATCTGTCCTCT 
   CTCCCCACTTGAAGCAGATGACCTGGAAAGTCCCTTATCTGAAGAATTCTTACAAGAGATGGGAAACA 
   TTCAAGAGATTTCTCAGTCCCTCGGAGAGGAGAGTTCCGGAAGCTTTAGTTTTGCGGACTACCAGTAC 
   TTAGGGAGCTGTCCAGGCTCGGAGGGCTCTGTCATCACAGgtaagggct……………ctttctctgtagAC 
   ACCCTCTCTCCAGCTTCCAGCCCCTCCTCAGTCAGCTGCCCTGCTGTCCCCACCAGTACAGATGAGTC 
   CCCTGGCAATGCACTGAACATCGAGTGTCGAATATGTGGGGACAAGGCCTCAGGATACCACTATGGAG 
   TCCACGCATGTGAAGGCTGCAAG 
 
Figure 5.13  Sequence of exons at the 5’ end of the PPARα P5 and P6 transcripts. The 
sequences of 5’RLM RACE transcripts are shown for (A) Kidney P5 and (B) Kidney P6.  Exons 
are shown in differing colours; red indicates alternative first exons for each transcript.  Partial 
introns are shown in lower case, with GT-AG donor and acceptor splice sites bold and underlined.  
Published ATG translation start codon is shown in yellow highlight
105.  The outer gene specific 
RACE primer is underlined. 
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       A   Adipose P1 
 
   CTGGCGCCGCCTACCCGGGCGGGCTGGCCCTGCGGACCCGCAGGCGGAGCGCAGCCTCAGgtgccca 
   gg……………gttctatagCCAAGACTGAAGTTCAAGGCCCTGCCTTCCCTGTGAACTGACATTTGTGAC 
   TGGTCAAGCTCAGGACACAAGACGTTGTCATCACAGgtaagaggg……………ctcctacagATTGGTGC 
   TCTGTGGCCCGCCTGGCCACAACCATTCAACATGGTGGACACAGAGAGCCCCATCTGTCCTCTCTCC 
   CCACTTGAAGCAGATGACCTGGAAAGTCCCTTATCTGAAGAATTCTTACAAGAGATGGGAAACATTC 
   AAGAGATTTCTCAGTCCCTCGGAGAGGAGAGTTCCGGAAGCTTTAGTTTTGCGGACTACCAGTACTT 
   AGGGAGCTGTCCAGGCTCGGAGGGCTCTGTCATCACAGgtaagggct……………ctttctctgtagACA 
   CCCTCTCTCCAGCTTCCAGCCCCTCCTCAGTCAGCTGCCCTGCTGTCCCCACCAGTACAGATGAGTC 
   CCCTGGCAATGCACTGAACATCGAGTGTCGAATATGTGGGGACAAGGCCTCAGGATACCACTATGGA 
   GTCCACGCATGTGAAGGCTGCAAG 
 
 
      B  Heart P4 
 
      TTCCCACAGCGTGGTGCATTTGGGCGTAACTCACCGGGAGGCGTTTCCTGAGACCCTCGGGGATCTT 
   AGAGGCGAGgtaactcga……………gttctatagCCAAGACTGAAGTTCAAGGCCCTGCCTTCCCTGTG 
   AACTGACATTTGTGACTGGTCAAGCTCAGGACACAAGACGTTGTCATCACAGgtaagaggg……………c 
   tcctacagATTGGTGCTCTGTGGCCCGCCTGGCCACAACCATTCAACATGGTGGACACAGAGAGCCC 
   CATCTGTCCTCTCTCCCCACTTGAAGCAGATGACCTGGAAAGTCCCTTATCTGAAGAATTCTTACAA 
   GAGATGGGAAACATTCAAGAGATTTCTCAGTCCCTCGGAGAGGAGAGTTCCGGAAGCTTTAGTTTTG  
   CGGACTACCAGTACTTAGGGAGCTGTCCAGGCTCGGAGGGCTCTGTCATCACAGgtaagggct………… 
   …ctttctctgtagACACCCTCTCTCCAGCTTCCAGCCCCTCCTCAGTCAGCTGCCCTGCTGTCCCCA 
   CCAGTACAGATGAGTCCCCTGGCAATGCACTGAACATCGAGTGTCGAATATGTGGGGACAAGGCCTC 
   AGGATACCACTATGGAGTCCACGCATGTGAAGGCTGCAAG 
 
Figure 5.14  Sequence of exons at the 5’ end of the PPARα P1 and P4 transcripts.  The 
sequences of 5’RLM RACE transcripts are shown for (A) Adipose P1 and (B) Heart P4.  Exons are 
shown in differing colours; red indicates alternative first exons for each transcript.  Partial introns 
are shown in lower case, with GT-AG donor and acceptor splice sites bold and underlined.   
Published ATG translation start codon is shown in yellow highlight
105.  The outer gene specific 
RACE primer is underlined. 
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5.2.3  All the novel PPARα transcripts intron exon boundaries conform to the GT-AG 
  splice site rule  
 
Sequences at exon/intron junctions of all the novel PPARα 5’UTR exons were scrutinised to 
determine if their boundaries conform to the GT-AG splice site rule.  This rule stipulates that the 
first 2 nucleotides within an intron (the 5’ donor splice site) are GT (within the consensus 
GTAAG), whilst the last 2 nucleotides within the intron (the 3’ acceptor splice site) are AG (within 
the consensus PyPyPyPyPyPyNCAG).   
 
A more detailed look at the sequence of the PPARα introns within the novel exons showed that 
they all conformed to the GT AG splice site rule, with 5’ end of introns containing the GT splice 
donor sequence and the 3’ end containing the AG splice acceptor sequence.  The remainder of the 
sequences at all donor and acceptor splice sites were very similar to consensus and are shown in 
table 5.1. 
 
Table 5.1  Alternative  PPARα 5’UTR exon/intron junctions conform to the GT-AG 
splice site rule.  5’ (donor) and 3’ (acceptor) intron splice site consensus sequences are indicated.  
The sequences at P1, P2, P3, P4, P5 and P6 transcript exon/intron boundaries are shown.  Splice 
site sequences within introns are shown in lowercase; consensus sequence matches are shown in 
blue, mismatches are shown in red.  Exons are shown in black capitals and sizes of exons are given.  
All transcript exon boundaries conform to the GT-AG splice site rule.   
 
 
 
Transcript 
 
Exon 
(bp) 
 
5’ Donor Splice Site 
Consensus 
5’-gtaagt-3’ 
 
3’ Acceptor Splice Site 
Consensus 
5’-PyPyPyPyPyPyncag-3’ 
 
Exon 
(bp) 
 
Adipose P1 
 
Liver P2 
 
Liver P3 
Heart P4 
 
Kidney P5 
 
 
Kidney P6 
 
1C (60) 
2 (87) 
1E (318) 
2 (87) 
2A (145) 
1E (76) 
2 (87) 
1A (94) 
1B (92) 
2 (87) 
1D (68) 
2 (87) 
 
CCTCAGgtgccc 
TCACAGgtaaga 
GGCGAGgtaact 
TCACAGgtaaga 
CTTCTGgtaggt 
GGCGAGgtaact 
TCACAGgtaaga 
CACGAGgtaaac 
CGCCAGgtaact 
TCACAGgtaaga 
AGTGAGgtgggt 
TCACAGgtaaga 
 
cgttctatagCCAAGA 
cctcctacagATTGGT 
cgttctatagCCAAGA 
cctcctacagATTGGT 
cctcctacagATTGGT 
cgttctatagCCAAGA 
cctcctacagATTGGT 
tgtctggtagACCTGA 
cgttctatagCCAAGA 
cctcctacagATTGGT 
cgttctatagCCAAGA 
cctcctacagATTGGT 
 
2 (87) 
3 (247) 
2 (87) 
3 (247) 
3 (247) 
2 (87) 
3 (247) 
1B (92) 
2 (87) 
3 (247) 
2 (87) 
3 (247)   171
5.2.4  A comparison of the rat PPARα 5’UTR exons after 5’RACE with corresponding 
exons in mouse and human 5’UTR reveals more homology than previously known. 
 
To determine if the novel rat PPARα 5’UTR exons are conserved between species, the pre and post 
5’RLM RACE sequence was aligned with that of mouse (ENSMUSG00000022383) and human 
PPARα (ENSG00000186951) 
103 using the Ensembl genomic alignment tool and the genomic 
location of 5’UTR exons was subsequently compared.  In addition, the Clustal 2.0.12 multiple 
sequence alignment tool 
259 was used to determine the percent homology of the common 5’UTR 
exons between species both before and after the RACE procedure (appendix 1).  
  
A diagram comparing the 5’UTR genomic organisation between species pre and post 5’RACE can 
be found in figure 5.15.  Prior to the RACE procedure, rat, mouse and human PPARα 5’UTR were 
known to share 3 common exons; rat exon 1, 2 and 3.  Rat exon 1 is homologous to mouse exon 1B 
and Ensembl exon X in the human 5’UTR, but the human and mouse exons are longer at both the 
5’ and the 3’ end.  Rat exon 2 is homologous to mouse exon 2 and human exon 1A and the 3 
species exon boundaries all align at both the 5’ and 3’ end apart from the human exon which is 
83bp longer at the 3’ end.  All 3 species share the same exon 3 and align perfectly apart from the 
human exon 3 being 3 nucleotides longer at the 5’ end.  No additional exons were shown to exist in 
the rat 5’UTR.  However, the mouse 5’UTR has an additional exon, 1A, which was not present in 
the rat transcript prior to the 5’RACE and likewise the human 5’UTR had 6 exons (A, Y, B, 1B, 
2A, 2B) which were not present in the rat transcript prior to 5’RACE.   
 
After the 5’RACE procedure, the rat, mouse and human PPARα 5’UTR’s were found to share 4 
common exons; rat exon 1C, 1E, 2 and 3.  Exons 2 and 3 in the rat were unchanged after 5’RACE. 
The previously unidentified exon, 1C, found in the rat 5’UTR was shown to be homologous to the 
mouse exon 1A and human exon A. The 5’ end of this exon is longer in the human and mouse 
corresponding exons, but all share the same 3’ exon boundary.  The RACE also found rat exon 1E 
to be longer at the 5’end than previously known, bringing it more inline with the mouse and human 
corresponding exons.  After 5’RACE, all exons found in the mouse 5’UTR were shown to be 
present in the rat 5’UTR, whereas the human 5’UTR had 5 exons present (Y, B, 1B, 2A, 2B) which 
were not found in the rat 5’UTR.  In addition, rat exons 1A, 1E, 1D and 2A identified by 5’RACE 
had no corresponding exons in the human or mouse 5’UTR. 
 
Prior to the race procedure, the homology of the rat 5’UTR exons 1, 2 and 3 to the corresponding 
exons in the mouse were 94%, 94% and 92% respectively and to the corresponding human exons 
64%, 75% and 77% (table 5.2).  After the race procedure the homology of these 3 exons were 
exactly the same for mouse, whereas for the human exon X, homology to exon 1E in the rat 
dropped from 64% to 50%.  Furthermore, the novel exon 1C in the rat identified by the RACE 
procedure was found to have 91% identity to the corresponding mouse exon and 65% identity to the corresponding human exon.  Subsequent to this, 1.5Kb of regulatory region upstream of the 
predominant exon 1E in the rat was also compared between species and found to have 88% 
homology to the corresponding regulatory region in the mouse and 69% homology to the 
equivalent human sequence. 
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Figure 5.15  A comparison of the rat PPARα 5’UTR genomic organisation with human 
and mouse 5’UTR before and after 5’ RLM RACE procedure.  The genomic location of 
PPARα 5’UTR exons are shown for human, mouse and rat (A) Prior to rat PPARα RACE, (B) 
After rat PPARα RACE.  Non-coding 5’UTR exons are shown in red, coding exons in blue and 
3’UTR exons in pink.  Species differ in the 5’UTR exons, whereas all coding exons are shared 
between species.  Identification of additional 5’UTR exons by PPARα RACE in the rat brings it 
more inline with the genomic positioning of the more complex mouse and human 5’UTR exons - in 
particular the identification of exon 1C which is conserved in mouse and human and the extension 
of exon 1E at the 5’ end.   173
Table 5.2  Clustal 2.0.12 sequence alignment scores for rat PPARα 5’UTR exons with 
corresponding human and mouse 5’UTR exons.  CLUSTAL 2.0.12 multiple sequence alignment 
scores are shown for 5’UTR exons in the rat against corresponding human and mouse 5’UTR 
exons.  The percentage identity between species both before and after 5’RLM RACE results are 
indicated. 
 
 
 
Exon / Promoter 
 
 
Alignment 
 
 
Alignment 
 
% Identity 
before 
RACE 
 
 
% Identity 
after RACE 
 
Rat Exon 3 v Mouse Exon 3  
v Human Exon 3 
 
 
Rat Exon 2 v Mouse exon 2 
v Human exon 1A 
 
 
Rat Exon 1E v Mouse Exon 1B 
v Human Exon X 
 
 
Rat Exon 1C v Mouse exon 1A 
v Human exon A 
 
 
1.5Kb Upstream Promoter of 
Exon 1E Rat, 1B Mouse,  
Human Exon X 
 
 
Mouse 
Rat 
Rat 
 
Mouse 
Rat 
Rat 
 
Mouse 
Rat 
Rat 
 
Mouse 
Rat 
Rat 
 
Mouse 
Rat 
Rat 
 
 
Human 
Mouse 
Human 
 
Human 
Mouse 
Human 
 
Human 
Mouse 
Human 
 
Human 
Mouse 
Human 
 
Human 
Mouse 
Human 
 
78 
92 
77 
 
74 
94 
75 
 
52 
94 
64 
 
71 
- 
- 
 
70 
88 
69 
 
- 
92 
77 
 
- 
94 
75 
 
- 
94 
50 
 
- 
91 
65 
 
- 
- 
- 
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5.2.5  The alternative PPARα transcripts have structurally diverse 5’UTR and P3 has the 
potential to produce a variant N-terminal extended protein 
 
The structure of the 5’UTR of the alternative PPARα transcripts were analysed to determine if any 
had the potential to be regulated translationally and to see if any could give rise to variant proteins.  
To investigate the structure and the potential for translational regulation, the sequences of all 6 
5’UTR (P1-P6) were compared for overall length, GC content and free folding energy, whilst to 
determine if alternative functional ORF were present, upstream sequences were scrutinised for 
uATG, surrounding Kozak sequences and termination codons.   
 
As a consequence of the different transcription start sites and alternative splicing, the alternative 
transcripts have 5’UTR which differ considerably in length.   The P2 transcript has the longest 
5’UTR of 444bp, followed by P5 with a 5’UTR of 312bp.  The remainder of the transcripts are 
considerably shorter and have similar lengths of 202bp, 194bp 186bp and 184 bp for P4, P6, P1 and 
P3 respectively.  The GC content of the alternative 5’UTR’s is more constant between transcripts.  
The highest GC content is found for the P1, P2 and P6 5’UTR with values of 62% GC for P1 and 
P6 and 61% GC for P2.  For P3 P4 and P5 their GC content is slightly lower with values of 51%, 
56% and 53% respectively.   
 
In order to calculate the minimum free energy and the most energetically favourable conformations 
of the alternative 5’UTR’s, DNA sequences of 5’UTR’s were analysed by Zucker RNA mfold 2.3 
software 
260.  Diagrams showing folding structure of the alternative transcript 5’UTR’s can be 
found in appendix 2.  The minimum free energy values calculated ranged from; -169.95 Kcal/mol 
for P2, -101.54 Kcal/mol for P5, -74.65 Kcal/mol for P1 and -71.87 Kcal/mol for P6, to -64.18 
Kcal/mol for P4 and -56.15 Kcal/mol for P3.  These highly negative values indicate that all 
transcripts have a stable secondary structure, in particular that of P2 and P5 5’UTR’s.   
 
The alternative 5’UTR were next scrutinised for potential alternative initiator codons within their 
5’UTR.  Sequence analysis revealed that there were no additional initiation codons within the 
5’UTR for P1, P2, P4, P5 or P6.  Consequently the main ORF would be utilized and all these 
variants would produce the same protein (figures 5.16, 5.17, 5.23, 5.24, 5.25).  However for P3, the 
novel exon 2A within its 5’UTR contained 4 possible ATG codons upstream of the published ATG 
initiator codon (figure 5.18), all positioned within 109bp of the main ORF initiation codon.  For 
convenience, these uATG were termed uATG 1-4.   
 
To further check if the uATG could be functional, the sequence surrounding the uATG 1-4 was 
analysed for Kozak sequence (GCC G/A CCATGG) 
261 (table 5.3).  None of the alternative uATG 
1-4 or the known PPARα initiator ATG for the main ORF conform 100% to the Kozak consensus 
sequence.  The initiator codon for the published ORF does however contain the conserved bases -
3A and +4G which are associated with increased translation efficiency 
262.  However, sequence   175
(Ko C 
G/A
analysis of the uATG revealed that uATG1 contains the -3A, uATG 2 the -3G and uATG 4 
contains the +4G base, thus indicating that initiation could occur at these uATG 
251.  Sequence 
analysis confirms that only uATG 3 does not contain either of these conserved bases.   
 
Analysis of each of these uATG for potential ORF revealed that uATG 1, 3 and 4 are terminated 
after 30bp, 45bp and 21 bp respectively and are therefore unlikely to encode a functional protein 
(figures 5.19, 5.21, 5.22).  Conversely, uATG 2 is in frame with the published ATG codon and no 
termination codons were identified upstream of the main ATG.  Consequently, no barrier is present 
to prevent the formation of alternative in frame proteins (figure 5.20).  Collectively, these results 
indicate that uATG 2 being 87bp upstream of the published ATG codon could potentially give rise 
to an alternative PPARα protein with a 29 amino acid extended N terminal domain.   
 
Table 5.3  Alternative PPARα transcript ATG initiation sites and surrounding kozak 
sequence.  Main ORF ATG initiation site for the P1 P2 P4 P5 and P6 transcripts and potential 
alternative ATG initiation sites for the P3 transcript along with their surrounding sequence are 
shown.    Consensus sequences matches are shown in blue, conserved bases associated with 
increased translation efficiency are underlined and sequence mismatches are shown in red.   
Potential strength of initiation is indicated 
251. 
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           CTGGCGCCGCCTACCCGGGCGGGCTGGCCCTGCGGACCCGCAGGCGGAG 
CGCAGCCTCAG…………CCAAGACTGAAGTTCAAGGCCCTGCCTTCCCTGTGAACTGACATT 
TGTGACTGGTCAAGCTCAGGACACAAGACGTTGTCATCACAG…………ATTGGTGCTCTGTG 
GCCCGCCTGGCCACAACCATTCAACATGGTGGACACAGAGAGCCCCATCTGTCCTCTCTC 
CCCACTTGAAGCAGATGACCTGGAAAGTCCCTTATCTGAAGAATTCTTACAAGAGATGGG 
AAACATTCAAGAGATTTCTCAGTCCCTCGGAGAGGAGAGTTCCGGAAGCTTTAGTTTTGC 
GGACTACCAGTACTTAGGGAGCTGTCCAGGCTCGGAGGGCTCTGTCATCACAGACACCCT 
CTCTCCAG…………CTTCCAGCCCCTCCTCAGTCAGCTGCCCTGCTGTCCCCACCAGTACAG 
ATGAGTCCCCTGGCAATGCACTGAACATCGAGTGTCGAATATGTGGGGACAAGGCCTCAG 
GATACCACTATGGAGTCCACGCATGTGAAGGCTGCAAG…………GGCTTCTTTCGGCGAACT 
ATTCGGCTAAAGCTGGCGTACGACAAGTGTGATCGAAGCTGCAAGATTCAGAAAAAGAAC 
CGGAACAAATGCCAGTACTGCCGTTTCCACAAGTGCCTGTCCGTCGGGATGTCACACAAT 
G…………CAATCCGTTTTGGAAGAATGCCAAGATCTGAGAAAGCAAAACTGAAGGCAGAAAT 
CCTTACCTGTGAACACGATCTGAAAGATTCGGAAACTGCAGACCTCAAATCTCTGGCCAA 
GAGAATCCACGAAGCCTACCTGAAGAACTTCAACATGAACAAGGTCAAGGCCCGGGTCAT 
ACTCGCAGGAAAGACTAGCAACAATCCG…………CTTTTGTCATACATGACATGGAGACCTT 
GTGCATGGCTGAGAAGACGCTTGTGGCCAAGATGGTAGCCAACGGCGTTGAAAACAAGGA 
GGCAGAGGTCCGATTCTTCCACTGCTGCCAGTGCATGTCCGTGGAGACCGTCACCGAGCT 
CACGGAATTTGCCAAGGCTATCCCAGGCTTTGCAAACTTGGACTTGAATGACCAGGTTAC 
CTTGCTGAAGTACGGTGTGTATGAAGCCATCTTCACGATGCTGTCCTCCTTGATGAACAA 
AGACGGGATGCTGATCGCGTACGGCAATGGCTTCATCACCCGAGAGTTCCTAAAGAACCT 
GAGGAAGCCATTCTGCGACATCATGGAACCCAAGTTTGACTTCGCTATGAAGTTCAATGC 
CCTCGAACTGGATGACAGTGACATTTCCCTTTTTGTGGCTGCTATAATTTGCTGTGGAG… 
………ATCGGCCTGGCCTTCTAAACATAGGATACATTGAGAAGTTGCAGGAGGGGATTGTGC 
ACGTGCTCAAGCTCCACCTGCAGAGCAACCATCCGGATGATACCTTTCTCTTCCCAAAAC 
TCCTTCAAAAAATGGTGGACCTCCGGCAGCTGGTCACGGAGCATGCGCAGCTCGTGCAGG 
TCATCAAGAAGACCGAGTCAGACGCGGCGTTGCACCCACTGTTGCAAGAGATCTACAGAG 
ACATGTACTGATTTTTCCTGAGATGGTAGGCCGTTGCCACTGTTCAGGGACCTCTGAGGT 
CTGCGGCCCCATACAGGAGAGCAGGGATTTGCACAGATGGCCTCCCTCCTTACCCTTGGA 
GATGAAGAGGGCTGAGCCTAGGCAATGCAGGCTCCTCCCACATCCTTACTTTCTGAATGA 
GCACTTCTAAGACTTCCTGCTACTGAAATGGTGGTGATCAGAGGCTAGTAGGATTCAGAC 
AATTACAG 
5’ UTR 
 
186bp 
3’ UTR 
237bp 
ORF 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  1406bp 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.16  PPARα P1 transcript has no alternative initiator codons within the 5’UTR.  
The rat PPARα P1 transcript sequence is shown.  P1 is composed of 8 exons (exon boundaries are 
indicated by dotted lines).  The initiator codon (ATG) and terminator codon (TGA) from the main 
1406bp ORF are highlighted in yellow.  Highly conserved bases from the Kozak sequence (-3 and 
+4) are underlined and in bold.  The 5’UTR is shown in red text, the ORF is shown by blue text 
and the 3’UTR is shown in pink text.  There are no alternative ATG initiation sites within the 
5’UTR for this transcript. 
  176                                                     AGACCCA 
CAGCCACTGGCGAGGGCACACGCTAGGAAGGGCACACGCGTGCGACTTTCGGGGCCCCTG 
GAACTGTCCGCTACTTCGAGTCCCCTTGAGCGCCGTGTGCCGGCTCTGAACATTGGCGTT 
CGCAGCTGTTTTGTGGGCTGGAGGGTTCGTGGAGTCCTGGAACTGAAGCGACGCTGGGTC 
CTCTGGTTGTCCCCTTGAGGGGAGGGCACACGAGCGGGGACATCGGGGCGCTCCCTTCCC 
ACAGCGTGGTGCATTTGGGCGTAACTCACCGGGAGGCGTTTCCTGAGACCCTCGGGGATC 
TTAGAGGCGAG…………CCAAGACTGAAGTTCAAGGCCCTGCCTTCCCTGTGAACTGACATT 
TGTGACTGGTCAAGCTCAGGACACAAGACGTTGTCATCACAG…………ATTGGTGCTCTGTG 
  177
GCCCGCCTGGCCACAACCATTCAACATGGTGGACACAGAGAGCCCCATCTGTCCTCTCTC 
CCCACTTGAAGCAGATGACCTGGAAAGTCCCTTATCTGAAGAATTCTTACAAGAGATGGG 
AAACATTCAAGAGATTTCTCAGTCCCTCGGAGAGGAGAGTTCCGGAAGCTTTAGTTTTGC 
GGACTACCAGTACTTAGGGAGCTGTCCAGGCTCGGAGGGCTCTGTCATCACAGACACCCT 
CTCTCCAG…………CTTCCAGCCCCTCCTCAGTCAGCTGCCCTGCTGTCCCCACCAGTACAG 
ATGAGTCCCCTGGCAATGCACTGAACATCGAGTGTCGAATATGTGGGGACAAGGCCTCAG 
GATACCACTATGGAGTCCACGCATGTGAAGGCTGCAAG…………GGCTTCTTTCGGCGAACT 
ATTCGGCTAAAGCTGGCGTACGACAAGTGTGATCGAAGCTGCAAGATTCAGAAAAAGAAC 
CGGAACAAATGCCAGTACTGCCGTTTCCACAAGTGCCTGTCCGTCGGGATGTCACACAAT 
G…………CAATCCGTTTTGGAAGAATGCCAAGATCTGAGAAAGCAAAACTGAAGGCAGAAAT 
CCTTACCTGTGAACACGATCTGAAAGATTCGGAAACTGCAGACCTCAAATCTCTGGCCAA 
GAGAATCCACGAAGCCTACCTGAAGAACTTCAACATGAACAAGGTCAAGGCCCGGGTCAT 
ACTCGCAGGAAAGACTAGCAACAATCCG…………CTTTTGTCATACATGACATGGAGACCTT 
GTGCATGGCTGAGAAGACGCTTGTGGCCAAGATGGTAGCCAACGGCGTTGAAAACAAGGA 
GGCAGAGGTCCGATTCTTCCACTGCTGCCAGTGCATGTCCGTGGAGACCGTCACCGAGCT 
CACGGAATTTGCCAAGGCTATCCCAGGCTTTGCAAACTTGGACTTGAATGACCAGGTTAC 
CTTGCTGAAGTACGGTGTGTATGAAGCCATCTTCACGATGCTGTCCTCCTTGATGAACAA 
AGACGGGATGCTGATCGCGTACGGCAATGGCTTCATCACCCGAGAGTTCCTAAAGAACCT 
GAGGAAGCCATTCTGCGACATCATGGAACCCAAGTTTGACTTCGCTATGAAGTTCAATGC 
CCTCGAACTGGATGACAGTGACATTTCCCTTTTTGTGGCTGCTATAATTTGCTGTGGAG… 
………ATCGGCCTGGCCTTCTAAACATAGGATACATTGAGAAGTTGCAGGAGGGGATTGTGC 
ACGTGCTCAAGCTCCACCTGCAGAGCAACCATCCGGATGATACCTTTCTCTTCCCAAAAC 
TCCTTCAAAAAATGGTGGACCTCCGGCAGCTGGTCACGGAGCATGCGCAGCTCGTGCAGG 
TCATCAAGAAGACCGAGTCAGACGCGGCGTTGCACCCACTGTTGCAAGAGATCTACAGAG 
ACATGTACTGATTTTTCCTGAGATGGTAGGCCGTTGCCACTGTTCAGGGACCTCTGAGGT 
CTGCGGCCCCATACAGGAGAGCAGGGATTTGCACAGATGGCCTCCCTCCTTACCCTTGGA 
GATGAAGAGGGCTGAGCCTAGGCAATGCAGGCTCCTCCCACATCCTTACTTTCTGAATGA 
GCACTTCTAAGACTTCCTGCTACTGAAATGGTGGTGATCAGAGGCTAGTAGGATTCAGAC 
AATTACAG 
5’ UTR 
444bp 
3’ UTR 
237bp 
ORF 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  1406bp 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.17  PPARα P2 transcript has no alternative initiator codons within the 5’UTR.  
The rat PPARα P2 transcript sequence is shown.  P2 is composed of 8 exons (exon boundaries are 
indicated by dotted lines).  The initiator codon (ATG) and terminator codon (TGA) from the main 
1406bp ORF are highlighted in yellow.  Highly conserved bases from the Kozak sequence (-3 and 
+4) are underlined and in bold.  The 5’UTR is shown in red text, the ORF is shown by blue text 
and the 3’UTR is shown in pink text.  There are no alternative ATG initiation sites within the 
5’UTR for this transcript.  
 
 
                 AGAGACTTGGAGACGCGGGAACCAGAAGGAAGACTCCCGGCAG            
 
 
  178
GACTTCCTTGACTGAGAAAGTACAATCCTACAATGAATTGTGACCTTTGGAGGAATGAAT 
GAACTTAGAGGGGGCTTTCCGGATGGGAGAAAGCATCTTCTG…………ATTGGTGCTCTGTG 
GCCCGCCTGGCCACAACCATTCAACATGGTGGACACAGAGAGCCCCATCTGTCCTCTCTC 
CCCACTTGAAGCAGATGACCTGGAAAGTCCCTTATCTGAAGAATTCTTACAAGAGATGGG 
AAACATTCAAGAGATTTCTCAGTCCCTCGGAGAGGAGAGTTCCGGAAGCTTTAGTTTTGC 
GGACTACCAGTACTTAGGGAGCTGTCCAGGCTCGGAGGGCTCTGTCATCACAGACACCCT 
CTCTCCAG…………CTTCCAGCCCCTCCTCAGTCAGCTGCCCTGCTGTCCCCACCAGTACAG 
ATGAGTCCCCTGGCAATGCACTGAACATCGAGTGTCGAATATGTGGGGACAAGGCCTCAG 
GATACCACTATGGAGTCCACGCATGTGAAGGCTGCAAG…………GGCTTCTTTCGGCGAACT 
ATTCGGCTAAAGCTGGCGTACGACAAGTGTGATCGAAGCTGCAAGATTCAGAAAAAGAAC 
CGGAACAAATGCCAGTACTGCCGTTTCCACAAGTGCCTGTCCGTCGGGATGTCACACAAT 
G…………CAATCCGTTTTGGAAGAATGCCAAGATCTGAGAAAGCAAAACTGAAGGCAGAAAT 
CCTTACCTGTGAACACGATCTGAAAGATTCGGAAACTGCAGACCTCAAATCTCTGGCCAA 
GAGAATCCACGAAGCCTACCTGAAGAACTTCAACATGAACAAGGTCAAGGCCCGGGTCAT 
ACTCGCAGGAAAGACTAGCAACAATCCG…………CTTTTGTCATACATGACATGGAGACCTT 
GTGCATGGCTGAGAAGACGCTTGTGGCCAAGATGGTAGCCAACGGCGTTGAAAACAAGGA 
GGCAGAGGTCCGATTCTTCCACTGCTGCCAGTGCATGTCCGTGGAGACCGTCACCGAGCT 
CACGGAATTTGCCAAGGCTATCCCAGGCTTTGCAAACTTGGACTTGAATGACCAGGTTAC 
CTTGCTGAAGTACGGTGTGTATGAAGCCATCTTCACGATGCTGTCCTCCTTGATGAACAA 
AGACGGGATGCTGATCGCGTACGGCAATGGCTTCATCACCCGAGAGTTCCTAAAGAACCT 
GAGGAAGCCATTCTGCGACATCATGGAACCCAAGTTTGACTTCGCTATGAAGTTCAATGC 
CCTCGAACTGGATGACAGTGACATTTCCCTTTTTGTGGCTGCTATAATTTGCTGTGGAG… 
………ATCGGCCTGGCCTTCTAAACATAGGATACATTGAGAAGTTGCAGGAGGGGATTGTGC 
ACGTGCTCAAGCTCCACCTGCAGAGCAACCATCCGGATGATACCTTTCTCTTCCCAAAAC 
TCCTTCAAAAAATGGTGGACCTCCGGCAGCTGGTCACGGAGCATGCGCAGCTCGTGCAGG 
TCATCAAGAAGACCGAGTCAGACGCGGCGTTGCACCCACTGTTGCAAGAGATCTACAGAG 
ACATGTACTGATTTTTCCTGAGATGGTAGGCCGTTGCCACTGTTCAGGGACCTCTGAGGT 
CTGCGGCCCCATACAGGAGAGCAGGGATTTGCACAGATGGCCTCCCTCCTTACCCTTGGA 
GATGAAGAGGGCTGAGCCTAGGCAATGCAGGCTCCTCCCACATCCTTACTTTCTGAATGA 
GCACTTCTAAGACTTCCTGCTACTGAAATGGTGGTGATCAGAGGCTAGTAGGATTCAGAC 
AATTACAG 
 
5’ UTR 
3’ UTR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
ORF   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.18  PPARα P3 transcript has four possible alternative upstream initiator codons 
within the 5’UTR.  The rat PPARα P3 transcript sequence is shown.  P3 is composed of 7 exons 
(exon boundaries are indicated by dotted lines).  The initiator codon (ATG) and terminator codon 
(TGA) from the main 1406bp ORF are highlighted in yellow.  Four possible initiation sites (uATG) 
within the unique alternative first exon for this transcript are shown in green and for convenience 
are termed uATG 1-4 according to their position.  The main 5’UTR is shown in red text, the ORF 
is shown by blue text and the 3’UTR is shown in pink text.    
   
                 AGAGACTTGGAGACGCGGGAACCAGAAGGAAGACTCCCGGCAG                
  179
GACTTCCTTGACTGAGAAAGTACAATCCTA   CAATGAATTGTGACCTTTGGAGGAATGAAT  ORF 
30bp    GAACTTAGAGGGGGCTTTCCGGATGGGAGAAAGCATCTTCTG…………ATTGGTGCTCTGTG 
  GCCCGCCTGGCCACAACCATTCAACATGGTGGACACAGAGAGCCCCATCTGTCCTCTCTC 
 
CCCACTTGAAGCAGATGACCTGGAAAGTCCCTTATCTGAAGAATTCTTACAAGAGATGGG   
  AAACATTCAAGAGATTTCTCAGTCCCTCGGAGAGGAGAGTTCCGGAAGCTTTAGTTTTGC 
  GGACTACCAGTACTTAGGGAGCTGTCCAGGCTCGGAGGGCTCTGTCATCACAGACACCCT 
  CTCTCCAG…………CTTCCAGCCCCTCCTCAGTCAGCTGCCCTGCTGTCCCCACCAGTACAG 
 
ATGAGTCCCCTGGCAATGCACTGAACATCGAGTGTCGAATATGTGGGGACAAGGCCTCAG   
GATACCACTATGGAGTCCACGCATGTGAAGGCTGCAAG…………GGCTTCTTTCGGCGAACT   
  ATTCGGCTAAAGCTGGCGTACGACAAGTGTGATCGAAGCTGCAAGATTCAGAAAAAGAAC 
  CGGAACAAATGCCAGTACTGCCGTTTCCACAAGTGCCTGTCCGTCGGGATGTCACACAAT 
 
G…………CAATCCGTTTTGGAAGAATGCCAAGATCTGAGAAAGCAAAACTGAAGGCAGAAAT   
CCTTACCTGTGAACACGATCTGAAAGATTCGGAAACTGCAGACCTCAAATCTCTGGCCAA   
  GAGAATCCACGAAGCCTACCTGAAGAACTTCAACATGAACAAGGTCAAGGCCCGGGTCAT 
  ACTCGCAGGAAAGACTAGCAACAATCCG…………CTTTTGTCATACATGACATGGAGACCTT 
 
GTGCATGGCTGAGAAGACGCTTGTGGCCAAGATGGTAGCCAACGGCGTTGAAAACAAGGA 
 
GGCAGAGGTCCGATTCTTCCACTGCTGCCAGTGCATGTCCGTGGAGACCGTCACCGAGCT   
  CACGGAATTTGCCAAGGCTATCCCAGGCTTTGCAAACTTGGACTTGAATGACCAGGTTAC 
  CTTGCTGAAGTACGGTGTGTATGAAGCCATCTTCACGATGCTGTCCTCCTTGATGAACAA 
  AGACGGGATGCTGATCGCGTACGGCAATGGCTTCATCACCCGAGAGTTCCTAAAGAACCT 
 
GAGGAAGCCATTCTGCGACATCATGGAACCCAAGTTTGACTTCGCTATGAAGTTCAATGC   
CCTCGAACTGGATGACAGTGACATTTCCCTTTTTGTGGCTGCTATAATTTGCTGTGGAG…   
  ………ATCGGCCTGGCCTTCTAAACATAGGATACATTGAGAAGTTGCAGGAGGGGATTGTGC 
  ACGTGCTCAAGCTCCACCTGCAGAGCAACCATCCGGATGATACCTTTCTCTTCCCAAAAC 
 
TCCTTCAAAAAATGGTGGACCTCCGGCAGCTGGTCACGGAGCATGCGCAGCTCGTGCAGG   
TCATCAAGAAGACCGAGTCAGACGCGGCGTTGCACCCACTGTTGCAAGAGATCTACAGAG   
  ACATGTACTGATTTTTCCTGAGATGGTAGGCCGTTGCCACTGTTCAGGGACCTCTGAGGT 
  CTGCGGCCCCATACAGGAGAGCAGGGATTTGCACAGATGGCCTCCCTCCTTACCCTTGGA 
 
GATGAAGAGGGCTGAGCCTAGGCAATGCAGGCTCCTCCCACATCCTTACTTTCTGAATGA 
 
GCACTTCTAAGACTTCCTGCTACTGAAATGGTGGTGATCAGAGGCTAGTAGGATTCAGAC   
  AATTACAG 
 
 
 
Figure 5.19  Use of PPARα P3 transcript uATG 1 codon results in termination after 30bp.  
The rat PPARα P3 transcript sequence is shown.  P3 is composed of 7 exons (exon boundaries are 
indicated by dotted lines).  The initiator codon (ATG) and terminator codon (TGA) from the main 
1406bp ORF are highlighted in yellow.  The alternative uATG1 initiation codon and TGA 
termination codon are highlighted in green.  The highly conserved -3 base from the Kozak 
sequence is underlined and in bold.  The resulting 5’UTR is shown in red text, the 30bp ORF is 
shown by blue text and the 3’UTR is shown in pink text.    
 
 
  180
                 AGAGACTTGGAGACGCGGGAACCAGAAGGAAGACTCCCGGCAG              
GACTTCCTTGACTGAGAAAGTACAATCCTACAATGAATTGTGACCTTTGGAGGAATGAAT 
GAACTTAGAGGGGGCTTTCCGGATGGGAGAAAGCATCTTCTG…………ATTGGTGCTCTGTG 
GCCCGCCTGGCCACAACCATTCAACATGGTGGACACAGAGAGCCCCATCTGTCCTCTCTC 
CCCACTTGAAGCAGATGACCTGGAAAGTCCCTTATCTGAAGAATTCTTACAAGAGATGGG 
AAACATTCAAGAGATTTCTCAGTCCCTCGGAGAGGAGAGTTCCGGAAGCTTTAGTTTTGC 
GGACTACCAGTACTTAGGGAGCTGTCCAGGCTCGGAGGGCTCTGTCATCACAGACACCCT 
CTCTCCAG…………CTTCCAGCCCCTCCTCAGTCAGCTGCCCTGCTGTCCCCACCAGTACAG 
ATGAGTCCCCTGGCAATGCACTGAACATCGAGTGTCGAATATGTGGGGACAAGGCCTCAG 
GATACCACTATGGAGTCCACGCATGTGAAGGCTGCAAG…………GGCTTCTTTCGGCGAACT 
ATTCGGCTAAAGCTGGCGTACGACAAGTGTGATCGAAGCTGCAAGATTCAGAAAAAGAAC 
CGGAACAAATGCCAGTACTGCCGTTTCCACAAGTGCCTGTCCGTCGGGATGTCACACAAT 
G…………CAATCCGTTTTGGAAGAATGCCAAGATCTGAGAAAGCAAAACTGAAGGCAGAAAT 
CCTTACCTGTGAACACGATCTGAAAGATTCGGAAACTGCAGACCTCAAATCTCTGGCCAA 
GAGAATCCACGAAGCCTACCTGAAGAACTTCAACATGAACAAGGTCAAGGCCCGGGTCAT 
ACTCGCAGGAAAGACTAGCAACAATCCG…………CTTTTGTCATACATGACATGGAGACCTT 
GTGCATGGCTGAGAAGACGCTTGTGGCCAAGATGGTAGCCAACGGCGTTGAAAACAAGGA 
GGCAGAGGTCCGATTCTTCCACTGCTGCCAGTGCATGTCCGTGGAGACCGTCACCGAGCT 
CACGGAATTTGCCAAGGCTATCCCAGGCTTTGCAAACTTGGACTTGAATGACCAGGTTAC 
CTTGCTGAAGTACGGTGTGTATGAAGCCATCTTCACGATGCTGTCCTCCTTGATGAACAA 
AGACGGGATGCTGATCGCGTACGGCAATGGCTTCATCACCCGAGAGTTCCTAAAGAACCT 
GAGGAAGCCATTCTGCGACATCATGGAACCCAAGTTTGACTTCGCTATGAAGTTCAATGC 
CCTCGAACTGGATGACAGTGACATTTCCCTTTTTGTGGCTGCTATAATTTGCTGTGGAG… 
………ATCGGCCTGGCCTTCTAAACATAGGATACATTGAGAAGTTGCAGGAGGGGATTGTGC 
ACGTGCTCAAGCTCCACCTGCAGAGCAACCATCCGGATGATACCTTTCTCTTCCCAAAAC 
TCCTTCAAAAAATGGTGGACCTCCGGCAGCTGGTCACGGAGCATGCGCAGCTCGTGCAGG 
TCATCAAGAAGACCGAGTCAGACGCGGCGTTGCACCCACTGTTGCAAGAGATCTACAGAG 
ACATGTACTGATTTTTCCTGAGATGGTAGGCCGTTGCCACTGTTCAGGGACCTCTGAGGT 
CTGCGGCCCCATACAGGAGAGCAGGGATTTGCACAGATGGCCTCCCTCCTTACCCTTGGA 
GATGAAGAGGGCTGAGCCTAGGCAATGCAGGCTCCTCCCACATCCTTACTTTCTGAATGA 
GCACTTCTAAGACTTCCTGCTACTGAAATGGTGGTGATCAGAGGCTAGTAGGATTCAGAC 
AATTACAG 
5’ UTR 
97bp 
3’ UTR 
237bp 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ORF 
  1493bp 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  5.20  Use of PPARα P3 transcript uATG 2 codon may produce a 5’ extended 
transcript.  The rat PPARα P3 transcript sequence is shown.  P3 is composed of 7 exons (exon 
boundaries are indicated by dotted lines).  The initiator codon (ATG) and terminator codon (TGA) 
from the main 1406bp ORF are highlighted in yellow.  The alternative uATG2 initiation codon is 
highlighted in green.  ATG2 is in frame with the main ORF and consequently has the potential to 
form a 5’ extended transcript. The highly conserved -3 base from the Kozak sequence is underlined 
and in bold.  The resulting 5’UTR is shown in red text, the extended 1493bp ORF is shown by blue 
text and the 3’UTR is shown in pink text.    
   
  181
                 AGAGACTTGGAGACGCGGGAACCAGAAGGAAGACTCCCGGCAG              
  GACTTCCTTGACTGAGAAAGTACAATCCTACAATGAATTGTGACCTTTGGAGGAATGAAT 
   
ORF  GAACTTAGAGGGGGCTTTCCGGATGGGAGAAAGCATCTTCTG…………ATTGGTGCTCTGTG   
45bp    GCCCGCCTGGCCACAACCATTCAACATGGTGGACACAGAGAGCCCCATCTGTCCTCTCTC     
CCCACTTGAAGCAGATGACCTGGAAAGTCCCTTATCTGAAGAATTCTTACAAGAGATGGG   
  AAACATTCAAGAGATTTCTCAGTCCCTCGGAGAGGAGAGTTCCGGAAGCTTTAGTTTTGC 
 
GGACTACCAGTACTTAGGGAGCTGTCCAGGCTCGGAGGGCTCTGTCATCACAGACACCCT   
  CTCTCCAG…………CTTCCAGCCCCTCCTCAGTCAGCTGCCCTGCTGTCCCCACCAGTACAG 
 
ATGAGTCCCCTGGCAATGCACTGAACATCGAGTGTCGAATATGTGGGGACAAGGCCTCAG   
  GATACCACTATGGAGTCCACGCATGTGAAGGCTGCAAG…………GGCTTCTTTCGGCGAACT 
 
ATTCGGCTAAAGCTGGCGTACGACAAGTGTGATCGAAGCTGCAAGATTCAGAAAAAGAAC   
  CGGAACAAATGCCAGTACTGCCGTTTCCACAAGTGCCTGTCCGTCGGGATGTCACACAAT 
 
G…………CAATCCGTTTTGGAAGAATGCCAAGATCTGAGAAAGCAAAACTGAAGGCAGAAAT   
  CCTTACCTGTGAACACGATCTGAAAGATTCGGAAACTGCAGACCTCAAATCTCTGGCCAA 
 
GAGAATCCACGAAGCCTACCTGAAGAACTTCAACATGAACAAGGTCAAGGCCCGGGTCAT   
  ACTCGCAGGAAAGACTAGCAACAATCCG…………CTTTTGTCATACATGACATGGAGACCTT 
 
GTGCATGGCTGAGAAGACGCTTGTGGCCAAGATGGTAGCCAACGGCGTTGAAAACAAGGA   
  GGCAGAGGTCCGATTCTTCCACTGCTGCCAGTGCATGTCCGTGGAGACCGTCACCGAGCT 
  CACGGAATTTGCCAAGGCTATCCCAGGCTTTGCAAACTTGGACTTGAATGACCAGGTTAC   
CTTGCTGAAGTACGGTGTGTATGAAGCCATCTTCACGATGCTGTCCTCCTTGATGAACAA   
  AGACGGGATGCTGATCGCGTACGGCAATGGCTTCATCACCCGAGAGTTCCTAAAGAACCT 
 
GAGGAAGCCATTCTGCGACATCATGGAACCCAAGTTTGACTTCGCTATGAAGTTCAATGC   
  CCTCGAACTGGATGACAGTGACATTTCCCTTTTTGTGGCTGCTATAATTTGCTGTGGAG… 
 
………ATCGGCCTGGCCTTCTAAACATAGGATACATTGAGAAGTTGCAGGAGGGGATTGTGC   
  ACGTGCTCAAGCTCCACCTGCAGAGCAACCATCCGGATGATACCTTTCTCTTCCCAAAAC 
 
TCCTTCAAAAAATGGTGGACCTCCGGCAGCTGGTCACGGAGCATGCGCAGCTCGTGCAGG   
  TCATCAAGAAGACCGAGTCAGACGCGGCGTTGCACCCACTGTTGCAAGAGATCTACAGAG 
 
ACATGTACTGATTTTTCCTGAGATGGTAGGCCGTTGCCACTGTTCAGGGACCTCTGAGGT   
  CTGCGGCCCCATACAGGAGAGCAGGGATTTGCACAGATGGCCTCCCTCCTTACCCTTGGA 
 
GATGAAGAGGGCTGAGCCTAGGCAATGCAGGCTCCTCCCACATCCTTACTTTCTGAATGA   
  GCACTTCTAAGACTTCCTGCTACTGAAATGGTGGTGATCAGAGGCTAGTAGGATTCAGAC 
 
AATTACAG   
 
 
 
Figure 5.21  Use of PPARα P3 transcript uATG 3 codon results in termination after 45bp.  
The rat PPARα P3 transcript sequence is shown.  P3 is composed of 7 exons (exon boundaries are 
indicated by dotted lines).  The initiator codon (ATG) and terminator codon (TGA) from the main 
1406bp ORF are highlighted in yellow.  The alternative uATG3 initiation codon and TGA 
termination codon are highlighted in green.  No highly conserved bases from the Kozak sequence 
are present for this ATG.  The resulting 5’UTR is shown in red text, the 45bp ORF is shown by 
blue text and the 3’UTR is shown in pink text.    
   
 
                 AGAGACTTGGAGACGCGGGAACCAGAAGGAAGACTCCCGGCAG              
    GACTTCCTTGACTGAGAAAGTACAATCCTACAATGAATTGTGACCTTTGGAGGAATGAAT 
ORF   
GAACTTAGAGGGGGCTTTCCGGATGG
  182
GAGAAAGCATCTTCTG…………ATTGGTGCTCTGTG  21bp   
    GCCCGCCTGGCCACAACCATTCAACATGGTGGACACAGAGAGCCCCATCTGTCCTCTCTC 
 
CCCACTTGAAGCAGATGACCTGGAAAGTCCCTTATCTGAAGAATTCTTACAAGAGATGGG   
  AAACATTCAAGAGATTTCTCAGTCCCTCGGAGAGGAGAGTTCCGGAAGCTTTAGTTTTGC 
  GGACTACCAGTACTTAGGGAGCTGTCCAGGCTCGGAGGGCTCTGTCATCACAGACACCCT   
CTCTCCAG…………CTTCCAGCCCCTCCTCAGTCAGCTGCCCTGCTGTCCCCACCAGTACAG   
  ATGAGTCCCCTGGCAATGCACTGAACATCGAGTGTCGAATATGTGGGGACAAGGCCTCAG 
 
GATACCACTATGGAGTCCACGCATGTGAAGGCTGCAAG…………GGCTTCTTTCGGCGAACT   
  ATTCGGCTAAAGCTGGCGTACGACAAGTGTGATCGAAGCTGCAAGATTCAGAAAAAGAAC 
 
CGGAACAAATGCCAGTACTGCCGTTTCCACAAGTGCCTGTCCGTCGGGATGTCACACAAT   
  G…………CAATCCGTTTTGGAAGAATGCCAAGATCTGAGAAAGCAAAACTGAAGGCAGAAAT 
 
CCTTACCTGTGAACACGATCTGAAAGATTCGGAAACTGCAGACCTCAAATCTCTGGCCAA   
  GAGAATCCACGAAGCCTACCTGAAGAACTTCAACATGAACAAGGTCAAGGCCCGGGTCAT 
 
ACTCGCAGGAAAGACTAGCAACAATCCG…………CTTTTGTCATACATGACATGGAGACCTT   
  GTGCATGGCTGAGAAGACGCTTGTGGCCAAGATGGTAGCCAACGGCGTTGAAAACAAGGA 
 
GGCAGAGGTCCGATTCTTCCACTGCTGCCAGTGCATGTCCGTGGAGACCGTCACCGAGCT   
  CACGGAATTTGCCAAGGCTATCCCAGGCTTTGCAAACTTGGACTTGAATGACCAGGTTAC 
 
CTTGCTGAAGTACGGTGTGTATGAAGCCATCTTCACGATGCTGTCCTCCTTGATGAACAA   
  AGACGGGATGCTGATCGCGTACGGCAATGGCTTCATCACCCGAGAGTTCCTAAAGAACCT 
 
GAGGAAGCCATTCTGCGACATCATGGAACCCAAGTTTGACTTCGCTATGAAGTTCAATGC   
  CCTCGAACTGGATGACAGTGACATTTCCCTTTTTGTGGCTGCTATAATTTGCTGTGGAG… 
 
………ATCGGCCTGGCCTTCTAAACATAGGATACATTGAGAAGTTGCAGGAGGGGATTGTGC   
  ACGTGCTCAAGCTCCACCTGCAGAGCAACCATCCGGATGATACCTTTCTCTTCCCAAAAC 
 
TCCTTCAAAAAATGGTGGACCTCCGGCAGCTGGTCACGGAGCATGCGCAGCTCGTGCAGG   
  TCATCAAGAAGACCGAGTCAGACGCGGCGTTGCACCCACTGTTGCAAGAGATCTACAGAG 
  ACATGTACTGATTTTTCCTGAGATGGTAGGCCGTTGCCACTGTTCAGGGACCTCTGAGGT   
CTGCGGCCCCATACAGGAGAGCAGGGATTTGCACAGATGGCCTCCCTCCTTACCCTTGGA   
  GATGAAGAGGGCTGAGCCTAGGCAATGCAGGCTCCTCCCACATCCTTACTTTCTGAATGA 
 
GCACTTCTAAGACTTCCTGCTACTGAAATGGTGGTGATCAGAGGCTAGTAGGATTCAGAC   
  AATTACAG 
 
 
 
Figure 5.22  Use of PPARα P3 transcript uATG 4 codon results in termination after 21bp.  
The rat PPARα P3 transcript sequence is shown.  P3 is composed of 7 exons (exon boundaries are 
indicated by dotted lines).  The initiator codon (ATG) and terminator codon (TGA) from the main 
1406bp ORF are highlighted in yellow.  The alternative uATG3 initiation codon and TGA 
termination codon are highlighted in green.  The highly conserved +4 base from the Kozak 
sequence is underlined and in bold.  The resulting 5’UTR is shown in red text, the 21bp ORF is 
shown by blue text and the 3’UTR is shown in pink text.      
  183
                                                       TTCCC              
ACAGCGTGGTGCATTTGGGCGTAACTCACCGGGAGGCGTTTCCTGAGACCCTCGGGGATC 
TTAGAGGCGAG…………CCAAGACTGAAGTTCAAGGCCCTGCCTTCCCTGTGAACTGACATT 
TGTGACTGGTCAAGCTCAGGACACAAGACGTTGTCATCACAG…………ATTGGTGCTCTGTG 
GCCCGCCTGGCCACAACCATTCAACATGGTGGACACAGAGAGCCCCATCTGTCCTCTCTC 
CCCACTTGAAGCAGATGACCTGGAAAGTCCCTTATCTGAAGAATTCTTACAAGAGATGGG 
AAACATTCAAGAGATTTCTCAGTCCCTCGGAGAGGAGAGTTCCGGAAGCTTTAGTTTTGC 
GGACTACCAGTACTTAGGGAGCTGTCCAGGCTCGGAGGGCTCTGTCATCACAGACACCCT 
CTCTCCAG…………CTTCCAGCCCCTCCTCAGTCAGCTGCCCTGCTGTCCCCACCAGTACAG 
ATGAGTCCCCTGGCAATGCACTGAACATCGAGTGTCGAATATGTGGGGACAAGGCCTCAG 
GATACCACTATGGAGTCCACGCATGTGAAGGCTGCAAG…………GGCTTCTTTCGGCGAACT 
ATTCGGCTAAAGCTGGCGTACGACAAGTGTGATCGAAGCTGCAAGATTCAGAAAAAGAAC 
CGGAACAAATGCCAGTACTGCCGTTTCCACAAGTGCCTGTCCGTCGGGATGTCACACAAT 
G…………CAATCCGTTTTGGAAGAATGCCAAGATCTGAGAAAGCAAAACTGAAGGCAGAAAT 
CCTTACCTGTGAACACGATCTGAAAGATTCGGAAACTGCAGACCTCAAATCTCTGGCCAA 
GAGAATCCACGAAGCCTACCTGAAGAACTTCAACATGAACAAGGTCAAGGCCCGGGTCAT 
ACTCGCAGGAAAGACTAGCAACAATCCG…………CTTTTGTCATACATGACATGGAGACCTT 
GTGCATGGCTGAGAAGACGCTTGTGGCCAAGATGGTAGCCAACGGCGTTGAAAACAAGGA 
GGCAGAGGTCCGATTCTTCCACTGCTGCCAGTGCATGTCCGTGGAGACCGTCACCGAGCT 
CACGGAATTTGCCAAGGCTATCCCAGGCTTTGCAAACTTGGACTTGAATGACCAGGTTAC 
CTTGCTGAAGTACGGTGTGTATGAAGCCATCTTCACGATGCTGTCCTCCTTGATGAACAA 
AGACGGGATGCTGATCGCGTACGGCAATGGCTTCATCACCCGAGAGTTCCTAAAGAACCT 
GAGGAAGCCATTCTGCGACATCATGGAACCCAAGTTTGACTTCGCTATGAAGTTCAATGC 
CCTCGAACTGGATGACAGTGACATTTCCCTTTTTGTGGCTGCTATAATTTGCTGTGGAG… 
………ATCGGCCTGGCCTTCTAAACATAGGATACATTGAGAAGTTGCAGGAGGGGATTGTGC 
ACGTGCTCAAGCTCCACCTGCAGAGCAACCATCCGGATGATACCTTTCTCTTCCCAAAAC 
TCCTTCAAAAAATGGTGGACCTCCGGCAGCTGGTCACGGAGCATGCGCAGCTCGTGCAGG 
TCATCAAGAAGACCGAGTCAGACGCGGCGTTGCACCCACTGTTGCAAGAGATCTACAGAG 
ACATGTACTGATTTTTCCTGAGATGGTAGGCCGTTGCCACTGTTCAGGGACCTCTGAGGT 
CTGCGGCCCCATACAGGAGAGCAGGGATTTGCACAGATGGCCTCCCTCCTTACCCTTGGA 
GATGAAGAGGGCTGAGCCTAGGCAATGCAGGCTCCTCCCACATCCTTACTTTCTGAATGA 
GCACTTCTAAGACTTCCTGCTACTGAAATGGTGGTGATCAGAGGCTAGTAGGATTCAGAC 
AATTACAG 
5’ UTR 
202bp 
3’ UTR 
237bp 
 
 
 
 
 
 
 
 
 
 
 
 
 
ORF    1406bp 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.23  PPARα P4 transcript has no alternative initiator codons within the 5’UTR.  
The rat PPARα P4 transcript sequence is shown.  P4 is composed of 8 exons (exon boundaries are 
indicated by dotted lines).  The initiator codon (ATG) and terminator codon (TGA) from the main 
1406bp ORF are highlighted in yellow.  Highly conserved bases from the Kozak sequence (-3 and 
+4) are underlined and in bold.  The 5’UTR is shown in red text, the ORF is shown by blue text 
and the 3’UTR is shown in pink text.  There are no alternative ATG initiation sites within the 
5’UTR for this transcript.    
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 ACACAATAGGAAGCTTTGCAGATCAGCAGAGGGCAAGCCAGTGACCCTCAGAGGCCTTG              
 GGTGGTTCCTGGAGAGGACTTACATAAGTCACGAG…………ACCTGAGTTAGCAGCAGAACA   
5’ UTR   CTCTGAATAAGGAGGCAACATTCCTGCACGTGGACTCTGGTCTTTGGAGCTTGGGACCTG  312bp 
 
CTGTACGCCAG…………CCAAGACTGAAGTTCAAGGCCCTGCCTTCCCTGTGAACTGACATT   
TGTGACTGGTCAAGCTCAGGACACAAGACGTTGTCATCACAG…………ATTGGTGCTCTGTG   
GCCCGCCTGGCCACAACCATTCAACATGG   TGGACACAGAGAGCCCCATCTGTCCTCTCTC 
 CCCACTTGAAGCAGATGACCTGGAAAGTCCCTTATCTGAAGAATTCTTACAAGAGATGGG 
 
AAACATTCAAGAGATTTCTCAGTCCCTCGGAGAGGAGAGTTCCGGAAGCTTTAGTTTTGC   
GGACTACCAGTACTTAGGGAGCTGTCCAGGCTCGGAGGGCTCTGTCATCACAGACACCCT   
 CTCTCCAG…………CTTCCAGCCCCTCCTCAGTCAGCTGCCCTGCTGTCCCCACCAGTACAG 
 ATGAGTCCCCTGGCAATGCACTGAACATCGAGTGTCGAATATGTGGGGACAAGGCCTCAG 
 
GATACCACTATGGAGTCCACGCATGTGAAGGCTGCAAG…………GGCTTCTTTCGGCGAACT   
ATTCGGCTAAAGCTGGCGTACGACAAGTGTGATCGAAGCTGCAAGATTCAGAAAAAGAAC   
 CGGAACAAATGCCAGTACTGCCGTTTCCACAAGTGCCTGTCCGTCGGGATGTCACACAAT 
 G…………CAATCCGTTTTGGAAGAATGCCAAGATCTGAGAAAGCAAAACTGAAGGCAGAAAT 
 
CCTTACCTGTGAACACGATCTGAAAGATTCGGAAACTGCAGACCTCAAATCTCTGGCCAA   
GAGAATCCACGAAGCCTACCTGAAGAACTTCAACATGAACAAGGTCAAGGCCCGGGTCAT    ORF 
1406bp   ACTCGCAGGAAAGACTAGCAACAATCCG…………CTTTTGTCATACATGACATGGAGACCTT 
 GTGCATGGCTGAGAAGACGCTTGTGGCCAAGATGGTAGCCAACGGCGTTGAAAACAAGGA 
 
GGCAGAGGTCCGATTCTTCCACTGCTGCCAGTGCATGTCCGTGGAGACCGTCACCGAGCT   
CACGGAATTTGCCAAGGCTATCCCAGGCTTTGCAAACTTGGACTTGAATGACCAGGTTAC   
 CTTGCTGAAGTACGGTGTGTATGAAGCCATCTTCACGATGCTGTCCTCCTTGATGAACAA 
 AGACGGGATGCTGATCGCGTACGGCAATGGCTTCATCACCCGAGAGTTCCTAAAGAACCT 
 
GAGGAAGCCATTCTGCGACATCATGGAACCCAAGTTTGACTTCGCTATGAAGTTCAATGC   
CCTCGAACTGGATGACAGTGACATTTCCCTTTTTGTGGCTGCTATAATTTGCTGTGGAG…   
 ………ATCGGCCTGGCCTTCTAAACATAGGATACATTGAGAAGTTGCAGGAGGGGATTGTGC 
 ACGTGCTCAAGCTCCACCTGCAGAGCAACCATCCGGATGATACCTTTCTCTTCCCAAAAC 
 
TCCTTCAAAAAATGGTGGACCTCCGGCAGCTGGTCACGGAGCATGCGCAGCTCGTGCAGG   
TCATCAAGAAGACCGAGTCAGACGCGGCGTTGCACCCACTGTTGCAAGAGATCTACAGAG   
 ACATGTACTGATTTTTCCTGAGATGGTAGGCCGTTGCCACTGTTCAGGGACCTCTGAGGT 
 CTGCGGCCCCATACAGGAGAGCAGGGATTTGCACAGATGGCCTCCCTCCTTACCCTTGGA 
3’ UTR   
GATGAAGAGGGCTGAGCCTAGGCAATGCAGGCTCCTCCCACATCCTTACTTTCTGAATGA  237bp   
GCACTTCTAAGACTTCCTGCTACTGAAATGGTGGTGATCAGAGGCTAGTAGGATTCAGAC   
 AATTACAG 
 
 
Figure 5.24  PPARα P5 transcript has no alternative initiator codons within the 5’UTR.  
The rat PPARα P5 transcript sequence is shown.  P5 is composed of 9 exons (exon boundaries are 
indicated by dotted lines).  The initiator codon (ATG) and terminator codon (TGA) from the main 
1406bp ORF are highlighted in yellow.  Highly conserved bases from the Kozak sequence (-3 and 
+4) are underlined and in bold.  The 5’UTR is shown in red text, the ORF is shown by blue text 
and the 3’UTR is shown in pink text.  There are no alternative ATG initiation sites within the 
5’UTR for this transcript.  
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  AGGTGCCCAGGGGCGGGAGGGCACGCGCGAGGACGGGAGCCAGGCGTCCCCCGTCCC 
GGGACAGTGAG…………CCAAGACTGAAGTTCAAGGCCCTGCCTTCCCTGTGAACTGACATT 
TGTGACTGGTCAAGCTCAGGACACAAGACGTTGTCATCACAG…………ATTGGTGCTCTGTG 
GCCCGCCTGGCCACAACCATTCAACATGGTGGACACAGAGAGCCCCATCTGTCCTCTCTC 
CCCACTTGAAGCAGATGACCTGGAAAGTCCCTTATCTGAAGAATTCTTACAAGAGATGGG 
AAACATTCAAGAGATTTCTCAGTCCCTCGGAGAGGAGAGTTCCGGAAGCTTTAGTTTTGC 
GGACTACCAGTACTTAGGGAGCTGTCCAGGCTCGGAGGGCTCTGTCATCACAGACACCCT 
CTCTCCAG…………CTTCCAGCCCCTCCTCAGTCAGCTGCCCTGCTGTCCCCACCAGTACAG 
ATGAGTCCCCTGGCAATGCACTGAACATCGAGTGTCGAATATGTGGGGACAAGGCCTCAG 
GATACCACTATGGAGTCCACGCATGTGAAGGCTGCAAG…………GGCTTCTTTCGGCGAACT 
ATTCGGCTAAAGCTGGCGTACGACAAGTGTGATCGAAGCTGCAAGATTCAGAAAAAGAAC 
CGGAACAAATGCCAGTACTGCCGTTTCCACAAGTGCCTGTCCGTCGGGATGTCACACAAT 
G…………CAATCCGTTTTGGAAGAATGCCAAGATCTGAGAAAGCAAAACTGAAGGCAGAAAT 
CCTTACCTGTGAACACGATCTGAAAGATTCGGAAACTGCAGACCTCAAATCTCTGGCCAA 
GAGAATCCACGAAGCCTACCTGAAGAACTTCAACATGAACAAGGTCAAGGCCCGGGTCAT 
ACTCGCAGGAAAGACTAGCAACAATCCG…………CTTTTGTCATACATGACATGGAGACCTT 
GTGCATGGCTGAGAAGACGCTTGTGGCCAAGATGGTAGCCAACGGCGTTGAAAACAAGGA 
GGCAGAGGTCCGATTCTTCCACTGCTGCCAGTGCATGTCCGTGGAGACCGTCACCGAGCT 
CACGGAATTTGCCAAGGCTATCCCAGGCTTTGCAAACTTGGACTTGAATGACCAGGTTAC 
CTTGCTGAAGTACGGTGTGTATGAAGCCATCTTCACGATGCTGTCCTCCTTGATGAACAA 
AGACGGGATGCTGATCGCGTACGGCAATGGCTTCATCACCCGAGAGTTCCTAAAGAACCT 
GAGGAAGCCATTCTGCGACATCATGGAACCCAAGTTTGACTTCGCTATGAAGTTCAATGC 
CCTCGAACTGGATGACAGTGACATTTCCCTTTTTGTGGCTGCTATAATTTGCTGTGGAG… 
………ATCGGCCTGGCCTTCTAAACATAGGATACATTGAGAAGTTGCAGGAGGGGATTGTGC 
ACGTGCTCAAGCTCCACCTGCAGAGCAACCATCCGGATGATACCTTTCTCTTCCCAAAAC 
TCCTTCAAAAAATGGTGGACCTCCGGCAGCTGGTCACGGAGCATGCGCAGCTCGTGCAGG 
TCATCAAGAAGACCGAGTCAGACGCGGCGTTGCACCCACTGTTGCAAGAGATCTACAGAG 
ACATGTACTGATTTTTCCTGAGATGGTAGGCCGTTGCCACTGTTCAGGGACCTCTGAGGT 
CTGCGGCCCCATACAGGAGAGCAGGGATTTGCACAGATGGCCTCCCTCCTTACCCTTGGA 
GATGAAGAGGGCTGAGCCTAGGCAATGCAGGCTCCTCCCACATCCTTACTTTCTGAATGA 
GCACTTCTAAGACTTCCTGCTACTGAAATGGTGGTGATCAGAGGCTAGTAGGATTCAGAC 
AATTACAG 
5’ UTR 
194bp 
3’ UTR 
237bp 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ORF   
1406bp   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.25  PPARα P6 transcript has no alternative initiator codons within the 5’UTR.  
The rat PPARα P6 transcript sequence is shown.  P6 is composed of 8 exons (exon boundaries are 
indicated by dotted lines).  The initiator codon (ATG) and terminator codon (TGA) from the main 
1406bp ORF are highlighted in yellow.  Highly conserved bases from the Kozak sequence (-3 and 
+4) are underlined and in bold.  The 5’UTR is shown in red text, the ORF is shown by blue text 
and the 3’UTR is shown in pink text.  There are no alternative ATG initiation sites within the 
5’UTR for this transcript.   186
5.2.6  Analysis of three distinct upstream regulatory regions from the multiple PPARα 
  transcriptional start sites indicates that they differ in the presence of CpG islands, 
  core promoter elements and transcription factor binding sites. 
 
In order to determine potential areas of importance for regulation of both basal and simulated 
transcriptional PPARα activity, the upstream sequence of the multiple TSS were analysed for CpG 
islands, core promoter elements and transcription factor binding sites.  To achieve this, first exons 
and 1000bp of upstream sequence from the PPARα TSS were analysed by MethPrimer software for 
CpG islands using the criteria; Island size > 100, GC Percent > 50.0 and Observed/Expected > 0.6. 
263. In addition, the potential regulatory regions were analysed for core promoter elements and 
transcription factor binding sites using the MatInspector program 
264.  Only core promoter elements 
or relevant transcription factor binding sites with the maximum core similarity of 1.0 are shown, 
i.e. the highest conserved bases of a response element match the sequence exactly.   
 
Two CpG islands were found in the upstream regulatory region of the P1/P2/P4/P6 TSS 
(figure5.26).  These TSS were all located within a proximal 796bp CpG island positioned -470 to 
+326 relative to the P2 TSS, whilst the second, upstream CpG island of 430bp was found -970 to -
541 relative to the P2 TSS.  Furthermore, the CpG islands were found to contain a total of 12 Sp1 
response elements.  The P3 and P5 upstream regulatory sequences were not GC rich and 
consequently MethPrimer did not identify any CpG islands. 
 
Upon scrutinizing the sequences surrounding all the PPARα TSS, no TATA box or Initiator 
consensus were identified.  However, several other core promoter elements were identified within 
the upstream regulatory regions of the P1 P2 P5 and P4 TSS; 3 perfect TFIIB Recognition 
Elements (BRE), 2 Motif Ten Elements (MTE) and 4 X Core Promoter Element 1 (XCPE1).   
However, none of these core promoter elements identified were located in their normal positions 
relative to the TSS (table5.4).  In addition no core promoter elements were found in the regulatory 
regions for the P3 and P5 transcripts.   
 
Several putative transcription factor binding sites were identified by the MatInspector software in 
the upstream regulatory region of the P1, P2, P4 and P6 TSS, including that for; hepatocyte nuclear 
factor 3 (HNF3) (a perfect sequence score), nuclear factor 1 (NF-1), Chicken ovalbumin upstream 
promoter transcription factor (Coup TF), activator protein 1 (AP1), Stat, cAMP response element 
binding protein (CREB), PPAR/RXR, VDR/RXR, Myc/Max, sterol regulatory element binding 
protein (SREBP), E2F and nuclear factor kappa-light-chain-enhancer of activated B cells (NFкB) 
(figure 5.27).  Some of these factors were also found in the P3 regulatory region; Stat, Stat 3, 
PPAR/RXR, VDR/RXR, NF-1 whilst additional response elements were also identified; CCAAT, 
Octamer 1 (OCT 1), GATA binding protein 2 (Gata 2), HNF1α, HNF4, CCAAT/enhancer-binding 
protein (C/EBP) andGATA1 (figure 5.28).  For the P5 regulatory region, putative response elements for Stat3, OCT1, HNF4, PPAR/RXR, HNF1 CEBPβ were identified as found previously 
and in addition a CREB2 response element was also identified (figure 5.29).   
 
 
 
 
 
   
 
GTGCGCTGAAAGTTTCCTTTCCCTAGTAGGCTTTCCTGGTCGCTCATCGCCACAAATAGCATAGTGGCAGGCCCAGCG  
 
  TGAGGACAGACAGGAGGGCTGGCATAGCACACATTTCATTCCCAAAGGAGCAGCGTCCTGAGGCGTTGGCACCCCGGG
   
  GGCTATGTGCATTCCGTGATCAGAGATCCAGGGGTGAAGCAAACAAAGCGGTTGCTCCCAGTCGCAGCCTGCCCCCTG
   
CGCTGTCAGTTGGCAGAGTCCCAGTGCCTGAGCTGGACATAGTCAGCCCCTCAACTTCCCCCTTCCCCCAGCGTACAC
   
  AGAGGGGCCGCAGCCCGGGGCGGGGCAGAGGCGGAGGGTCGAAGCGGCCGCGCCTCCCCGCGACCGTCCTCGATGCCC
   
TTCAGCCTCTGCCTTCCCCGCCCGCCACACCCACCCTGGCACCTCCGACACCTGTTGCCGCGTGCCCCAGCTCGCTCT  
    TCCTTTCTCCCCATTTCGCATCCTGGGGCTCTGAAGATCAGATCCCGCCTGCCCGCCCGCCACCCCACGAAGTCCCGG
   
  GACTCGGGGCACGCGCTCCACGATCTAGACCAGTTCACCGAGGGCACCCGGTGGGAAGCTCTACCAGACCCGCAGCCT
   
TGAACTTCAGTTCTGGCCGGTGCGCGGGGCTGGGAGCAGAAAGGCGCGCTCGCCCAGGCGCGCCCTTCCCACAGGGCT    
  GTCTCGCCCGTCGGGTGACCTTGGGCAGTCCCTTCACCTAGCCAGCCTCAGTTTACCAACAGATGCCCGAGCCCCGAG
   
  187
GCACTAAATGGGCATCGAGGAGAACTGCCCAGGGCCTCTTAGGCCCCGCCCTCACAGCAGCGGCCAATCAGATGCTGC  
    CGTCCGGGGGGTGTGTCTCGTTCTGAACCGCGGCCCGGGCCTAGAGGGCGGGGTTTCCGGGGCGGTCACCTCGCCGCG
   
  GGACCCCGCAGGGGACGTCCGAGGGGCGGCGCGTGTCGTGGGGGCGCGGCTGGCACGGGCGCGCGTAGGCGGTGCCGG
                                                                     +1 P1   
GCAGGGGCCCCGGACGCTGCGGCCCCACGACAGGGGTGACGGGGGCGGAGACAGCCGCTCGAGCCCCTCCTGGCGCCG                                                    +1 P6 
  CCTACCCGGGCGGGCTGGCCCTGCGGACCCGCAGGCGGAGCGCAGCCTCAGGTGCCCAGGGGCGGGAGGGCACGCGCG
   
AGGACGGGAGCCAGGCGTCCCCCGTCCCGGGACAGTGAGGTGGGTGGACAGGGAGGGGAGGGGCTCGGTGGCGCATGC  
                         +1 P2   
GCGTGGACCAGGGGCGCGGGTCTGGAGACCCACAGCCACTGGCGAGGGCACACGCTAGGAAGGGCACACGCGTGCGAC
   
  TTTCGGGGCCCCTGGAACTGTCCGCTACTTCGAGTCCCCTTGAGCGCCGTGTGCCGGCTCTGAACATTGGCGTTCGCA
   
GCTGTTTTGTGGGCTGGAGGGTTCGTGGAGTCCTGGAACTGAAGCGACGCTGGGTCCTCTGGTTGTCCCCTTGAGGGG  
                                 +1 P4 
  AGGGCACACGAGCGGGGACATCGGGGCGCTCCCTTCCCACAGCGTGGTGCATTTGGGCGTAACTCACCGGGAGGCGTT
   
TCCTGAGACCCTCGGGGATCTTAGAGGCGAGGTAACTCGAGGCCCCGGGACAGACTGATT   
 
 
 
 
Figure  5.26  Two CpG islands are located in the P1/P2/P4/P6 upstream regulatory 
sequence.  The upstream regulatory sequence of the P1/P2/P4/P6 TSS is shown.  CpGs are 
highlighted in green, CpG islands are indicated in black, whilst non CpG island areas are shown in 
grey.  Two CpG islands are present a 430bp island and a 796bp island.  Transcript TSS are 
indicated in blue.   188
Table 5.4  Positions of core promoter elements within the P1/P2/P4/P6 regulatory region 
of PPARα as identified by MatInspector software.  The consensus sequence and normal position 
relative to TSS +1 are shown.  The number of core promoter elements identified and their actual 
positions relative to the nearest TSS are indicated. 
 
 
 
Core 
Promoter 
Element 
 
 
Consensus 
 
Position 
relative to 
TSS +1 
 
N
o of 
Sites  
 
Position Found 
 
BRE 
 
 
 
TATA box 
 
Inr 
 
MTE 
 
 
 
DPE 
 
XCPE1 
 
 
 
 
XCPE2 
 
 
 
G/C-G/C-G/A-C-G-C-C 
 
 
 
T-A-T-A-A/T-A-A-A/G 
 
C/T-C/T-A-N-A/T-C/T-C/T 
 
C-G/C-A-A/G-C-G/C-G/C-A-A-C 
 
 
 
A/G-G-A/T-T/C-G/A/C-T 
 
G/A/T-G/C-G-T/C-G-G-G/A-A-
G/C+1-A/C 
 
 
 
A/C/G-C-C/T-C-G/A-T-T-G/A-C-
C/A+1-C/T 
 
-37 to -32 
 
 
 
-31/-30 
 
-2 to +4 
 
+18 to +27 
 
 
 
+28 to +33 
 
-8 to +2 
 
 
 
 
-9 to +2 
 
3 
 
 
 
0 
 
0 
 
2 
 
 
 
0 
 
4 
 
 
 
 
0 
 
-13 to -7 of P2 TSS 
-105 to -99 P1 TSS 
-724 to -717 of P1 TSS 
 
 
 
 
 
-18 to +3 to P6 TSS or  
+41 to +60 to P1 TSS 
-423 to -402 to P1 TSS 
 
 
 
+11 to +21 to P6 TSS 
-152 to -142 to P1 TSS 
-263 to -253 to P1 TSS 
-576 to -565 to P1 TSS  
AGCAGCGTCCTGAGGCGTTGGCACCCCGGGGGCTATGTGCATTCCGTGATCAGAGATCCAGGGGTGAAGCAAACAAAGCG                                                                                                                                                                        HNF3 1.000, 1.000 (+) 
                               NF-1 1.000, 0.912 (+)________________
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 GTTGCTCCCAGTCGCAGCCTGCCCCCTGCGCTGTCAGTTGGCAGAGTCCCAGTGCCTGAGCTGGACATAGTCAGCCCCTC
            Sp1 1.000, 0.891 (-)                         NFKappa B 1.000, 0.826 (-)                                                               Sp1 1.000, 1.000 (+)                                         
 AACTTCCCCCTTCCCCCAGCGTACACAGAGGGGCCGCAGCCCGGGGCGGGGCAGAGGCGGAGGGTCGAAGCGGCCGCGCC
                                                                     BRE 1.000, 1.000 (+)                                             VDR/RXR 1.000, 0.925 (-)      Sp1 1.000, 0.956 (-)___                                   PPAR/RXR 1.000, 0.770 (-)  
 TCCCCGCGACCGTCCTCGATGCCCTTCAGCCTCTGCCTTCCCCGCCCGCCACACCCACCCTGGCACCTCCGACACCTGTT
                                                                                               E2F1/DP2 1.000, 0.809 (-) 
Sp1 1.000 0.935 (-) ______________                                                                                                                                                              
 GCCGCGTGCCCCAGCTCGCTCTTCCTTTCTCCCCATTTCGCATCCTGGGGCTCTGAAGATCAGATCCCGCCTGCCCGCCC
                                                                                                                                                                  XCPE1 1.000, 0.830 (-) 
 ___                                                            MYC/MAX 1.000, 0.919 (+)   GCCACCCCACGAAGTCCCGGGACTCGGGGCACGCGCTCCACGATCTAGACCAGTTCACCGAGGGCACCCGGTGGGAAGCT
                       
COUP-TF 1.000, 0.888 (-)____________                                                                                MTE 1.000, 0.776 (-)__________   CTACCAGACCCGCAGCCTTGAACTTCAGTTCTGGCCGGTGCGCGGGGCTGGGAGCAGAAAGGCGCGCTCGCCCAGGCGCG
                                                                          Sp1 1.000, 0.896 (+)                               
                       SREBP 1.000, 0.868 (-)  
CCCTTCCCACAGGGCTGTCTCGCCCGTCGGGTGACCTTGGGCAGTCCCTTCACCTAGCCAGCCTCAGTTTACCAACAGAT
               E2F1/DP1 1.000, 0.817 (-)                      NFKappaB 1.000, 0.941 (-) 
                                              XCP   E1 1.000, 0.877 (-)    
GCCCGAGCCCCGAGGCACTAAATGGGCATCGAGGAGAACTGCCCAGGGCCTCTTAGGCCCCGCCCTCACAGCAGCGGCCA                                                                                                                                             Sp1 1.000, 0.969 (-) 
                                                                                                                                                        Sp1 1.000, 0.916 (+) 
ATCAGATGCTGCCGTCCGGGGGGTGTGTCTCGTTCTGAACCGCGGCCCGGGCCTAGAGGGCGGGGTTTCCGGGGCGGTCA  
                                                                                                                                                      Sp1 1.000, 0.955 (+) 
 ___                        Sp1 1.000, 0.946 (+)___                                     
 CCTCGCCGCGGGACCCCGCAGGGGACGTCCGAGGGGCGGCGCGTGTCGTGGGGGCGCGGCTGGCACGGGCGCGCGTAGGC
  
                                          
XCPE1 1.000, 0.845  (+)                                                                                      BRE 1.000, 1.000 (-)   
Sp1 1.000, 0.953 (+)___             +1P1  
 GGTGCCGGGCAGGGGCCCCGGACGCTGCGGCCCCACGACAGGGGTGACGGGGGCGGAGACAGCCGCTCGAGCCCCTCCTG
                                       CREB 1.000, 0.940 (+) 
                                                                                   VDR/RXR 1.000, 0.897 (+) Sp1 1.000,0.963 (+)   GCGCCGCCTACCCGGGCGGGCTGGCCCTGCGGACCCGCAGGCGGAGCGCAGCCTCAGGTGCCCAGGGGCGGGAGGGCACG
           Sp1 1.000, 0.924 (+)                MTE 1.000, 0.803 (+)   +1P6        MYC/MAX 1.000, 0.921 (+) 
                                                          XCPE1 1.000, 0.879 (+)   
                                                               E2F1/DP1 1.000, 0.825 (+)   CGCGAGGACGGGAGCCAGGCGTCCCCCGTCCCGGGACAGTGAGGTGGGTGGACAGGGAGGGGAGGGGCTCGGTGGCGCAT
                                                                                                                                                                                     
MYC/MAX 1.000, 0.926 (-)   +1 P2     
GCACACGCGTGCG GCGCGTGGACCAGGGGCGCGGGTCTGGAGACCCACAGCCACTGGCGAGGGCACACGCTAGGAAGG A              BRE 1.000, 1.000 (-)                                                                                                                NMYC 1.000, 0.922 (-) 
  
CTTTCGGGGCCCCTGGAACTGTCCGCTACTTCGAGTCCCCTTGAGCGCCGTGTGCCGGCTCTGAACATTGGCG   
                                      E2F1/DP2 1.000. 0.787 (-) 
                              Stat3 1.000, 0.967 (-)___________ 
 TTCGCAGCTGTTTTGTGGGCTGGAGGGTTCGTGGAGTCCTGGAACTGAAGCGACGCTGGGTCCTCTGGTTGTC 
                                                                                                     STAT1 1.000, 0.804 (+)                                               +1 P4 
 CCCTTGAGGGGAGGGCACACGAGCGGGGACATCGGGGCGCTCCCTTCCCACAGCGTGGTGCATTTGGGCGTAA 
                                                                                                                                                                                           AP1 1.000, 0.912 (-) 
   
 
Figure  5.27  Sequence of the PPARα P1/P2/P4/P6 upstream regulatory region showing 
potential transcription factor binding sites and core promoter elements.  The sequence of the 
P1/P2/P4/P6 Upstream Regulatory Region is shown.  TF binding sites and core promoter elements 
are underlined.  In addition Sp1 binding sites are highlighted red and core promoter elements in 
yellow.  All sites are scored and marked with the strand they are located on (+ or -).  The core 
similarity of the sequence is the first number. The maximum core similarity of 1.0 is only reached 
when the highest conserved bases of a matrix match exactly in the sequence and only those sites 
with a score of 1.0 are shown.  The second figure is the matrix similarity which takes into account 
all bases over the whole matrix length.  A perfect match has a score of 1.00 and a "good" match has 
a score of >0.80.  Perfect sequences are highlighted in purple.  TSS are indicated.   
TCTGCGTGGGTGTCTAATGGTTTGCCAATGCATGAGCCCTGCTCTCTGGATGTCTGGACTCACGAGCTGCCCTGATGCAG   
           
TCCAGAATCCATGGCATAGTTCGATAACCAAGGCGG
  190
GGTCTTACTCTGCATCCCCTCACGTTCTATTCCCGTGCATAAAG  
                    HNF-1α 1.000, 0.852 (-)   
                       HNF-4 1.000, 0.952 (-)___________                  RX    R 1.000, 0.762 (-)   AGTGATGCTTTAGAGAATAATCCGTCCTGAGGACTTTGAACTTTGGCTGCAGTGGGGATCATGTCTGAGTAGGTGAAAGT
                                                                                                  PPAR/RXR 1.000, 0.735 (-)                      
  ______________                                                        
  TATTGACCATGGAAATCAGCCTTGCAGTGTGTGGGCTGCCATGCCCTTGGACCTCACAGTTTAGGGAAGCATTTTGCTCA
                                                                                                     STAT 1.000, 0.905 (+)   
                                      
AGTATTATCATTGCCCCCCTACCCCACCCCACATACACATACTTTGAAAAATACTGCAGATGTTGCCAGATGAGGGCAGG   GATA2 1.000, 0.945 (-)    
   
  GGAAACTTGGCTCACTTTCCCCGCTTGCTGCTTCCCAAGCGGGAACCTGAAGTCCTTGAAATTTCAGATTATGACCTCCA
                                                                                                                                                              
   
TTATCCCTTCTCCAAAAATGTCCCTTTGTCCAGTGTGTTTTCCATTAGGAAAGACATCCTATTTCTGTTGTTTTGAAGTC  
                   HNF-4 1.000, 0.837 (-)                                                          
  ATAGAGACAAGCCTGTCCTGCTGCATTCAGTGCGGAGCATTGACGGAGGAATGTCACTCTTAGAAAAGGTTCAGTTGTGC
                                                                    
               __   Stat3 1.000, 0.940 (-)___ 
GAAGATGTGTAGGTGCACGAGACCCAGGAAGAAAGGAGGCTTGAGAAGGAAGCATGCAGCAAAGAAAGGAGTCTGAGTGG  
              
CAAT 1.000, 0.903 (+)                                     
  TGTAAATGTATGCAGAGCCAATGCTTTTTGAAAGGCAGAGTTGGGAGAGCTCATGTGCCAGTGATCAGCATGGGACCAAG
                                                                                NF-1 1.000, 0.967 (+) 
   
CCACGTACGGCAGCACACACCTGTAATTCACATTTGGGCATCTAAGGCAGGTGGATTGTTGCTAGTTCTCCAACGGCATG  
                     OCT1 1.000, 0.869 (-)   
    GGCTAAACAGCAACAACAAAGGGGATGTAGGGTGGAAAGGTTGGCGGTGTCTTGGGCGTTAGCCAAAGCAGAAGTGGGCA
                                                     NF-1 1.000, 0.826 (+) 
   
  GGATAAGGTGAACAATGAGAGGGTGAACTGCAGGTGGTGGACAGAGTGCACCCACCCTTGCCACCGGACCTGGAACCCAG
GATA 1.000, 0.938 (+)                                                Stat3 1.000, 0.962 (-)   
                                     GATA 1.000, 0.987 (+)    ATGGGACCATGAGAGTGGAGTCGGGAGTGTACATCCAGGCTGATAAGTGGAGGCTACCAGGAAGGTTGTTCTTAGCCATG
                                                    Stat3 1.000, 0.966 (-) 
             _____VDR/RXR 1.000, 0.861 (+)______                                                                       CEBP  1.000, 0.928 (-)          
  TGGATGGCAGAGGTGACAGAGGAAGTCTCAGGTGGATGGCTTCCCCCTAGGAGGTTCCTTGCAGGATTCCAGGCTTGGAG
                                                                                                                                                                                Stat3 1.000, 0.944 (+) 
   
CCGGCAGGCAGGGAACTTAGCAGGATTCAGAAGGAAAAGTGATACATGTGCGGCTTTCTTTTACACTACAGACCAAACAT    
   
  TATCAACTTTTCCCCTGCCCTATTCTCTACTTGGATGAATCTAATAAAGGTAGCTTTTAGTGTCTAGGGCAGAAGTCTAA
  HNF-4 1.000, 0.763 (-)                                                                                                                                                                               
VDR/RXR 1.000, 0.751 (+)   
HNF-1 1.000, 0.861 (-)______                                        +1P3   
TGAAGGTGAATGTTTAACCACGCTCAAGGGCAGCTGATAATCTCAAAAGCAATAGAGGCAGAGACTTGGAGACGCGGGAA   (+)   
                    
  CCAGAAGGAAGACTCC 
 
 
Figure  5.28  Sequence of the PPARα P3 upstream regulatory region showing potential 
transcription factor binding sites and core promoter elements.  The sequence of the P3 
Upstream Regulatory Region is shown.  TF binding sites are underlined.  There are no Sp1 binding 
sites or core promoter elements present.  All sites are scored and marked with the strand they are 
located on (+ or -).  The core similarity of the sequence is the first number. The maximum core 
similarity of 1.0 is only reached when the highest conserved bases of a matrix match exactly in the 
sequence and only those sites with a score of 1.0 are shown.  The second figure is the matrix 
similarity which takes into account all bases over the whole matrix length.  A perfect match has a 
score of 1.00 and a "good" match has a score of >0.80.  P3 TSS is indicated.  
 
   
  TAGAAGGCCATGACTGTCCTGGAACTTG
  191
CTTGTGGACCAGGCTAGCCTCGAACTCACGGTGTGAAGTTCATGGTCCTACC
             Stat3 1.000, 0.966 (-) 
    TCTGGTCTAGGTCAGGACAAACATCCTCTGGGAATTAAACTTGTCTTCTTGTCTCTACACTGAGACTCTCACAGTACACA
      
                            GTGGGTCACTCTGCAAGTCCAAGCTCTGGATTGGATAAAAGACACCCATGACCCAGGGCCCAGAGGCATAGCCCACTGGG
   
    GATGTAGTCACATGTACCCACAAGGAGAGTGTCTGTGCACTGCTGGGGGGAGGGGAGGGAGCAAATAGCAGAGTTACTGT
   
  HNF-4 1.000, 0.881 (-)_______________                                                                                                                                                       
GAGTAGGGTGCTTTGACCTTCCAAGGTATACAAAGACAGACATCTGACCCATGGTGAGCAAAGGCAGTCTGTAAACTTAG                    PPAR/RXR 1.000, 0.747 (-)                                                                            HNF-4 1.000, 0.820 (+) 
  PPAR/RXR1.000, 0.805 (+)______ 
GTTTGGAGACAGGTTAATTATCAAAAAGGGTAGTGTGTCCATGAGACAGCAGTTTCTGAGCAGAAGGTTCCAGACCCTGC     RAR/ RXR 1.000, 0.786 (+)  OCT1 1.000, 0.949 (+) 
            HNF1 1.000, 0.915 (+)   
                                                               AGACCTCCAGTGAGTTTATATCTTTGCTCACCACCTCCACCCAGGTGACAGCCTGTATTTGACGTAACTCTCAATCCAAC
                                                                                                                                                         CREB2 1.000, 1.000 (+) 
                                                     VDR/RXR 1.000, 0.752 (-)________________ 
TGTTGTTCTGATGGGATCGCAGCCCTGCTTAAAACCAGGCTTCCCATTGTCCCCAGGACAAATGCCAGACCTCCATACTC
                                                       HNF-4 1.000, 0.849 (+) 
  PPAR 1.000, 0.805 (-)_____________                                                                                              
CCCCTTCCCCTCCTCAGCTTCCTGGGCAGGACCCCACCCACCTCTGCCCACCTTATATCACTTCCACCGTCTCCTTCCTT
                                                           
    
GAGCCTGGCTCTCCTTCTTTCCATGGCTTTTAAATTGCCTGATGCCAACCCCCAAGACCCCCAGAGCACCAGGCTCTTAT                          
   
GTCTGCCAGAGCCTGGGGTGTCAAGCCAGCAGTTGGCCTCTGTACCAGATAAGTGCAGATCGCAGAGTGGATATGAGGTC  
 
                                       
  TGAGAGCATCCTCACTCTCTCCAGGTGGCTTCTGCCCTTGATTTCCTCATCTGTGAAGTGGGAGTGGGTGGAGCCAGCCA
                                                    CEBP β 1.000, 0.945 (-)      VDR/RXR 1.000, 0.859 (+)     
  CCTTCCATGGCTACTGTGAGTCTCATGTCTAAGGTGAACATAGTTTGTCCCCTGGATAGTGAGTGCCAGTCCTAGGGTGG
   
 
  CATCCAAGGACATACAAGGGTTGGTCTTCACTGAAGTCCACTTCGGTCCACCAGCAATCAGCTTCCTACTTTTCCATCAG
       
    CAAATACCTACTTCCCCTGCCCTGGTGGACTTCTACCACCTGATTGAAGGCACACTTCCAGGAGATCAGAGGCCACTATC
                                           VDR/RXR 1.000, 0.796 (-)                                                          Stat3 1.000, 0.960 (+) 
              +1 
CTGGCAGATGACACACAATAGGAAGCTTTGCAGATCAGCAGAGGGCAAGCCAGTGACCCT 
 
 
 
 
Figure  5.29  Sequence of the PPARα P5 upstream regulatory region showing potential 
transcription factor binding sites and core promoter elements.  The sequence of the P5 
Upstream Regulatory Region is shown.  TF binding sites are underlined.  There are no Sp1 binding 
sites or core promoter elements present.  All sites are scored and marked with the strand they are 
located on (+ or -).  The core similarity of the sequence is the first number. The maximum core 
similarity of 1.0 is only reached when the highest conserved bases of a matrix match exactly in the 
sequence and only those sites with a score of 1.0 are shown.  The second figure is the matrix 
similarity which takes into account all bases over the whole matrix length.  A perfect match has a 
score of 1 and a "good" match has a score of >0.80.  Perfect sequences are highlighted in purple.  
P5 TSS is indicated.   192
5.2.7 The  PPARα P2 and P1 promoters are active in HepG2 Cells, but the P3 promoter 
  region is inactive 
 
Promoter regions corresponding to the liver specific and adipose specific PPARα mRNA 
transcripts were termed according to their transcript ID (P1-3).  These promoter regions were 
designed to extend from the region ~50bp downstream of their respective transcription start sites to 
at least 1Kb upstream.  This resulted in two partially overlapping promoters for P1 and P2 (figure 
5.30) and a distinct downstream promoter for P3 as previously shown (figure 5.28).  A diagram 
indicating the positions of promoters relative to each other is given in figure 5.31.   
 
To investigate the activity of the alternative PPARα transcript promoters, they were cloned into the 
pGL3 Basic luciferase reporter vector and used in transient transfections.  Initially, 1µg and 2µg of 
the PPARα-pGL3 luciferase reporter constructs (P1–pGL3, P2-pGL3 and P3-pGL3) were 
transfected into HepG2 cells.  In addition, the promoter-free pGL3 basic vector was transfected as a 
control.   
 
Results show that the activity of the P3-pGL3 construct is similar to that of the promoter-less pGL3 
Basic vector with luciferase activities of 20.9 and 34.1 for 1µg and 2µg of transfected plasmid 
respectively (figure 5.32).  Conversely, the activity of P1-pGL3 is higher at 81.28 for 1µg and 
172.5 for 2µg plasmid.  In addition, activity of the P2-pGL3 construct is highest with 147.6 for 1µg 
and 284.0 for 2µg plasmid.  These results indicate that the P3 promoter region is inactive in HepG2 
cells, whilst the P1 and P2 promoters are both active in HepG2 cells, with P2 having the highest 
activity. 
 
 
 
 
 
 
  
 
  
 AGCAGCGTCCTGAGGCGTTGGCACCCCGGGGGCTATGTGCATTCCGTGATCAGAGATCCAGGGGTGAAGCAAACAAAGCG
                                                                                                                                                                       HNF3 1.000, 1.000 (+)                                 NF-1 1.000, 0.912 (+)________________
  193
 
 GTTGCTCCCAGTCGCAGCCTGCCCCCTGCGCTGTCAGTTGGCAGAGTCCCAGTGCCTGAGCTGGACATAGTCAGCCCCTC
            Sp1 1.000, 0.891 (-)                         NFKappa B 1.000, 0.826 (-)                                                               Sp1 1.000, 1.000 (+)                                         
 AACTTCCCCCTTCCCCCAGCGTACACAGAGGGGCCGCAGCCCGGGGCGGGGCAGAGGCGGAGGGTCGAAGCGGCCGCGCC
                                                                      BRE 1.000, 1.000 (+) 
                                          VDR/RXR 1.000, 0.925 (-)      Sp1 1.000, 0.956 (-)___                                   PPAR/RXR 1.000, 0.770 (-)    TCCCCGCGACCGTCCTCGATGCCCTTCAGCCTCTGCCTTCCCCGCCCGCCACACCCACCCTGGCACCTCCGACACCTGTT
                                                                                           E2F1/DP2 1.000, 0.809 (-) 
Sp1 1.000 0.935 (-) ______________                                                                                                                                                                GCCGCGTGCCCCAGCTCGCTCTTCCTTTCTCCCCATTTCGCATCCTGGGGCTCTGAAGATCAGATCCCGCCTGCCCGCCC
                                                                                                                                                                  XCPE1 1.000, 0.830 (-) 
  ___                                                            MYC/MAX 1.000, 0.919 (+) 
GCCACCCCACGAAGTCCCGGGACTCGGGGCACGCGCTCCACGATCTAGACCAGTTCACCGAGGGCACCCGGTGGGAAGCT
                       
  COUP-TF 1.000, 0.888 (-)____________                                                                                MTE 1.000, 0.776 (-)__________ 
CTACCAGACCCGCAGCCTTGAACTTCAGTTCTGGCCGGTGCGCGGGGCTGGGAGCAGAAAGGCGCGCTCGCCCAGGCGCG                                                                           Sp1 1.000, 0.896 (+)                               
                     SREBP 1.000, 0.868 (-)  
CCCTTCCCACAGGGCTGTCTCGCCCGTCGGGTGACCTTGGGCAGTCCCTTCACCTAGCCAGCCTCAGTTTACCAACAGAT            E2F1/DP1 1.000, 0.817 (-)                    NFKappaB 1.000, 0.941 (-) 
                                               XCPE1 1.000, 0.877 (-)    
GCCCGAGCCCCGAGGCACTAAATGGGCATCGAGGAGAACTGCCCAGGGCCTCTTAGGCCCCGCCCTCACAGCAGCGGCCA  
                                                                                                                                          Sp1 1.000, 0.969 (-)                                                                                                                              Sp1 1.000, 0.916 (+) 
 ATCAGATGCTGCCGTCCGGGGGGTGTGTCTCGTTCTGAACCGCGGCCCGGGCCTAGAGGGCGGGGTTTCCGGGGCGGTCA
                                                                                                                                                      Sp1 1.000, 0.955 (+)   ___                        Sp1 1.000, 0.946 (+)___                                     
 CCTCGCCGCGGGACCCCGCAGGGGACGTCCGAGGGGCGGCGCGTGTCGTGGGGGCGCGGCTGGCACGGGCGCGCGTAGGC
  
                                          
  XCPE1 1.000, 0.845  (+)                                                                                      BRE 1.000, 1.000 (-) 
Sp1 1.000, 0.953 (+)___             +1P1    GGTGCCGGGCAGGGGCCCCGGACGCTGCGGCCCCACGACAGGGGTGACGGGGGCGGAGACAGCCGCTCGAGCCCCTCCTG
                                       CREB 1.000, 0.940 (+) 
                                                                                  VDR/RX   R 1.000, 0.897 (+) Sp1 1.000,0.963 (+) 
GCGCCGCCTACCCGGGCGGGCTGGCCCTGCGGACCCGCAGGCGGAGCGCAGCCTCAGGTGCCCAGGGGCGGGAGGGCACG            Sp1 1.000, 0.924 (+)                MTE 1.000, 0.803 (+)   +1P6        MYC/MAX 1.000, 0.921 (+) 
                                                           XCPE1 1.000, 0.879 (+) 
                                                               E2F1/DP1 1.000, 0.825 (+)      
CGCGAGGACGGGAGCCAGGCGTCCCCCGTCCCGGGACAGTGAGGTGGGTGGACAGGGAGGGGAGGGGCTCGGTGGCGCAT
                                                                                                                                                                                     
MYC/MAX 1.000, 0.926 (-)   +1 P2     
GCGCGTGGACCAGGGGCGCGGGTCTGGAGACCCACAGCCACTGGCGAGGGCAC   
           BRE 1.000, 1.000 (-)                                                                                                                 
  
  
 
 
 
Figure  5.30  Sequence of the overlapping PPARα P1 and P2 cloned promoter regions 
showing potential transcription factor binding sites and core promoter elements.  The 
sequence of the P2 and P1 cloned promoter regions are shown.  The region unique to the P2 
promoter is shown in blue text and transcription start sites are indicated in pink.  TF binding sites 
and core promoter elements are underlined.  In addition Sp1 binding sites are highlighted red and 
core promoter elements in yellow.  All sites are scored and marked with the strand they are located 
on (+ or -).  The core similarity of the sequence is the first number. The maximum core similarity 
of 1.0 is only reached when the highest conserved bases of a matrix match exactly in the sequence 
and only those sites with a score of 1.0 are shown.  The second figure is the matrix similarity which 
takes into account all bases over the whole matrix length.  A perfect match has a score of 1.00 and 
a "good" match has a score of >0.80.  Perfect sequences are highlighted in purple.  
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Figure 5.31  Schematic diagram showing relative locations of PPARα P1, P2 and P3 cloned 
promoters and their positioning relative to Ensembl transcription start site and 5’UTR exons.  
Location of PPARα 5’UTR Exons on the genomic sequence are shown in red.  All positions are 
shown relative to the Ensembl transcription start site (+1).  Cloned promoter locations are shown in 
orange for P1, P2 and P3, along with their exact positions relative to Ensembl transcription site. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
pGL3 Basic P1-pGL3 P2-pGL3 P3-pGL3
0
100
200
300
400
1g Plasmid
2g Plasmid
PPAR Promoter Construct
L
u
c
i
f
e
r
a
s
e
 
 
U
n
i
t
s
/

g
 
 
P
r
o
t
e
i
n
 
(

 
S
E
M
)
 
Figure 5.32  The  PPARα P1 and P2 promoters are active in HepG2 cells, but the P3 
promoter is inactive.  Activities of 1µg and 2µg of the alternative PPARα promoters (P1, P2 and 
P3) and control (pGL3 Basic empty vector) in HepG2 cells are shown (n=2).     195
5.2.8  The alternative PPARα promoter constructs respond differently to factors known 
  to activate PPARα transcription in HepG2 cells 
 
It has previously been shown that PPARα gene expression is induced by factors including dex 
86 
and CFA 
93.  To investigate the activity of the alternative PPARα promoters in response to such 
treatments, the PPARα-pGL3 luciferase reporter constructs (P1, P2 and P3) were transfected into 
HepG2 cells and subjected to treatment for 24 hours with increasing concentrations of either dex or 
CFA.  In addition, the promoter-free pGL3 basic vector was transfected as a control.  The 
responses of the promoters P1-3 to the treatments can be seen in figures 5.33-5.34.    
 
Results showed that the pGL3 basic vector, which contains no promoter or enhancer sequences, 
was inactive in both experiments and did not respond to either treatment.  In addition, the p3-pGL3 
construct was also inactive and unresponsive to treatment in both experiments, with levels 
consistently similar to that of the pGL3-Basic control.  There was therefore no effect of dex or CFA 
on the activity of the control or P3 promoter in HepG2 cells.   
 
As expected, the P1 and P2 promoters were active in both transfections.  Both the P1-pGL3 and 
P2-pGL3 promoter constructs were able to respond to dex treatment (figure 5.33).  Dex increased 
activity of the P2-pGL3 construct from 3.36 in untreated cells to 6.73 at 10µM (p=0.001), whilst it 
increased the activity of P1-pGL3 from 2.54 in untreated cells to 5.8 at 1µM (p=0.01) and 8.2 at 
10µm (p=0.001).  CFA treatment also increased the activity of the P2 promoter from 8.53 in 
untreated cells, to 27.32 at 80µM (p=0.001) and 48.69 at a concentration of 100µM (48.69 
p=0.001) (figure 5.34). There was a drop in activity of the P1 promoter from 24.56 in untreated 
cells, to 8.59 at a concentration of 60µM (p=0.001).  There were no other changes in P1 activity in 
response to leptin treatment.  Therefore, leptin treatment was able to increase the activity of the P2 
construct but not that of the P1 construct. 
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Figure 5.33  Dexamethasone activates the PPARα P1 promoter and the P2 promoter, but 
not the P3 promoter in HepG2 cells.  Activities of the alternative PPARα promoters (P1, P2 and 
P3) and control (pGL3 Basic empty vector) are shown in response to increasing concentrations of 
the synthetic glucocorticoid dex (n=3).  ** p<0.001, *** p<0.001 relative to untreated (0nM) 
(Bonferoni’s Test). 
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Figure  5.34  Clofibric acid activates the PPARα P2 promoter, but not the P3 or P1 
promoters in HepG2 cells.  Activities of the alternative PPARα promoters (P1, P2 and P3) and 
control (pGL3 Basic empty vector) are shown in response to increasing concentrations of the 
PPARα agonist CFA (n=3).  *** p<0.001 relative to untreated (0µM) (Bonferoni’s Test). 
  1975.2.9 PPARα P2 promoter deletion constructs indicate locations of main basal activity 
 
To further characterise the PPARα P2 promoter, a series of P2-pGL3 promoter deletion constructs 
were made, which progressivly lost ~200bp sequence from the 5’ end of the promoter.  These 
promoter constructs were named according to their size (figure 2.11).  To investigate the activity of 
these P2 deletion promoters, they were transfected into HepG2 cells. The responses of the 
promoters P1-3 to the treatments can be seen in figure 5.35.  A list of the binding sites present in 
each deletion construct can be found in table 5.5. 
 
Results indicated that there were no significant differences in activity for any of the promoter 
constructs.  Despite this, results indicated that the 845, 589 and 462 5’ deletion promoter constructs 
had the highest promoter activity with levels of 132.59, 159.45 and 161.75 respectively, while in 
comparison the larger constructs 1096, P2 and P1 were less active with values of 55.38, 100 and 
76.89 respectively indicating the possible presence of repressive elements in the 1096 5’ deletion 
construct.  The least activity was found in the smallest 198bp construct which contained only the 
unique region of the P2 promoter, with a value of 36.83.   
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Figure 5.35  PPARα P2 promoter 5’ deletion constructs indicate locations of main basal 
activity.  Activities of the PPARα P1 promoter, P2 promoter and the 5’ promoter deletion 
constructs and are shown (n=3).  The activities of all promoters are shown relative to the P2 
promoter which is set at 100.  
  198  199
Table  5.5  Location of core promoter elements and transcription factor binding sites 
within the deletion constructs.  Table indicates the presence of both core promoter elements and 
transcription factor response elements specific to the different deletion constructs and the number 
of sites present.  Deletion constructs are listed with the smallest at the top and increase in size at the 
5’ end as they are listed.  Sites listed are in addition to those presented in the shorter constructs. 
 
 
 
Deletion Fragment 
 
Element Present 
 
 
Number Present 
 
P2 Unique Region 
 
 
 
 
 
462bp 
 
 
 
 
 
598bp 
 
 
845bp 
 
 
 
 
 
 
 
 
1096bp 
 
 
 
 
 
 
 
P2 
 
 
BRE 
VDR/RXR 
Sp1 
Myc/Max 
E2F/DP1 
 
MTE 
XCPE1 
BRE 
CREB 
Sp1 
 
XCPE1 
Sp1 
 
MTE 
XCPE1 
Sp1 
Myc/Max 
SREBP 
NFкB 
CoupTF 
E2F/DP1 
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5.3 Discussion 
 
PPARα is a nuclear hormone receptor which has a diverse range of functions. For example, it not 
only plays a key role in energy homeostasis by controlling important metabolic processes such as 
fatty acid metabolism and lipoprotein metabolism 
108, but also functions in the control of the 
inflammatory response 
67.  Consequently, the effects of PPARα expression are seen on a variety of 
target genes, in a variety of tissues and at specific times and levels according to particular 
metabolic and physiological conditions.  For example, the effects of PPARα expression and 
activation are mediated on several enzymes which are key regulators of fatty acid β-oxidation in 
specific tissues such as the liver, skeletal muscle and heart and this activity is crucial in the liver 
during fasting, to provide an alternative energy source for the peripheral tissues.  In addition to this, 
evidence is also accumulating indicating a lipolytic role for PPARα in adipose tissue under specific 
hormonal conditions 
232, when normally PPARα expression in this tissue is low.  Furthermore, as 
part of its anti-inflammatory role, PPARα has cell specific effects on the expression and signalling 
of inflammatory genes 
67.  This function and tissue specific expression of PPARα means that 
control of PPARα expression needs to be highly regulated in each tissue and cell type to ensure that 
its expression is appropriate to the metabolic and physiological status.  Nuclear hormone receptors 
usually have complex gene regulation to accommodate these needs and this is typically mediated 
by differential promoter usage and alternative splicing to produce multiple 5’UTR transcript 
variants.  These variants can provide the versatility, flexibility and fine tuning needed to maintain a 
tightly controlled tissue specific expression profile and this has been shown to be the case for the 
PPAR family 
103.     
 
It is well established that PPARα expression is controlled by hormones such as glucocorticoids and 
insulin in addition to its own ligands 
87,93 and more recently by other nuclear hormone receptors 
94-
96.  Evidence also exists in rats that PPARα expression is epigenetically altered by a protein 
restricted maternal diet in the livers of offspring 
77,212.  In addition, work in this report has identified 
that PPARα expression is altered by neonatal leptin treatment in a tissue specific manner.  To date, 
the exact mechanisms underlying the regulation of PPARα transcription by these factors have not 
been investigated.  Furthermore, the organisation of the rat PPARα gene 5’UTR has not been 
studied since its initial identification in 1992 and consequently is currently thought to consist of 
just one transcript, the regulatory region of which has not been characterised.  Given that human 
PPARα and to a lesser extent mouse PPARα both have a complex genomic organisation, it is 
probable that this is the case for the rat PPARα gene.  To understand how the above factors can 
affect gene expression, in particular that of leptin and in order to understand how tissue specific 
regulation is controlled, any PPARα transcript variants and their corresponding regulatory regions 
first need to be identified and characterised.  This will enable the mechanisms underlying 
regulation of PPARα to be studied, which will be of utmost importance in understanding the role of 
PPARα in health and disease.   201
In this chapter, the 5’UTR of the rat PPARα gene has been characterised.  Subsequently, six 
PPARα mRNA variants have been identified, termed P1-P6 which differ in their 5’UTR due to 
tissue specific differential promoter usage and alternative splicing of exons.  In addition to this, the 
study identified five distinct novel exons within the 5’UTR.  The 5’UTR of the six transcripts were 
shown to differ in structure; length, GC content, free folding energy and presence of uATG and 
uORF.  To study the regulation of PPARα gene expression, the rat PPARα promoters which drive 
expression of the adipose and liver specific transcripts were mapped, cloned and characterised.  
They were shown to differ in the presence of core promoter elements and transcription factor 
binding sites and subsequently differed in both their basal activity and response to known activators 
of transcription.   
 
The first stage in identifying the location of the PPARα promoter was to locate the genes 
transcription start site and this was achieved using an established method which reliably amplifies 
full length capped 5’ ends of mRNA, the 5’RLM RACE.  Previously, rat PPARα was not known to 
have any mRNA variants and only three exons were found to encode the 5’UTR 
105.  However in 
this study six transcript variants were identified using the RACE procedure and they were 
identified from a variety of tissues which are known to vary in PPARα expression levels; two 
transcripts were identified in liver (P2 and P3), one in adipose tissue (P1), one in the heart (P4) and 
finally two in the kidney (P5 and P6).   Furthermore, no transcript was identified in more than one 
tissue.  Altogether five distinct new exons were identified, bringing the total number of exons 
forming the 5’UTR to eight.  Each variant transcript was shown to possess a novel first exon and 
this high number of first exons implies that PPARα regulation by transcriptional control is 
important and that alternative promoters play a central role in its tissue specific gene regulation.  
 
The presence of transcript variants is common not only to PPARα, but also to the other members of 
the PPAR family.  The PPARα 5’UTR variants identified in different species have much in 
common with those found for PPARδ, i.e. multiple transcript variants with limited similarity 
between species.  This is in contrast to PPARγ, which has very few transcript variants that are 
highly conserved between species.  However, subsequent to the 5’ RACE procedure, the genomic 
organisation of human, mouse and rat PPARα was found to have more homology than previously 
shown, in particular the finding of a 5’ extended exon 1B in the rat P2 transcript and novel exon 1A 
in the rat P1 transcript, which are also present in both the human and mouse 5’UTR.  In addition to 
this, the rat P1 and P2 PPARα transcript variants are very similar with those identified in the 
mouse; the rat P2 transcript is equivalent to the mouse variant 1 and the newly identified P1 
transcript is equivalent to the mouse variant 2. 
 
Although the different human and rat PPARα 5’UTR do share some common exons, none of the 
5’UTR variants identified in rat have been found in human PPARα.  However, it is possible that 
exons/5’UTR identified in the rat may be present in the human PPARα organisation but are as yet   202
unidentified, as the human transcripts were all identified in the liver, whereas the rat P1, P4, P5 and 
P6 transcripts were identified in either adipose, heart or kidney.  Conversely, seven alternative 
5’UTR transcripts were identified for human PPARα in the liver, whereas only 2 were identified in 
rat liver (P2 and P3).  However, it is possible that more rat PPARα transcript variants exist, but 
were missed in the RACE procedure.  If the initial PCR product contained different 5’ RACE 
transcripts of the same size, then a population of different transcripts would have been transformed 
into bacterial cells.  As such, many clones would need to be sequenced to determine if this was the 
case.  As only one liver clone and two adipose clones were sequenced, it is possible that other liver 
and adipose specific transcripts exist.  This is also the case for the 5’RACE PCR products which 
were sequenced, as the PCR product could be composed of a population of different 5’RACE 
transcripts of the same size.  To determine if any transcripts have been missed, all the PCR 
products should have been cloned and then a larger amount of clones sequenced.   
 
Another limitation of the 5’RLM RACE is that the full length transcripts were not able to be 
sequenced, thus any transcripts differing in the coding region from exon 5 onwards would be 
missed by this procedure.  As such, the presence of exons 5-9 is presumed in the transcript variants.  
For this reason, it could not be determined if an equivalent of the human truncated variant lacking 
exon 6 
257 was present in the rat tissues.  To determine if the remainder of exons are present, a PCR 
could be performed to amplify the cDNA using a 5’ primer specific to the unique regions of each 
5’UTR.  This could then be sequenced to determine the exons present in the remainder of each 
transcript.  A final limitation of the RACE is its inability to inform of the relative abundance of 
each transcript in the different tissues.  For example, two transcripts were identified in the liver, but 
it is unknown if they are expressed at differing or similar levels.  This information could be 
determined by using an RNase protection assay.  
 
The finding that the six PPARα transcripts have differing 5’UTR is of importance to its gene 
regulation, as the presence of variant 5’UTR is thought to be an evolutionary mechanism to 
increase the scope of both translational control and transcriptional control.  For example, the 
presence of a long 5’UTR, high GC content and secondary structure, of uATG and uORF are all 
associated with reduced translation efficiency of the main ORF 
251.  As all of these factors were 
shown to be present in one or more of the alternative PPARα 5’UTR, this consequently implies that 
translational regulation of PPARα may be affected.   
 
Whilst the relatively high GC content of the 5’UTR was fairly consistent between transcripts, the 
length of the 5’UTR varied from 184bp for the P3 transcript to 312bp for the P5 transcript and 
444bp for the P2 transcript.  This was mirrored in the minimum free energy values of the 
transcripts, i.e. the longer 5’UTR’s were associated with more negative free energy values.  The 
5’UTRs form a natural secondary structure according to their minimum free energy. The more 
negative the minimum free energy, the more energy is released when forming base pairs and the   203
more stable the secondary structure.  Therefore the transcripts with longer 5’UTR, such as P2 and 
P5 were predicted to have the strongest strong secondary structures, which can potentially impede 
translation by normal mechanisms.  This is not a problem when individual secondary structures 
such as hairpin loops within the 5’UTR have values <30Kcal/mol, as they can be “melted” by the 
ribosome during the normal scanning process 
265.  However, as all the PPARα transcripts contain 
hairpins with stabilities greater than this, it indicates that the structure of all the transcripts may 
impede ribosomal movement along the 5’UTR by the scanning mechanism 
265.  Therefore, the 
minimum free energy values and potential stable folding patterns of the PPARα 5’UTRs indicate 
that they may all be subject to translational regulation. 
  
The P3 transcript stood out from the rest of the PPARα transcripts, because it had a particularly 
complex 5’UTR structure.  Although it had the shortest 5’UTR and the lowest GC content and the 
least negative minimum free energy value, this was still at a level which could possibly impede the 
initiation of translation 
265.  Of particular interest this transcript differed from all the other PPARα 
transcripts due to the presence of four uATG the 5’UTR, the position and context of which could 
inhibit translation.  According to the scanning method of translation initiation, translational 
initiation will commence at the first AUG from the 5’ end within a context that favours initiation 
266.  Furthermore, initiation codons do not have to conform 100% to Kozak sequence to enable 
initiation of translation, but the efficiency of translation is vastly increased by the presence of 
highly conserved bases at -3 (G/A) and +4 (G) 
261.  To have one of these conserved bases can result 
in adequate initiation, whereas two present will result in good initiation 
251.  Of the four uATG’s 
present in P3 5’UTR, three were found to have an adequate Kozak consensus which could therefore 
initiate translation.   
 
Of these three uATG codons, one has the potential to produce a protein with a 29 amino acid 
extended N-terminal.  This would be akin to that of PPARγ2 which has an extended N terminal of 
30 amino acids and 28 amino acids in mice and humans respectively compared to the predominant 
PPARγ1 protein.  Furthermore, the P3 transcript has much in common with PPARγ2; its promoter 
is GC rich, its 5’ UTR is very short containing just 1 exon in the 5’UTR and the N terminal 
extension is of a similar length.  Experiments have shown that the PPARγ2 N terminal extension 
houses an N terminal ligand independent activation domain (AF-1), which mediates 5-6 times 
activation than PPARγ1 under ligand depleted conditions and this activity can be augmented by 
insulin treatment.  Furthermore, this ligand independent activation domain in the N terminal is 
found in several other nuclear hormone receptors, including GR, oestrogen receptor and thyroid 
hormone receptor 
104.  It is therefore possible that the P3 may contain an AF-1 domain, which may 
function under specific metabolic conditions.  To determine if P3 could give rise to a larger protein, 
a western blot could be performed on the same liver tissue used in the 5’RLM RACE.   
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Two of the uATG in the P3 5’UTR also have the potential to form short uORF which terminate 
prior to the Bona fide ATG codon.  It is well accepted that the presence of uATG and uORF can 
interfere with translation of the main ORF by forming a ribosome initiation complex at the uATG 
262 and this therefore implies that the translational regulation of the P3 transcript could be further 
affected.  For example, two alternate BRCA1 transcripts which differ in the first exon of their 
5’UTR possess 5’UTR of very different lengths.  The long 5’UTR was shown to have reduced 
translation efficiency compared to the variant with shorter 5’UTR and further analysis showed that 
this was due the presence of uORF and stable secondary structures impeding translation 
267.  
Another example of translational inhibition by the 5’UTR is that of suppressor of cytokine 
signalling-1 (Socs-1).  Here, two uATG in the 134bp 80% GC rich 5’UTR were found to repress 
gene expression due to translation initiation at these upstream ATG sites.  Despite the presence of 
several hairpin loops, translation was found to be by the normal cap dependent scanning 
mechanism 
268.  It is therefore possible that translation of the P3 transcript may occur by the normal 
scanning mechanism, but this may be a modified version to cope with the uATG.  For example; 
leaky scanning could occur, whereby not all ribosomes recognize the uATG, or reinitiation may 
take place, whereby the ribosomes can reinitiate at the Bona fide ATG after the short uORF.   
 
In some genes, the presence of inhibitory factors such as secondary structures and uORF is 
associated with an alternative form of translational initiation, IRES, a cap independent mechanism 
of translational initiation common during periods of stress 
251,269.  This type of translational 
initiation occurs for the AML1/RUNX1 gene which is controlled by two distinct promoters 
270.  
Here, one transcript has a very long 1631bp 5’UTR containing CpG islands, 15 uATG and several 
short uORF.  Consequently, this transcript is not translated well and uses an alternative IRES 
mechanism.  Conversely, the shorter transcript has a 452bp UTR that contains two uATG and is 
translated well by cap dependent mechanisms 
270, which is in contrast to Socs-1 regulation.     
Furthermore, the presence of uATG and uORF in the 5’UTR is also common to both human and 
mouse PPARδ and the use of IRES has been postulated for both of these genes 
76,85.  It has been 
found that hPPARδ variants with longer 5’UTR are translated with reduced efficiency compared to 
those with shorter 5’UTR and researchers found an inverse relationship between translation 
efficiency and uATG number 
85.  Likewise, the main mPPARδ transcript possesses a long 548bp 
5’UTR containing 8 uAUG codons, all of which form uORFs.  Furthermore, this transcript was 
predicted to have a highly negative minimum free energy of -207.5Kcal/mol.  This transcript was 
found to be regulated at the translational level as experiments indicated that the longer 5’UTR 
attenuated translational efficiency 
76.   
 
Clearly when comparing the 5’UTR of all these different genes, it is not always clear by the 
structural features present if they will affect normal mechanisms of translation, for example as 
indicated by the differing Socs-1 and AML1/RUNX examples which have similar structural 
features but differing translational mechanisms.  Results indicate that all the PPARα transcripts   205
possess secondary structures which have the potential to impede translation, which may prevent 
normal scanning mechanisms.  It is possible that these secondary structures could be overcome by 
ribosome shunting, whereby the ribosome disassociates at the secondary structure then re-
associates just downstream of it, or alternatively the IRES mode of translational initiation could be 
employed.  In addition, the presence of uATG in the P3 5’UTR may be overcome by leaky 
scanning or reinitiation.  Further experiments need to be performed on all the transcripts using a 
coupled transcription translation system to determine if translational regulation is affected the 
structure of their 5’UTR.  For the P3 transcript, it would be interesting to mutate the uATG to see if 
any repressive effects on translation were removed.  It would be also be interesting to determine if 
IRES occurs for any of the transcripts and this could be determined using bicistronic constructs. 
 
To functionally characterise the regulatory regions controlling the PPARα transcripts, a reporter 
gene strategy was employed which could test the activity of each regulatory region and it response 
to known activators of transcription.  The promoter regions controlling the liver (P2 and P3) and 
adipose (P1) specific transcripts were therefore determined according to the position of their 
respective transcription start sites.  This resulted in two partially overlapping GC rich promoters for 
the P1 and P2 transcripts and a distinct downstream promoter for the P3 transcript.  The heart (P4) 
and kidney (P5, P6) transcripts did not have their corresponding promoters cloned as they were 
identified towards the end of the study.  The resulting basal and stimulated activity of the variant 
PPARα promoters differed and computational analysis of the promoter regions by MatInspector 
identified the presence of several putative core promoter elements and interesting transcription 
factor binding sites which could be responsible for the differences in promoter activity.   
 
Activity of the P1 and P2 promoters was high throughout experiments, indicating that they were 
fully functioning promoters, but despite this no TATA or Inr elements were identified in proximal 
regions.  However, several potential core promoter elements were identified by MatInspector in the 
P2/P1 promoters which may direct initiation of transcription, including several potential BRE, 
MTE and XCPE1 sites, but none were located in their normal positions relative to the transcription 
start sites.  Furthermore, it is unlikely that the BRE and MTE core promoter elements are functional 
as normally BRE act in conjunction with a TATA box and likewise MTE with an Inr element 
271.  
The P1/P2 promoters did however possess the characteristics of typical GC rich promoters 
common to nuclear hormone receptors; i.e. the absence of TATA and Inr elements and the presence 
of CpG islands containing multiple Sp1 response elements.  As such it is possible that the XCPE1 
element maybe functional, as these elements typically occur in CpG island containing TATA-less 
promoters and frequently act in conjunction with activators such as Sp1 
272.  However, regardless of 
whether Sp1 acts in conjunction with XCPE1, it is probable that Sp1 plays a key role in directing 
transcription initiation at the P1/P2 promoters, as Sp1 can interact directly with TATA binding 
protein (TBP) and TBP associated factor 4 (TAF 4) to direct basal transcription machinery 
273.  
Furthermore, Sp1 could act synergistically with the many Sp1 sites found throughout the promoter   206
region.  This could occur either between closely positioned Sp1 sites or by looping out the 
connecting DNA between distant Sp1 sites. This ability of Sp1 to act synergistically is, however, 
promoter dependent and would need to be tested 
273.  Further experiments would therefore be 
needed to test the role of all these core promoter elements in directing transcription, for example by 
mutating the putative sites and ascertaining the effect on transcription.  Furthermore, the finding 
that both the human and mouse dominant promoters have similar structures which are GC rich CpG 
island containing regulatory regions which contain multiple Sp1 response elements and no TATA 
box or Inr 
102,103, indicates that mechanisms of direction of transcription could be similar between 
species.  
 
The P3 promoter had a contrasting structure to that of the P1 and P2 promoters, such that it did not 
contain any CpG islands and consequently had no Sp1 response elements present. The P3 promoter 
was found to be inactive in all experiments performed, indicating that it could not function as a 
promoter in HepG2 cells.  This low activity indicates that either important proximal promoter 
sequences or possibly upstream elements had been missed out of the promoter region.  In 
agreement with this, no core promoter elements were identified by MatInspector within this 
promoter.  It would therefore necessary to clone a larger promoter fragment in order to determine 
promoter activity and its regulation.  It is, however, also possible that this promoter is inactive as it 
needs stimulation by hormonal factors which were not present in this in vitro system.   
 
It has previously been reported that PPARα transcription is induced by CFA 
93 and dex 
86.  
Interestingly, the response of the adipose specific (P1) and liver specific (P2) promoters to these 
treatments differed.  Indeed, both these treatments activated PPARα transcription in a dose 
dependent fashion, but only dex activated both the promoters, whereas CFA treatment only 
activated the P2 promoter.  
 
Auto regulation of gene expression is commonly found among nuclear hormone receptors 
including the androgen receptor and GR 
94.  Furthermore, ligands of PPARα have been reported to 
induce PPARα gene expression at the transcriptional level 
94.  It is therefore probable that any 
transcriptional regulation of PPARα induced by CFA could be a form of auto regulation.  When the 
cells were treated with 100µM CFA, the P2 promoter activity increased over 5 fold, whereas the P1 
promoter activity remained unchanged.  As the P2 promoter is identical to the P1 promoter apart 
from an extra 170bp at the 3’ end, elements responsible for CFA activation of the P2 promoter 
must be present in this unique region.  However, upon scrutinising of the unique region of the 
promoter, no PPRE was identified and surprisingly, a PPAR/RXR response element was identified 
within the shared part of the promoter region.  As the P1 construct did not respond to CFA, it 
indicates that this response element is not functional.  However, nuclear hormone receptors can 
sometimes bind alternative hormone response elements and experiments have unequivocally shown 
that human PPARα can regulate its own expression in vitro by binding a HNF-4 response element   207
which contains a DR1 motif 
94.  Although this is not present in the unique region of the P2 
promoter, a VDR/RXR site is present which contains a DR1 motif.  It is thus possible that PPARα 
could auto regulate its own expression via this response element, which could be investigated by 
mutating the VDR/RXR response element.  However, it should be noted that there is a potential 
VDR/RXR site in the shared region of the P1/P2 promoter, but as P1 did not respond to CFA 
treatment, it is likely that this too is not functional.  Auto regulation by PPARα could be confirmed 
by the use of cyclohexamide which prevents protein synthesis and this could elucidate whether 
alterations in promoter activity are direct by PPARα, or indirectly by an unknown transcription 
factor.   
 
Reporter gene experiments have also showed that the ‘unique region’ of the P2 promoter alone was 
able to direct transcription.  Two BRE core promoter elements were identified within this region of 
promoter, but are incorrectly positioned relative to the TSS and therefore unlikely to be involved in 
transcription initiation.  There is however an Sp1 site present in the unique region, which is in close 
proximity to an E2F response element.  This Sp1 site may act alone to direct transcription 
initiation, but may also act with E2F.  It has been shown that Sp1 and E2F are frequently found 
closely associated and these TF can act synergistically to vastly increase transcription, as has been 
shown for the dihydrofolate reductase gene (DHFR) 
274.  It is therefore possible that the “Unique 
region” Sp1 site is important in initiating transcription from the P2 promoter.  There are also two 
Myc/Max enhancer box (E-box) sites present in this region of the P2 promoter.  These transcription 
factors generally activate gene expression and act on around 15% of all genes and may therefore 
function to increase transcription of the PPARα P2 promoter. 
 
Although it is widely known that dex regulates PPARα expression via GR, the exact mechanisms 
and location of response elements responsible for this activation of PPARα are not known.  We 
have shown that both the P1 and P2 promoters respond to dex treatment, indicating that response 
elements responsible for this activation of activity are present in the shared region of these 2 
promoters.  Previous experiments have shown that GR activation of PPARα promoter is direct 
86.  
However data from this study does not agree that dex is acting directly via GR, as MatInspector 
analysis did not identify any glucocorticoid response elements (GRE) within this region of the 
P1/P2 promoter, although this does not prove that GR can not bind to the promoter.   
Glucocorticoids have many effects, therefore it is possible that its actions on the PPARα promoters 
could be indirect via an unidentified transcription factor.  For example, a putative NF-1 response 
element was identified by MatInspector in the P1/P2 promoter shared region.  Generally an 
activator of transcription, NF-1 can be regulated by GR and therefore is a possible indirect means 
of regulation by GR in the absence of a GRE in the promoter.  Interestingly, NF-1 was also 
identified in the promoter region of the human PPARα promoter 
103.  To fully understand dex 
activation of the PPARa promoter, the use of cyclohexamide could again help determine if   208
activation of the PPARa promoter is direct by GR or indirect via another transcription factor such 
as NF-1.  
 
Next, in order to identify the location of elements important to the transcriptional regulation of the 
PPARα P2 transcript, a series of promoter deletion constructs were made.  The main area able to 
induce transcriptional activity was found to reside in a 462bp deletion fragment, a region of the 
promoter containing the unique region of the P2 promoter and an extra 364bp of 5’ sequence 
common to the P2 and P1 promoters.  Activity of this fragment was 4 fold higher than the shorter 
unique region promoter.  This 462bp fragment contained several incorrectly positioned core 
promoter elements (perfect BRE, MTE, XCPE1), but more interestingly, 5 Sp1 sites.  It may well 
be that increased transcription of this fragment is due to the synergistic effect of these extra 5 sp1 
sites in conjunction with the downstream Sp1 site in the unique region of the promoter.  In addition 
to this, a potential CREB site was identified in the 462bp promoter, which interestingly was also 
found in the human PPARα promoter 
103.  This CREB site at the 3’ end of the P1/P2 shared region 
could potentially be responsible for activation of PPARα under times of stress by glucagon and 
adrenaline signalling.  This would mean that as well as activating enzymes to stimulate lipolysis, 
glucagon could activate a key transcription factor which directs fatty acid oxidation.  The 598bp 
promoter construct was larger than the 462bp construct at the 5’ end and had the same activity as 
the shorter construct.  Not surprisingly, it was only found to contain an additional XCPEI and a Sp1 
site.  However, by adding on an extra 247bp at the 5’ end, the 845bp fragment had less activity than 
smaller 598bp fragment, indicating the presence of possible repressive elements.  In agreement 
with this, this region contains potential response elements for transcription factors which could act 
in a repressive manner; CoupTF and NFкB.  For example, CoupTF has been shown to act in a 
negative manner on PPARα activity by binding PPRE to antagonise PPARα signalling 
275.  It is 
therefore possible that in addition CoupTF could act on its own response element to have a 
negative effect on PPARα expression.  In addition, the pro inflammatory NFкB can exert both 
positive and negative regulation of transcription.  It has previously been shown that PPARα exerts 
some of its anti-inflammatory effects by negatively regulating/antagonising NFкB and AP1 
signalling pathways 
276, it is possible that in turn NFкB, which is found in most cell types, could 
repress PPARα gene expression by means of a response element in the PPARα promoter.  The 
1096bp fragment also had much less activity than the shorter fragments at the 5’ end, indicating 
that further repressive elements may be present.  Again, another NFкB site is present which may 
have a negative effect on transcription.   
 
To narrow down the response elements responsible for activation of promoters by dex, experiments 
should be performed on the PPARα promoter deletion constructs.  Clearly the transcription factors 
thought to be responsible for activation and repression of promoter activity would need to be 
mutated to determine if they are functional.  It would also be interesting to look at the effect of   209
insulin on the promoters, as it has been shown previously that insulin can prevent activation of 
PPARα transcription by dex 
87.   
 
Despite the lack of basal promoter activity, analysis of the liver specific P3 promoter revealed some 
interesting potential transcription factor binding sites which could be involved in both the positive 
and negative regulation of PPARα gene expression.  The P3 promoter did not respond to any 
treatment, but as mentioned previously, this may be because elements which could initiate 
transcription were missed out of the promoter.  The P3 promoter was, however found to contain 
potential transcription factor binding sites which could be of importance in PPARa regulation, such 
as PPAR/RXR which could mediate auto regulation and 2 NF1 sites which could mediate the 
effects of dex.  In addition, 3 potential HNF-4 sites were identified in the promoter.  HNF-4 is a 
nuclear receptor which is highly expressed in the liver and involved in metabolic homeostasis and 
response elements for HNF-4 are frequently found in promoters of metabolic genes, including 
those of lipid metabolism.  As PPARα is down regulated in the livers of HNF-4 liver knock out 
mice 
96 and HNF-4 over-expression has been shown to upregulate PPARα expression 
95, it is 
therefore possible that these response elements are responsible for activation of PPARα 
transcription.  Furthermore, it has been shown that PPARα can bind HNF-4 response elements, 
therefore the 3 HNF4-RE could provide further sites for auto regulation by PPARα 
94.  Lastly, a 
potential C/EBP response element was also identified by MatInspector in the P3 promoter region.  
C/EBP has been shown to be involved in the transcriptional repression of human PPARα by Il-6 in 
HepG2 cells 
99 and may therefore act in a repressive manner on the P3 promoter.  As several of the 
response elements identified in the P3 promoter were not found in the P2 promoter, the P3 
promoter may therefore provide additional strength/fine tuning of gene expression in the liver.   
 
Experiments determining the activity of the liver and adipose specific promoters have shown that in 
HepG2 cells, the adipose specific (P1) and liver specific promoter (P2) had similar basal activity, 
however it is known in vivo that expression of PPARα is high in liver and low in adipose tissue.  
Several factors could account for this.  Firstly, it may be that in adipose tissue, the different array of 
factors present within the cell result in a lower expression of PPARα.  However, the promoter 
regions of these transcripts were found to be very similar, although there were few differences in 
response elements present.  It may therefore be that higher expression in the liver compared to that 
in adipose tissue may be due to the presence of the additional liver specific transcript (P3).  For this 
reason, it would be very useful to determine the activity of the two liver promoters in vivo, i.e. their 
strengths under normal and differing metabolic conditions.   Finally, one last possibility is that the 
liver and adipose differences in gene expression are a result of other forms of regulation, such 
translational regulation by 5’UTR structure. 
 
Although the P5 promoter was not characterised in transfections, MatInspector identified some 
interesting potential transcription factor binding sites which may play a role regulating PPARα   210
transcription in the kidney.  These included several RXR heterodimer response elements, two 
PPRE and four HNF-4 response elements which all may be involved in PPARα auto regulation.   
 
Work presented in this chapter has identified that the rat PPARα gene has tissue specific transcripts 
and promoters which allow PPARα regulation to be more versatile, in keeping with its role as a 
nuclear hormone receptor.  The alternative promoters increase the scope for transcriptional control 
in a tissue specific manner, for example by providing diversity in the regulatory elements present 
between tissues and furthermore by providing diversity in the same tissue by the presence of 
multiple promoters.  These features enable PPARα to respond differently to different factors and 
metabolic conditions such as was shown for P1 and P2 promoters.  The use of different promoters 
also results in differing 5’UTR with varying structure which may further effect PPARα gene 
expression by modulating translation efficiency and in addition may even result in a variant protein 
which is activated under differing metabolic conditions.   
 
The work completed in this chapter will provide a basis for studying the effects of leptin treatment 
on the PPARα promoter.  In particular how leptin treatment may alter PPARα expression, the exact 
mechanisms involved, which transcripts are involved and to identify how neonatal leptin treatment 
could induce gene expression changes which persist into adulthood.   211
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6.1 Introduction 
 
6.1.1  Leptin receptor signalling mechanisms 
 
The leptin receptor (OB-R) is the product of the db gene and a member of the class I cytokine 
receptor family known to stimulate transcription via activation of Stat proteins 
118.  Leptin receptors 
typically possess three domains; an extracellular domain which permits ligand binding, a single 
membrane spanning domain and an intracellular domain which contains the motifs necessary for 
transmitting the signal.  However, in both humans and rodents, alternative splicing of the leptin 
receptor yields six variant isoforms; OB-Ra, OB-Rb, OB-Rc, OB-Rd, OB-Re and OB-Rf.  All six 
isoforms possess the extracellular domain, but only five possess membrane spanning domain and 
the intracellular cytoplasmic domain (OB-Ra-d, OB-Rf).  OB-Re is the isoform which only 
contains the extracellular domain and this forms a soluble receptor thought to be involved in leptin 
transport.  The remaining isoforms all possess intracellular domains of differing size and as a result 
are classified into either long (OB-Rb) or short (OB-Ra, OB-Rc, OB-Rd, OB-Rf).  These 
alternative isoforms of leptin receptor therefore differ in their signalling capacities according to the 
motifs present in the intracellular domain 
277.   
 
Leptin signalling has been shown to occur predominantly via the long form of the receptor, OB-Rb, 
which is expressed throughout peripheral tissues as well as the CNS, with particularly high 
expression in the hypothalamus.  As OB-Rb has no intrinsic kinase activity, leptin receptor 
signalling pathways involve recruitment of a cytoplasmic kinase, Jak2.  Jak activation results in the 
phosphorylation of tyrosine (tyr) residues on the intracellular domain of the receptor, in particular 
tyr 985 and 1138, which provide docking sites for downstream signalling molecules.  However, 
consistent with its many physiological functions and near ubiquitous distribution, leptin participates 
in a number of signalling pathways mediated by Jak2, tyr 985 and 1138, including Jak/Stat, 
Mitogen-activated protein kinase ( MAPK), Phosphoinositide 3-kinase (PI3K) and 5’-AMP-
activated protein kinase (AMPK) signalling pathways 
277(figure 6.1).  
 
OB-Rb is the only isoform of the leptin receptor which contains all the intracellular motifs required 
for Jak Stat signalling, leptins predominant signalling mechanism.  Activation of this pathway 
results in the recruitment of cytoplasmic kinases (Jak2) and the resulting phosphorylation of tyr 
residues on OB-Rb, which permit the binding and activation of Stats and subsequent transcription 
of target genes in the nucleus.  This signalling pathway occurs in both central and peripheral tissues 
as a result of leptin binding.  For example, leptin activates one of its key hypothalamic target genes, 
POMC via Stat3 signalling 
278.  Furthermore, it also activates Suppressor of cytokine signalling 3 
(Socs-3), a gene whose product attenuates leptin receptor mediated signalling in a well established 
mechanism of negative feedback, which is implicated in obesity related leptin resistance.   
   213
In peripheral tissues, some of leptins major effects on energy metabolism have been shown to occur 
via Stat3 signalling.  For example, leptin acts via OB-Rb and Stat3 to decrease insulin synthesis in 
pancreatic β cells 
120 and intravenous leptin increases OB-Rb mediated Stat3 phosphorylation after 
only 3 minutes in the liver, muscle and adipose tissue 
279.  Of particular interest, is that leptin 
signalling via OB-Rb and Stat3 is widely implicated in adipose tissue.  For example, in the DIO rat, 
the reduced adipocyte OB-Rb which results from HF feeding results in reduced Stat3 activation 
243 
and injections of leptin in mice result in increased Stat3 phosphorylation in WAT 
244, whilst leptin 
treatment on excised fat pads activates Stats 
121,279 and also in 3T3 cells 
279.  Furthermore, it has 
been identified that the leptin mediated depletion of adipocyte fat in adult rats requires OB-Rb on 
adipocytes and results in increased phosphorylation of Stat3 
280.  In addition, mice with adipocyte 
specific Stat3 knock out have impaired leptin-induced lipolysis 
281.  Interestingly, the leptin-
induced depletion of adipocyte fat only occurs with normal PPARα signalling 
239, implying that 
Stat3 is the mechanism by which OB-Rb activates PPARα.  These experiments, therefore, provide 
overwhelming evidence that leptin signalling via Stat3 in adipose tissue plays a key role in energy 
metabolism, particularly in relation to its role in inducing lipolysis and reversing differentiation in 
adult rats.   
 
Interestingly, leptin receptor mediated signalling of POMC, one of leptins major hypothalamic 
target genes, has been found to occur by a non-canonical Stat3 mechanism in the rat.  The POMC 
promoter region which responds to leptin mediated Stat3 signalling does not contain a Stat3 
binding element (SBE) and experiments found that Stat3 could not bind this promoter fragment 
directly, but instead Sp1 bound upon leptin treatment.  Further studies uncovered that Stat3 
mediated leptin signalling of POMC absolutely requires this Sp1 response element within its 
promoter and researchers concluded that Stat3 binds to a pre-existing Sp1/DNA complex to 
mediate POMC gene expression 
282.  Interestingly, in the DIO rat, which has similar metabolic 
disturbances as the UN offspring in the IUGR rat study, methylation of a CpG just upstream of this 
Sp1 response site is increased and correlates with reduced POMC gene expression in response to 
leptin treatment 
185. 
 
The use of this novel Stat3/Sp1 mechanism of gene activation occurs in another leptin target gene, 
Tissue inhibitor of metalloproteinase 1 (TIMP-1).  Again, no SBE was identified within the TIMP-
1 promoter region which responds to leptin treatment.  Here, leptin receptor signaling results in 
phosphorylation of Stat3 and the subsequent activation of Sp1 and its translocation to the nucleus, 
whereby Stat3 binds Sp1 at the Sp1 response element within the TIMP1 promoter to increase gene 
expression 
283.  In addition to this, another cytokine has been shown to activate gene transcription 
via Stat3 in a similar manner; Interleukin-6 has been shown to induce transcription of the VEGF 
gene in a GC rich SBE free promoter, but here as with POMC, activated Stat3 translocates to the 
nucleus to interact directly with a pre-bound Sp1/DNA complex 
284.  
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Figure 6.1  Leptin receptor signalling mechanisms.  In the absence of ligand, OB-Rb forms 
a homodimer.  Leptin binding induces a conformational change and results in a non-covalently 
associated Jak2 binding the intracellular box1 motif.  Jak2 subsequently auto-phosphorylates on 
tyrosine residues and also phosphorylates OB-Rb tyrosine residues, including tyr 985 and tyr 1138.  
Stat3:  Stat3 binds phosphorylated tyr 1138 and is itself then phosphorylated by Jak2.  Stat3 
homodimerises and translocates to the nucleus to bind to Stat binding element (SBE) whereby it 
activates transcription of target genes, e.g. POMC and SOCS3.  AMPK: Activated AMPK 
phosphorylates ACC resulting in its inhibition.  ACC functions to catalyse the irreversible 
formation of malonyl CoA from acetyl CoA, which inhibits CPT-1.  AMPK also activates malonyl-
CoA decarboxylase to reduce malonyl CoA levels.  Thus this cascade results in the reduction of 
Malonyl CoA and therefore the disinhibition of CPT-1, thus increasing CPT-1 activity and fatty 
acid β-oxidation.  MAPK: SHP-2 binds tyr 985 which then becomes phosphorylated and recruits 
Grb-2 to induce the p21 Ras-ERK pathway and expression of target genes including c-fos and c-
jun.  PI3K/PDE3B/cAMP: Leptin signalling can result in the recruitment and phosphorylation of 
IRS2 by Jak2.  IRS2 associates with p85 to activate PI3K, which results in activation of ser/thr 
kinases such as phosphoinositide-dependent kinase 1 (PDK1).  This in turn can activate another 
ser/thr kinase, Akt.  Subsequent activation of PDE3B causes decreased cAMP levels and reduced 
PKA activation.  Leptin Resistance: SOCS3 is a SH2 domain containing protein which binds Tyr 
985 to inhibit Stat3 signalling by inhibiting Jak2 and preventing tyr phosphorylation of OB-Rb.  
SOCS3 also inhibits ERK signalling by competing for tyr 985.  Protein tyrosine phosphatase 1B 
(PTP1B) de-phosphorylates Jak2 to negatively regulate leptin signalling.   
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The long form of leptin receptor (OB-Rb) can also activate MAPK (Ras-Raf-ERK) signalling 
pathways.  This occurs predominantly via phosphorylation of tyr 985 which provides a docking site 
for SH-2 domain containing phosphatases (SHP2) which mediate downstream signalling that 
results in the expression of target genes such as c-fos.  In addition, the MAPK pathway can be also 
activated by the short form of the leptin receptor (OB-Ra) by a mechanism which occurs 
independently of tyr 985 and involves a direct association of Jak2 with SHP-2.  However, this 
signalling mechanism is not as efficient as the tyr 985 mediated mechanism 
277.  The MAPK 
pathway has been identified in several peripheral tissues.  For example, leptin increases MAPK 
phosphorylation by activation of OB-Rb in both adipose tissue and the liver 
279 and phosphorylated 
MAPK is induced in WAT of mice but not OB-Rb KO mice 
244.  In addition, leptin has been shown 
to activate PPAR’s via an ERK-cPLA2 pathway, whereby phosphorylation of cytosolic 
phospholipase A2 (cPLA2) results in the release of unsaturated FA from membrane phospholipids 
in C2C12 cell, the subsequent activation of PPARα and its increased binding to the PPRE of target 
genes 
285. 
 
Another important signalling pathway mediated by leptin is the PI3K/PDE3B/cAMP pathway.   
Here, via recruiting insulin receptor substrates (IRS), leptin can act through components of the 
insulin signalling pathway to bring about activation of PI3K and downstream protein kinases such 
as PDE3B and GSK3.  Activation of the PI3K/PDE3B/cAMP pathway plays an important role in 
mediating leptins effect to reduce food intake in the hypothalamus.  Leptin signalling of NPY 
occurs by a Stat3 independent pathway, as experiments have found that inhibiting Stat3 signalling 
does not affect NPY expression.  Instead, leptin exerts its negative effects on NPY in the 
hypothalamus by recruitment of IRS2 and activation of PI3K.  Inhibiting PI3K abolished inhibition 
of NPY neurons by leptin and thus inhibition of food intake.  Data indicates this signalling pathway 
also occurs in peripheral tissues.  For example, IRS-1 associated PI3K activity is increased in 
response to leptin in adipose tissue and IRS-2 associated PI3K activity is increased in the liver 
244,279.  Furthermore, in pancreatic β cells PI3K activation of phosphodiesterase 3B (PDE3B), 
resulting in reduced cAMP levels and Protein kinase A (PKA) activation, are thought to be 
involved in leptin mediated reduction of insulin secretion in pancreatic β cells 
120. 
 
Leptin is also known to activate AMPK, a serine threonine kinase which is involved in cellular 
energy homeostasis and whose activity is dependent on the energy status of the cell, as well as 
hormones and growth factors.   This enzyme is activated by allosteric activation by AMP and 
phosphorylation by upstream kinases and its effects are mediated by the phosphorylation of 
downstream targets. This cascade of events results in increased catabolic processes including 
increased fatty acid oxidation and glucose uptake to provide energy for the cell, whilst inhibiting 
anabolic processes.  Leptin has been found to stimulate fatty acid oxidation by activating AMPK in 
skeletal muscle 
286 and this can occur both as a direct effect of leptin on muscle in involving an   216
increase in intracellular AMP concentration, or by centrally mediated sympathetic signalling via 
the α-adrenergic pathway 
286.  
  
It has also been shown using RTPCR and siRNA techniques specific to PPARα that leptin 
mediated AMPK activity has direct transcriptional effects on PPARα in skeletal muscle 
287.  
Subsequently, it was shown in a mouse muscle cell line that leptin activates the AMPK α2-β2-γ1 
subunit which in turn translocates to the nucleus to activate expression of PPARα and therefore its 
target genes to induce fatty acid oxidation 
288.  Furthermore, two nuclear localisation signals were 
identified in the α2 subunit of AMPK 
288.  Researchers postulated that the effects of AMPK 
activation on PPARα gene transcription may be mediated by Sp1 and CRSP (Cofactor Required for 
Sp1 Activation) as there are many Sp1 sites in the PPARα promoter 
288.  CRSp1 is a cofactor 
needed for Sp1 mediated transcriptional initiation by RNA polymerase II.  Researchers showed that 
AMPK activation phosphorylates CRSP and that both Sp1 and CRSP3 RNAi experiments inhibited 
activation of PPARα gene expression by leptin in the C2C12 cells 
288.  Therefore it is possible that 
the effect of leptin on PPARα transcription in adipose tissue is mediated by AMPK to increase fatty 
acid oxidation not only by altering the activity of specific enzymes, but also by affecting PPARα 
transcription.  Indeed, OB-Rb signalling has been shown to increase AMPK activity in adipocytes 
243.  However, leptin mediated AMPK activation does not occur in all tissues.  For example, leptin 
treatment to isolated rat hearts does not involve activation of AMPK, despite activating fatty acid 
oxidation and reducing TAG within heart 
289.   
 
 
6.1.2 Aims 
 
 
In Chapter 4 of this report, results have shown that the expression of several genes involved in 
energy balance is increased in response to neonatal leptin treatment in the adipose tissue adult 
female rats.  It is not yet known how leptin mediates these changes in expression, but evidence 
suggests it may be due to direct peripheral effects of leptin on the adipocyte rather than central 
mechanisms 
232.  To provide a mechanism which could account for the long term effects on gene 
expression, it is proposed that genes altered by neonatal leptin treatment such as PPARα are 
epigenetically altered themselves as a result of the leptin by an unknown mechanism, or that 
upstream signalling mechanisms are persistently altered such as Stat3 mediated leptin signalling, 
resulting in increased target gene expression within adipocytes.   
 
Consequently, there were two principal aims for this chapter; The first aim was to identify the exact 
mechanism by which leptin signalling is able to affect PPARα gene expression and the second to 
determine if the PPARα promoter itself was epigenetically altered as a result of neonatal leptin 
treatment in adipose tissue of adult female offspring from the IUGR rat study.  As literature 
suggests that leptin signalling occurs predominantly by Stat3 in adipocytes to induce lipolysis and   217
that this lipolysis requires OB-Rb 
280, Stat3 
281 and PPARα 
239 to occur, the first question was 
addressed by employing a reporter gene approach to investigate Stat3 signalling of the alternative 
PPARα promoters and secondly, methylation of individual CpGs within the PPARα promoter was 
investigated using a gold standard of DNA methylation assessment, pyrosequencing.   
 
Data presented in this chapter identifies the mechanism by which leptin signalling acts on the 
PPARα promoter.  It also characterises the methylation status of a significant region of the PPARα 
promoter in adipose tissue from control and leptin treated offspring of the IUGR rat study.     218
6.2 Results 
 
6.2.1  The P1 and P2 PPARα promoters respond differently to leptin treatment in HepG2 
cells  
 
It has previously been shown that PPARα gene expression is induced by leptin 
232,239.  In addition, 
as shown in Chapter 4, neonatal leptin treatment in rats may induce long term alterations in PPARα 
expression in adipose tissue.  To investigate the activity of the alternative PPARα promoters in 
response to leptin, the PPARα-pGL3 luciferase reporter constructs (P1, P2 and P3) were transfected 
into HepG2 cells and subjected to treatment for 24 hours with a concentration gradient of leptin.  In 
addition, the promoter-free pGL3 basic vector was transfected as a control.  The responses of the 
promoters P1-3 to leptin treatment are shown in figure 6.2.    
 
Results showed that the pGL3 basic vector which contains no promoter or enhancer sequences was 
inactive and did not respond to leptin treatment.  In addition, the P3-pGL3 construct was also 
inactive in this experiment and unresponsive to treatment, with levels consistently similar to that of 
the pGL3-Basic control.  There was therefore no effect of leptin treatment on the activity of the 
control or P3 promoter region analysed in this experiment.   
 
As shown previously, the P1 and P2 promoters were active in HepG2 cells.  However, leptin 
treatment was only able to increase activity of the P2 promoter.  Leptin increased activity of the P2-
pGL3 construct from 45.44 in untreated cells to 99.00 at a concentration of 500ng/µl (p=0.001) and 
to 125.45 at a concentration of 1000ng/ml (p=0.001).  There was a drop in activity of the P1 
promoter from 41.45 in untreated cells, to 22.62 at a concentration of 100ng/ml (p=0.05).  There 
were no other changes in P1 activity in response to leptin treatment.  So as seen with CFA, leptin 
treatment was able to increase the activity of the P2 construct but not that of the P1 construct.  
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Figure 6.2  Leptin activates the PPARα P2 promoter, but not the P1 or P3 promoters in 
HepG2 cells.  Activities of the alternative PPARα promoters (P1, P2 and P3) and control (pGL3 
Basic empty vector) are shown in response to increasing concentrations of the adipokine leptin 
(n=3).  *p<0.01, *** p<0.001 relative to untreated (0ng/ml) (Bonferroni’s Test). 
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6.2.2  The expression of the PPARα P2 specific transcript but not the P1 specific transcript 
is significantly altered by neonatal leptin treatment in the adipose tissue of adult 
female offspring from the IUGR rat study 
 
Work in chapter 4 showed that neonatal leptin treatment increased PPARα expression in the 
adipose tissue of female offspring from the IUGR rat study.  In order to ascertain if this increase in 
PPARα expression was due to alterations in expression of the adipose specific transcript (P1), real 
time PCR was performed with validated gene specific primers specific to the P1 and P2 PPARα 
transcripts using cDNA from adipose tissue of female offspring.  Resulting gene expression data 
were normalised to 18s cDNA and analysed by the ΔCT method 
228.  Results were converted to % 
of the control group (AD Chow 100%) and a 1 way ANOVA performed, followed by Bonferroni’s 
post hoc test.  Graphs showing differences in mRNA expression for both the P1 and P2 transcripts 
with statistical analysis can be found in figure 6.3.  All results are described relative to the control 
group only.  In addition, a 3 way ANOVA was performed to analyse single factor and interaction 
effects on gene expression.  The results of the 3 way ANOVA are shown in table 6.1. 
 
Results showed that there were no significant differences in mRNA expression between the control 
(AD Chow) and UN offspring or between control offspring and offspring fed high fat diet (AD or 
UN) for either the P1 transcript or the P2 specific transcript. There was therefore no effect of 
maternal diet or postnatal diet on the expression of the P1 or P2 PPARα transcripts in the adipose 
tissue of female offspring.  In addition, there was no effect of neonatal leptin treatment on the 
expression of P1 transcript (figure 6.3a).  Therefore the P1 transcript was unaltered in all treatment 
groups.   
 
Conversely, expression of the P2 specific transcript was increased in leptin treated offspring fed a 
chow diet from both AD dams (216.8% p=0.01) and UN dams (221.6% p=0.05) (figure 6.3b).   In 
addition to this, its expression was increased in leptin treated offspring fed a high fat diet from AD 
dams (216.6% p=0.001) and UN dams (218.4% p=0.001).  Therefore expression of the P2 specific 
PPARα transcript was increased in all leptin treated offspring.  These data indicate that the P2 
specific transcript is likely to be responsible for the changes in PPARα expression seen in Chapter 
4.  
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Figure 6.3  The expression of the P1 and P2 PPARα transcripts is not significantly altered 
by maternal diet or postnatal diet in the adipose tissue of adult female offspring.  The 
expression of the PPARα P2 specific transcript but not the P1 specific transcript is 
significantly altered by neonatal leptin treatment.  Real time PCR data for expression of PPARα 
P1 Transcript (A) and PPARα P2 Transcript (B) are shown in response to maternal diet (ad libitum 
[AD] and undernutrition [UN]), postnatal diet (Chow [C] and High Fat [HF]) and neonatal leptin 
treatment (Leptin [L]) (n=8/group). Values with different letters are significantly different (p<0.05) 
by Bonferroni’s post hoc test.  
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Table 6.1  Table showing tests of between subject effects on the mRNA expression of 
PPARα P1 and P2 in the adipose tissue of female offspring.  Single factor effects (MD, T, PND) 
and interaction effects (MD*T, MD*PND, T*PND, MD*T*PND) are shown.   Significant effects 
(P<0.05) are indicated in red.  There were no significant single factor or interaction effects for P1.  
There was a single factor effect for P2 (T).  There were no interaction effects for P2.  
 
 
Variable 
 
 
Anova 
 
Maternal 
Diet 
(MD) 
 
Treatment 
(T) 
 
Postnatal 
Diet 
(PND) 
 
MD*
T 
 
MD* 
PND 
 
T* 
PND 
 
MD*
T* 
PND 
 
 
P1 
P2 
 
 
0.991 
0.000 
 
0.716 
0.532 
 
 
0.772 
0.000 
 
0.859 
0.802 
 
0.561 
0.389 
 
0.504 
0.144 
 
0.991 
0.901 
 
0.853 
0.175 
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6.2.3  MatInspector analysis of the unique region of the liver specific P2 PPARα promoter 
indicates an absence of Stat3 binding elements but the presence of a potential Sp1 
binding site 
 
In order to determine potential areas of importance for regulation of PPARα transcription by leptin, 
the unique region of the P2 promoter, i.e. that which is not present in the P1 promoter and therefore 
responded to leptin treatment, was analysed for response elements which could mediate leptin 
signaling.  This sequence had previously been analysed in chapter 5 by the MatInspector program 
264 for core promoter elements and transcription factor binding sites and this is shown just for the 
unique figure 6.4.  Only core promoter elements or relevant transcription factor binding sites with 
the maximum core similarity of 1.0 are shown, i.e. the highest conserved bases of a response 
element match the sequence exactly.   
 
MatInspector did not identify any Stat3 binding elements (SBE) within the defined promoter 
regions.  Several putative transcription factor binding sites were identified by the MatInspector 
software in the unique region of the P2 promoter; VDR/RXR, Sp1, 2 Myc/Max and E2F/DP1, 
whilst 3 possible core promoter elements were identified; XCPE1, BRE and MTE.  As identified in 
chapter 5, the core promoter elements are not located in their normal positions relative to TSS.  The 
only response element present known to signal the effects of leptin is the Sp1 consensus: 5'-
(G/T)GGGCGG(G/A)(G/A)(C/T)-3'.  As reports have previously shown that Stat3 can activate 
promoters via a Stat3/Sp1 cooperative mechanism 
282,283, this analysis indicates that the P2 
promoter may respond to leptin treatment via interaction of Stat3 with Sp1 at a site located in the 
unique region of the P2 promoter.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
     
    
   
                                                                                 VDR/RXR 1.000, 0.897 (+) Sp1 1.000,0.96
  224
3 (+)     GGCCCTGCGGACCCGCAGGCGGAGCGCAGCCTCAGGTGCCCAGGGGCGGGAGGGCACG  
                             MTE 1.000, 0.803 (+)                      MYC/MAX 1.000, 0.921 (+) 
                                                                 XCPE1 1.000, 0.879 (+) 
                                                              E2F1/DP1 1.000, 0.825 (+)           
 
    CGCGAGGACGGGAGCCAGGCGTCCCCCGTCCCGGGACAGTGAGGTGGGTGGACAGGGA 
   
   
                                                                      MYC/MAX 1.000, 0.926 (-)                                    +1 P2 
 GGGGAGGGGCTCGGTGGCGCATGCGCGTGGACCAGGGGCGCGGGTCTGGAGACCCACA   
                                    BRE 1.000, 1.000 (-)       
   
   GCCACTGGCGAGGGCAC                                                        
                                                                                                                                                        
   
 
 
 
 
 
Figure  6.4  The sequence of the “unique” region of the P2 promoter indicating the 
location of potential core promoter elements and transcription factor binding sites.  The 
sequence of the unique region of the P2 cloned promoter region is shown.  The region unique to the 
P2 promoter is shown in blue text and the P2 transcription start site is indicated in pink.  TF 
binding sites and core promoter elements are underlined.  The Sp1 binding site is highlighted red 
and core promoter elements in yellow.  All sites are scored and marked with the strand they are 
located on (+ or -).  The core similarity of the sequence is the first number. The maximum core 
similarity of 1.0 is only reached when the highest conserved bases of a matrix match exactly in the 
sequence and only those sites with a score of 1.0 are shown.  The second figure is the matrix 
similarity which takes into account all bases over the whole matrix length.  A perfect match has a 
score of 1.00 and a "good" match has a score of >0.80.  Perfect sequences are highlighted in purple. 
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6.2.4  A highly potent Stat3 inhibitor prevents activation of the liver specific P2 PPARα 
promoter by leptin 
 
To verify that leptin activation of the P2 promoter is via a Stat3 signalling mechanism, a highly 
selective, potent Stat3 inhibitor (PpYLKTK-mts) was employed in transfections to inhibit 
signalling specific to Stat3.  To investigate the P2 promoter response to leptin in conjunction with 
Stat3 inhibitor, the P2-pGL3 luciferase reporter construct was transfected into HepG2 cells and 
subjected to treatment for 24 hours with 1000ng/ml leptin in the presence and absence of the Stat3 
inhibitor.  In addition, the P1 promoter which previously did not increase in activity in response to 
leptin treatment and the promoter-free pGL3 basic vector were transfected as controls.  The 
response of the promoters to leptin and Stat3 inhibitor treatments are shown in figure 6.5. 
 
Results indicated that the control pGL3 basic vector was inactive in HepG2 cells and did not 
respond to treatment with leptin or Stat3 inhibitor.  As previously shown, leptin treatment 
significantly increased P2 activity from 50.39 in untreated cells, to 121.87 in leptin treated cells 
(P=0.01) and this activity increased to 170.86 (P=0.001) with 1nM Stat3 inhibitor alongside the 
leptin treatment (figure 6.5).  There was no significant difference in P2 activity in leptin treated 
cells with a Stat3 inhibitor concentration of 10nM, 100nM, 1µM or 10µM when compared to 
untreated cells.  Consistent with previous results, leptin treatment did not increase activity of the P1 
promoter.  When Stat3 inhibitor was given in addition to the leptin treatment, there was again no 
significant difference in P1 promoter activity, except at a concentration of 100nM, whereby activity 
was reduced from 73.37 in untreated cells to 23.89 (P=0.05).  These data indicate that the Stat3 
inhibitor can specifically prevent activation of the P2 promoter by leptin at concentrations of 10nM 
or higher.  
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Figure 6.5  Stat3 inhibitor specifically prevents the activation of the PPARα P2 promoter 
by leptin.   Activities of the alternative PPARα promoters (P1 and P2) and control (pGL3 Basic 
empty vector) are shown in response to 1000ng/ml leptin treatment (L) ± increasing concentrations 
of a Stat3 inhibitor (S3I) (n=3).  *p<0.05, ** p<0.001, *** p<0.001 relative to untreated 
(Bonferoni’s Test). 
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6.2.5  Mutation of the Sp1 response element present within the unique region of the liver 
specific P2 PPARα promoter prevents its activation by leptin 
  
To determine if the Sp1 site within the unique region of the P2 promoter is involved in Stat3 
mediated leptin signalling (figure 6.6a), promoter mutants were prepared in which the Sp1 response 
element was mutated to prevent Sp1 binding (P2 Sp1M-AT and P2 Sp1M-R1).  For the Sp1M-AT 
mutant the internal GC was mutated to AT, whilst for the R1 mutant the whole consensus sequence 
was converted to an EcoR1 restriction site (GAATTC).  To investigate the activity of the mutant P2 
promoters in response to leptin treatment, the promoter constructs P2 Sp1M-AT, P2 Sp1M-R1 and 
the wildtype P2-pGL3 construct were transfected into HepG2 cells subjected to treatment for 24 
hours with 1000ng/ml leptin.   The response of the promoters to leptin treatment is shown in figure 
6.6. 
 
Activity of the wildtype P2 promoter increased in response to 1000ng/ml leptin treatment to 241% 
compared to untreated cells.  Although this was a clear increase in P2 activity, it did not reach 
significance as found in previous experiments.  Similarly, activity of the P2 Sp1M-AT mutant 
increased to 294% in cells treated with 1000ng/ml leptin compared to untreated, but again, this did 
not reach significance.  However, activity of the P2 Sp1M-R1 mutant promoter did not increase 
with 1000ng/ml leptin treatment and instead there was a small drop in activity to 73% of the 
activity of untreated cells.  Although none of the results reached significance, the clear trends 
indicate that the P2 Sp1M-R1 mutant could prevent activation of the P2 promoter by leptin, 
whereas  the AT mutant was unable to prevent activation of the PPARα P2 promoter by leptin. 
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Figure 6.6  Mutation of the Sp1 response element present in the unique region of the liver 
specific P2 PPARα promoter prevents its activation by leptin.  (A) The unique region of the P2 
promoter contains an Sp1 site which could potentially by involved in the leptin mediated activation 
of this promoter.  (B)  Activities of the P2 PPARα promoter, the mutant Sp1M-AT and the Sp1M-
RI P2 promoter ± 1000ng/ml leptin treatment are shown (n=3).     229
6.2.6  Methylation of the P1 and P2 PPARα luciferase promoter constructs abolishes all 
promoter activity 
 
To determine if any of the PPARα promoter constructs are sensitive to CpG methylation, the P1-
pGL3, P2-pGL3, P3-pGL3 and the pGL3 Basic control constructs were all methylated with HpaII 
methylase and CpG methylase.  In addition, all the promoter constructs were mock methylated as a 
control.  To investigate the effect of methylation on the activity of these promoter constructs, they 
were transfected into HepG2 cells and their activity assessed.  The response of the promoters to 
each form of methylation is shown in figure 6.7. 
 
Results showed that the pGL3 basic vector, which contains no promoter or enhancer sequences, 
was inactive and not significantly affected by either CpG or HpaII methylation.  In addition, the 
P3-pGL3 construct was also inactive and unresponsive to both CpG and HpaII methylation, with 
levels consistently similar to that of the pGL3-Basic control.  There was therefore no effect of 
methylation on the activity of the control or P3 promoter in HepG2 cells.  Mock methylation did 
not significantly affect the activity of any of the promoter constructs.   
 
The P1 and P2 promoters were both active in HepG2 cells.  In addition, the activity of both the P1-
pGL3 and P2-pGL3 promoter constructs was completely abolished by both HpaII and CpG 
methylase treatment (figure 6.7).  HpaII methylation resulted in the methylation of 11 CpGs in the 
P1 promoter and 12 CpGs in the P2 promoter.  HpaII methylase decreased activity of the P1-pGL3 
construct from 58.9 in untreated cells to 0.81 (p=0.001), whilst it decreased the activity of P2-pGL3 
from 67.46 in untreated cells to 2.49 (p=0.001).  CpG methylation resulted in methylation of 98 
CpGs in the P1 promoter and 114 CpGs in the P2 promoter.  CpG methylase decreased activity of 
the P2-pGL3 construct from 67.46 in untreated cells to 0.62 (p=0.001), whilst it decreased the 
activity of P1-pGL3 from 58.9 in untreated cells to 0.64 (p=0.001).  Therefore, both the P2 and P1 
promoters were highly sensitive to methylation.  
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Figure  6.7  Methylation of the P1 and P2 PPARα promoter constructs by HpaII 
methylase and CpG methylase prevents all promoter activity.  Activities of the alternative 
PPARα promoters (P1-pGL3 and P2-pGL3 and P3-pGL3) and control (pGL3-basic) are shown in 
response to methylation with CpG methylase and HpaII methylase (n=3).  *** p<0.001 relative to 
unmethylated (Bonferroni’s Test). 
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6.2.7  Pyrosequencing analysis of 30 CpGs within the proximal CpG island of the PPARα 
P2 promoter in adipose tissue of adult female offspring fed a high fat diet indicates 
that all CpGs are unmethylated and unaltered by neonatal leptin treatment 
 
In order to ascertain if the methylation status of individual CpGs within the P2 promoter were 
modified in response to neonatal leptin treatment in the adipose tissue of adult female offspring 
from the IUGR rat study, pyrosequencing was performed using genomic DNA extracted from 
adipose tissue of AD offspring fed a HF diet given either saline or leptin treatment (n=8 / diet-
treatment group).  Pyrosequencing was performed with validated bisulfite PCR and sequencing 
primers using bisulfite converted genomic DNA as a template.  Due to technical limitations, the 
whole of the promoter could not be optimised for pyrosequencing.  The area of the PPARα 
promoter successfully pyrosequenced was within the CpG island and MSP region upstream of the 
P2 transcription start site (TSS) and included the CpG within the Sp1 response element in the P2 
unique region (figure 6.8).  Bisulfite treatment controls were included in the pyrosequencing assay 
design and the allowed percentage of unconverted bisulfite DNA for passed quality was set at the 
standard 4.5%.  Resulting methylation data were analysed by the students unpaired T-test.  Graphs 
showing differences in methylation for individual CpGs within the PPARα promoter with statistical 
analysis can be found in figures 6.9-6.10.   
 
Analysis of PPARα methylation by pyrosequencing indicated that methylation of the PPARα 
promoter was low throughout the two amplicons, with all CpGs possessing methylation levels 
below 10%, regardless of treatment.  As the bisulfite conversion threshold was set at 4.5%, any 
CpGs which had methylation levels below this were too low to be measured reliably by this 
technique.  Therefore, for this reason, although methylation was significantly affected by neonatal 
leptin treatment for several CpGs (CpG 7, 11, 12, 17), as all these were below the bisulfite 
conversion threshold they were not reliable data.  Furthermore, all the remaining CpGs with 
methylation levels above the threshold showed no significant alterations in methylation in response 
to neonatal leptin treatment.   
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Figure 6.8  Location of the PPARα pyrosequencing region relative to P1 and P2 TSS, 
unique region of P2 promoter, MSP region and CpG islands.   The PPARα pyrosequencing 
region is upstream of the P2 TSS within the PPARα MSP region and includes the Sp1 site present 
in the unique region of the P2 promoter.  
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Figure  6.9  Pyrosequencing analysis Of CpGs 1-18 within the PPARα promoter in 
adipose tissue of adult female offspring fed a high fat diet confirms that all CpGs are 
unmethylated in offspring given both saline or leptin treatment.  Pyrosequencing data showing 
mean % methylation levels ± SD for CpGs 1-9 (A) and 10-18 (B) of the PPARα promoter are 
shown offspring from ad libitum High fat [AD HF] offspring given either saline or leptin treatment 
(n=8/group).  *p<0.05  **p<0.01 (Students unpaired T-Test). 
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Figure  6.10    Pyrosequencing analysis of CpGs 19-30 within the PPARα promoter in 
adipose tissue of adult female offspring fed a high fat diet confirms that all CpGs are 
unmethylated in offspring given both saline or leptin treatment.  Pyrosequencing data showing 
mean % methylation levels ± SD for CpGs 19-30 of the PPARα promoter are shown offspring from 
ad libitum High fat [AD HF] offspring given either saline or leptin treatment (n=8/group). 
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6.3 Discussion 
 
In an established rat model of programming, IUGR offspring fed a high fat diet become obese and 
present with metabolic disturbances in adult life, including hyperphagia, hyperleptinemia and 
hyperinsulinism.  Giving these offspring leptin treatment during a critical period of neonatal 
development has been shown to prevent the weight gain and associated disturbances found in these 
adult offspring 
122.  This indicates that the early leptin treatment facilitates a reprogramming of 
energy balance, which results in a reduced capacity to store fat within adipocytes throughout life.  
Mechanisms by which the neonatal leptin treatment may influence the capacity to store fat may be 
mediated centrally, e.g. by reduced feeding, but it is also possible that the leptin may act directly on 
peripheral tissues to mediate its effects on bodyweight.  This hypothesis is supported by the finding 
that disruption of leptin receptor signalling on adipocytes results in increased fat mass in mice 
when fed a high fat diet despite normal hypothalamic leptin signalling 
244.  Furthermore, in adult 
rats leptin can induce a novel form of lipolysis in which rats are depleted of all visible body fat and 
this has been shown to occur via direct action of leptin on the adipocyte 
232.  These studies both 
indicate that adipose specific leptin signalling plays an important role in leptins ability to reduce 
body fat.   
 
Work in Chapter 4 of this report has shown that neonatal leptin treatment results in persistent 
alterations in the expression of genes involved with energy balance in the adipose tissue of adult 
female rats, including an increase in the expression of leptin Receptor, PPARα and it target genes 
CPT-1 and AOX.  Upregulated leptin receptor indicates that increased leptin signalling may be 
responsible for these gene expression changes.   In addition, as PPARα and its target genes are not 
normally expressed in adipose tissue, this increased expression may play a fundamental role in the 
reduced weight gain observed in these rodents.  It was therefore hypothesised that in the IUGR rat 
study, the neonatal leptin treatment may have acted directly on the adipocytes to influence the 
expression of genes involved in energy balance such that reduced TAG storage took place.   
However, for this hypothesis to be valid, the leptin treatment must have acted in a manner to 
persistently increase the expression of such genes.  Such an effect could involve the epigenetic 
modification of the gene promoters, for example DNA methylation.  Evidence exists that PPAR’s 
including PPARα are sensitive to methylation changes during development brought on by altered 
maternal nutrition 
77,212.  It is therefore possible that the transcription factors themselves may be 
altered in response to the neonatal leptin treatment.   
 
It remains to be determined if epigenetic alterations are responsible for the changes in PPARα 
expression, or if altered leptin receptor signalling is responsible.  Furthermore, the exact 
mechanisms of the regulation of PPARα transcription by leptin are unknown.  The aim of this 
chapter was therefore to elucidate the mechanism by which leptin is able to increase the expression 
of PPARα and to determine if alterations in DNA methylation of the PPARα promoter explain how   236
the effects persist through to adulthood.  To address these questions a reporter gene strategy was 
employed to study the regulation of PPARα by leptin and Pyrosequencing was performed to assess 
the methylation status of the PPARα promoter.  
 
Work in this Chapter showed that the alternative PPARα promoters differed in their response to 
leptin treatment in vitro and were also shown to be differentially regulated by neonatal leptin 
treatment in vivo.  The mechanism underlying the regulation of PPARα promoter by leptin was 
investigated and was found to function via a non-canonical mechanism which involved Sp1.   
Furthermore, the PPARα promoter was shown to be sensitive to methylation in vitro, but in 
offspring from the IUGR rat study a significant region of the PPARα promoter was shown to be 
unmethylated in both control and leptin treated offspring. 
 
It is known that leptin treatment can increase the expression of PPARα.  For example, it has been 
shown in Chapter 4 that neonatal leptin treatment results in increased PPARα expression in the 
adipose tissue of adult offspring, whilst leptin treatment to differentiating 3T3 adipocytes also 
increased PPARa expression.  The exact mechanisms and location of response elements 
responsible for this activation of PPARα by leptin are not known.  To determine how leptin is able 
to alter PPARα promoter activity, a reporter gene strategy was performed using the liver specific 
(P2 and P3) and adipose specific (P1) PPARα promoters.   
 
Interestingly, the response of the adipose specific (P1) and liver specific (P2) promoters to leptin 
differed.   As expected, leptin treatments activated PPARα transcription in a dose dependent 
fashion, but only of the P2 specific promoter, whereas activity of the P1 promoter remained 
unchanged.  As the P2 promoter is identical to the P1 promoter apart from an additional 170bp at 
the 3’ end, response elements responsible for leptin activation of the P2 promoter must be present 
in this unique region.  Furthermore, the pharmacological amount of leptin required to activate 
PPARα promoter activity is consistent with the high amounts needed to induce fatty acid oxidation 
in adipocytes of adult rats and also with the levels given to neonate rats to reverse programming.  
To confirm that this effect of leptin is direct, cyclohexamide could be employed in transfections.  
Furthermore the use of Actinomycin D, which prevents transcriptional elongation, could be used to 
confirm that leptins effects are at the transcriptional level.   
 
Next, the mechanism by which leptin treatment affects PPARα promoter activity was investigated.  
Studies have indicated that leptin can induce a variety of signalling mechanisms in adipose tissue to 
alter target gene expression, including Jak/Stat signaling 
121,244,279-281, MAPK signaling 
244,279 and 
AMPK signaling 
243.  It was therefore possible that several signalling mechanisms could be 
involved in activating PPARα transcription, although evidence suggests that Stat3 is the most likely 
mechanism to activate PPARα expression as a result of leptin mediated lipolysis 
239.  It was   237
therefore possible that in the IUGR rats, leptin mediated Stat3 signalling was responsible for the 
proposed lipolysis occurring in the adipose tissue.  
 
To determine if leptin was able to affect PPARα transcription by Stat3 signaling, the unique region 
of the P2 promoter sequence was initially searched for Stat3 binding elements (SBE).  However, 
upon inspection of the unique region of this promoter, no SBE were identified.   However, several 
papers have identified a novel transcriptional activation mechanism for leptin Stat3 in SBE free 
promoters, whereby Stat3 has been shown to function cooperatively with Sp1 to activate 
transcription without itself binding to DNA, i.e. by a Stat3/Sp1 cooperative mechanism 
282,283.  
Given these data, it was hypothesised this could be the case for PPARα as its promoter is very GC 
rich and indeed MatInspector analysis identified a Sp1 response element within the P2 promoter 
unique region.  So it was proposed that leptin activates the liver PPARα P2 promoter via a non-
canonical co-operative Stat3-Sp1 mechanism. 
 
Firstly, the role of Stat3 in PPARα signaling was assessed by employing a Stat3 inhibitor in 
transfections.  If Stat3 was involved in leptin signaling of PPARα, then Stat3 inhibitors should 
abolish the effect of leptin treatment.  Indeed, results indicated that a specific Stat3 inhibitor at low 
concentrations prevented activation of the P2 promoter by leptin, indicating that Stat3 signaling 
was involved in PPARα transcription despite the lack of a SBE in the unique promoter region.   
 
To determine whether the Sp1 consensus sequence within the P2 unique region was directly 
involved in the activation of PPARα promoter by Stat3 signaling, it was subjected to site directed 
mutagenesis to prevent any Sp1 binding to DNA, therefore preventing any Stat3 mediated 
activation of the promoter.  Mutation of the internal GC of the Sp1 site to AT did not prevent 
activation by leptin.  However, a more severe mutation of the Sp1 site to an EcoRI restriction site 
prevented activation of the PPARα P2 promoter by leptin, indicating that this site could be 
involved in Stat3 mediated leptin signaling.  By mutating this site, the binding of several 
transcription factors predicted to bind by MatInspector could also be affected, but as the Stat3 
inhibitor prevented activation by leptin, in conjunction with previous findings of Sp1 to mediate 
Stat3 activation 
282-284, it is probable that that Sp1 is the transcription factor involved.  Collectively, 
these two results indicate that leptin induces PPARα gene expression by Stat3 signaling 
mechanisms which act at the unique region of the PPARα P2 promoter via a non-canonical Sp1 
mediated mechanism.   
 
To absolutely confirm the role of Sp1 in Stat3 mediated leptin signaling, additional work could be 
performed.  This should firstly confirm the role of Sp1, such as the use of Sp1 RNAi to verify its 
role in activation of PPARα transcription.  More importantly, Stat3/Sp1 protein/DNA binding 
needs to be demonstrated upon activation by leptin.  This could be verified by two complementary 
methods; firstly by electromobility shift assay (EMSA) to show that Stat3/Sp1 binds the unique   238
region of the PPARα promoter in leptin treated cells and secondly performing a transient ChIP 
using Sp1/Stat3 antibodies to show binding at promoter upon leptin activation.  Furthermore, co-
immunoprecipitation could show physical interaction between the two proteins. 
 
Despite the finding that Stat3 is involved in leptin activation of PPARα, other signaling 
mechanisms cannot be ruled out, in particular AMPK, which has been found to induce PPARα 
transcription in skeletal muscle 
287,288.  It is therefore possible that this signaling mechanism could 
occur in adipose tissue.  It was suggested that AMPK induces PPARα expression via Sp1 
288, 
however, the finding that Stat3 inhibitor prevents activation of the PPARα promoter in this chapter 
argues against AMPK activation of PPARα.  Furthermore, it has been shown that hyperleptinemia 
induced in adult mice to reduce fat mass does not alter AMPK activity in adipose tissue 
239.  
Another potential mechanism is MAPK signaling, which has been found in response to leptin in 
adipose tissue 
244,279.  However no response elements which could mediate the effects of this 
signaling cascade, such as AP1, were identified in the unique region of the P2 promoter. 
 
Work in Chapter 4 found that the expression of PPARα is up-regulated in the adipose tissue of 
adult offspring given neonatal leptin treatment.  As PPARα has been shown to have tissue specific 
transcripts resulting from alternative promoter usage, it was hypothesised that the increase in 
PPARα expression seen in these leptin treated offspring would be due to an increase in the adipose 
specific transcript, P1.  However, real time PCR with transcript specific primers showed that the 
increase in PPARα expression in these offspring was not due to an increase in the adipose specific 
P1 transcript, but due to an increase in the liver specific P2 transcript.  It would have been 
interesting to determine if the liver specific P3 transcript was also up-regulated by neonatal leptin 
treatment, however RT-PCR primers could not be designed in the novel exon 2a.  Expression of the 
remaining heart and kidney specific transcripts was not performed as they were identified at the 
end of the study.   
 
These experiments have therefore shown that the effects of leptin treatment are the same in vitro as 
in vivo, i.e. leptin can activate PPARα gene transcription, but only via the liver specific P2 
promoter.  These results imply that neonatal leptin treatment during a period of adipose tissue 
plasticity somehow facilitates a switch from the unresponsive adipose specific P1 promoter to the 
responsive liver specific P2 promoter, thereby facilitating an increase in PPARα gene expression in 
a tissue in which it is not normally expressed.    
 
Persistent alterations in gene expression can be explained by epigenetic mechanisms such as altered 
DNA methylation.  In general, hypomethylation can result in increased gene expression, whilst 
hypermethylation can lead to reduced gene expression.  Therefore, one mechanism which may 
explain the long term increase in PPARα gene expression in response to neonatal leptin treatment is 
a reduction in the methylation status of its promoter.  Altered methylation of the PPARa promoter   239
activity in response to nutritional status is not a novel concept, as it has previously been found to be 
altered in response to maternal nutrition in PR rats 
77,212.  Of particular interest is the methylation 
status of the Sp1 response element in the PPARa promoter which is involved in directing 
transcription of the liver specific P2 promoter by Stat3 mediated leptin signaling, as the binding of 
Sp1 sites to its response element have previously been shown to be sensitive to DNA methylation 
194,195.  Furthermore, it has been shown that methylation of a single CpG just upstream of Sp1 site 
involved in Stat3 mediated POMC signaling is altered in DIO, facilitating reduced expression of 
POMC in response to leptin 
185.  Therefore, it was hypothesised that leptin treatment may result in 
reduced methylation of the CpG within the Sp1 site in the unique region of the P2 promoter, 
facilitating the potential for increased P2 PPARα expression when stimulated.   
 
In Chapter 4 of this report, the use of MSP to investigate methylation of the PPARa promoter in the 
IUGR offspring failed to show any differences in DNA methylation between treatment groups.  
However, this technique is a crude measure of methylation status and areas of methylation are 
masked by unmethylated CpGs.  This is important, because evidence indicates that alterations in 
DNA methylation as a result of environmental stress during development such as altered nutrition 
tend to be specific to certain CpGs rather than a broad effect on methylation 
208,212 and would 
therefore be missed by MSP.  More sensitive methods exist that can measure methylation of a 
single CpG, such as pyrosequencing, a sequencing by synthesis technology which relies on the 
ability of bisulfite treatment to differentiate between methylated and unmethylated cytosine.   
 
Firstly, to determine if the PPARα promoter itself is sensitive to alterations in DNA methylation, 
the tissue specific promoters were chemically methylated and used in a reporter gene experiments.  
As expected, these experiments unequivocally showed that both P1 and P2 PPAR promoter activity 
is sensitive to methylation of CpGs within their promoters.  Next, the methylation status of 
individual CpGs within the PPARα promoter were assessed in response to leptin treatment in AD 
offspring fed a HF diet.  The original intention was to pyrosequence as much of the PPARa 
promoter as possible.  However, due to the considerable GC nature of the promoter, the region 
which could be sequenced was limited to the area previously analysed by MSP, but contained the 
CpG of interest within the Sp1 response element.  However, pyrosequencing of both control and 
leptin treated offspring indicated that for all the CpGs measured, methylation levels were generally 
low and although leptin treatment did result in reduced methylation at some CpGs, any differences 
in methylation were not significant.  However, it is quite possible that within the cell populations, 
the CpGs in some individual cells may have been methylated and alterations in the methylation of 
these CpGs by leptin treatment may have induced larger alterations in gene transcription. 
 
Therefore all epigenetic studies performed on the PPARα promoter in this report indicate that 
alterations in the DNA methylation of this particular region of the PPARa promoter does not 
underlie the persistent increase in PPARa expression found in leptin treated offspring.  However, it   240
cannot be ruled out that methylation of downstream CpGs could affect Sp1 binding and therefore 
activation of the P2 promoter, but unfortunately initial attempts to pyrosequence this region were 
unsuccessful.  However, it is also possible that the long term changes in PPARα gene expression 
may be due to altered signalling upstream of PPARα, for example altered leptin receptor signalling 
on the adipocytes.  Future work should therefore involve pyrosequencing the leptin receptor to look 
at its methylation status in response to leptin treatment. 
 
In addition, it would also be interesting to determine if Polycomb group (PcG) proteins could be 
involved in expression of PPARα in adipose tissue.  Components of the PcG complex are able to 
direct methylation of lysine 27 of histone 3, thus inducing a repressive state without the need for 
DNA methylation 
191 and have been shown to be involved in both genomic imprinting and X 
chromosome inactivation 
161.  This repression is reversible and therefore in the context of the IUGR 
rats, it is possible that neonatal leptin treatment somehow causes a loss of PcG repression, 
facilitating an increase in PPARα expression.  Furthermore, the removal of PcG repression could 
account for the switch in promoter usage in adipose tissue if the repression was associated with the 
liver P2 promoter.  The participation of PcG in PPARα transcription could be determined by 
performing a CHiP directed at methylated H3 K27 in the leptin treated and the control offspring.   
 
The possible role of PcG proteins is further supported by the fact that PcG proteins tend to bind the 
promoters of genes encoding transcription factors, in particular those involved with development.  
Loss of PcG regulation of the PPARa promoter could therefore provide an epigenetic mechanism 
which could account for the maintenance of increased gene expression over time and cell divisions 
despite the absence of the initial stimulator, i.e. leptin.   
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7.0 Discussion 
 
Over the past 20 years, evidence has accumulated from both human epidemiological data and 
animal studies, linking an adverse prenatal environment due to factors such as poor maternal 
nutrition, with an increased risk of disease in later life, including; obesity, insulin resistance, 
dyslipidemia and hypertension.  Molecular studies have linked these altered adult phenotypes to 
persistent alterations in the expression and methylation of genes involved in key metabolic 
pathways, such as the transcription factors GR and PPARα.  One study which employs a well 
established rat model of global undernutrition, the IUGR rat, results in offspring which are obese 
with associated metabolic disturbances including hyperphagia, reduced locomotor activity, 
hyperinsulinemia and hyperleptinemia.  Intriguingly, it has been found that neonatal leptin 
treatment can normalise all these disturbances and reduce the excessive weight gain seen in these 
adult offspring.  
 
Work in this study has focused on two key areas.  Firstly, using the IUGR rat model, this study 
investigated the expression and DNA methylation status of genes involved in energy balance in the 
liver and adipose tissue of offspring in response to maternal nutrition, postnatal nutrition and 
neonatal leptin treatment.  Secondly, given the history of altered epigenetic regulation of PPARα in 
programmed offspring and its central role in fatty acid metabolism, this study also mapped, cloned 
and characterised the PPARα promoter and investigated its regulation by leptin. 
 
 
7.1  Summary of main findings 
 
Results from this study revealed that there were no effects of maternal undernutrition or postnatal 
nutrition on the expression of several key genes involved in energy balance in the liver or adipose 
tissue.  Contrastingly, neonatal leptin treatment was able to induce persistent changes to the 
expression of these key genes in adipose tissue, including the transcription factors PPARα, PPARγ 
and their target genes.  However, there was no evidence of altered DNA methylation in the 
promoters of these genes, therefore differential DNA methylation in the measured regions did not 
underpin the long term effects induced by leptin treatment.  
 
The rat PPARα promoter was mapped, cloned and characterised in order to investigate its 
regulation by leptin.  As part of this process, six PPARα mRNA variants were identified, which 
differed in their 5’UTR due to differential promoter usage and transcription start sites. The 5’UTR 
of the six transcripts were shown to differ in their structure, length, GC content, free folding energy 
and presence of uATG and uORF, indicating that they may differ in both their transcriptional and 
translational regulation, thus allowing PPARα regulation to be more versatile.  Of these transcripts, 
one transcript was identified in adipose tissue (P1) and two were identified in the liver (P2 and P3)   243
and the promoters specific to these transcripts were cloned and characterised using a reporter gene 
strategy.  They were shown to differ in their basal activity, response to known activators of 
transcription, and to leptin treatment.  The adipose specific P1 promoter was found to be 
unresponsive to leptin treatment, whilst the liver specific P2 promoter was responsive to leptin 
treatment, owing to the differences in their promoter regions.  The mechanism underlying the 
activation of the P2 PPARα promoter by leptin was investigated and shown to function via a non-
canonical Stat3-Sp1 mechanism acting at a region that is unique to the P2 promoter.  Furthermore, 
the increase in PPARα expression in the leptin treated rats was found to be due to an increase in the 
P2 transcript, whilst the P1 transcript remained unaltered.   
 
 
7.2  Discussion of main findings 
 
Unlike offspring from dams fed a PR maternal diet, no effects on gene expression were identified 
as a result of maternal undernutrition in the liver or adipose tissue from IUGR offspring.  However, 
these are two very different animal models and it is likely that different genes, pathways or tissues 
may have been affected by the maternal undernutrition in the IUGR rat as opposed to the PR rat.  It 
is possible that the maternal undernutrition induced a PAR, in which offspring predicted a poor 
postnatal supply of nutrients and adapted their metabolism to increase their capacity to store fat, for 
example by altering the regulation of genes of fatty acid synthesis and storage in liver and adipose 
tissue.  It is also possible that leptin sensitivity may have been reduced in these offspring at the 
adipocyte, such as altered Socs-3 signaling downstream of leptin receptor.  These features would be 
consistent with the predisposition to obesity and its associated metabolic disturbances in IUGR 
offspring.  Furthermore, at the level of the hypothalamus, it is possible that the IUGR neonates 
were hypoleptinemic, which may have resulted in an absent or premature leptin surge.  If this were 
the case, then hypothalamic function may have been compromised due to altered hypothalamic 
circuitry and gene expression, which would contribute to the resulting leptin resistance.   
Furthermore, evidence in other animal models indicates that high fat postnatal feeding may induce 
epigenetic alterations in the POMC promoter to induce leptin resistance, thus this may also be 
present in the IUGR offspring fed a high fat postnatal diet. 
 
This study indicated that early leptin treatment facilitated a reprogramming of energy balance, 
which resulted in a reduced capacity to store fat within adipocytes throughout life, despite high fat 
feeding.  It is therefore proposed, that leptin administration during early development acted both 
centrally and peripherally to mediate the reversal of programming seen in leptin treated offspring.  
As such, neonatal leptin treatment would have replicated the normal leptin surge to facilitate a 
restoration of normal hypothalamic wiring and gene expression, thus restoring leptin sensitivity and 
preventing the onset of hyperphagia and reduced energy expenditure in adult life.  It is further 
proposed that the leptin treatment also had persistent effects at the level of the adipocyte.  Two   244
mechanisms are proposed for the adipose specific effects of neonatal leptin treatment on PPARα 
expression identified in this study: 
 
i) Leptin treatment may have induced epigenetic alterations which affected the liver specific P2 
PPARα promoter in adipose tissue.  Data from this study indicates that that leptin exerts a 
regulatory effect on specific PPAR promoters.  Normally, in adipose tissue the PPARα P1 
promoter is active (but at low levels), whilst the P2 promoter is inactive.  Therefore one possible 
explanation for the increase in P2 PPAR expression in adipose tissue is that leptin induced 
epigenetic alterations which resulted in a selective change in PPAR promoter activation 
facilitating use of the responsive P2 promoter rather than the unresponsive adipose specific P1 
promoter.  Although no alterations in DNA methylation were identified in the region of the PPARα 
promoter measured, it is still possible that during development, the PPARα P2 promoter was 
silenced by DNA methylation in a region downstream to that measured, thus demethylation 
induced by leptin treatment may have activated expression of the P2 specific transcript.   
Alternatively, expression of the PPARα P2 transcript may be prevented in normal circumstances 
due to repression by PcG proteins.  Thus PcG proteins would repress specifically at the unique 
region of the P2 promoter to maintain its silence in adipose tissue.  Thus an alternative explanation 
for the effect of leptin treatment, is that it caused a loss of PcG repression specific to this unique 
region of the P2 promoter, facilitating an increase in liver specific P2 PPARα transcript in adipose 
tissue, thus enabling a switch in promoter usage from the unresponsive P1 promoter to the 
responsive P2 promoter in a tissue in which it is not normally expressed.   
 
ii) Alternatively, the peripheral effects on PPARα expression may have been mediated by the 
persistent upregulation of leptin receptor on the adipocytes to increase leptin sensitivity, which 
resulted in increased Jak/Stat signaling.  If true, then altered epigenetic mechanisms are likely to 
have been responsible for the increased leptin receptor expression.  It is proposed that the increased 
Jak/Stat signaling upregulated the expression of the PPARα P2 transcript, via a non-canonical 
mechanism in which Stat3 interacted with Sp1 at the unique region of the PPARα P2 promoter.  To 
achieve this, it is proposed that leptin activated Stat3, which either translocated to the nucleus to 
activate PPARα transcription by binding the pre-bound Sp1, or the activated Stat3 phosphorylated 
Sp1, translocated to the nucleus and bound the unique region of the PPARα promoter via Sp1.   
This therefore would facilitate a persistent increase in the expression of the P2 PPARα transcript in 
a tissue in which it is not normally expressed, whilst the P1 transcript would be unaffected. 
 
In addition to PPARα upregulation, several other genes involved in energy balance were 
persistently increased in leptin treated IUGR offspring.  Thus one theory which could support the 
real time data from this study is as follows: neonatal leptin treatment induced in an increase in the 
expression of PPARγ2 in adipocytes, which led to a corresponding increase in the expression of its 
target gene, Lpl.  Lpl facilitated the uptake of fatty acids into the adipocyte from the triglyceride component of lipoproteins in the blood, which would have normally been converted back to TAG 
for storage.  Instead, in this model the PPARα P2 transcript was upregulated, which induced 
increased expression of its target genes; AOX and CPT-1, key rate limiting genes involved in fatty 
acid metabolism not normally expressed in adipocytes.  As a result, the fatty acids taken up by the 
adipocyte were shuttled to the β-oxidation pathway as opposed to storage pathway (figure 7.1).  
This model explains both the phenotypic changes (i.e. reduced weight gain) and the gene 
expression changes found in the leptin treated programmed adult offspring.  Thus the fat cell was 
transformed from a fat storing cell to a fat metabolising cell.  Furthermore, this is a persistent effect 
owing to the specific period of leptin administration during a plastic phase of early neonatal 
development. 
 
 
 
 
↑LPL
TAG
CO2
ADIPOCYTE
Stat3
Stat3
P P ↑ObRb
FA
FA
TAG
↑PPARα
↑Cpt1 ↑AOX
↑PPARγ
Glycerol
↑ Fatty Acid
Β-Oxidation
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  7.1  Proposed effect of neonatal leptin treatment on adipocytes according to 
altered gene expression profiles.  It is proposed that the increase in expression of PPARs and their 
target genes facilitate an increase in fatty acid β-oxidation within adipocytes. 
 
 
 
7.3 Future  work 
 
Several issues remain unresolved in this study.  Firstly, no genes were shown to be altered in 
response to maternal undernutrition in IUGR offspring.  Therefore, to confirm the hypothesis that 
  245  246
undernutrition induces an increased capacity to store fat, future work should measure the 
expression of genes of fatty acid synthesis and storage in both IUGR offspring and those treated 
with leptin.  Work in this report also indicated that leptin activates PPARα via a non-canonical 
Stat3 mechanism, however, Stat3/Sp1 protein/DNA binding needs to be demonstrated upon 
activation by leptin.  This could be verified by EMSA to show that Stat3/Sp1 can bind the unique 
region of the PPARα promoter in leptin treated cells, and secondly by performing a transient ChIP 
using Sp1/Stat3 antibodies to show binding at promoter upon leptin activation.   
 
Clearly, the mechanism which induces the persistent alterations in PPARα gene expression still 
needs to be clarified. For example, if altered leptin receptor signaling is responsible, leptin receptor 
needs to be analysed for epigenetic alterations.  This should include both DNA methylation and 
histone modifications associated with its promoter.  In addition, further analysis of the PPARα 
promoter needs to be performed to determine if there are any alterations in DNA methylation 
downstream of the region analysed in this report.  Further studies are also needed to determine if 
there are any differences in histone modifications present at the PPARα P2 promoter in leptin 
treated offspring.  As yet histone modifications in the PPARα promoter region of the different 
offspring groups are unknown.  Histone status could be investigated using ChIP assays to look at 
differences in histone modification between leptin treated and saline treated offspring.  In 
particular, methylation of H3 K27 should be measured at the unique region of the P2 promoter, to 
determine if PcG proteins are involved in repression.   
 
To support the mechanisms proposed in this discussion, further work needs to be undertaken.  To 
explore the hypothesis concerning leptin’s actions on the hypothalamus, further animal studies are 
needed to identify alterations in the programmed neonate.  This work should identify if neonates 
are hypoleptinemic, and if the leptin surge is blunted or premature in these IUGR offspring and if 
this is due to adipose specific alterations in leptin expression.  Furthermore any alterations in the 
leptin surge should be followed up with an analysis of hypothalamic projections and leptin specific 
hypothalamic signaling, in particular gene expression and methylation of appetite control genes, to 
determine leptin sensitivity.  Furthermore, all these factors need to be measured in leptin treated 
offspring also.  To support the proposed mechanisms acting at the level of the adipocytes, specific 
gene expression and epigenetic data should be measured in key genes at the time of neonatal leptin 
treatment to understand the changes in epigenetic regulation as they are set up.  This should 
therefore include investigating the epigenetic and gene expression status of genes before and after 
neonatal leptin treatment.  In particular changes associated with repression at the PPARα P2 
promoter need to be investigated. 
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7.4 Implications 
 
Accumulating evidence in human epidemiological cohorts and animal models suggest that the 
increased prevalence of obesity and its metabolic disturbances may be programmed in utero by a 
poor maternal nutrition.  Furthermore, studies are emerging implicating altered epigenetic 
regulation of gene transcription in the underlying mechanisms.  In this IUGR rat study, neonatal 
leptin treatment during a specific period of plasticity reversed the programmed phenotype, which 
may have involved alteration to epigenetic marks both centrally and peripherally.  As the IUGR rat 
model exhibits similarities to the disturbances identified in human IUGR, the underlying 
mechanisms may be similar in humans, thus implicating leptin treatment during an equivalent 
period of developmental plasticity as a therapeutic intervention in individuals who have 
hypoleptinemia, in order to minimise the risk of chronic disease such as obesity and its metabolic 
disturbances in adult life.   Appendix 1 
Clustal 2.0.12 multiple sequence alignment 
 
   
mouse ---CTTAGCGCTCTGTGGCCTGCCTGGCCACATCCATCCAACATGGTGGACACAGAGAGC     rat   ---ATTGGTGCTCTGTGGCCCGCCTGGCCACAACCATTCAACATGGTGGACACAGAGAGC  
human TAGCTTGGAGCTCGGCGGCACAACCAGCACCATCTGGTCGCGATGGTGGACACGGAAAGC    
          ** * **** * ***    *  **  ** *    *   *********** ** *** 
   
mouse CCCATCTGTCCTCTCTCCCCACTGGAGGCAGATGACCTGGAAAGTCCCTTATCTGAAGAA  
  rat   CCCATCTGTCCTCTCTCCCCACTTGAAGCAGATGACCTGGAAAGTCCCTTATCTGAAGAA  
human CCACTCTGCCCCCTCTCCCCACTCGAGGCCGGCGATCTAGAGAGCCCGTTATCTGAAGAG  
        **  **** ** *********** ** ** *  ** ** ** ** ** ***********  
 
  mouse TTCTTACAAGAAATGGGAAACATTCAAGAGATTTCTCAGTCCATCGGTGAGGAGAGCTCT  
rat   TTCTTACAAGAGATGGGAAACATTCAAGAGATTTCTCAGTCCCTCGGAGAGGAGAGTTCC     human TTCCTGCAAGAAATGGGAAACATCCAAGAGATTTCGCAATCCATCGGCGAGGATAGTTCT  
      *** * ***** *********** *********** ** *** **** ***** ** **    
 
mouse GGAAGCTTTGGTTTTGCAGACTACCAGTACTTAGGAAGCTGTCCGGGCTCCGAGGGCTCT    
rat   GGAAGCTTTAGTTTTGCGGACTACCAGTACTTAGGGAGCTGTCCAGGCTCGGAGGGCTCT  
  human GGAAGCTTTGGCTTTACGGAATACCAGTATTTAGGAAGCTGTCCTGGCTCAGATGGCTCG  
      ********* * *** * ** ******** ***** ******** ***** ** *****  
   
mouse GTCATCACAG  
  rat   GTCATCACAG  
human GTCATCACGG    
 
Figure  1.    Multiple sequence alignment of mouse, rat and human PPARα exon 3.   
Sequences of mouse, rat and human PPARα exon 3 were aligned using Clustal W2.0.12.  Bases 
conserved between all 3 species are marked with *.  Identity for rat and mouse is 92%, identity for 
rat and human is 77% and identity for mouse and human is 78%.  
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mouse CCAAG-TTGAAGTTCAAGGCCCTGCCTTCCCTGTGAACTGAC--GTTTGTGGCTGGTCAA  
rat   CCAAGACTGAAGTTCAAGGCCCTGCCTTCCCTGTGAACTGAC--ATTTGTGACTGGTCAA  
human CCAGG-CTGAAGCTCAGGGCCCTGTCTGCTCTGTGGACTCAACAGTTTGTGGCAAGACAA  
      *** *  ***** *** ******* ** * ***** *** *    ****** *  * *** 
 
mouse GTTCGGGA-ACAAGACGTTGTCATCACAG-------------------------------  
rat   GCTCAGGACACAAGACGTTGTCATCACAG-------------------------------  
human GCTCAGAA-CTGAGAAGCTGTCACCACAGGTAAATAGAAGGTTTAATTTACTGTTTCCAG  
      * ** * *    *** * ***** *****                                
 
mouse ---------------------------------------------------- 
rat   ---------------------------------------------------- 
human ATGGAAATATTTAAGTGTTTTCAGTGTTTACTTCTGTTGCACTACAGACCAG  
Figure 2.  Multiple sequence alignment of mouse and rat PPARα exon 2 and human 
PPARα exon 1A.  Sequences of mouse and rat PPARα exon 2 and human PPARα exon 1A were 
aligned using Clustal W2.0.12 
259.  Bases conserved between all 3 species are marked with *.  
Identity for rat and mouse is 94%, identity for rat and human is 75% and identity for mouse and 
human is 74%.  
 
 
 
 
 
 
  249
 
 
mouse GGAGACCCACAGCCACTGGAGAGGGCACACGCTAGGAAGGGCACACGCGTGCGAGTTTTC  
rat   ------------------------------------------------------------ 
human ----GTGCGCGGCTGGGGACCTGAGGGCGAGG-AGCGAGGACACACACCGAGGACTCTTG  
                                                                       
 
mouse --AGGGCCCGCGGAACTGTCCGCCACTTCGAGTCCCCTGGAGCGCCGTGCGCCGGCTCCG  
rat   ------------GAACTGTCCGCTACTTCGAGTCCCCTTGAGCGCCGTGTGCCGGCTCTG  
human CGAGGGATCTCGGGGCC-----CAGCTCGGCCTCCCTCCTAGCGCTGGGGGCCTGCCCGG  
                  *  *      *  **  *  ****    ***** * * *** ** * * 
 
mouse AACATTGGTGTTCGCAGCTGTTTTGGGGGCTGGAGGGTTCGTGGAG------TCCTGGAA  
rat   AACATTGGCGTTCGCAGCTGTTTTGTGGGCTGGAGGGTTCGTGGAG------TCCTGGAA  
human AACCC--GAGTCCGCGGCTGTCCCTGGGGTTTGGCGCTGCGCGGAGGTCGGGTCTGGGGA  
      ***    * ** *** *****     *** * *  * * ** ****      **  ** * 
 
mouse CTGGAGCGACGCTGGGTCCTCTGGTTGTCCCCTGGAGGGGAGGGCACACGGGCGGGGACA  
rat   CTGAAGCGACGCTGGGTCCTCTGGTTGTCCCCTTGAGGGGAGGGCACACGAGCGGGGACA  
human CCGCAGCGACTCTGGGTCTTCGGGTTGTCCCCTCGGAGGGAGGGCCCACGGGCGGGGACA  
      * * ****** ******* ** *********** *  ******** **** ********* 
 
mouse TCGGGGCGCTCCCTTCTCACGGCGTGGTGCATTTGGG-CGTATCTCAC-CGGGAGGCGTT  
rat   TCGGGGCGCTCCCTTCCCACAGCGTGGTGCATTTGGG-CGTAACTCAC-CGGGAGGCGTT  
human TCGGGACTTGCCCTTTCCTCGGCGCAGCGGAGCTGGGGCGTCGCCGACTCAGAAGGTGCT  
      ***** *   *****  * * ***  * * *  **** ***  *  ** * * *** * * 
 
mouse TCCTGAGACCCTCGGGGAACTTAGAGGAGAGGTAACTGGAGGCTCCCTGACAGACTGATT  
rat   TCCTGAGACCCTCGGGGATCTTAGAGGCGAG-----------------------------  
human TTCCGAGACCTCCAGGGATCTCCGAGGCGAGGAAACCCGGG--CCCCGGACAGACCGACC  
      * * ******  * **** **  **** ***                              
 
mouse CTGGGGTCACAGCCTAGGCTTTGCTGGGGACCTGAGAAACGCTGCCG  
t
 
Figure 3.   Multiple sequence alignment of mouse PPARα exon 1B, rat PPARα exon 
1E and human PPARα exon X before 5’RACE.  Sequences of mouse exon 1B, rat exon 1E 
(prior to the 5’RACE procedure) and human PPARα exon X were aligned using Clustal W2.0.12 
259.  Sequences conserved between all 3 species are marked with *.  Identity for rat and mouse is 
94%, identity for rat and human is 64% and identity for mouse and human is 52%.  
 
 
 
 
 
 
 
   
mouse GGAGACCCACAGCCACTGGAGAGGGCACACGCTAGGAAGGGCACACGCGTGCGAGTTTTC    
rat   --AGACCCACAGCCACTGGCGAGGGCACACGCTAGGAAGGGCACACGCGTGCGA-CTTTC    
human ----GTGCGCGGCTGGGGACCTGAGGGCGAGG-AGCGAGGACACACACCGAGGACTCTTG  
               * * **    *    * *  *  *  **  *** ***** *    **   **  
   
mouse --AGGGCCCGCGGAACTGTCCGCCACTTCGAGTCCCCTGGAGCGCCGTGCGCCGGCTCCG    
rat   --GGGGCCCCTGGAACTGTCCGCTACTTCGAGTCCCCTTGAGCGCCGTGTGCCGGCTCTG  
  human CGAGGGATCTCGGGGCC-----CAGCTCGGCCTCCCTCCTAGCGCTGGGGGCCTGCCCGG  
         ***  *  **  *      *  **  *  ****    ***** * * *** ** * *   
   
mouse AACATTGGTGTTCGCAGCTGTTTTGGGGGCTGGAGGGTTCGTGGAG------TCCTGGAA  
  rat   AACATTGGCGTTCGCAGCTGTTTTGTGGGCTGGAGGGTTCGTGGAG------TCCTGGAA  
human AACCC--GAGTCCGCGGCTGTCCCTGGGGTTTGGCGCTGCGCGGAGGTCGGGTCTGGGGA    
      ***    * ** *** *****     *** * *  * * ** ****      **  ** * 
   
  mouse CTGGAGCGACGCTGGGTCCTCTGGTTGTCCCCTGGAGGGGAGGGCACACGGGCGGGGACA  
rat   CTGAAGCGACGCTGGGTCCTCTGGTTGTCCCCTTGAGGGGAGGGCACACGAGCGGGGACA    
human CCGCAGCGACTCTGGGTCTTCGGGTTGTCCCCTCGGAGGGAGGGCCCACGGGCGGGGACA  
        * * ****** ******* ** *********** *  ******** **** ********* 
   
mouse TCGGGGCGCTCCCTTCTCACGGCGTGGTGCATTTGGG-CGTATCTCAC-CGGGAGGCGTT    
rat   TCGGGGCGCTCCCTTCCCACAGCGTGGTGCATTTGGG-CGTAACTCAC-CGGGAGGCGTT  
  human TCGGGACTTGCCCTTTCCTCGGCGCAGCGGAGCTGGGGCGTCGCCGACTCAGAAGGTGCT  
      ***** *   *****  * * ***  * * *  **** ***  *  ** * * *** * *   
   
mouse TCCTGAGACCCTCGGGGAACTTAGAGGAGAGGTAACTGGAGGCTCCCTGACAGACTGATT  
  rat   TCCTGAGACCCTCGGGGATCTTAGAGGCGAG-----------------------------  
human TTCCGAGACCTCCAGGGATCTCCGAGGCGAGGAAACCCGGG--CCCCGGACAGACCGACC    
      * * ******  * **** **  **** ***                                
 
  mouse CTGGGGTCACAGCCTAGGCTTTGCTGGGGACCTGAGAAACGCTGCCG  
 
 
Figure 4.   Multiple sequence alignment of mouse PPARα exon 1B, rat PPARα exon 
1E and human PPARα exon X after 5’RACE.  Sequences of mouse exon 1B, rat exon 1E (after 
the 5’RACE procedure) and human PPARα exon X were aligned using Clustal W2.0.12 
259.  
Sequences conserved between all 3 species are marked with *.  Identity for rat and mouse is 94%, 
identity for rat and human is 50% and identity for mouse and human is 52%. 
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  mouse -------------------------------------------------GGAGGCAGCCG  
rat   ------------------------------------------------------------ 
  human GGGCCGTGGACGCGGCGGCCCCGCGGCGGGGGCAGCGGGCGGCGGGGGCGGAGGCGGCCG  
                                                                       
   
mouse CTTACGCCCCTCCTGGCGCCTCCT-CCTGGGCGCGCTTGGCCCTGCGGACCCGCAGGCGG     rat   ------------CTGGCGCCGCCTACCCGGGCGGGCT-GGCCCTGCGGACCCGCAGGCGG  
human CTAGCGCCCTGCCCGGCGCCGCCTCCTTCGGCGTTC---GCCCCACGGACCGGCAGGCGG    
                  * ****** *** *   ****  *   ****  ****** ******** 
   
mouse AGTGCAGC--CTCAG  
  rat   AGCGCAGC--CTCAG  
human CGGACCGCGGCCCAG  
         *  * **  * ***
 
Figure 5.   Multiple sequence alignment of mouse PPARα exon 1A, rat PPARα exon 
1C and human PPARα exon A after 5’RACE.  Sequences of mouse exon 1A, rat exon 1C (after 
the 5’RACE procedure) and human exon A were aligned using Clustal W2.0.12 
259.  Sequences 
conserved between all 3 species are marked with *.  Identity for rat and mouse is 91%, identity for 
rat and human is 65% and identity for mouse and human is 71%. 
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PPARα alternative 5’UTR predicted secondary structures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  PPARα P1 5’UTR predicted secondary structure.  The most energetically 
favourable conformation of the PPARα P1 5’UTR is shown as analysed by Zucker RNA mfold 2.3 
software 
260.  The minimum free energy was calculated as -74.65Kcal/mol. 
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Figure 2.  PPARα P2 5’UTR predicted secondary structure.  The most energetically 
favourable conformation of the PPARα P2 5’UTR is shown as analysed by Zucker RNA mfold 2.3 
software 
260.  The minimum free energy was calculated as -169.95 Kcal/mol. 
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Figure 3.  PPARα P3 5’UTR predicted secondary structure.  The most energetically 
favourable conformation of the PPARα P3 5’UTR is shown as analysed by Zucker RNA mfold 2.3 
software 
260.  The minimum free energy was calculated as -56.15 Kcal/mol. 
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Figure 4.  PPARα P4 5’UTR predicted secondary structure.  The most energetically 
favourable conformation of the PPARα P4 5’UTR is shown as analysed by Zucker RNA mfold 2.3 
software 
260.  The minimum free energy was calculated as -64.18 Kcal/mol. 
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Figure 5.  PPARα P5 5’UTR predicted secondary structure.  The most energetically 
favourable conformation of the PPARα P5 5’UTR is shown as analysed by Zucker RNA mfold 2.3 
software 
260.  The minimum free energy was calculated as -101.54 Kcal/mol. 
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Figure 6.  PPARα P6 5’UTR predicted secondary structure.  The most energetically 
favourable conformation of the PPARα P6 5’UTR is shown as analysed by Zucker RNA mfold 2.3 
software 
260.  The minimum free energy was calculated as -71.87 Kcal/mol. 
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